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Summary
The immune system has immense clinical potential for combating pathogens and 
tumourigenesis. More specifically, CD8+ T cells have the ability to eradicate infected and 
malignant cells. In light of this, the factors that may influence the speed at which antigen 
is detected, the magnitude of the response and the efficiency of pathogen/tumour 
clearance require ongoing investigation.
The src homology 2 (SH2) domain containing protein tyrosine phosphatase -1  (SHP-1) is a 
negative regulator of T cell signalling pathways. Prior to this study, in vitro data had 
demonstrated that SHP-1 deficient CD8+ T cells possess a hyper-responsive phenotype 
when stimulated with cognate peptide. Therefore, the remit of this study was to establish 
whether this in vitro observation has an in  vivo relevance.
In order to explore the role of SHP-1 in an in vivo setting, CD8+ T cells from the 
spontaneous mouse mutant, motheaten, which lacks SHP-1 expression were utilised. 
Specifically, CD8+ T cells were purified from motheaten (SHP-1 deficient) and control 
(SHP-1 sufficient) mice and adoptively transferred to recipient mice where they could be 
studied.
This study demonstrates that following adoptive transfer, naive SHP-1 deficient CD8+ T 
cells exhibit an enhanced in vivo expansion upon antigenic stimulation, which notably 
results in the killing of more peptide labelled target cells. Furthermore, SHP-1 deficient 
CD8+T cells also exhibit an enhanced memory response upon antigenic challenge. These 
findings suggest that modulation of SHP-1 expression may improve the efficacy of tumour 
immunotherapy strategies, which use antigen specific CD8+ T cells to eradicate malignant 
cells in tumour-bearing patients.
In further support of potentially targetting SHP-1 expression in CD8+ T cells used in 
immunotherapy strategies, it has been importantly shown in this study that mice 
receiving SHP-1 deficient CD8+ T cells exhibit an enhanced protection against pulmonary 
tumour formation when compared to mice receiving SHP-1 sufficient CD8+ T cells.
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1Chapter 1 
Introduction
1.1 The Immune System
The immune system is fundamental for the existence of multicellular animals. It offers host 
protection against invading pathogenic microorganisms, such as virus, bacteria, fungi and 
parasites. In addition to providing protection against these extrinsic threats, the immune 
system also plays a role in protecting against intrinsically generated hazards, such as 
malignant cells.
However, the immune system has a dual responsibility. In addition to protecting the host 
from infectious organisms and malignancies, the immune system has to be self-tolerant in 
order to prevent host cells from being harmed by the effector mechanisms it can deploy. In 
light of these demands, the immune system is regulated in such a way as to maintain 
homeostatic harmony. Nevertheless, in a dysregulated state the immune system is 
responsible for autoimmune diseases, such as type I diabetes and multiple sclerosis. The 
immune system may also react inappropriately as demonstrated by the occurrence of 
allergies. Moreover, the power of the immune system is demonstrated in a clinical setting, 
when transplant recipients reject organs, and immunodeficient individuals exhibit an 
increased susceptibility to infection and tumour development.
The cells of the immune system are generated in the bone marrow from pluripotent 
haematopoietic stem cells. Once mature, they are found throughout the body in anticipation 
of pathogen invasion or tumour development. The detection of a pathogen or tumour is 
enhanced by the presence of the lymphatic system, which consists of lymphoid channels and 
tissues that drain extracellular fluid from tissues.
The cellular components of the Immune system have classically been divided into innate 
immunity, which provides primary protection against an assault, and adaptive immunity, 
which provides more effective defence against an infection or developing tumour.
1.1.1 Innate Immunity
Innate immunity has two modes that aim to provide protection to the host against an 
assault. A component of the first mode involves non-specific mechanisms of preventing 
pathogen entry to the host. These are attributed to the presence of preformed chemical, 
microbiological and mechanical barriers, such as the tight junctions between epithelial cells 
of the skin and gut. The first mode also involves broadly-specific innate immune cells such as 
macrophages and neutrophils. They are resident in peripheral tissues and are capable of 
recognising pathogens, via the expression of pattern recognition receptors (PRRs) that 
recognise common molecular patterns on the surface of a wide range of pathogens. Some of 
these receptors assist with the binding and subsequent phagocytosis of the pathogen, which 
is then destroyed within the cell. Innate-like lymphocytes, such as y6 T cells and NKT cells 
(Chan et a i, 2003) can also act as sentinels at peripheral sites, and provide an immediate 
response upon recognition of antigen.
If an assault is successful at breaching this first line of innate defence, an inducible and 
broadly-specific innate immune response occurs, which involves cellular elements and 
possibly the complement system. The release of inflammatory mediators from innate cells 
during initial detection of a pathogen mediates this phase of an innate response. It involves 
the active recruitment of innate cells, such as monocytes, neutrophils and natural killer (NK) 
cells from the blood to the site of pathogen invasion or tumourigenesis.
Pathogens and tumours have developed sophisticated mechanisms of evading an innate 
immune response and in order to prevent long-term damage from occurring to the host,
3adaptive immune cells unite with innate cells in combating the assault. Innate antigen 
presenting cells (APCs), such as dendritic cells (DCs), process and present peptide antigens 
that are able to activate adaptive immune cells. In addition, cytokines produced by innate 
cells under inflammatory conditions act to ensure efficient priming of adaptive immune cells.
1.1.2 Adaptive Immunity
Adaptive immunity is an induced and highly specific response to pathogenic microorganisms 
or tumourigenesis. It is comprised of humoral immunity, involving B cells, and a cell- 
mediated immunity, involving T cells. The initiation of an adaptive response does not 
coincide with the subsidence of the innate response. Moreover, components of the innate 
and adaptive immune responses act conceitedly to combat an assault. B and T cells are 
primed within secondary lymphoid organs, such as the spleen, peripheral lymph nodes and 
mucosal associated lymphoid tissue (MALT).
Mature conventional B cells leave the bone marrow and circulate between the 
cardiovascular and lymphatic systems. The antigen receptor on B cells, termed the B cell 
receptor (BCR) is a cell surface immunoglobulin. Once activated, B cells differentiate into 
plasma cells that secrete antibody molecules of the same specificity as the BCR. Antibodies 
are able to directly bind and neutralise pathogens and their components, or mark them for 
lysis or phagocytosis.
Immature T cells leave the bone marrow and undergo further development in the thymus 
before entering the cardiovascular and lymphatic systems as naive T cells. From here they 
survey lymphoid tissue for cognate antigen. Upon recognition of cognate antigen, T cells 
undergo clonal expansion and acquire effector function in order to provide protection from 
pathogen invasion or tumourigenesis. T cells possess an antigen receptor, termed the T cell 
receptor (TCR), composed of an a and 3 chain (Garcia et al., 1999; Garcia et a!., 1996). TCRs
recognise antigenic peptides that are displayed at the surface of cells by glycoproteins, 
termed major histocompatability complex (MHC) molecules (Davis and Bjorkman, 1988). The 
peptides displayed by MHC molecules of a cell are generated by the intracellular degradation 
of proteins. Overall, the process of antigen binding by T cells is a tri-molecular process 
involving the TCR, a peptide and a MHC molecule. There are two types of a|3 T cells, which 
are marked by the expression of the surface proteins, CD4 and CD8. The expression of these 
proteins also marks the effector capabilities of the T cell subsets.
Those T cells expressing the CD4 protein (CD4+) recognise peptide fragments from the 
intravesicular degradation of proteins, which are subsequently presented by MHC class II 
molecules on APCs. They provide help to other cells during an immune response by releasing 
specific cytokines and by engaging with other cells via receptor ligand interactions. The 
differentiation of activated CD4+ T cells into various subsets, which have distinct roles, is 
mediated by the release of cytokines from APCs. CD4+ T helper l(Th l) cells control 
intravesicular bacteria and extracellular pathogens by activating macrophages and B cells 
respectively. CD4+ Th2 cells can also activate B cells and are involved in antibody class 
switching of B cells in order to control parasitic infections. A third subset of helper T cells, 
called Thl7 cells, act early in the adaptive immune response and elicit a neutrophil response 
to combat bacterial infections. More recently, T follicular helper cells have been shown to 
play an important role in the formation of germinal centres and in antibody isotype 
switching of B cells (Vogelzang et al., 2008) and therefore constitute a fourth subset of 
helper T cells. CD4+ T cells can also have a regulatory role by suppressing T cell responses to 
both foreign and auto-antigens. Natural regulatory T cells (Tregs) develop in the thymus 
whereas adaptive Tregs gain their suppressive function in the periphery. Tregs exert their 
suppressive actions by either releasing inhibitory cytokines or conditioning APCs so they are 
less effective at priming T cells.
Those T cells expressing the CD8 protein (CD8+) recognise peptides derived from the 
cytosolic degradation of proteins that are presented by MHC class I molecules. Most somatic 
cells including APCs express MHC class I molecules at their surface. The role of a CD8+ T cell is 
to detect and directly eradicate cells displaying cognate antigen and are therefore called 
cytotoxic T lymphocytes (CTLs). The antigenic peptide can be derived from viruses, cytosolic 
bacteria and proteins associated with malignant conversion. CD4+ T cells provide help to 
CD8+ T cells during their priming and differentiation and are required for the optimal 
formation and maintenance of a CD8+ memory T cell pool. Indeed, it is a hallmark of 
adaptive immune cells to persist as long-lived memory cells following antigen induced 
activation. This provides a host with a more sensitive and vigorous response upon re­
encounter with an antigen.
61.2 Antigen recognition by T cells
1.2.1 MHC molecules and peptide presentation
MHC class I molecules consist of two non-covalently linked polypeptide chains. The 
polymorphic a chain is encoded in the MHC locus of chromosome six, and in the assembled 
molecule spans the cell membrane. The second chain is the non-polymorphic p2- 
microglobulin, which does not have a transmembrane region. The assembled molecule 
contains four domains; three are contributed by the a chain (al, a2 and a3) and one by p2- 
microglobulin (Bjorkman et al., 1987). Domains a l and a2, are furthest away from the 
membrane, and fold in such a way to form a single structure termed the peptide-binding 
cleft. The peptide-binding cleft of the MHC class I molecules consists of two separated a 
helices on a bed of antiparallel |3 sheets (figure 1.1).
MHC class I molecules bind short peptides, which are stabilised by the formation of 
hydrogen bonds and ionic interactions between atoms at the free amino and carboxyl 
terminals of the peptide, and invariant sites at each end of the MHC molecule binding cleft.
The peptide binds in an extended fashion with other residues aside from those at the amino 
and carboxyl terminus making additional interactions with the MHC molecule. These 
residues are termed anchor residues, and a given MHC variant will preferentially bind 
peptides with the same or similar residues at defined positions along the length of the 
peptide. Typically, peptides of 8-10 amino bind to MHC class I molecules (Madden et al.,
1993), although longer peptides can be accommodated by kinking of the peptide backbone 
or by post-binding cleavage of the peptide by exopeptidases.
MHC class I molecules acquire their peptide cargo during their biosynthesis and assembly 
inside the endoplasmic reticulum (ER). Endogenously and exogenously sourced proteins 
present within a nucleated cell are processed in the cytoplasm to yield peptides.
Endogenous peptides may be derived from normally expressed cytosolic, membrane and 
secreted proteins, but also from proteins associated with malignant transformation. 
Exogenous proteins can be derived from the direct infection of cells, as with virus and 
cytosolic bacteria. Furthermore, exogenous proteins and peptides can be cross presented on 
MHC class I molecules by specialist APCs (Heath and Carbone, 1999). APCs can phagocytose 
necrotic cells (Albert et al., 1998a; Albert et al., 1998b; Subklewe et al., 2001) or engulf 
extracellular fluid (macropinocytosis) (Sallusto et al., 1995) into their vesicular system. From 
here the proteins and peptides are transferred to the cytosol by a mechanism called 
retrotranslocation, where they are processed ready for presentation (Rodriguez et al., 1999). 
Proteins destined for processing are labelled covalently with the peptide, ubiquitin, which 
signals for their subsequent degradation by a protease pomplex called the proteasome (Rock 
et al., 2002). The standard proteasome degrades proteins under normal physiological 
conditions, whereas the immunoproteasome is activated in response to IFNy and does not 
require proteins to be ubiquinated for degradation (Van den Eynde and Morel, 2001). 
Peptide fragments are moved from the cytoplasm, by the chaperone activities of heat shock 
proteins (HSPs) (Li et al., 2002), to the ER via a heterodimeric transport molecule called, 
transporter associated with antigen processing (TAP), which is present in the ER membrane 
(Lankat-Buttgereit and Tampe, 2002). Once in the lumen of the ER, the peptides are 
transferred to newly synthesised MHC class I molecules, which are associated with TAP, via 
the TAP associated protein, tapasin. The assembled and stabilised peptide:MHC class I 
complex is then transported to the outer cell membrane.
Other pathways also exist that allow for the cross-presentation of peptides by MHC class I 
molecules. The first mechanism is both TAP and proteasome independent, and involves the 
putative release of peptides from endosomes at the cell surface (Pfeifer et al., 1993). The 
resulting high concentration of peptides at the cell surface can then force an exchange with
8a lower stability peptide that is already bound to an MHC class I molecule. Similarly, peptides 
generated by the extracellular action of enzymes, or those that are released from lysed or 
apoptotic cells, may act in the same manner (Smith et al., 1992). In a research situation, the 
exogenous administration of a peptide to cells leads to the presentation of the peptide by 
MHC class I molecules. The second mechanism involves internalisation of peptide:MHC class 
I complexes from the surface of cells, which are subsequently transported, via vesicles, to 
acidified endosomal compartments termed, MHC class II compartments (MHC). The acidic 
nature of the MIIC mediates the release of the peptide from the binding groove, allowing 
other peptides to bind. The new peptide:MHC class I complex is then transported back to the 
surface of the cell (Schirmbeck et al., 1995).
MHC class II molecules are composed of heterodimers of membrane-anchored a and P 
chains, which together contain four extracellular domains. MHC class II molecules bind 
peptides that are variable in length, with anchor residues present at central residues of the 
peptides (Stern et al., 1994). MHC class II molecules acquire their peptide cargo in MIIC, post 
synthesis, whilst en route to the plasma membrane (Hiltbold and Roche, 2002).
1.2.2 a6 T cell receptors
An ap T cell may express approximately 30,000 TCR at its surface. Each is comprised of an a 
and P transmembrane chain, which create one antigen binding site (Chothia et al., 1988). 
When assembled, the TCR chains have an extracellular portion consisting of a variable and 
constant region, and a stalk segment. Each chain has a hydrophobic transmembrane region 
containing positively charged amino acid residues. Each chain also contains a short 
cytoplasmic tail. Cysteine residues present in each chain lead to the formation of 
intramolecular and interchain disulphide bonds, with the latter forming between the stalk
9segments of each chain. In addition, carbohydrate residues present in the constant and 
variable regions mediate interchain interactions, via the formation of hydrogen bonds.
The T cell repertoire of an individual is capable of recognising a wide range of peptidic 
antigens. This diversity is achieved by variations in the amino acid sequence at the antigen 
binding site. Bone marrow progenitor and immature T cells contain TCR genes in their 
inherited configuration. Somatic recombination of the gene segments at the TCR a and P loci 
enables a diverse number of antigen receptors to be generated. The human TCR a chain loci 
contains 1 constant, 37 functional variable (V) and >50 joining (J) region gene segments. The 
human TCR 3 chain loci contains 2 constant, 47 functional variable and 12-13 joining gene 
segments, and unlike the TCR a loci, 2 diversity (D) gene segments (Davis and Bjorkman,
1988). Somatic recombination of the V, (D) and J gene segments is mediated by a group of 
enzymes called the VDJ recombinases (Agrawal and Schatz, 1997). Recombinase-activating 
gene (RAG) -1 and -2 proteins recognise DNA sequences called recombination signal 
sequences (RSSs) that flank each TCR gene segment (Grawunder et al., 1998). The enzymes 
act by bringing the V, D and J segments together and cleaving the DNA at specific sites, 
forming DNA hairpins. The DNA is subsequently ligated to yield a full length recombined VJ 
(TCRa) or VDJ (TCRP) variable domain exon without intervening DNA segments, which then 
joins a constant gene region.
Diversity of TCR is achieved by the recombination of different V, (D) and J gene segments of 
the a and p gene loci (Arstila et al., 1999). In addition to this combinatorial diversity, 
junctional diversity can lead to an even greater TCR diversity due to its imprecise nature 
(Gauss and Lieber, 1996). Junctional diversity can involve three types of sequence change, 
which are not mutually exclusive and may occur simultaneously during a single gene 
rearrangement. During the last stages of V(D)J recombination and in preparation for DNA 
ligation, the hairpin itself or neighbouring DNA is cut in a single-stranded manner.
Exonuclease activity may remove templated nucleotides from the gene segments junctions, 
and as long as this does not create a stop or nonsense codon, new sequences are produced. 
Nucleotides may also be added at this stage and depending upon their mode of introduction 
are termed P- or N-nucleotides. If the cutting of DNA takes place within the coding sequence 
at the junction site, the hairpin will open, creating a single stranded tail. DNA repair enzymes 
then introduce complementary P-nucleotides to form double stranded DNA, thus creating 
short palindromic sequences. If the hairpins are nicked in the non-coding intervening DNA of 
the RSSs, the lymphocyte specific enzyme called terminal deoxyribonucleotidyl transferase 
adds random, non-germline encoded nucleotides, termed N nucleotides, to sites of 
recombination.
In the assembled TCR, the V(D)J encoded regions determine the antigen binding specificity of 
the TCR (figure 1.1). The V regions of both chains contain complementary-determining 
regions (CDRs) 1 and 2. The CDR3 loop encompasses the highly variable junctions of either 
the VJ (TCRa) or VDJ (TCRp) gene encoded segments; therefore TCR diversity is concentrated 
in this area. X-ray crystallographic studies of TCRs engaged with peptide:MHC class I 
molecules have shown that the TCR orientates diagonally across the occupied peptide 
binding cleft when viewed from above the MHC (Garcia et al., 1996). The CDR3 regions of 
the TCR a and 0 chains bind to the middle of the peptide, whereas the CDR1 and CDR2 
regions bind to the end of the bound peptide and also the MHC molecule (Garboczi et al., 
1996).
1.2.3 T cell coreceptors
In conjunction with the binding of TCRs to peptide:MHC molecules, other cell surface 
proteins, called CD8 and CD4, also interact with MHC molecules (Konig, 2002). They are 
required for the generation of effective T cell responses and are therefore termed T cell
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coreceptors. They bind to membrane proximal domains of the MHC molecule that are 
distinct from the peptide binding domains (Tanabe et al., 1992). The CD8 molecule, which is 
expressed by CTLs, consists of an a and p chain linked by a disulphide bridge. The CD8 
coreceptor can also exist as a homodimer of two a chains. The immunoglobulin-like domains 
of CD8, which are found furthest from the membrane, bind to an invariant site on the a3 
domain and the base of the a l and a2 domains of the MHC class I molecule (figure 1.2). The 
cytoplasmic domains of the a CD8 chain are capable of interacting with intracellular proteins 
involved in TCR signalling pathways (Shaw et al., 1990). The CD4 coreceptor, expressed by 
helper and regulatory T cells, is distantly related to CD8. It is composed of a single chain 
consisting of four immunoglobulin-like domains, with the membrane proximal domain (Dl) 
making contact with MHC class II molecules.
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Figure 1.1: T cell receptor binding to a peptide.MHC complex.
In A, the a  (pink) and p (blue) chains of the alloreactive mouse T cell receptor (2C) are shown above a 
peptide (dVE8) MHC class I (green) complex (H2-Kb). The CDR regions o f the TCR are shown in colour and 
numbered accordingly. B and C view the peptide MHC complex from above showing the peptide binding 
cleft, which consists of two separated a  helices on a bed of antiparallel p sheets. In B, all peptide MHC 
complex residues involved in contact are labelled. C shows the CDRs of the TCR superimposed onto the 
peptide MHC complex; dark pink for those from the a  TCR chain and blue for those from the p TCR chain. 
Figures adapted from Garcia et al., 1998.
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Figure 1.2 The C08 coreceptor binds to MHC class I molecules at a distant site to that of TCR binding
Figure A shows a hypothetical representation of the relative positions of the TCR (pink) and CD8 
coreceptor (red and blue) bound to the same MHC class I molecule (yellow and green). Figure B is a 
schematic representation of figure A and shows the binding of the CD8 coreceptor to the a 2 and a 3 of the 
peptide MHC class I complex. Figure A taken from Gao et al., 1997.
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1.3 Antigenic CD8* T cell responses
The ultimate role of a CD8+ T cells is to clear antigen recognised by its TCR. This involves the 
activation of naive T cells and their progressive acquisition of CTL function during 
differentiation. Three distinct signals are required by a naive CD8+ T cell to become fully 
activated and undergo clonal expansion. They are signals disseminated from the TCR, 
costimulatory and cytokine receptors. A cardinal response of T cell activation is the 
production of the mitogenic cytokine, IL-2. This can act in both an autocrine and paracrine 
manner to further facilitate T cell proliferation and differentiation (Cantrell and Smith, 1984).
The a and 3 chains of the TCR possess no intrinsic signalling capacity and therefore associate 
electrostatically with invariant accessory chains that assist with TCR signalling (Manolios et 
al., 1994). The invariant chains form the CD3 complex (figure 1.3), which is composed of e6 
and ey heterodimers. Each has an extracellular domain connected by transmembrane 
regions to cytoplasmic tails. The apTCR heterodimer also associates with the TCR£ chain, 
which is a homodimer linked by a disulphide bond. The  ^ chains have a cytoplasmic tail, 
transmembrane domain and a short extracellular domain.
T cell signalling pathways involve the coordinated actions of transmembrane, membrane- 
associated and intracellular proteins, which may be enzymes or act as adaptors. The proteins 
can have a positive or negative influence on T cell signalling pathways. This ensures that T 
cells respond appropriately to antigenic stimulation. One of the proximal steps in TCR 
signalling is the phosphorylation of tyrosine (V) residues belonging to key proteins (Hsi et al.,
1989). This is a post translational modification that can either alter the activity of a protein 
or create docking sites to allow proteins to interact (Pawson and Scott, 1997). Phosphates 
(p) are added to tyrosine residues by protein tyrosine kinases (PTKs), whilst the reverse 
reaction is performed by protein tyrosine phosphatases (PTPs) (Chan etal., 1994). Therefore,
the tyrosyl-phosphorylated state of a T cell at any given time is a balance between the 
catalytic activities of PTKs and PTPs (Neel and Tonks, 1997).
1.3.1 TCR signalling (summarised in figure 1.3)
The mechanism by which TCR engagement with peptide:MHC leads to T cell stimulus is not 
fully understood. A proposed mechanism that involves oligomerisation of TCRs is supported 
by the in vitro observation that cross-linking TCR with anti-CD3 antibodies induces T cell 
activation. It seems that the close proximity of several TCR complexes and their associated 
proteins is required for the initiation of intracellular signalling. Indeed, the structure of the 
TCR is compatible with the formation of dimers (Fields et al., 1995; Reich et al., 1997) and it 
has been shown in vitro that TCRs bound to peptide MHC complexes tend to form dimers 
(Garboczi et al., 1996). In vivo, the oligomerisation of antigen specific TCRs may be 
precluded by the low concentration of MHC molecules displaying antigenic peptide on a 
given APC. Alternatively, oligomerisation of TCRs may be achieved when they interact with 
both a cognate peptide:MHC molecule and a MHC molecule displaying a self peptide.
Although oligomerisation of TCRs may allow early signalling events, further events are 
required for sustained signalling to be achieved. The serial triggering model of TCR signalling 
suggests that numerous TCRs belonging to a given T cell engage with a relatively lower 
number of peptide MHC complexes on an APC. As a result this allows for sufficient triggering 
of an individual TCR and therefore signal transduction.
The TCR signalling cascade involves a series of events involving protein-protein and protein- 
lipid interactions (Norian and Koretzky, 2000; Zhang and Samelson, 2000). The presence of 
protein domains containing conserved amino acid motifs facilitates such interactions. Src 
Homology 2 (SH2) domains are approximately 100 amino acids in length and bind to context- 
specific phosphorylated (p) Y residues (Pawson, 1995). PY residues are present within
immunoreceptor tyrosine-based activation motifs (ITAMs) of TCR associated CD3 chains and 
have a consensus amino acid sequence of YXX[L/l]X6-12pYXX[L/l] (where X is any amino acid) 
(Cambier, 1995). SH3 domains are between 50-75 amino acids in length and contain the 
consensus motif XPpXP (where P is a preference for proline), which binds to polyproline 
sequence motifs. Phospho-tyrosine-binding (PTB) domains bind pY motifs, but differ from 
SH2 domains in structure and sequence preference. They bind to pY of the consensus 
sequence, NPXpY, which are preceded by amino acids in a P turn (Kavanaugh et al., 1995). 
Finally, the Pleckstrin Homology (PH) domain mediates binding of proteins to anionic 
phospholipids (Pawson and Scott, 1997).
Upon initial T cell stimulus, the formation of a three dimensional molecular structure at the 
junction between the T cell and APC (Dustin and Chan, 2000), termed the immunological 
synapse (IS) further facilitates TCR signalling. Components necessary for TCR signalling 
congregate at the IS and form a supramolecular activation complex (SMAC) (Monks et al.,
1998). With regards to the T cell, the initial cluster comprises adhesion molecules 
surrounded by engaged TCRs. The initial SMAC then undergoes changes leading to the 
formation of a SMAC that is comprised of a concentric triple ring structure. The inner and 
outer peripheral SMAC (pSMAC) contains adhesive molecules such as CD2 and LFA-1. This 
ensures that the APC and T cell remain together for a sufficient duration to allow signal 
transduction. The central SMAC (cSMAC) contains the necessary proteins for TCR signal 
transduction. These include engaged TCRs, the CD3 complex, CD45 (transmembrane protein 
tyrosine phosphatase), protein kinase C-0 (PTK-0), CD28 and CD8 its associated intracellular 
PTK, Lck (Monks et al., 1998). Intracellularly, the PTKs, Lck and Fyn locate within the cSMAC 
and the actin binding protein, talin, is found in the pSMAC (Dustin and Cooper, 2000). 
Alterations in the geometry of the IS may assist in initiating TCR signalling pathways. 
Moreover, molecular components of the TCR signalling pathway may be selectively involved
during the formation of the IS, based upon the size of their extracellular domains (Wild et al., 
1999).
Phosphorylation of the ITAM motifs of the TCR complex invariant chains is one of the early 
events in TCR induced signalling. This is carried out by the coordinated activity of members 
of the Src family kinases, Lck and Fyn. These PTKs are associated with the inner leaflet of the 
plasma membrane by amino terminal myristylation and palmitoylation. Lck also interacts 
non-covalently with the CD8 or CD4 coreceptor (Koegl et al., 1994; Turner et al., 1990), 
which brings it in close proximity with its substrates. The event that leads to the activation of 
the PTKs is not known, but the removal of an inhibitory phosphate by CD45, and 
engagement of either their SH2 or SH3 domains induces their activation (Ashwell and D'Oro,
1999). Fully phosphorylated ITAMs allows zeta-chain associated protein of 70KDa (ZAP-70) to 
be recruited to the TCR via binding of its tandem SH2 domains to ITAMs (Chu et al., 1998). 
ZAP-70 is then activated by Lck mediated tyrosine phosphorylation (Chan et al., 1995; 
Neumeister et al., 1995). Once activated, ZAP-70, which belongs to the Syk family of PTKs, 
phosphorylates the scaffold protein, linker of activated T cells (LAT), which allows Grb2 
related adaptor proteins downstream of She (GADS) to bind to LAT's cytoplasmic domain 
(Zhang etal., 2000). GADS is constitutively associated, via a SH3 domain, with SH2 containing 
leukocyte phosphoprotein of 76KDa (SLP-76) (Asada et al., 1999), which is subsequently 
phosphorylated by ZAP-70.
This leads to the recruitment and activation of phospholipase Cyl (PLCyl). PLCyl binds via its 
SH2 domain to phosphorylated motifs present in LAT and SLP-76 (Paz et al., 2001). ZAP-70 
phosphorylates PLCyl leading to its initial activation (Williams et al., 1999), but additional 
phosphorylation is required for full activation of PLCyl. A member of the Tec family of 
tyrosine kinases, inducible T cell kinase (Itk), is responsible for the sustained activation of 
PLCyl. Itk is recruited to the plasma membrane by binding of its PH domain to
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phosphoinositol trisphosphate (PIP3), a product of PI3-Kinase (PI3K), which is activated 
during TCR signalling. Itk also binds via its SH3 and SH2 domains to SLP-76 (Bunnell et al.,
2000) and is therefore placed in close proximity to PLCyl, which is then fully activated. PLCyl 
catalyses the generation of diacylglyceride (DAG) and Inositol 1,4,5 trisphosphate (IP3) by the 
metabolism of phosphatidylinositol bisphosphate (PIP2).
IP3 diffuses into the cytosol and binds to the IP3 receptors on the ER, which triggers the 
release of calcium (Ca2+) into the cytosol from the endoplasmic reticulum (Berridge, 1993). 
The depletion of intracellular Ca2+ stores leads to capacitative Ca2+ entry from the 
extracellular surroundings by the activation of calcium release-activated calcium channels in 
the plasma membrane (Putney and Bird, 1993). Sustained levels of cytosolic Ca2+ leads to the 
indirect activation of the transcription factor, nuclear factor of activated T cells (NFAT) 
(Crabtree and Clipstone, 1994). The binding of Ca2+ to the protein calmodulin allows it to 
associate with the serine/theronine phosphatase, calcineurin. Calcineurin removes 
phosphorylated residues on constitutively expressed NFAT, thereby allowing translocation to 
the nucleus.
DAG diffuses in the plasma membrane and activates the guanosine exchange factor (GEF), 
Ras guanine nucleotide releasing protein (RasGRP), and also PKC-6. RasGRP activates the 
small G protein Ras, by exchanging Ras-bound guanosine-diphosphate (GDP) with 
guanosine-triphosphate (GTP) (Ebinu et al., 1998). Ras can also be activated by another GEF, 
called son of sevenless (SOS), which is recruited to the LAT and SLP-76 scaffold, via Growth 
Factor Receptor Binding Protein 2 (Grb2). Activated Ras then initiates a mitogen-activated 
kinase (MAPK) cascade involving the sequential phosphorylation of Raf, Mitogen-activated 
or extracellular signal-regulated protein kinase (Mek) (Kyriakis et al., 1992) and extracellular 
signal-related kinase (Erk). Activated Erk gains entry to the nucleus where it phosphorylates 
the transcription factor Elk-1. This binds to the serum response element in the promoter of
the gene for the transcription factor c-Fos, which leads to an increase of its gene 
transcription. Dimers form between c-Fos and c-Jun, with the latter being constitutively 
expressed in T cells, and phosphorylated by the MAP kinase, JNK, in order to facilitate its 
translocation to the nucleus. Together, c-Fos and c-Jun form the transcriptional regulator AP- 
1 (Whitmarsh and Davis, 1996).
The association of PKC-0 with DAG at the plasma membrane allows it to phosphorylate the 
scaffold protein, caspase recruitment domain-containing membrane-associated guanylate 
kinase protein-1 (CARMA-1), which then forms a membrane-associated complex involving 
the proteins, Mucosa associated lymphoid tissue lymphoma translocation gene-1 (MALT-1) 
and B cell lymphoma 10 (BcllO). Subsequently, a complex of serine kinases, which are 
collectively termed, IkB kinase (IKK) (Karin and Ben-Neriah, 2000), associate with the 
complex and mediate the activation of the transcription factor, NFkB. In un-stimulated cells 
this transcription factor exists in an inhibited state by its association with, IkB (inhibitor of 
NFkB). Activated IKK phosphorylates IkB, which induces its ubiquitination and degradation. 
This releases NFkB from inhibition allowing it to translocate to the nucleus and to stimulate 
the transcription of its target genes (May and Ghosh, 1998).
The multiple signalling pathways stemming from TCR engagement with cognate 
peptide:MHC complexes converge on the promoter of the IL-2 gene. Moreover, AP-1, NFAT, 
NFkB and constitutively expressed transcription factors bind to regulatory elements of the 
IL-2 gene promoter and induce expression of IL-2 (Fraser et al., 1993), which in turn drives T 
cell proliferation and differentiation.
1.3.2 Costimulatory signalling
In conjunction with signalling through the TCR, signals from accessory molecules, termed 
costimulatory receptors, are required for T cell activation and clonal expansion. The
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costimulatory molecule, CD28, is a homodimeric disulphide linked membrane protein 
constitutively expressed by T cells (Chambers, 2001). It binds to the costimulatory ligands, 
B7.1 and B7.2, which are expressed by activated APCs (Lenschow et al., 1996). When 
engaged by its ligands, CD28 can enhance IL-2 production (Fraser et al., 1993), by firstly 
inducing transcription factors that bind to the promoter of the IL-2 gene and secondly by 
stabilising IL-2 mRNA (figure 1.3).
CD28 is found in the pSMAC of the IS and upon engagement with its ligand becomes tyrosine 
phosphorylated on the motif, YXXM. This allows CD28 to recruit PI3K to the TCR signalling 
complex (Stein et al., 1994), which can activate Akt, and as a result promote IL-2 production 
through activation of MAP kinases (Kane et al., 2001). Furthermore, PI3K may promote T cell 
survival by inducing the synthesis of anti-apoptdtic proteins (Boise et al., 1995). 
Phosphorylation of CD28 on another motif, YXN, leads to the recruitment of Grb2 and thus 
the associated GEF, SOS. This acts to enhance TCR signalling directly by facilitating activation 
of the MAP kinase Erk, leading to enhanced IL-2 production due to the formation of the API 
transcription factor. In addition, CD28 can also release the PTKs, Lck and Itk from inhibition 
by engaging with their SH3 domains, and therefore assisting with the downstream 
production of IL-2.
CD28 is also involved in the reorganisation of the cortical cytoskeleton (Wulfing and Davis, 
1998) and redistribution of lipid rafts (Bi and Altman, 2001), which are both important in the 
formation of the IS and therefore TCR signalling. Actin polymerisation and accumulation of 
filamentous actin at the site of CD28 engagement leads to the polarisation of molecules to 
the IS. Changes in the actin cytoskeleton are attributed to the activity of a Rho family G 
protein, Rac (Martin et al., 1995). Rac is activated by the GEF, Vav (Han et al., 1997), which is 
further activated upon ligation of CD28. In turn, a change in the cytoskeleton drives the 
redistribution of lipid rafts, which allows for the optimal recruitment of PKC-0 (Coudronniere
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et al., 2000). Therefore, the cooperative actions of Vav and PKC-0 lead to the activation of 
NFkB, which can assist with the production of IL-2 (Dienz et al., 2000).
In addition to CD28, other costimulatory molecules, which are expressed by T cells once they 
are activated, provide additional signals that favour T cell activation and proliferation. ICOS 
(Inducuible costimulator), CD27, CD40 ligand (CD40L) and 4-1BB expressed by activated T 
cells bind counter-molecules expressed on activated antigen presenting cells. The binding of 
CD40L and 4-1BB to CD40 and 4-IBBL respectively, provide bi-directional stimulation, with 
both the T cell and APC being stimulated to further enhance T cell activation.
1.3.3 Inhibitory signalling
As well as expressing receptors that have a costimulatory function, T cells also express 
inhibitory receptors that help regulate the immune response. The inhibitory signalling 
pathways are mediated by immunoreceptor tyrosine-based inhibitory motifs (ITIMs), 
present in the cytoplasmic tail of inhibitory receptors. The sequence contains a large 
hydrophobic residue such as isoleucine or valine two residues upstream of a tyrosine 
residue, [S/I/V/L]XYXX[I/V/L] (Burshtyn et al., 1999). When phosphorylated, the motif can 
recruit PTPs and inositol phosphatases, via their SH2 domains. Inositol phosphatases remove 
the phosphate from PIP3 to give PIP2, which abrogates the recruitment of proteins such as 
Tec kinases and Akt to the cell membrane and therefore interrupts the signalling pathways 
these proteins are involved in.
Expression of the CD28-related receptor, CTLA-4 is induced upon T cell activation and binds 
to the same ligands (B7.1 and B7.2) as CD28 present on APCs (Chen, 2004). CTLA4 binds the 
B7 ligands with approximately 20 times more avidity than CD28 and delivers an inhibitory 
signal (Scalapino and Daikh, 2008). It is thought that signalling from CTLA-4 is mediated via 
the recruitment of phosphatases to the phosphorylated ITIMs. The role of PTPs is discussed
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in more detail in following sections. CTLA-4 limits the proliferative response of a T cell by 
limiting IL-2 production by the T cell. PD1 is another inhibitory receptor and contains two 
cytoplasmic ITIMs, and is expressed transiently by activated T cells (Keir et al., 2008). PD1 
can bind two ligands: PD1L, which is constitutively expressed by a range of cells, and PDL2, 
which is expressed by APCs during an inflammatory response. The coordinated expression of 
PD1 on T cells and its ligand on antigen presenting and tissue cells plays an important role in 
maintaining peripheral tolerance (Okazaki et al., 2006).
In addition to the role intracellular signalling pathways disseminated from the TCR play in 
antigenic T cell responses, they are also involved in the maturation of T cells in the thymus.
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Figure 1.3: TCR engagement with peptide MHC class I complexes results in the transcription of genes necessary for T cell activation and proliferation. This process is 
coordinated by the action of enzymes, adaptor proteins and transcription factors (see key). For IL-2 production, the transcription factors NFAT, API and NFkB are all 
required. Signals from the costimulatory receptor, CD28, are also required for the activation of T cells. Following ligation of CD28 with B7 ligands, which are expressed 
by APCs, CD28 is capable of directly recruiting many proteins involved in TCR signalling pathways (shaded areas). CD28 can also aid the TCR signalling cascade by 
promoting the coalescence of lipid rafts, which contain key proteins involved in TCR signalling. See the main text for abbreviations and full description.
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1.4 T cell maturation
The process of T cell maturation that occurs in the thymus shapes the T cell repertoire found 
in the periphery. This shaping involves the removal of T cells that have the potential to be 
self-reactive and is termed central tolerance. Naive T cells that leave the thymus are also 
self-restricted with regards to MHC molecules in addition to being nonreactive to self 
peptides (Zerrahn etal., 1997; Zinkernagel etal., 1978).
Initial interactions with thymic stromal cells signal to the progenitor cells to commit to the T 
cell lineage (Anderson et al., 1996). Following a period of differentiation, the cells undergo 
multiple rounds of division due to stimulation by the homeostatic cytokine, IL-7, which is 
released by thymic cells. At this stage, the immature T cells are termed double negative, as 
they lack expression of either the CD4 or CD8 coreceptors (Kruisbeek, 1993). Double 
negative thymocytes begin to rearrange their TCR 3 chains by somatic recombination. If 
successful, the 3 chain is expressed at the cell surface with a surrogate invariant TCR a chain, 
termed pre-T cell a, thus forming the pre-TCR complex, which also includes the CD3 
complex. Triggering of the CD3:pre-TCR complex promotes cell survival, proliferation and 
TCR a recombination, but it inhibits recombination of the second chain TCR3 locus; a process 
termed allelic exclusion. Failure to rearrange and express either the a or 3 TCR chains at the 
appropriate time leads to cell death, although the a chain can undergo successive attempts 
at rearrangement until the T cell is either positively selected or undergoes apoptosis 
(Marrack and Kappler, 1997).
Surviving cells express both coreceptors and are called double positive thymocytes. The TCR 
on the double positive cells interacts with self peptide:MHC complexes expressed by thymic 
cells and APCs within the thymus (Hogquist et al., 1997). Those thymocytes that interact 
sufficiently with peptide:MHC are positively selected, and depending upon the class of MHC
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molecule the TCR is interacting with, the expression of the opposing coreceptor ceases, and 
a T cell positive for either CD4 or CD8 is produced. An alternative model suggests that 
commitment to the CD4 or CD8 lineage is independent of TCR specificity and occurs prior to 
selection (Itano et al., 1994). The functional potential of the T cell is also defined at the same 
stage as surface phenotype, but the mechanism is not fully understood. Cells that are unable 
to recognise peptide:MHC complexes fail positive selection and undergo apoptosis. In 
conjunction with positive selection, double positive thymocytes are also subject to negative 
selection (Kishimoto and Sprent, 1997). This involves those T cells that react too avidly with 
self peptides:MHC complexes undergoing apoptosis, which therefore prevents them from 
entering the peripheral T cell pool where they could potentially elicit an autoimmune 
response.
Mice that are transgenic for rearranged a and P TCR chain genes, predominately express the 
transgenic TCR at the surface of their T cells. As the transgene does not require any further 
rearrangement, it is expressed earlier than the endogenous TCRP chains. As a result, 
rearrangement of the endogenous p TCR chain is completely inhibited due to allelic 
exclusion (Uematsu et al., 1988). Rearrangement of the endogenous TCR a chain is partially 
inhibited, although there is a preference for the transgenic a and p TCR chains to form a pair.
1.5 T cell immunosurvelllance
1.5.1 Naive CD8* T cell surveillance of lymphoid tissue
Upon leaving the thymus a naive CD8+ T cell enters the cardiovascular system and goes on a 
journey of surveillance for cognate antigen. This involves naive T cell homing to secondary 
lymphoid organs, including peripheral lymph nodes, the spleen and MALT. It is here that 
naive T cells interact with APCs in search of cognate antigen (Wiedle etal., 2001).
Peripheral lymph nodes are organised lymphoid structures that occur at the point of 
convergence between blood and lymphatic vessels. They are serviced by specialised post 
capillary venules, termed high endothelial venules (HEVs) (Girard and Springer, 1995) and 
also afferent lymphatic vessels, which deliver lymph from the periphery. Lymph is created by 
the continual filtration of blood in peripheral tissue and can contain soluble antigens and 
APCs, such as dendritic cells. Overall, lymph nodes provide a specific site where naive CD8+ T 
cells can survey for antigens that may be present in peripheral tissue. In order for a naive 
CD8+ T cell to achieve this scanning it must leave the cardiovascular system and enter the 
parenchyma of a lymph node.
The binding of chemokines and adhesion molecules expressed by high endothelial cells 
(HECs) to counter-receptors expressed by naive CD8+ T cells, mediates the recruitment of 
naive CD8+ T cells to lymph nodes. The entry of naive CD8+ T cells to lymph nodes is a non­
antigen specific process, initiated by the light attachment of the T cell to the HEVs. This 
primary step is mediated by the action of the selectin, L-selectin (CD62L), which binds to 
mucin-like molecules collectively known as vascular addressins (Arbones et al., 1994). L- 
selectin binds to sulphated siayl-lewisx carbohydrate moieties of either CD34 or 
glycosylation-dependent cell adhesion molecule-l(GlyCAM-l). This tethering mediates the 
rolling of the T cell along the surface of the HEVs (figure 1.4). Chemokines that are released
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by HECs, and also from stromal cells of the lymph nodes, bind to the proteoglycan matrix on 
the lumen side of the HEVs. The close physical proximity of a tethered T cell to the HECs, 
allows the extracellular matrix-bound chemokines to bind to T cell expressed chemokine 
receptors (del Pozo et al., 1995). The secondary lymphoid tissue chemokine (SLC), CCL21 
(Gunn et al., 1998), binds to the chemokine receptor, CCR7, which is expressed by naive 
CD8+ T cells. This binding constitutes the second step in T cell homing to lymph nodes as it 
leads to the activation of the integrin, leukocyte functional antigen-1 (LFA-1, aLP2) (Stein et 
al., 2000), which is expressed by naive CD8+ T cells (figure 1.4). The activation of LFA-1 is 
associated with an increase in its affinity for the ligands, intercellular adhesion molecule-1 
(ICAM-1, CD54) and ICAM-2 (CD102). In addition, there is an increase in the lateral 
movement of LFA-1 within the cell membrane, leading to an enhanced avidity of binding 
(Kucik et al., 1996), and therefore firm adhesion of the naive CD8+ T cell to the HEVs. 
Consequently, the naive CD8+ T cell is able to make the final step in the process of homing to 
secondary lymphoid organs, which is the crossing of the HEC barrier, a process termed 
diapedesis (Cinamon et al., 2001a; Cinamon et al., 2001b) (figure 1.4). To achieve this, the 
naive CD8+ T cell produces matrix metalloproteinases that enables it to break through the 
basement membrane on the apical surface of the HEV (Leppert et al., 1995).
Once the naive T cell has fully extravasated and entered the lymph node, CCR7 on the T cell 
mediates chemotaxis from the paracortex to discrete areas known as T zones. CCR7 binds 
the chemoattractant CCL19, which is produced by lymph node stromal and DCs and also 
CCL18, which is produced by DCs (Luther et al., 2002) (figure 1.4). The T cell continues its 
surveillance within the T zones by sampling dendritic cells for cognate antigen. If cognate 
antigen is not detected the naive T cell will pass from the T zone to medullary sinuses and 
then exit the lymph node in the efferent lymph, and re-enter the cardiovascular system via 
the draining of lymph into the thoracic duct (Gowans and Knight, 1964). This process is
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mediated by the lipid, sphingosine-1 phosphate (SIP), which exists as a concentration 
gradient between lymphoid tissue and the cardiovascular system. The T cell expressed 
sphingosine-1 phosphate receptor mediates the chemotaxis of the T cell towards a higher 
concentration of SIP that is present in the blood (Matloubian et al., 2004).
Mucosal surfaces represent a major entry point for pathogens, and are therefore serviced 
extensively by the immune system, which includes gut- (G), nasal- (N) and bronchus- (B) 
associated lymphoid tissues (ALTs). GALT includes the tonsils, intraepithelial lymphocytes, 
isolated lymphoid follicles and Peyer's patches (PPs). PPs are aggregations of lymphoid 
follicles that are found in the ileum of the small intestines. PPs appear as dome-like 
lymphoid clusters located in the lamina propria layer of the mucosa that extend into the sub­
mucosa. They contain a large number of B cell follicles, below which are T cell zones. 
Amongst the enterocytes that overlay the PP are specialised epithelial cells, called microfold 
cells. The microfold cells are able to sample antigen from the intestinal lumen, which they 
pass to APCs within the PPs (Gebert et al., 2000). The process of naive CD8+ T cell homing to 
Peyer's patches follows the same pattern as for peripheral lymph nodes, although L-selectin 
binds to mucosal vascular addressin cellular adhesion molecule-1 (MAdCAM-1) (Berlin et al., 
1993), which is expressed by HEVs of PPs and other mucosal endothelial cells (figure 1.4). T 
cells leave the PPs via efferent lymph vessels and pass through the mesenteric lymph nodes 
before re-rentering the cardiovascular system via the thoracic duct.
The spleen collects antigen from the blood and is therefore involved in the control of blood- 
borne pathogens. CD8+ T cells enter the spleen in the trabecular artery, which branches into 
a central arteriole. This in turn leads to smaller blood vessels that terminate in a specialised 
zone called the perifollicular zone. T cells leave the blood and enter the white pulp of the 
spleen through open blood-filled spaces of the perifollicular zone (Pabst, 1988). Once T cells 
have extravasated and entered the spleen, they reside within the periarteriole lymphoid
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sheath, which is a component of the white pulp. Unlike lymph nodes and PPs the spleen is 
not in direct contact with the lymphatic system, instead T cells leave the spleen via the 
trabecular vein.
The interaction of naive T cells with non-cognate peptide:MHC class I complexes displayed 
by APCs is important for naive T cell survival. In addition, the binding of the homeostatic 
cytokine, IL-7, to its respective receptor on naive CD8+ T cells is also important for their 
survival (Schluns et al., 2000). If a naive T cell encounters its cognate antigen, the process of 
trafficking through lymphoid tissue ceases (Dustin et al., 1997). The T cell then remains in 
the lymphoid tissue and continues to interact with the APC displaying cognate peptide.
1.5.2 Antigen presentation to naive CDSf T cells
Antigen, in the form of peptide bound to MHC class I complexes can potentially be 
presented to naive CD8+ T cells by a number of different cells. By far the most efficient, and 
physiologically relevant APC with regards to CD8+ T cells are conventional DCs, which are 
distinguishable by expression of the integrin, ax^ 2 (CDllc:CD18). DCs may acquire antigenic 
proteins by direct infection with virus, or by the processes of phagocytosis and 
macropinocytosis (discussed earlier). In addition, DCs resident in lymph nodes may acquire 
antigen indirectly, via delivery from Langerhan cells that have migrated from the periphery 
(Carbone et al., 2004). In order for DCs to fulfil their role as an APC, the antigenic peptides 
that they have acquired need to be presented in the correct context to initiate a CD8+ T cell 
response. Signalling pathways ensuing from the engagement of PRRs, inflammatory cytokine 
receptors, and also from the detection of damaged tissue can lead to the activation and 
differentiation of immature DCs. Firstly, DC activation is associated with the expression of 
chemokine receptors, which allow the DCs to migrate to lymph nodes from peripheral sites 
(Lin et al., 1998). Matured DCs arriving from the periphery, and those already present within
a lymphoid organ, will position themselves in T cell zones to maximise their interactions with 
T cells. Matured DCs will also undergo changes that lead to the enhanced efficiency of 
antigen processing, and therefore optimal presentation of antigenic peptides. The matured 
DCs will also express cytokines and costimulatory molecules that ensure the correct stimulus 
is delivered to T cells for their efficient activation. In effect, the activation and differentiation 
of DCs in response to infection and inflammation licenses them to prime naive CD8+ T cells.
Interestingly, antigen recognition in the absence of co-stimulation, in situations that may 
involve the direct priming of T cells by tissue cells, tumour cells or immature DCs (Lutz et al., 
2000; Probst et al., 2005), can render CD8+ T cells anergic or signal for them to undergo 
programmed cell death. This process, known as peripheral tolerance (Teague et al., 2008), 
maintains self-tolerance and therefore may abrogate autoimmune responses from being 
generated in the periphery (Miller et al., 1998). An anergic T cell is unable to produce IL-2 
and therefore cannot promote its own proliferation and differentiation upon encounter with 
antigenic peptide.
As naive T cells survey the DCs present in a secondary lymphoid organ they transiently bind 
with the DCs via pairings between cell adhesion molecules expressed on the T and DCs. 
These include LFA-1 binding with ICAM-1 (Scholer et al., 2008) and -2, CD2 with CD58, and 
ICAM-3 (CD50) with DC-SIGN (CD209), with the latter being exclusive to the interaction 
between naive T cells and DCs. As already discussed, three distinct signals provided by APCs 
are required for the efficient priming of naive CD8+T cells. These signals are those delivered 
through the TCR, costimulatory receptors and cytokine receptors of the naive T cell. As a 
naive T cell crawls over the surface of the DC presenting cognate peptide, its receptors 
engage with their corresponding ligands, which can potentially lead to T cell activation and 
clonal expansion.
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In addition to the signals provided by DCs to CD8+ T cells, those from CD4+ Thl cells can also 
be important for the activity of CD8+ T cells. CD4+ Thl cells can enhance a CD8+ T cell 
response by increasing the costimulatory potential of DCs. CD40L expressed by CD4+ Thl 
cells binds to CD40 on DCs, and as a result enhance the expression of costimulatory molecule 
ligands by the DCs (Hernandez et al., 2007). CD4+ T cells may also contribute to CD8+ T cell 
activation and proliferation, by the production of IL-2. The help provided by CD4+ Thl cell 
may be particularly important when antigen recognised by CD8+ T cells is derived from a 
pathogen or tumour that does not elicit an inflammatory response. In this situation, the 
CD4+ T cells ensure the DCs are activated appropriately in order to prime CD8+ T cells. In light 
of this, when a pathogen causes inflammation sufficient to activate DCs, primary CD8+ T cells 
responses may occur in the absence of CD4+ T cell help; CD8+ T cells can also be activated by 
DCs indirectly in a "bystander effect" (Raue et al., 2004). Activated DCs release IL-12 and IL- 
18, which bind to the respective receptors on CD8+ T cells. Rather than the CD8+ T cells 
becoming CTLs they are activated to release IFNy, which acts in a non-specific manner to 
clear a pathogen or tumour.
During the activation of T cells the surface expression of SIP receptors is downregulated, 
which sequesters the T cells in lymphoid tissue during clonal expansion. After several days of 
clonal expansion, the T cells upregulate the SIP receptor and exit the lymphoid tissue and 
re-enter the cardiovascular system. From here the activated CD8+ T cells migrate to sites of 
infection and inflammation were they can exert their effector function, which is to kill cells 
displaying cognate peptide bound to MHC class I molecules.
1.5.3 Activated CD8+ T cell surveillance of peripheral tissue
Upon activation, the role of a CD8+ T cell changes from one of lymphoid tissue surveillance to 
that of peripheral surveillance, with the ultimate aim being to clear cognate antigen derived
from a pathogen or tumour. Firstly, the T cell is required to detect sites of infection and 
inflamed tissue, and then to enter the tissue in order to screen for cognate antigen on tissue 
cells. The physical process of tethering, rolling and firm adhesion, which was described for 
naive CD8+ T cell homing to lymphoid tissues, also allows activated T cells to adhere to and 
cross endothelium at sites of infection or inflammation (figure 1.5). Activated T cells 
downregulate L-selectin, and are therefore unable to re-enter lymphoid tissue. Instead, 
activated T cells are able to bind P-selectin, by expression of P-selectin glycoprotein ligand-1 
(PSGL-1). P-selectin is constitutively expressed by endothelia at peripheral sites and allows 
activated T cells to migrate to non-inflamed tissues that may harbour target cells. As with 
naive T cell trafficking, the firm adhesion of a T cell on the blood vessel wall is mediated by 
the binding of integrins to ligands on endothelial cells. Increased expression of LFA-1 by 
activated T cells, is mirrored by the increased expression of its ligand, ICAM-1, by activated 
endothelial cells. A second integrin, very late activation antigen-4 (VLA-4), is exclusively 
expressed by activated T cells and binds the ligand, vascular cell adhesion molecules-1 
(VCAM-1) (van Dinther-Janssen et al., 1991), which is expressed by activated endothelial 
cells. The entry of only a limited number of antigen specific CD8+ T cells to an infected tissue 
can induce, and augment an inflammatory response, by the release of TNFa and IFNy. These 
inflammatory mediators operate locally to activate endothelial cells. Consequently, the 
endothelial cells exhibit enhanced expression of VCAM-1 (Wang et al., 2007b) and ICAM-1, 
which in turn enhances T cell recruitment to the area. The activated endothelium also 
undergoes conformational changes that allow easier access to the tissue for innate and 
adaptive immune cells.
Tissue-specific tropisms that are conferred to T cells during their initial priming by DCs come 
into operation during peripheral surveillance. The tropisms ensure that the activated clone 
of T cells homes to the tissue from which the antigen was derived. Activated CD8+ T cells
preferentially migrate to the lamina propria of the gut when primed in the PPs (Mora et al., 
2003). This tropism is mediated by DCs in the PPs under the action of a vitamin A derivative. 
The DCs in PPs express retinal dehydrogenase, which metabolises vitamin A to the reactive 
metabolite, retinoic acid. The DCs of PPs are able to induce the expression of the integrin, 
CX4P7 (Stagg et al., 2002), and the chemokine receptor, CCR9 (Zabel et al., 1999), on the naive 
CD8+ T cells (figure 1.5). These bind MAdCAM-1 and TECK (CCL25) respectively, which are 
expressed by endothelial cells of the small intestine. Similarly, T cells expressing CCR10 
preferentially home to the colon and salivary glands, which express the ligand, CCL28 
(Hieshima eta!., 2003). Once in the epithelial layer of the gut, the T cells may stop expressing 
a4p7, and instead express aE07, which binds E-cadherin on epithelial cells, and may act to 
sequester the T cells at the specific site. Activated T cells that preferentially home to the skin 
express a glycosylated form of PSGL-1, called cutaneous lymphocyte antigen (CLA), which 
binds to E-selectin expressed by cutaneous endothelium. The cutaneous endothelium also 
expresses the chemokine, TARC (CCL17). This binds to the chemokine receptor CCR4 
(Campbell et al., 1999), which is co-expressed with CLA by T cells (figure 1.5). Skin-homing T 
cells maybe further directed to the epidermis by expression of CCL27 by keratinocytes, 
which binds to CCR10 on T cells (Homey et al., 2002). Vitamin D metabolites produced in the 
skin by the action of UVB irradiation can confer skin-homing capabilities to T cells primed in 
the skin, by resident DCs (Sigmundsdottir et al., 2007).
1.5.4 CD8+ T cell effector function
Once an activated CD8+ T cell has extravasated it screens tissue cells through transient, 
antigen non-specific interactions. This is mediated through binding of CD2 and LFA-1, which 
are expressed at higher concentrations by activated versus naive T cells, to their respective 
ligands on tissue cells. In addition to the increased expression of adhesion molecules, 
activated T cells also express an alternative form of CD45, due to the alternate splicing of the
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RNA transcript. CD45RO associates with the CD8 coreceptor (Dornan et al., 2002) and allows 
for more sensitive detection of peptide.MHC class I complexes. Unlike the priming of naive T 
cells, activated T cells do not require costimulation in order to recognise and kill target cells. 
Upon recognition of cognate peptide:MHC class I complexes, the adhesive interactions 
between T cell and target cell are enhanced by an increase in the affinity of LFA-1 for ICAM- 
1. In order for the T cell to effectively kill a target cell, without damaging surrounding cells, 
the T cell undergoes a process of polarisation, which involves reorganisation of the 
cytoskeleton (Ryser et al., 1982) microtubule organisation centre and golgi apparatus 
(Stinchcombe et al., 2001). This ensures that the non-specific effector molecules are 
released from the T cell at the site of contact in a focused and targeted manner. The primary 
mode of killing by CD8+ T cells is attributed to production and release of cytotoxic granules 
from modified lysosomes containing the cytotoxic effector proteins: perforin, granulysin and 
serine proteases called granzymes (Raja et al., 2002). Perforin's main role is to act as a 
translocator of mulitmeric complexes containing the structural proteoglycan, serglycin, and 
granzymes (Metkar et al., 2002). Once in the cytoplasm of a target cell, granzymes trigger a 
caspase mediated proteolytic cascade, by cleavage induced activation of caspase-3. 
Activated caspases then activate caspase activated deoxyribonuclease (CAD), by cleavage of 
an associated inhibitory protein, which can then degrade genomic DNA. In addition, 
granzymes and activated caspase-3 also activate BH3-interacting domain death agonist 
protein (BID), which can then disrupt the mitochondrial outer membrane, leading to the 
release of cytocrome C from the inter-membrane space. The release of cytochrome C 
reinforces the caspase cascade that leads to cell death. Both pathways lead to apoptosis of 
the target cell and in turn its removal by phagocytic cells of the immune system. In addition 
to inducing apoptosis, cytotoxic molecules can also directly inhibit viruses by degrading viral 
DNA and therefore preventing virion formation. Activated T cells also express FasL, which is
35
a member of the TNF family and can induce apoptosis of target cells expressing Fas. Fas is 
also expressed by activated T cells and maybe involved in regulating T cell numbers post 
pathogen clearance (Fuse etal., 1997).
Once a target cell has been eliminated, the CD8+ T cell disengages and can then continue to 
kill other target cells.
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Figure 1.4: Naive T cells home to peripheral lymph nodes (LN), Peyer's patches (PP) and mesenteric (M) LNs in order to screen for cognate antigen. This is achieved by 
the coordinated action of homing molecules and their ligands, which are expressed by naive T cells and endothelial cells of high endothelial venules (HEVs). For naive T cell 
entry in to LNs, the binding of L-selectin to glycosylation dependent (Gly) cellular adhesion molecule-1 (CAM-1) or peripheral node addressin (PNAd)(l) brings the T cell into 
contact with the chemokine, CCL21 (2), which is released by the HEVs and binds to CCR7 on naive T cells. This enhances both the affinity and avidity of binding of 
lymphocyte function associated antigen-1 (LFA-1) for its ligand, Intercellular (I) CAM-1 (2), thereby leading to firm adhesion of the T cell on the HEV wall (3). The T cell is 
then able to cross the endothelial cell barrier and enter the lymphoid tissue parenchyma (4). A subset of T cells express the lymphocyte Peyer's patch adhesion molecule 
(LPAM-1, a437), and the chemokine receptor, CCR9. These bind to mucosal vascular addressin (Mad) CAM-1 and the chemokine, CCL25, respectively, which are both 
expressed by HEVs of PPs. This confers the T cells with preferential homing capabilities to the PPs. Once in a LN, T cells are further directed to T zones, by the release of 
chemokines from lymph node stromal cells (CCL21 and CCL19) and dendritic cells (CCL19 and CCL18) (A). Microfold cells of the PPs sample antigen from the intestinal 
lumen, and pass them on to DCs, which process and present the antigen to surveying T cells (B).
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Figure 1.5: Activated effector (TEFF) and effector memory (TEM) T cells home to sites of inflammation (A). Activated T cells preferentially express P-selectin 
glycoprotein ligand-1 (PSGL-1), the chemokine receptor, CXCR3, and the integrin, very late antigen-4 (VLA-4, cuPi). These bind to P-selectin, chemokines and 
vascular cell adhesion molecule (VCAM-1) respectively, which are expressed by activated endothelial cells of inflamed tissue. These homing molecules mediate the 
entry of T cells (4) in to inflamed tissues, beginning with the tethering of T cells to endothelial cells (1). This allows chemokines to bind to T cell expressed 
chemokine receptors (2), thus inducing T cell integrin activation (2), which leads to firm adhesion between T cells and endothelial cells (3). Once extravasated (4), T 
cells remain in the inflamed tissue if they detect cognate antigen (5). T cells that have been conferred tissue specific homing capabilities during their priming 
preferentially home to either the gut (B) or the skin (C). This is mediated by T cell expressed molecules that pair with tissue specific molecules expressed by 
endothelial cells in a non-inflammatory dependent manner. T cells expressing lymphocyte Peyer's patch activation molecule -1 (LPAM-1, a43?) and the chemokine 
receptor, CCR9, home to the lamina propria of the small intestine. Those T cells expressing cutaneous lymphocyte antigen (CLA) and the chemokine receptor, 
CCR4, preferentially home to the skin. Once in the dermis, T cells are further directed, and also retained, by the binding of CCL27, which is expressed by 
keratinocytes, to CCR10 on T cells. Further abbreviations: lymphocyte function-associated antigen (LFA-1, aLp2), intercellular adhesion molecule-1 (ICAM-1).
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1.6 CD8+ T cell memory
Following the elimination of a pathogen or tumour the associated CD8+ T cell response 
contracts. This is characterised by the apoptosis of antigen-specific T cells (Murali-Krishna et 
al., 1998). Some of the CD8+T cells remain as long-lived antigen-specific memory cells, which 
have the ability to rapidly proliferate and acquire effector function upon antigen re­
encounter (Barber et al., 2003; Wherry et al., 2003). Memory T cells are found at an 
increased frequency in comparison to the naive T cell pool they arose from (Hou et al., 1994; 
Murali-Krishna et al., 1998), and undergo antigen independent self-renewal under the 
influence of the homeostatic cytokines, IL-7, IL-15 and IL-21 (Becker et al., 2002; Goldrath et 
al., 2002; Kaech et al., 2003; Kieper et al., 2002; Schluns et al., 2000; Tan et al., 2002).
The memory T cell pool that forms is heterogeneous in nature but not totally distinct, with 
two predominating subsets classically defined by their surface expression of adhesion 
molecules, tissue location (figure 1.6) and efficiency at exerting effector function (Sallusto et 
al., 1999). CD8+ central memory T (TCm) cells constitutively express CD62L and CCR7 and 
preferentially home to lymphoid tissue (Weninger et al., 2001; Wherry et al., 2003), thus 
guard against systemic antigenic challenge. CD8+ effector memory T (TEm) cells do not 
express the lymphoid homing molecules and reside at peripheral sites, such as the liver, 
lungs and potential sites of infection (Masopust et al., 2001; Weninger et al., 2001; Wherry 
et al., 2003), thereby acting as sentinels for immediate protection against pathogen invasion.
The capability of CD8+ T Em cells to provide relatively immediate cytolytic function has been 
demonstrated (Sallusto et al., 1999; Wherry et al., 2003), although not all studies are in 
agreement (Ravkov et al., 2003; Unsoeld et al., 2002). In comparison to TEM cells, T Cm cells 
exhibit an enhanced capability to proliferate (Roberts et al., 2005; Wherry et al., 2003) and 
secrete IL-2 (Bachmann et al., 2005; Sallusto et al., 1999; Wherry et al., 2003) upon antigen 
re-encounter. Mouse studies have also suggested that a stem cell subset of memory CD8+ T
cells may also exists, which can give rise to all central and effector memory and effector 
CD8+ T cell subsets, but are distinct from naive T cells. Indeed, subsets of memory T cells 
share transcriptional programs of self-renewal with long term haematopoietic stem cells, 
highlighting their capacity for long term protection (Luckey et al., 2006).
Models have proposed that CD8+ T Cm and T Em T cells arise from separate lineages, based on 
the distinct nature of TCR repertoires of each subset found in humans (Baron et al., 2003). 
This model has been challenged by the demonstration that both subsets can be generated 
from a common naive T cell precursor (Bouneaud et al., 2005). Current research suggests 
that CD8+ T cells follow a linear differentiation pathway, with memory T cells forming either 
directly from effector T cells (naive -  effector - TEM -  TCm) (Marzo et al., 2005), or as 
intermediates between naive and effector T cells (naive -  TCm -  TEM -effector). In support of 
the latter model, CD8+ TEM and effector cells exhibit a shortened telomere length in 
comparison to naive and T Cm cells, suggesting they have undergone multiple rounds of 
division, and are therefore further along a linear differentiation pathway. Studies of acute 
and chronic viral infections have also supported the latter model of T cell differentiation 
(Appay et al., 2002). During an acute viral infection CD8+ T cells are successful in clearing the 
virus and a memory pool persists consisting of TCm and TEM cells. In the setting of a chronic 
viral infection, the memory T cell pool is continually exposed to antigen, therefore the T cells 
undergo repeated rounds of clonal expansion and differentiation. The chronic stimulation of 
antigen-specific CD8+ T cells is associated with changes in cell surface phenotype. The 
progressive differentiation is associated with the downregulation of CD62L and CCR7, which 
are associated with CD8+ TCM cells, and results in the predominance of TEM cells residing at 
peripheral tissues.
Along with changes in tissue location, chronically stimulated CD8+ T cells lose functional 
characteristics associated with TCm cells and gain those associated with TEM and effector
cells. Chronically stimulated T cells become replicatively senescent, which is a characteristic 
of CD8+ T Em and effector cells. This is attributed to their inability to respond to homeostatic 
signals from IL-7 and IL-15, as they downregulate the a chain of the IL-7 receptor and the p 
chain of the IL-2/IL-15 receptor (Boutboul et al., 2005; Wherry and Ahmed, 2004). The 
differentiation of T cells during chronic stimulation is also associated with an increased 
unresponsiveness to antigen, as they are unable to divide upon stimulation (Champagne et 
al., 2001; Wherry et al., 2005). This may be attributed to the downregulation of 
costimulatory molecules, such as CD28 (Appay and Rowland-Jones, 2002), and upregulation 
of inhibitory receptors (Barber et al., 2006; Thimme et al., 2005). They also become 
functionally exhausted and exhibit reduced cytolytic potential (Appay et al., 2000; Fuller et 
al., 2004). Additionally, the potential to release IL-2, which is a characteristic of CD8+ TCm 
cells is lost as T cells are chronically stimulated. With ongoing stimulation, highly 
differentiated CD8+ T cells may undergo apoptosis, thus removing them from the memory T 
cell pool.
In a physiological context, such as with HIV infected individuals, chronic stimulation can 
leave CD8+ T cells in an exhausted state, as determined by their surface phenotype and 
inability to both proliferate (Papagno et al., 2004) and control CMV infections (Sacre et al., 
2005). Both murine and non-human primate studies have demonstrated that CD8+ TCm cells 
confer enhanced protection against viral and bacterial challenge, compared to T Em cells 
(Roberts et al., 2005; Vaccari et al., 2005; Wherry et al., 2003). This is regardless of either a 
systemic or peripheral site challenge (Wherry et al., 2003).
The factors determining CD8+ T cell differentiation and the generation of memory T cell 
subsets have not been fully defined. APCs, other immune cells and non-immune cells 
orchestrate the process of CD8+ T cell differentiation via the actions of membrane-bound 
and soluble factors. Signals provided from cytokine receptors can influence lineage
commitment by CD8+ T cells. IL-2 promotes the formation of TEm cells, whereas IL-15 
preferentially generates TCm cells. CD8+ T cells produced in the presence of IL-21 retain the 
ability to secrete IL-2 after antigen exposure and have a stable phenotype characterised by 
CD28 expression (Li et al., 2005; Zeng et al., 2005).
These signals induce epigenetic changes leading to heritable gene expression patterns within 
CD8+ T cells. The epigenetic changes may include DNA methylation, methyl-CpG-binding 
proteins and histone modification (Wilson et al., 2002; Wilson et al., 2005), leading to 
changes in the accessibility of transcription factors that mediate the process of 
differentiation. For CD8+ T cells, the transcription factors, T-bet, and its paralog, 
eomesodermin may play a role in memory cell formation (Intlekofer et al., 2005). 
Furthermore, the process may also require transcriptional repressors, so that the 
differentiation state of memory cells is maintained. The action of the B cell associated, Bcl-6, 
its homologue, Bcl-6b (Ichii et al., 2002; Ichii et al., 2004), isoforms of lymphoid enhancer- 
binding factor 1 (Lef-1), and transcription factor 7 (Tcf7) may be required to arrest 
differentiation of CD8+ memory T cells (Willinger et al., 2006).
The action of CD4+ T cells on the formation and maintenance of CD8+ memory T cells has 
been demonstrated to be of critical importance. Helper CD4+ T cells contribute to CD8+ T cell 
function, persistence and ability to control a secondary challenge by a pathogen (Sun and 
Bevan, 2003). The exact mechanism of CD4+ help to CD8+ T cells has not been fully defined, 
and may occur during the priming of CD8+ T cells (Janssen et al., 2003) and/or during the 
maintenance of a CD8+ T cell pool (Antony et al., 2005; Sun and Bevan, 2003). Interestingly, 
CD8+ T cells primed in the absence of CD4+ T cells undergo death via TRAIL mediated 
signalling upon re-challenge (Janssen et al., 2005). Regulatory CD4+ T cells have been 
demonstrated to negatively influence memory CD8+ T cells in both a quantitative and 
qualitative manner (Murakami et al., 2002; Suvas et al., 2003).
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The ability of the immune system to deal with a pathogen by forming memory cells has been 
of great clinical importance whereby the introduction of various vaccination regimens has 
seen the disappearance of many diseases. With this in mind, the role of the immune system 
in dealing with tumourigenesis could also be of significant importance. In the year 2000,12% 
of the 56 million total deaths worldwide were attributable to cancer (World Health 
Organisation). The World Cancer Report (issued by the International Agency for Research on 
Cancer, which is part of the World Health Organisation) suggests this may increase by as 
much as 50% by the year 2020.
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Figure 1.6: CD8* T cells patrol lymphoid organs and peripheral tissue for cognate antigen
Naive T cells entering the blood from the thymus traffic to secondary lymphoid organs in search of cognate 
antigen. T cells that encounter their cognate antigen, which is displayed by dendritic cells, undergo clonal 
expansion. This involves differentiation into effector (CTL - cytotoxic lymphocytes), central and effector 
memory T cell subsets. Effector T cells migrate to peripheral tissue in order to provide host protection from 
infection or tumour development. Naive T cells that do not encounter antigen receive survival signals thus 
allowing them to continue immune surveillance. Memory T cell subsets disperse to peripheral tissue (effector 
memory) and lymphoid organs (central memory), thereby providing long-term protection from the pathogen 
or tumour that was the source of antigen.
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1.7 Tumour immunology
Six, cell-intrinsic hallmarks of tumourigenesis have been characterised and they include the 
ability of tumour cells to provide their own growth signals, ignore growth-inhibitory signals, 
avoid cell death, replicate without limits, sustain angiogenesis (formation of blood vessels) 
and invade tissue through basement membranes and capillary walls (Hanahan and 
Weinberg, 2000). The existence of cell intrinsic safety mechanisms, such as the DNA-damage 
response (Bartkova et al., 2005), have the potential to inhibit tumourigenesis (Lowe et al.,
2004).
In addition, the immune system also plays a role in preventing tumourigenesis. It has long 
been hypothesised that the immune system in a healthy individual has the capability of 
cancer surveillance, which involves the detection and eradication of tumour cells (figure 1.7). 
Indeed, the escape of tumourigenesis from the immune system constitutes the seventh 
hallmark of cancer (Dunn et al., 2004a, b). Individuals who are immunocomprimised, by 
virtue of genetic, viral or pharmacological factors, have a higher incidence of tumour 
development when compared to their immunocompetent counterparts. Indeed, transplant 
patients on immunosuppressive drugs are predisposed to developing tumours, such as 
melanomas (Hollenbeak et al., 2005; Jensen et al., 1999; Penn, 2000). Whereas melanomas 
have no known viral aetiology, the preferential development of tumours arising from the 
oncogenic actions of pathogens in some immunocomprimised individuals, suggests that the 
role of a healthy immune system in this scenario is acting to control pathogens that have the 
potential to induce malignant conversion. More direct in vivo evidence for tumour 
surveillance in humans comes from colorectal and ovarian cancer patients with data showing 
that the presence of lymphocytes at the site of tumour development correlates with a 
positive prognosis (Chiba et al., 2004; Galon et al., 2006; Pages et al., 2005). In addition, it
has been shown that healthy women possessing antibodies against the tumour-associated 
antigen, MUC-1, have a lower risk of developing ovarian cancer (Cramer et al., 2005).
More extensive evidence for the presence of tumour immunosurveillance has been 
provided by in vivo mouse studies. The generation of inbred congenic mouse strains has 
facilitated such research, as it specifically allows an anti-tumour immune response to be 
studied rather than an immune response due to differences in histocompatability. As a 
result, tumours can be transplanted between congenic mice, and cell lines from defined 
MHC backgrounds can also be used in vivo. Furthermore, genetically modified mice, which 
lack specific cellular or molecular immune elements allows the role of certain immune 
components involved in tumour surveillance to be highlighted. Similarly, the availability of 
monoclonal antibodies that bind to, and inhibit specific immune system components also 
facilitates the research in this field.
Pioneering in vivo tumour studies, which were performed by Ludwig Gross in the mid 
twentieth century, used congenic mice and the chemical carcinogen, methylcholanthrene 
(MCA), to demonstrate that mice are able to reject a transplanted tumour if they had 
previously been exposed to the tumour. These experiments indicated that tumour cells 
could be recognised by the immune system, leading to their targeted elimination.
1.7.1 Tumour antigens
A significant advance in the field of tumour immunology has been the discovery of tumour 
antigens, which allow for the identification and elimination of tumour cells by the immune 
system (Boon etal., 1997; Boon and Old, 1997).
Tumour specific antigens (TSA) are derived from proteins that are unique to the tumour and 
are encoded by mutated cellular genes or viral oncogenes. The mutation of a gene may lead 
to the production of altered peptides from the mutated protein. The mutated peptide may
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still bind MHC class I molecules, but with a slightly different amino acid sequence than the 
wild-type peptide, thereby creating a new epitope for T cell binding. Alternatively, the 
mutated peptide may undergo de novo binding to MHC class I molecules and therefore acts 
as a new antigen for T cell recognition.
Tumour associated antigens (TAA) are expressed by normal cellular genes that have become 
dysregulated during malignant conversion. The resulting antigen is expressed by a tumour 
cell at a concentration, location or time that is abnormal when compared to healthy cells 
and therefore contributes to tumour cell immunogenicity. With regards to T cells, TAAs can 
be broadly categorised into the following groups: normal cellular antigens, differentiation 
antigens, tissue-specific antigens and embryonic antigens (Robbins et al., 1996). Normal 
cellular genes can undergo amplification during malignancy, resulting in a higher level of 
expression by tumour cells when compared to normal cells. The transmembrane tyrosine 
kinase receptor, Her-2, is normally expressed by cardiac tissue but is overexpressed by 
breast cancer cells (Peoples et al., 1995). Differentiation antigens are expressed by a 
particular cell type at a specific time, but also by tumour cells, such as melanoma cell 
expression of proteins involved in melanin production (Kawakami et al., 1995). Tissue- 
specific antigens such as the cancer-testis antigens, which are normally expressed by male 
germ cells alone, are also expressed by tumour cells of unrelated tissue. An example of 
which are the melanoma antigen genes (MAGE) proteins which are normally expressed by 
testicular cells (Chaux et al., 1999a; Chaux et al., 1999b). Cancer-testis antigens can also be 
classed as TSAs, as male germ cells do not express MHC class I molecules. Therefore the 
expression of this type of antigen, by a tumour cell, would be the only way the immune 
system could encounter the antigen. Carcino-embryonic antigen (CEA) is normally expressed 
in the liver, pancreas and intestines of a human foetus but can also be expressed by tumour 
cells found in the colon. TRAs can also be non-peptidic in nature and can therefore be
recognised by other cells of the immune system. The antigens can be carbohydrates and 
lipids, which may be aberrantly produced by the action of a mutated protein. Also, proteins 
that are normally found located within the interior of a cell can be found at the surface of 
the cell as a result of malignant conversion, and may therefore act as antigens for certain cell 
types of the immune system.
1.7.2 The role of the immune system in tumourigenesis
Acute inflammation in response to an invading microbial pathogen plays a pivotal role in 
alerting the immune system to act in an efficient manner to deal with the assault. In a similar 
fashion, it has been proposed that innate and adaptive immune cells are able to detect 
tumour cells and therefore initiate an immune respdnse. The generation and release of 
metabolites, such as uric acid, and potential ligands for toll like receptors, by tumour cells 
may provide the danger signals required by the immune system in order to act. Once the 
immune system had been alerted to the presence of tumour cells, a defining step of the 
response is the production of IFNy. The cellular targets of IFNy include innate and adaptive 
immune cells, and tumour cells, with the latter being rendered more immunogenic as a 
result of exposure to IFNy. IFNy can also inhibit angiogenesis, which is a process involving the 
generation of new blood vessels in order to sustain tumour growth. In both humans and 
mice with malignancies, the lack of IFNy production leaves the host susceptible to tumour 
progression (Shankaran et al.f 2001; Street et al., 2002). Mice lacking expression of either 
IFNy, STAT-1, which is a component of the IFNy signalling pathway, or the IFNy receptor have 
a significantly greater incidence of carcinogen induced, spontaneous and genetically driven 
tumour progression (Lesinski et al., 2003; Mitra-Kaushik et al., 2004).
In vivo studies have implicated innate immune cells in having an important role in tumour 
surveillance. The production of IFNy during an immune response leads to the expression of
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TNF related apoptosis inducing ligand (TRAIL) by NK cells and DCs. TRAIL can induce 
apoptosis of a target cell when it engages with its receptor, TRAIL-R2, which is often 
upregulated in tumour cells in response to DNA damage. Mice that lack TRAIL expression or 
receive a TRAIL neutralising antibody exhibit a higher incidence of MCA induced tumour 
development (Takeda et al., 2002). The in vivo immunostimulatory regimen that uses 
imatinib mesylate (marketed as Gleevec) activates DCs that express TRAIL, resulting in the 
TRAIL-dependent regression of tumours (Chaput et al., 2006).
NK cells are innate cells that are capable of directly killing tumour cells and also producing 
cytokines. Their actions are coordinated by the expression of a variety of activatory and 
inhibitory receptors. NKG2D (Natural-killer group 2, member D) is a lectin-type activating 
receptor that is expressed at the surface of NK cells. Its ligands are MHC-class-l polypeptide 
related sequence A (MICA) and MICB in humans, and retinoic acid early transcript 1 (RAE1) 
and H60 in mice. Such ligands are expressed at the surface of infected, stressed or tumour 
cells. The inhibitory receptors of NK cells, such as KIRs (killer immunoglobulin-like receptors), 
bind MHC class I molecules, which means NK cells are capable of killing tumour cells that 
have downregulated MHC class I molecules. The administration of IL-12, which is a potent 
stimulator of NK and NKT cells leads to a delay and reduction in the appearance of MCA 
induced tumours in mice (Noguchi et al., 1996). In addition, mice treated with anti-asialo- 
GMI (Smyth et al., 2001), which targets NK cells and macrophages have a higher incidence of 
MCA induced tumour development.
More evidence for the role of innate cells in tumour surveillance has come from a single 
BALB/c mouse, which is able to reject aggressive sarcomas during routine production of 
ascites. The resulting strain has been termed "spontaneous regression/complete remission" 
(SR/CR) and investigations have demonstrated that the tumour protection is germline 
transmissible and effective against a number of tumour cell lines (Hicks et al., 2006a). The
protective immunity is also conferred to nude mice by back-crossing them with SR/CR mice, 
suggesting the phenotype is mainly attributable to innate immune cells (Hicks et al., 2006b).
Mice lacking expression of the recombinase activating genes (Rag) 1 and 2 have provided 
evidence for the role of lymphocytes in tumour surveillance, as they are unable to 
somatically re-arrange their antigen receptors and therefore produce lymphocytes (Shinkai 
et al., 1992). These mice have a higher incidence of carcinogen induced tumour formation 
and also spontaneous tumour development as they age. As the lack of Ragl and 2 
expression leads to an absence of a|3 T cells, B cells, NKT cells and y6 T cells, the contributing 
role of each cell type has been the focus of various studies.
Natural killer T cells are innate-like lymphocytes that arte characterised by co-expression of a 
semi-variant a|3TCR together with NK cell associated receptors. The TCRs of NKT cells 
recognise CDld molecules displaying glycolipid or non-peptidic ligands. An activated NKT cell 
can directly kill target cells and also release cytokines such as IFNy. Mice (Ja28'/ ) that lack 
NKT cells have an increased incidence of MCA induced tumour development. Furthermore, 
mice injected with a ligand (a-galactosylceramide) for CDld have a reduced incidence of 
tumour metastasis, mediated by the production of IFNy by NKT cells (Ambrosino et al., 
2008).
A second type of innate-like lymphocytes are the y6 T cells. In humans, y6 T cells make up 
50% of intraepithelial lymphocytes, whereas in mice they make up the total of this 
population. They express both the y6TCR, that recognises non-peptidic ligands, and the NK 
cells associated NKG2D receptor, which is able to recognise the stress proteins, MICA and 
MICB. Once activated, y6 T cells can exert direct cytolytic action and therefore kill target 
cells. Mice that are deficient for y6 (TCR67 ) T cells have a higher incidence of carcinogen 
induced tumour formation (Girardi et al., 2001). Apart from the cytolytic capabilities of y6 T
cells, it has been hypothesised that they may also be an important source of IFNy during the 
initial stages of tumour surveillance. The creation of bone marrow chimeric mice, which 
possess either yfi/IFNy'^ or y6/IFNy+/+T cells, has demonstrated that the presence y6 T cells 
that produce IFNy is important in preventing tumour progression (Gao eta!., 2003b).
Alongside the production of IFNy during an anti-tumour immune response, the cytolytic 
capability of the immune system is also crucial. Mice that are deficient for perforin, which is 
released in cytotoxic granules from CD8+ T cells, NKT, NK and y6 cells, have an increased 
incidence of carcinogen induced and spontaneous tumours (van den Broek et al., 1996). In 
concurrence with this observation, mice specifically lacking a(3 (TCRp7 ) T cells have a higher 
incidence or carcinogen induced tumour formation (Girardi et al., 2003). In further support 
of the role of a|3 T cells in tumour surveillance, mice that have been immunised with 
irradiated tumour cells and depleted of CD8+ T cells are unable to reject subsequent 
transplants of non-irradiated tumours. In humans, the bone marrow of patients with breast 
cancer contains CD8+ T cells specific for peptides derived from breast-cancer-associated 
proteins mucin-1 (MUC1) and Her-2, which can mediate destruction of autologous human 
tumours when transferred to immunodeficient non-obese diabetic mice (Beckhove et al., 
2004). CD8+ T cells also express the activatory receptor, NKG2D, which means they have the 
potential to become activated through interactions with the stress ligands presented by 
many human tumour cells. DNA based tumour vaccines that encode NKG2D ligands elicit 
both NK and CD8+ T cell-mediated anti-tumour immune responses, suggesting a role for 
NKG2D on CD8+ T cells (Zhou et al., 2006; Zhou et al., 2005a). In reality, a tumour-bearing 
host may not possess CD8+ T cells within their T cell pool that can recognise a specific TRA. 
This is due to thymic deletion of CD8+ T cells that have the potential to react to self-antigens 
expressed by tissue cells, and TAAs expressed by tumour cells in the periphery. Tumour 
reactive CD8+ T cells that may exist within a T cell pool are endowed with TCRs of varying
avidity for tumour antigen.MHC class I complexes. Those with low avidity TCRs may remain 
in an antigen ignorant state, due to their inability to respond to antigen, thus making them 
inept at mediating tumour regression. Tumour reactive CD8+ T cells with high avidity TCRs 
have the potential to respond to tumour antigen, but may exist in a chronically stimulated 
state by repeated exposure to the tumour derived antigens. Akin to chronic stimulation of 
anti-viral CD8+ T cells, the continual presence of tumour antigens can impair a CD8+ T cell 
response, by eliciting functional exhaustion and replicative senescence of the responding T 
cells (Anichini et al., 2004; den Boer et al., 2004; Zippelius et al., 2004).
1.7.3 Cancer immunoediting
Tumour surveillance can be viewed as a binary process/which involves either the success or 
failure of the immune system to protect against tumour development. As research has 
progressed, it has become apparent that the interplay between the immune system and 
tumourigenesis is more dynamic, with the immune system having a direct role in shaping 
tumour development. Indeed, the tumour may exist in a state of equilibrium, where it is 
chronically maintained by the immune system in a sub-clinically observed state (figure 1.7). 
In mouse tumour studies, mice that did not develop chemically induced tumours as 
expected, by comparison to those that did in the same experimental group, went onto 
develop tumours once their lymphocytes had been depleted (Koebel et al., 2007). This 
suggests that malignant cells were present within these mice but were kept in check by a 
functional immune system. Moreover, the existence of tumour equilibrium has been 
demonstrated in two organ transplant recipients, both of whom developed metastatic 
melanoma post kidney transplant (MacKie et al., 2003). The kidney donor had been treated 
for metastatic melanoma sixteen years prior to donation, suggesting the melanoma cells had 
been kept in a state of equilibrium within the donor.
The genetic instability of a tumour allows it to evolve in such a way as to escape the 
attention of the immune system, thus advancing from the equilibrium stage to one of escape 
and clinical detection of the tumour (figure 1.7). Indeed, tumour immunogenicity decreases 
under the selective pressure of a fully functional immune system. This was demonstrated by 
studies showing that a greater proportion of tumours transferred from immunodeficient 
mice, than those from immunocompetent mice, were rejected by immunocompetent 
recipient mice (Engel et al., 1997; Svane et al., 1997). A large number of epithelial-cell 
cancers and melanomas are able to evade CD8+ T cell mediated immune rejection by the 
downregulation, or loss of expression, of MHC class I molecules (So et al., 2005). 
Furthermore, tumour cells may also lose expression of molecules involved in antigen 
processing (Atkins et al., 2004a; Atkins et al., 2004b). Tumour cells can also avoid CD8+ T cell 
mediated cytolysis by overexpressing an inhibitor of the granzyme B and perforin mediated 
pathway of target cell lysis (Medema et al., 2001).
In addition to the immune system's inadvertent selection of tumour cells that are non- 
immunogenic, the cell intrinsic characteristics that are involved in the process of 
tumourigenesis (six hallmarks of tumourigenesis) can also act to subvert tumour 
immunosurveillance. Tumour cells produce soluble factors such as IL-4, IL-10 and IL-6, which 
act in an autocrine fashion to directly facilitate tumour growth. These molecules can also 
alter or inhibit an immune response. IL-4 and IL-10 can polarise a CD4+ T cell response from 
Thl to Th2, which is associated with a decline in anti-tumour activity (Stassi et al., 2003).
In order to avoid anti-growth signals, tumour cells are capable of disabling components of 
the TGF3 signalling pathway, therefore allowing escape from the anti-proliferative influences 
of TGF3. They also secrete TGF0, which allows them to inhibit cells of the immune system, 
directly, or indirectly by activating Treg cells (Ghiringhelli et al., 2005a; Ghiringhelli et al., 
2005b). Tregs are capable of suppressing the actions of anti-tumour CD8+ T cells (Antony et
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al., 2005; Sakaguchi, 2005; Turk et al., 2004; Viguier et al., 2004; Woo et al., 2001), and their 
presence at the site of tumour development is associated with poor survival of cancer 
patients (Curiel et al., 2004; Sato et al., 2005). In aim of avoiding apoptosis, tumour cells 
express a number of different molecules that are able to prevent cell death. The expression 
of survivin (Dohi et al., 2004) confers anti-apoptotic properties to the tumour cell, but also 
leads to the upregulation of FasL by the tumour cells. This can directly affect a T cell 
response, as FasL engagement of Fas on T cells can induce T cell death (Asanuma et al., 
2004).
In conjunction with the immunosuppressive nature of molecules produced by tumour cells 
that are vital for tumourigenesis, a tumour can further facilitate its own propagation by 
additional mechanisms. Tumour cells create a tolerogenic environment, by producing 
molecules that prevent the differentiation, maturation and function of DCs, thus rendering 
the T cells they engage with anergic. The tumour environment can also facilitate the 
development and recruitment of immune cells with suppressive capabilities, including 
subsets of NKT cells, macrophages and plasmacytoid DCs (Guiducci eta!., 2005; Terabe et al., 
2004). Plasmocytoid DCs have been shown to induce the clonal expansion of IL-10 producing 
CD8+ regulatory T cells (Wei et al., 2005). Tumour instructed myeloid cells can over produce 
nitric oxide and arginase-1, which can inhibit T cell function (Bronte and Zanovello, 2005). 
Tumour cells can also express, or induce tumour-associated cells to express, indoleamine 
2,3-dioxygenase (IDO). The IDO mediated metabolism of the essential amino acid 
tryptophan, to kyneurines, has a two-fold impact on T cells. Firstly, tryptophan is essential 
for the function of T cells and a reduced availability can impair T cell function (Uyttenhove et 
al., 2003). Secondly, the metabolites of tryptophan are directly toxic to T cells, leading to 
their apoptosis (Terness et al., 2002; Terness et al., 2006).
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In light of these observations, the understanding of the process involving immune system 
and tumour interaction has been broadened to one that encompasses tumour surveillance 
and also tumour equilibrium and escape, which are collectively termed tumour 
immunoediting (summarised in figure 1.7).
Although the presence of inflammation is important for tumour regression, it can in some 
cases assist with tumourigenesis. This tends to be in the situation where inflammation is 
chronic and cytokines are produced in abundance. Plasmacytoid DCs can be recruited to the 
tumour bed by pro-inflammatory mediators such P-defensins, and can contribute to 
angiogenesis (Coukos etal., 2005).
Cancer immunoediting
Cell Intrinsic 
tumour 
suppression
Normal tissue
0 - 0 ° l
f
0 0 51c(
Malignant
transformation
Tumour . .
.. S  Antigen
{  s  i
1) Elimination
Cancer 
immune surveillance
2) Equilibrium
Cancer persistence
Anti-tumour immune 
response
CD4+ T 
cell
y A n t ig e n \  
[presenting] 
\  cells /
CD8+ T
Antigen
3) Escape
Cancer progression
Clinical presentation
Myeloid 
suppressor 
cell
Anti-tumour immune 
response
T G F -p
•  sMICA/B  
Antigen loss 
variants
•  IL-10
IDO
Lack of high avidity tumour specific CD8+ T cells
Figure 1.7: Cancer immunoediting is composed of 3 phases: elimination (1), equilibrium (2) and escape (3). Transformation events, which may lead to malignant conversion 
of normal cells can be reversed by cell intrinsic pathways. Malignant cells can also be effectively detected and removed by cells of the immune system, which is known as 
cancer immunosurveillance. The immune system may also keep the developing tumour in a state of dormancy, where tumour cells and immunity enter into dynamic 
equilibrium that keeps tumour expansion in check. The selective pressure of an immune response and/or the genetic instability of the tumour cells allows the tumour cell to 
escape the attention of the immune system. In addition, tumours cells are able to subvert an anti-tumour response by enlisting regulatory cells and by releasing soluble 
factors that have inhibitory affects on immune cells. This further facilitates the progression of a malignancy, leading to clinical presentation of a tumour. Indolamine 2,3- 
dioxygenase (IDO); MHC class I chain-related antigens A and B (MICA/B); soluble (s).
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1.8 Conventional tumour therapies
Current tumour treatment strategies involve surgery, radiotherapy and chemotherapy to 
tackle a developing tumour, all of which have greatly improved the survival rate of tumour- 
bearing patients. Surgery is often the first mode of treatment, and involves removing the 
primary tumour and often the surrounding tissue and associated lymph nodes. Surgery is not 
permissible when the malignancy is diffuse, as with leukaemias, and when the tumour has 
metastasised to multiple sites throughout the body. In addition, the location of the tumour 
may preclude invasive surgery as the organ in question may be damaged beyond repair. 
Radiotherapy and chemotherapy take advantage of the hyper-proliferative phenotype of 
tumour cells. This enables the tumour cells to be targeted over cells undergoing normal 
rounds of cell division. Despite this preference for rapidly dividing cells, there can be serious 
short and long term side-effects associated with these modes of treatment. It is often 
challenging to administer the required dose of radiation when a tumour is neighboured by 
sensitive tissue. In addition, the hypoxic environment often created within bulky tumours 
renders the action of radiotherapy inefficient. Metabolites from chemotherapeutic drugs 
can accumulate within the body leading to hepatic and nephritic toxicity. Chemotherapeutic 
drugs and radiotherapy can also affect normal, rapidly dividing cells within the body, leading 
to the damage of mucosal tissues and also the suppression of bone marrow cells, with 
associated side-effects such has nausea and infection with opportunistic pathogens. In 
addition, they can also select for tumour cells that are resistant to these modes of 
treatment.
As a consequence of the inefficiencies, lack of complete remission and side-effects 
associated with surgery, radiotherapy and chemotherapy a more specific approach to cancer 
treatment has been sought. The immune system offers a highly specific alternative and
research in the field of tumour immunotherapy strives to develop strategies that harness the 
immune system or its components to mediate tumour protection or regression.
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1.9 Tumour immunotherapy
1.9.1 General approaches
The ability of cytokines to induce and enhance the actions of immune cells has led to the 
development of cytokine based tumour therapies. These involve the systemic transfer of 
purified cytokines to tumour-bearing patients, in order to promote an anti-tumour response. 
IL-2 has the ability to promote the expansion of tumour-specific T cells and counteract the 
effects of immunosuppressive cytokines, yet the treatment of melanoma or renal carcinoma 
patients with IL-2 has only been effective in approximately 10-20% of patients (Dutcher et 
al., 1989; Legha et al., 1996; Rosenberg et al., 1985; Rosenberg et al., 1994). The efficacy of 
such therapies can be hindered by the toxic side-effects of administering high systemic 
concentrations of cytokine that are necessary to induce an anti-tumour response. In 
attempts to overcome this problem, strategies have been developed to deliver cytokines to 
the site of tumour development in a sustainable manner (Veelken et al., 1997). This involves 
the in vitro transfection of irradiated autologous tumour cells with the genes of chosen 
cytokines. Once transferred in vivo the manipulated tumour cells home to the site of primary 
tumour development and secrete the cytokine. Although some clinical success has been 
obtained with such an approach, the generation of cells expressing cytokines can be time- 
consuming, which often delays treatment and allows the tumour to advance.
Despite the lack of productive in vivo B cell responses to tumours, monoclonal antibodies 
based immunotherapies have repeatedly been used to combat tumourigenesis. Monoclonal 
antibodies can be raised against TSAs and TAAs in animals, humanised and used in the clinic. 
Upon binding to a TAA or TSA on the surface of tumour cells the monoclonal antibodies 
induce the destruction of the tumour cell by phagocytic cells or the classical complement 
system. Alternatively, therapeutic monoclonal antibodies work by blocking or sequestering
factors Involved In angiogenesis, tumour cell division or by inhibiting delivery of growth 
signals to the tumour cells. Some monoclonal antibody therapies are based on 
immunoconjugates, which deliver toxins, radioisotopes, enzymes or cytokines to tumour 
cells (Bagshawe et al., 1999a). In the case of immunotoxins and immunradioisotopes, the 
immunoconjugate kills the tumour cells because the toxin or radioisotope is internalised 
following antibody binding to the tumour cell. The premise of antibody directed enzymes is 
to deliver an enzyme to a tumour cell that is capable of converting an inert pro-drug into an 
active cytotoxic drug within the tumour, thereby mediating its demise (Bagshawe et al., 
1999b). Immunocytokines may possess direct anti-tumour properties, or act to promote 
immune cell activity at the site of tumour growth. The efficacy of monoclonal antibody 
application is reliant upon the presence of a tumour antigen that can be bound successfully 
by an antibody, the extent to which antibodies distribute once administered, and the 
expression profile of the target antigen.
Based upon the tremendous impact vaccines have had on diseases with a pathogen 
aetiology, vaccine administration to combat tumourigenesis offers an appealing aim of 
tumour immunotherapy. Ideally, prophylactic vaccine regimens would be routinely used to 
prime individuals in order to prevent tumourigenesis (figure 1.8). To date, the only 
prophylactic vaccines that prevent tumourigenesis are those directed at pathogens that have 
the potential to induce malignant conversion. Routine prophylactic vaccine regimens used in 
some geographic locations that target the hepatitis B virus have been associated with a 
decline in the incidence of hepatocarcinoma (Vildosola, 2000). Similar success has been seen 
in trials involving vaccination against human papilloma virus (HPV), which lead to a 
decreased incidence of pre-cancerous cervical lesions (Garland et al., 2007; Villa et al., 2006). 
Researchers are also striving to develop vaccines against Helicobacter pylori in the aim of 
reducing the incidence of gastric lymphomas and carcinomas (Roggero et al., 1995). The
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development of prophylactic vaccines for tumours with no pathogen aetiology would be 
desirable but has yet to be realised. In contrast to a prophylactic approach, vaccines can also 
be applied in a therapeutic setting to combat pre-existing tumour development within a 
tumour-bearing host.
1.9.2 Therapeutic vaccination involving CD8+ T cells
The definition of MHC complex class I restricted tumour rejection antigens has driven the 
development of CD8+T cell based therapeutic cancer vaccines (Gilboa, 1999), which can be 
active or passive in nature (figure 1.8). The aim of active tumour vaccination is to elicit or 
augment an anti-tumour T cell response within a tumour-bearing host in order to mediate 
tumour regression. Passive vaccination involves the adoptive cell transfer (ACT) of tumour 
reactive T cells, thus conferring anti-tumour immunity to a tumour-bearing host. For both 
approaches, the desired TRA being targeted would be a TSA, thereby removing the 
possibility of autoimmune side-effects. When a TAA is the target of vaccination, any 
potential autoimmunity that arises may be restricted to non-essential tissue or be clinically 
manageable. Furthermore, the relatively lower expression of a TAA by tissue cells in 
comparison to tumour cells, may allow tissue to escape the attention of the antigen-reactive 
T cells (Gao et al., 2003a).
Peptide-based active vaccination involves the transfer of either a peptide or the protein 
from which the antigenic peptide is derived. A consideration when using a whole protein is 
the requirement of in vivo processing by either the standard or immunoproteasome, which if 
absent may preclude the generation of the desired peptide(s). The peptide should also be 
able to bind to HLA molecules within a potential vaccinee, to ensure that it is presented to T 
cells in order to elicit a response. The direct transfer of purified tumour rejection antigens 
has been used in trials involving patients with metastatic melanoma, eosophogeal, colon and
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prostate cancer. Vaccination of melanoma patients with peptides derived from either 
tyrosinase, gplOO, MAGE or MelanA-MART-1 have induced T cell responses in some patients, 
with a proportion of these exhibiting tumour regression (Jaeger et al., 1996). An alternative 
to transferring the tumour rejection antigen alone is to use heat shock proteins (HSPs), DCs 
or cytokines as adjuvants to increase the likelihood of generating an anti-tumour response. 
HSPs can elicit an inflammatory response and also act as chaperones for peptides between 
necrotic cells and APCs, therefore assisting in the process of stimulating T cells. The non­
specific nature of peptide binding to HSP allows both known purified peptides or a mixture 
of peptides from tumour cell lysates to be loaded on to HSPs prior to transfer. Therapeutic 
vaccination using HSPs has been trialled using patients with pancreatic, breast, colorectal 
and gastric cancer. A proportion of patients receiving HSPs exhibited expansion of T cell 
populations and some had favourable clinical outcomes. The superior T cell priming 
capabilities of DCs makes them an ideal adjuvant for tumour vaccination. Their ex-vivo 
activation may also overcome the lack of in vivo inflammatory signals that can leave 
endogenous DCs in an immature state. The source of peptides to load DCs may be tumour 
cell lysates, native peptides or peptides released from MHC class I molecules of tumour cells 
by acid treatment. Alternatively, researchers have introduced the DNA or RNA of known TRA 
to DCs, which is then expressed and processed by the DC. Melanoma patients receiving in 
vitro matured DCs that had been loaded with known melanoma peptides induced strong T 
cell expansion, but negligible tumour regression. Similar observations have been made in 
trials involving patients with breast, ovarian, colon, small cell lung and prostate cancer. More 
success has been gained when active vaccination with TAAs was used as an adjunct to the 
surgical removal of a primary tumour and its metastases. Stage II melanoma patients 
receiving a post-operative vaccine (called Canvaxin) prepared from irradiated allogeneic
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melanoma cells, had an improved long term prognosis compared to patients that did not 
receive the vaccine (Morton, 2004; Morton et al., 2002).
Unfortunately, the collective outcome of trials involving active vaccination for tumours have 
so far been disappointing, with objective response rates of only 5% or less according to 
response evaluation criteria in solid tumours (RECIST) (Rosenberg et al., 2004; Therasse et 
al., 2000).
The inefficiencies of active vaccination in mediating tumour regression have been attributed 
to many factors, including the lack of inflammatory signals and the absence of T cells in the 
periphery that can respond to a given tumour rejection antigen. Furthermore, if tumour 
specific T cells exist in a tumour-bearing host they may be present at low frequencies or 
possess low avidity TCRs, due to thymic selection (section 1.4). These factors may prevent an 
effective anti-tumour T cell response from being stimulated upon vaccination. In attempts to 
induce a response from low avidity T cells, repetitive administration of a vaccine has often 
been applied. However, this may act to further preclude an effective anti-tumour response, 
as the repetitive stimulation of the T cells promotes their differentiation to the point of 
exhaustion (Powell and Rosenberg, 2004). When high avidity T cells are present, repetitive 
vaccine administration may lead to their activation-induced apoptosis, as they are present in 
an already chronically stimulated state (Anichini et al., 2004; Dutoit et al., 2002). Overall, the 
use of an active vaccination to stimulate T cells may only act to exacerbate a pre-existing 
defunct anti-tumour T cell response of a tumour-bearing host. Furthermore, when a robust T 
cell response has been induced by a vaccine regimen it then faces other hurdles, which may 
avert tumour regression. These include peripheral tolerance and tumour-mediated 
regulatory mechanisms that suppress anti-tumour T cell responses (as discussed above). 
Indeed, the generation of large numbers of T cells alone, is not sufficient to consistently
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induce objective clinical responses (Ayyoub et al., 2003; Rosenberg et al., 2005; Rosenberg et 
al., 2003; Rosenberg eta!., 1998; Smith etal., 2003; Speiser etal., 2005).
In attempts to overcome the hurdles associated with therapeutic active vaccination, 
alternative T cell immunotherapy strategies have been sought. One approach with great 
potential is passive vaccination, which involves adoptive cell transfer (ACT). The premise of 
such an approach involving T cells is the ex-vivo generation of large numbers of T cells with 
appropriate specificity and avidity to mediate tumour regression upon re-introduction to the 
tumour-bearing host (figure 1.8).
In combination with the identification of a wide range of tumour antigens (Gilboa, 1999), the 
improvement of cell culture and isolation technology (Jotereau et al., 1991) has facilitated 
ACT approaches involving T cells. Various selection techniques have been applied in order to 
isolate autologous antigen-specific T cells from tumour-bearing patients. Patient PBMC can 
be stimulated with APCs displaying TRA(s), thus stimulating antigen specific T cells to 
expand. Alternatively, T cells can be expanded non-specifically by the use of CD3 and CD28 
antibodies. The ex-vivo generation of tumour-reactive T cells is often supported by their 
supplementation with T cell growth cytokines, such as IL-2. The resulting T cell clones or lines 
are quality tested, for parameters such as sterility and cytotoxicity before in vivo application. 
The process of acquiring activated T cells for ACT can be enhanced by priming the tumour- 
bearing patient with a vaccine prior to T cell harvest, thereby increasing the frequency of the 
antigen specific T cells (Chang et al., 1997; Li et al., 1999; Shu et al., 1989).
Multiple clinical trials have been performed to establish the efficacy of using adoptively 
transferred T cells to combat malignancies. The adoptive transfer of antigen-specific T cells 
has been successful in both preventing and treating malignancies with a viral component. 
More specifically, the transfer of Epstein Barr virus (EBV) specific allogeneic or autologous
PBMC or T cell lines has proven efficacious for the prevention and treatment of EBV-induced 
diseases. These malignancies can develop in patients who are immunosuppressed due to 
bone marrow or organ transplantation and included EBV-induced lymphoproliferative 
disease (Comoli et al., 2002; Heslop et al., 1994; Heslop and Rooney, 1997; Khanna et al., 
1999; O'Reilly et al., 1997; Rooney et al., 1995; Rooney et al., 1998), Nasopharyngeal 
carcinoma (Chua et al., 2001; Comoli et al., 2004; Straathof et al., 2005) and Hodgkin's 
disease (Bollard et al., 2004; Laport et al., 2003; Lucas et al., 2004; Roskrow et al., 1998). To 
build on these successes, multiple trials have been performed involving the targeting of 
tumours with no known viral aetiology, namely metastatic melanoma (see below), renal cell 
carcinoma (Thompson etal., 2003), breast (Visonneau etal., 2000) and prostate cancer (Ross 
et al., 1993).
In one such trial, CD8+ T cells specific for MelanA-MART-1 were purified from the PBMC of 
patients with metastatic melanoma, expanded ex-vivo in the presence of IL-2 and 
transferred back to patients. Eight out of twenty patients exhibited either minor, mixed or 
stable anti-tumour responses (Yee et al., 2002). The T cells were encouragingly detected at 
the site of the tumour development, but there was a selective outgrowth of tumours lacking 
expression of MelanA-MART-1 (Yee et al., 2000). Similarly, in another trial utilising T cells 
specific for one tumour antigen, the T cells engrafted successfully, but disappointingly 
selected for tumours that did not express the antigen (Mackensen et al., 2006). These 
studies highlight the caveat of transferring monoclonal tumour specific CD8+ T cells, in that 
tumour cells that either don't express the antigen, or evolve under the selective pressure of 
the T cells to not express the antigen, are left unchecked and continue to develop (Marincola 
et al., 2000; Norell et al., 2006).
A second approach of ACT has been to utilise CD8+ T cells of tumour infiltrating lymphocytes 
(TILs), which are purified from tumour biopsy specimens. The cells are expanded ex-vivo
with antibody and cytokines prior to infusion back to the tumour-bearing patient. This differs 
to using one clone of CD8+ T cells as the T cell population in this context is most likely to be 
polyclonal for the antigens expressed by the tumour from which they were purified. In pre- 
clinical mouse models, this approach has proved to be successful (Alexander and Rosenberg, 
1990) but in contrast, human clinical trials involving the transfer of TILs to patients with 
metastatic melanoma have proven to be unsuccessful in reaching objective clinical 
responses (Dreno et al., 2002; Figlin et al., 1999; Rosenberg et al., 2004). It was established 
that the TILs used in these trials did not persist for extended periods of time once 
transferred in vivo, and as a result, the T cell responses were only transient in nature.
In attempts to improve the clinical outcome of ACT> trials involving TILs, patients with 
metastatic melanoma were conditioned prior to the transfer of the expanded lymphocyte 
population. The conditioning step involved using the chemotherapeutic drugs, 
cyclophosphamide and fludarabine, which are immunosuppressive by inducing 
lymphopaenia, but do not have any direct anti-melanoma activity. Promisingly, as a result of 
this conditioning regimen, six out of thirteen patients in one clinical trial had partial 
responses, and a further two had mixed responses, which overall represents a 50% objective 
response (Dudley et al., 2002a; Dudley et al., 2005) (figure 1.8). Incidentally, the patients in 
this trial had already undergone episodes of conventional cancer therapy and also received 
IL-2 during TIL treatment. The conditioning regimen may augment the anti-tumour efficacy 
of TIL therapy by removing Tregs, cytokine sinks and/or improving the immunogenicity of 
the tumours (Berd and Mastrangelo, 1987a, b; Pages et al., 2005; Sato et al., 2005), thereby 
allowing the cells to function optimally and mediate tumour regression (Rapoport et al., 
2005; Wrzesinski and Restifo, 2005). Indeed, the T cells in this trial exhibited long term 
engraftment when compared to patients that had not received the chemotherapeutic drugs.
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In addition to the lymphodepletion of a tumour-bearing patient prior to T cell transfer, other 
components may be included as part of an ACT strategy in order to enhance an anti-tumour 
T cell response. These may include cytokine adjuvants (Cheever et al., 1982; Ku et al., 2000) 
and the administration of antibodies to either block inhibitory signals (Barber et al., 2006; 
Kim et al., 2001) or to enhance costimulatory signals to T cells (Sutmuller et al., 2001). In vivo 
mouse studies have demonstrated that the combination of lymphopenia, T cell transfer and 
administration of an altered peptide vaccine can enhance an anti-tumour response (Wang et 
al., 2005). During ACT immunotherapy, the co-transfer of CD4+ T cells has been responsible 
for the long term maintenance of CD8+ T cells (Wang et al., 2007a). An alternative approach 
to co-transferring tumour reactive CD4+ T cells would be to administer helper CD4+ T cell 
associated cytokines, such as IL-2, IL-7, IL-15 and IL-21 (Blattman et al., 2003; Klebanoff et 
al., 2004; Melchionda et al., 2005; Zeng et al., 2005). Current constraints that may preclude 
the efficacy of using TILs as a standard therapy include their acquisition, which is not always 
feasible as dictated by the cancer type, and the time it takes to generate sufficient numbers 
to infuse back to the patient (Dudley et al., 2003).
A common theme gleaned from clinical trials involving ACT of TILs or CD8+ T cells to combat 
tumour development has been the importance of the differentiation state of the CD8+T cells 
that are transferred. In clinical trials using adoptively transferred CD8+ T cells to treat 
metastatic melanoma, it is evident that the multiple rounds of ex-vivo stimulation result in 
CD8+ T cells that are unable to persist and therefore mediate tumour regression. The cells 
have a phenotype of more differentiated late effector T cells, akin to chronically stimulated T 
cells (Dudley et al., 2002b; Yee et al., 2002). In support of this, the repeated stimulation of 
mouse MHC class I restricted T cells (Overwijk et al., 2003) in an in vitro setting has been 
associated with a step-wise impairment of effector function and proliferative capacity, thus 
abrogating an effective anti-tumour response when transferred in vivo (den Boer et al.,
2004; Gattinoni et al., 2005; Sussman et al., 2004). It has been demonstrated that CD8+ T 
cells that are able to undergo repeated rounds of proliferation in vivo provide superior anti­
tumour properties (Dudley et al., 2002a; Gattinoni et al., 2005; Klebanoff et al., 2005). In 
addition, telomere length positively correlates with long term persistence of tumour reactive 
adoptively transferred CD8+ T cells, and as a result, tumour regression (Robbins et al., 2004; 
Zhou et al., 2005b). Overall, the transfer of tumour-reactive CD8+ TCm cells is found to be 
therapeutically superior in combating an established tumour, compared to CD8+ T Em cells 
(Klebanoff et al., 2005). The CD8+ Tcm cells have a greater proliferative capacity and ability to 
interact with antigen presenting cells than CD8+ T Em cells, which contributes to tumour 
regression.
Human clinical trials and mouse models have highlighted areas that need to be addressed in 
order to achieve objective clinical responses during ACT immunotherapy using CD8+ T cells. 
In addition to the pre-conditioning of tumour-bearing patients, the ability to acquire and 
generate tumour-reactive CD8+ T cells is of importance. The CD8+ T cells used for therapy 
need to be of the correct specificity, possess sufficiently avid TCRs and be at the optimal 
state of differentiation. Furthermore, CD4+ T cell help (or the associated cytokines) and 
polyclonal populations of CD8+ T cells may also improve the outcome of ACT therapies. 
These improvements may be facilitated by the development of T cell gene modification 
technologies and may allow for the production of tumour reactive CD8+ T cells that meet the 
desired criteria.
1.9.3 Genetic modification of CD8+ T cells for use in ACT immunotherapy
The genetic modification of T cells used in ACT strategies provides scope to further improve 
the clinical outcome of such therapies. The use of recombinant retrovirus to genetically 
modify T cells has proved to be effective in the treatment of patients with congenital and
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acquired immunodeficiency (Blaese et al., 1995; Mitsuyasu et al., 2000). The modified T cells 
have persisted for considerable lengths of time, thus demonstrating the feasibility of using 
such an approach to combat cancer. Disappointingly, retroviral insertional mutagenesis has 
led to malignancies in some circumstances (Hacein-Bey-Abina et al., 2003). The preferential 
use of lentiviruses over more traditionally used retroviruses may preclude such problems 
when engineering T cells. In comparative studies, lentiviral vectors have been shown to be 
less prone to insertional mutagenesis than retroviral vector counterparts (Montini et al.,
2006). Furthermore, HIV infected individuals do not have an increased incidence of T cell 
leukaemia, which further indicates lentiviral vectors are possibly safer than retroviral ones.
The genetic engineering of T cells may overcome the limitations associated with a pre­
existing T cell repertoire of a tumour-bearing patient, including the absence of CD8+ T cells 
with the required TCR specificity and avidity for antigen clearance. Furthermore, the type of 
tumour may preclude the physical acquisition of CD8+ T cells. Therefore, the ex-vivo 
generation of T cells with required tumour antigen specificity and avidity is a desired aim of 
ACT therapies.
One approach has been to introduce chimeric antigen receptors (CARs), termed T-bodies, to 
CD8+ T cells. Early T-bodies consisted of an external antibody-based domain, that confers 
specificity and the cytosolic domains containing the signal transduction components of the 
TCR (Ciceri et al., 2007). This endows a T cell with antigen specificity in a non-MHC class I 
molecule dependent manner, which may be of benefit when a tumour has evolved to not 
express MHC class I molecules. Indeed T cells possessing T-bodies have proven efficient in 
mediating tumour rejection in mouse models (Kershaw et al., 1996a; Kershaw et al., 1996b). 
New generation T-bodies also contain costimulatory molecule signalling domains (Loskog et 
al., 2006) in order to enhance T cell expansion in response to antigen (Krause et al., 1998). In 
a clinical setting, this approach seems safe, but requires further optimisation with regards to
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the persistence of the transferred T cells (Kershaw et al., 2006; Lamers et al., 2006; Park et 
al., 2007), expression of the transgene, the correct avidity of the T body to allow serial killing 
of target cells and the identification of suitable antigens expressed at the surface of tumour 
cells.
CD8+ T cells have also been engineered to express the a and |3 chains of TCRs with known 
avidity and antigen specificity. Clinical trials have been performed using adoptively 
transferred CD8+ T cells expressing a transgene encoding a TCR recognising the melanoma 
associated gplOO antigen. Patients were also lymphodepleted and given an infusion IL-2 
alongside the transferred T cells (Morgan et al., 2006). The T cells persisted in vivo, trafficked 
to the site of tumour development and mediated tumour regression in some patients. 
Potential side-effects of TCR gene transfer could include autoimmunity by three different 
mechanisms. Firstly, the possibility of novel TCR combinations encompassing the transgenic 
and endogenous a and |3 chains could generate mixed TCR dimers with new specificities. 
Secondly, triggering through the exogenous TCR could allow a normally antigen-ignorant 
endogenous TCR to become auto-reactive, due to the activated status of the T cell. Finally, if 
the TCR gene is derived from a donor that is not MHC-matched with the recipient it could 
lead to reactivity towards allogeneic MHC molecules. The development of strategies that 
could suppress endogenous TCR expression or ensure that the exogenous TCR chains 
preferentially pair could potentially eliminate these autoimmune concerns. Alternatively, the 
introduction of suicide genes, such as the herpes simplex virus thymidine kinase, could allow 
selective destruction of auto-reactive transferred T cells by administering gancyclovir (Bonini 
et al., 1997).
In addition to conferring specificity and avidity to CD8+ T cells, genetic manipulation may also 
assist with improving the function of CD8+ T cells used in ACT immunotherapy. Efforts have 
been made to improve T cell expansion by the introduction of constitutively expressed CD28
(Topp et al., 2003) or chimeric GM-CSF-IL-2 receptors (Evans et al., 1999), thereby enhancing 
the production and signals provided by IL-2. The long term In vivo persistence of transferred 
T cells has correlated with improved clinical responses. With this in mind, the survival of T 
cells has been improved in vitro by the introduction of the catalytic subunit of telomerase 
(Rufer et al., 2001) or Bcl-2 (Lin and Wang, 2002).
The introduction of chemokine receptors to T cells has the potential to target their effector 
function to sites of malignancy. The chemokine receptor CXCR4 may be useful to target CTL 
to bone marrow for treating leukaemia or tumour metastases of the bone (Peled et al.,
1999). T cell function can also be improved by protecting the T cells from extrinsic inhibitory 
influences, such as that imposed by the cytokine, TGF0. The introduction of a dominant 
negative TGF|3 receptor to T cells enhanced their tumour reactive activity in vitro, when 
compared to unmodified counterparts (Bollard et al., 2002). Similarly, the removal of 
intrinsic inhibitory factors may also help improve T cell function. One such candidate is 
Casitas B cell lymphoma (Cbl-b), which is a member of the mammalian Cbl E3 ubiquitin 
ligases (Thien and Langdon, 2001). Mice lacking Cbl-b expression developed fewer UVB 
induced skin malignancies and rejected transplanted tumours (Loeser et al., 2007). The 
adoptive transfer of Cbl-b^' T cells conferred tumour protection to the recipient mice. The 
enhanced anti-tumour activity may be attributed to their resistance to Treg suppression, 
enhanced expansion, formation of an increased memory T cell pool and rapid tumour 
infiltration (Loeser et al., 2007).
The transfer of genes encoding particular proteins that enhance T cell activity is one way to 
improve ACT therapies. A different approach is required when the action of a protein needs 
to be removed in order to achieve the same end. Pharmacological inhibitors of specific 
proteins may provide one such avenue but this relies on the development of specific drugs
for each protein concerned. One technology that has wider applications, and could 
potentially be used for any protein with a known DNA sequence, is RNA interference (RNAi).
Therapeutic tumour vaccinationProphylactic tumour vaccination
Tumour bearing hostNo tumour present
ActiveAim: to elicit protective immunity 
against an antigen.
Aim: to boost or elicit an anti-Endogenous T
Transfer of tumour 
rejection antigen.
Transfer of pathogen or 
tumour derived antigen. Anti-tumour 
memory T cell 
pool
HSPs, DCs, modified tumour 
cells and cytokines are used 
as adjuvants.
Transferred T cell 
response
t
expansion of tumour 
reactive T cells.
T cell modification
Infusion back to tumour 
bearing host.
Introduction of tumour 
specific TCR genes.
Figure 1.8: Tumour immunotherapy approaches
Both prophylactic and active therapeutic vaccination approaches aim to activate T cells within the host, 
thereby providing anti-tumour immunity. Prophylactic approaches often target pathogens that have the 
potential to aid malignant conversion. Passive vaccination approaches do not alter cells within the tumour- 
bearing host, but involve the adoptive transfer o f tumour reactive T cells. The T cells are obtained from a 
tumour-bearing host and cultured in vitro prior to their reintroduction. This allows the cells to be expanded to 
sufficient numbers and tested for tum our antigen reactivity. It has been found that depleting the host of 
endogenous lymphocytes, prior to T cell transfer, greatly improves the efficacy of this type of immunotherapy.
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1.10 RNA interference
Since its discovery in plants (Hamilton and Baulcombe, 1999) and formal description in the 
nematode, Caenorhabditis elegans (Fire et al., 1991; Fire et al., 1998), RNA interference 
(RNAi) has been used as a standard methodology for silencing the of expression of specific 
mammalian genes. RNAi involves the processing of double-stranded RNA (dsRNA), which is 
subsequently used as template by the RNAi pathway to post-transcriptionally silence gene 
expression (Elbashir et al., 2001a; Elbashir et al., 2001b).
The processing of dsRNA into shorter double-stranded siRNA (typically 19-25 nucleotides) is 
performed by the ribonuclease, Dicer (figure 1.9). Each strand of the resulting siRNA has a 3 
prime hydroxyl group and a 5 prime phosphate group (Vermeulen et al., 2005; Zamore et al.,
2000). The short siRNA are subsequently unwound and incorporated into the multi-protein 
silencing complex, termed RNA-induced silencing complex (RISC). Only one of the strands of 
the siRNA is used as a template to guide mRNA recognition, whilst the second strand is 
degraded (Rand et al., 2005). This selection is partially mediated by the RISC associated 
RNase, argonaute (Preall et al., 2006). Argonaute uses the single stranded RNA as a template 
for targeting complementary mRNA sequences for degradation (figure 1.9).
A significant hurdle to overcome during the development of siRNA technologies for 
mammalian application has been how to introduce dsRNA without provoking an anti-viral 
response (Williams and Haque, 1997). An anti-viral response of a cell involves the binding of 
the enzyme, dsRNA-dependent protein kinase (PKR) to dsRNA, which leads to wide-spread 
RNAi, in a sequence-independent manner. It was later discovered that the introduction of 
short dsRNA, of less than 30bp, could initiate the sequence-specific RNAi pathway but avoid 
an anti-viral response (Elbashir et al., 2001b). A number of standard transfection 
mechanisms can be used to introduce dsRNA to cells. The efficiency of transfection, the
74
potency of the siRNA sequence and the amount an individual cell receives ail have an impact 
of the overall efficacy of a siRNA approach. A second approach to introducing dsRNA to cells 
has been to introduce DNA that encodes short hairpin RNAs (shRNA). They can be 
introduced to cells as DNA vectors by standard transfection techniques, to give transient or 
stable expression, and also by viruses. The DNA encodes for the sense and antisense strands 
of the dsRNA separated by a short nucleotide sequence, termed a spacer. The expression of 
the RNA can be driven by constitutive or inducible promoter systems (Paddison et al., 2004). 
Once expressed the complementary RNA sequences pair and form dsRNA, with a hairpin of 
unpaired nucleotides at one end. The shRNA is then processed by Dicer to form siRNA, which 
is incorporated into the RISC complex.
The effectiveness of a siRNA or shRNA sequence is based upon the siRNA structure and 
determined at the point of RISC assembly. Many algorithms are now available for choosing 
effective sequences for a given gene. The algorithms apply thermodynamic criteria, which 
can identify sequences that facilitate the incorporation of the antisense strand of the siRNA 
into RISC. These criteria were based on studies showing that there is an unequal 
incorporation of the siRNA sequence into RISC (Khvorova et al., 2003; Reynolds et al., 2004; 
Schwarz et al., 2003; Silva et al., 2003). The algorithms also allow sequences that may have 
off-target effects to be excluded. With the availability of siRNA technologies it may be 
feasible to target negative regulators of T cell signalling pathways. One other candidate for 
such modality is the PTP known as Src homology 2 domain containing PTP-1 (SHP-1).
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Figure 1.9: The basis of siRNA mediated regulation of gene expression using lentiviral particles 
containing shRNA sequences
Lentiviral particles can be produced that contain the shRNA sequence for specific downregulation of a 
chosen protein. Following integration the shRNA is produced and exported from the nucleus into the 
cytoplasm. The hairpin of the shRNA is cleaved by the enzyme, DICER, thereby yielding a siRNA sequence. 
The siRNA is then incorporated into RISC, which firstly unwinds the RNA duplex and secondly retains one 
stand to use as a template to  recognise corresponding mRNA transcripts for cleavage. The mRNA 
fragments are degraded by normal cellular machinery, thus leading to  the loss of translation and 
therefore protein function.
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1.11 Protein tyrosine phosphatases
The activation of T cells in response to antigen is dependent upon the PTK mediated 
phosphorylation of tyrosine residues. Factors that affect the net level of tyrosine 
phosphorylation can be predicted to have an influence on the outcome of TCR engagement 
with its ligand. PTPs remove the phosphate group from tyrosine residues and therefore 
effect tyrosine based signalling (Fischer et al., 1991).
The family of protein phosphatases or the phosphatasome, includes 38 classical tyrosine- 
specific PTPs, 22 of which are expressed in lymphoid and myeloid immune cells and are 
conserved between humans and mice. Many PTPs were identified by reverse genetics, 
whereby the conserved hallmark residues in the PTP domain facilitated the isolation of 
cDNAs encoding the enzymes. The family can be further classified into 17 intracellular and 
21 transmembrane members (Alonso et al., 2004; Li and Dixon, 2000). Typically, PTPs have a 
single functional catalytic domain, of approximately 240 amino acids, with the characteristic 
motif, l/VHCXXGXXRS/T (Dixon, 1995). In addition to their intracellular PTP domain, the 
transmembrane PTPs also contain extracellular immunoglobulin, fibronectin, meprin/A5 
antigen/PTPp (MAM) and carbonic anhydrase domains (Alonso et al., 2004). The intracellular 
PTPs possess motif(s) and domain(s) that mediate protein-protein and protein-phospholipid 
interactions. The intracellular PTPs can be further classified based on the possession of 
distinct non-catalytic domains. SHP-1 and SHP-2, which share 60% overall homology, belong 
to the same sub-family of PTPs as they possess SH2 domains.
The crystal structures of PTP1B, SHP-1, SHP-2 and a PTP, YopH from the bacterium Yersinia 
have revealed a common mechanism of catalysis by PTPs. Catalysis proceeds via two steps 
(Barford et al., 1994a; Hof et al., 1998; Stuckey et al., 1994; Yang et al., 1998); the first being 
the formation of an enzyme-substrate complex (Denu et al., 1996), involving the transfer of
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the phosphate to the enzyme and thus a dephosphorylated substrate; the second step 
involves hydrolysis of the enzyme thio-phosphate intermediate to yield the enzyme and 
released phosphate (Denu et al., 1996). The archetypal PTP, PTP1B, accommodates the pY 
substrate in a catalytic binding pocket at the base of which lies an active site cysteine 
(Barford et al., 1994a; Barford et al., 1994b). Approximately 30-40 residues distal to the 
active site cysteine is an aspartate residue involved in catalysis and moved into position as a 
result of substrate binding (Denu et al., 1996). Hydrogen bonds are formed between the 
oxygens of the phosphoryl group, and the guanidium group of the active site arginine, and 
the backbone amide N-H groups of the active site loop. The thiolate anion of the active site 
cysteine mediates the nucleophillic attack of the P-0 bond of the substrate, leading to the 
formation of a phosphoryl-cysteine enzyme intermediate and a dephosphorylated substrate 
(Denu et al., 1996). The aspartate may function as a general base in this instance, by 
extracting a proton from a water molecule thus allowing hydrolysis of the phosphoenzyme 
by the hydroxyl group, and therefore completing the reaction by release of a phosphate and 
rejuvenated enzyme (Li and Dixon, 2000).
1.11.1 5HP-1 (also known as SHP, SH-PTP-1, PTP1C and HCP)
SHP-1 is an intracellular member of the family of protein tyrosine phosphatases, and has 
been implicated in the negative regulation of a diverse range of signalling pathways in 
leukocytes.
SHP-l's pattern of expression encompasses all haematopoietic cells, at all stages of their 
differentiation, certain epithelial cells (Matthews et al., 1992; Plutzky et al., 1992a; Plutzky et 
al., 1992b; Yi et al., 1992b) and oligodendrocytes of the central nervous system (Horvat et 
al., 2001; Massa et al., 2000). Two major forms of SHP-1 have been indentified in humans 
and mice, and differ at the 5'untranslated regions of the initial coding nucleotides due to
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two transcription initiation sites, thus giving SHP-1 polypeptides of 595 or 597 amino acids 
(Banville et al., 1995; Martin et al., 1999; Tsui et al., 2002), with the former being primarily 
expressed in haematopoietic cells.
The three-dimensional structure of SHP-1 has been revealed by crystallography of an 
experimentally generated isoform lacking 61 amino acids at the carboxyl terminus (Yang et 
al., 2003). The images have revealed three main domains; two SH2 domains at the amino 
terminus followed by a PTP domain (figure 1.10), as previously predicted from the translated 
sequence of human, rat and mouse SHP-1 (Matthews et al., 1992; Plutzky et al., 1992a; Shen 
et al., 1991; Yi et al., 1992a). More specifically, residues 1-108 and 116-208 form the amino 
(N) and carboxyl (C) SH2 domains, and residues 270-532 form the PTP domain. SHP-1 also 
contains a C-terminal domain rich in basic amino acids (Yang etal., 2003).
The SH2 domains of SHP-1 have two defined roles; allosteric inhibition of the PTP domain 
and mediation of the binding of SHP-1 to its ligands. Evidence suggesting that the SH2 
domains of SHP-1 have an auto-regulatory role have come from in vitro studies of SHP-1 
lacking the SH2 domains (Pei et al., 1993; Zhao et al., 1993), which unlike full length SHP-1 
exhibits catalytic activity. Truncation of each SH2 domain in turn has revealed that the NSH2 
domain has an inhibitory influence over SHP-1 activity (Pei et al., 1993; Zhao et al., 1993). 
The phosphotyrosine binding sites of the SH2 domians are orientated away from the PTP 
domain, but unlike the CSH2 domain, the NSH2 domain makes extensive interactions with 
the PTP domain (Yang et al., 2003). This may serve to sterically occlude the PTP active site 
and prevent any interaction with potential substrates. Whereas the NSH2 of SHP-1 may have 
a direct regulatory role on the PTP domain, both SH2 domains need to be engaged for full 
SHP-1 activity. Engagement of individual SH2 domains with phosphotyrosyl peptides is 
associated with a moderate increase in SHP-1 activity, whereas engagement of both SH2 
domains leads to a 100 fold increase in PTP activity (Lechleider et al., 1993; Pluskey et al.,
1995; Sugimoto et al., 1994). Moreover, mutation of a critical arginine of both SH2 domains, 
which is involved in phosphopeptide binding has revealed that both SH2 domains need to be 
engaged for optimal activity (Pei et al., 1996).
In a physiological setting, the NSH2 and CSH2 domains of SHP-1 bind to tandem (Bruhns et 
al., 1999; Burshtyn et al., 1999; Kabat et al., 2002), tyrosine phosphorylated HIM motifs, 
present on members of the Inhibitory-Receptor Superfamily (IRS), which constitute the 
major ligands of SHP-1 (Long, 1999; Ravetch and Lanier, 2000) (figure 1.11). Members of the 
IRS are transmembrane proteins with ITIM motifs present within their cytoplasmic domains. 
As a result, SHP-1 is located at the plasma membrane when associated with its ligand. The 
ITIM motif for SHP-1 has been defined as [S/V/l/L]pYXX[L/V] (where X is any amino acid) 
(Beebe et al., 2000; Burshtyn et al., 1997; Vely et al., 1997) and the spacing between ITIMs 
can range between 19 and 31 amino acids (Blery and Vivier, 1999). It may also be feasible for 
the SH2 domains of SHP-1 to bind to ligands expressing a single ITIM, but with the 
requirement that both SH2 domains must be engaged for SHP-1 activation, such as during 
ligand dimerisation.
In an inactive configuration, the NSH2 domain of SHP-1 interacts with the PTP domain (figure 
1.12). Furthermore, the phosphotyrosine binding site of the NSH2 domain is present in a 
distorted state and unable to bind to ITIMs. Ligand engagement by the CSH2 domain is 
predicted to lead to conformational changes in the NSH2 domain, which restores the ligand 
binding pocket, thus allowing binding to an ITIM. Once both SH2 domains are engaged by 
ITIMs, the PTP domain is released from auto-inhibition (Pei et al., 1996) and is therefore free 
to interact with potential substrates (figure 1.11).
By using different biochemical approaches, researchers have endeavoured to identify the 
substrate(s) of SHP-1, but to date no bona fide substrate(s) of SHP-1 have been formally
identified. In vitro studies have demonstrated that SHP-1 is capable of dephosphorylating a 
number of candidate substrates (Chiang and Sefton, 2001; Raab and Rudd, 1996; Somani et 
al., 2001), but with the caveat being the physiological relevance of such substrates. Based on 
the assumption that the substrate(s) of SHP-1 should be hyperphosphorylated in its absence, 
the phosphotyrosyl state of candidate proteins has been assessed (Johnson et al., 1999; Pani 
et al., 1996; Pani et al., 1995; Sathish et al., 2001). These included proteins involved in TCR 
and BCR signalling pathways, such as PTKs (Src-, Syk- and Btk family members), invariant 
chains of the TCR and BCR (CD3, zeta, Ig a and 3 chains) and various downstream adaptors 
and effectors. A second approach has involved examining the molecular consequences of 
triggering inhibitory receptors, with the premise that the recruitment and activation of SHP- 
1 will leave the substrate(s) in a dephosphorylated state and facilitate their identification 
(Binstadt et al., 1998; Binstadt et al., 1996; Dietrich et al., 2001; Valiante et al., 1996). The 
generation of SHP-1 substrate trapping mutants has provided another potential mode to 
identifying SHP-1 substrates. PTP mutants maintain their binding capacity for their 
substrate(s) but are unable to catalyse substrate dephosphorylation, due to specific 
alterations of key amino acids of the WDP loop (Garton et al., 1996). SHP-1 substrate 
trapping mutants (C453S or D419A) were unable to directly purify substrates from cell 
lysates (Timms et al., 1998). An indirect approach using the trapping mutants involved 
expressing them in cell lines (Berg et al., 1999; Dustin et al., 1999; Mizuno et al., 2000; 
Timms et al., 1998; Wu et al., 1998). In this context the substrate(s) of SHP-1 would 
theoretically be left in a hyperphosphorylated state and thus aid their identification. The 
above studies have indicated certain proteins as potential substrate(s) of SHP-1, but due to 
their indirect nature the authenticity of the indentified proteins as SHP-1 substrates remains 
unclear.
The carboxy terminus domain of SHP-1 possesses two tyrosine residues, which mediate 
interactions with other proteins and may give SHP-1 an adaptor role. When phosphorylated, 
the tyrosine residues at the carboxy tail of SHP-1 are able to recruit the adaptor protein, 
Grb-2, which in turn can be complexed with other proteins, such as the inhibitory protein, 
suppressor of cytokine signalling (SOCS-1) (Minoo et al., 2004). The tyrosine residues of the C 
terminal domain also interact with the adaptor protein 3BP2 (Yu et al., 2006), which in turn 
binds ZAP-70, Vav and PLCy, which further demonstrates the potential role of SHP-1 as an 
adaptor protein. It has been demonstrated that SHP-1 associates both basally and post TCR 
triggering to lipid rafts (Fawcett and Lorenz, 2005). The identification of a novel, six amino 
acid lipid raft-targeting motif, in the C terminal domain of SHP-1 may assist with this 
localisation to membrane microdomains (Sankarshanan et al., 2007). Furthermore, in vitro 
studies have shown that the binding of anionic phospholipids to SHP-1, via the presence of a 
high-affinity binding site in the C terminal domain, can lead to activation of the PTP domain 
(Frank et al., 1999; Zhao et al., 1993). There is also evidence that tyrosine phosphorylation of 
the C terminal domain may influence the NSH2 mediated inhibition of PTP activity (Zhang et 
al., 2003).
A great deal of the research into the function of SHP-1 has been facilitated by the availability 
of the spontaneous mouse mutant strains, termed motheaten and motheaten viable. The 
mutations were originally reported as recessive single gene mutations, transmitted in a 
Mendelian manner (Green and Shultz, 1975; Shultz et al., 1984). The mutations were 
mapped to chromosome six, and subsequently to the gene encoding SHP-1 (Shultz et al., 
1993; Yi et al., 1992a). Homozygosity of either mutation causes a lethal autoreactive disease, 
resulting in a mean lifespan of 3 weeks for motheaten mice and 9 weeks for motheaten 
viable mice.
82
The motheaten allele contains a single nucleotide deletion of a cytidine residue, which 
generates a cryptic 5' splice donor for a 3' acceptor site, and results in a deletion of 101 
nucleotides of mRNA encoding the last half of the N-SH2 domain. This creates a frameshift, 
which results in the generation of an early termination codon. Consequently, the predicted 
protein of 102 amino acids contains a disrupted N-SH2 domain and no C-SH2 or PTP domain 
(figure 1.12). Therefore mice homozygous for the motheaten allele lack SHP-1 activity.
The motheaten viable allele has a single base pair substitution leading to the loss of a highly 
conserved splice donor consensus sequence and consequently produces two aberrant 
transcripts. The first transcript involves the activation of a downstream splice donor, which 
results in an insertion of 69 nucleotides. The second transcript is generated by the activation 
of an upstream cryptic splice donor that results in a deletion of 15 nucleotides. Both 
alterations maintain the reading frame and therefore an entire SHP-1 protein is produced, 
but with either a 23 amino acid insertion or 5 amino acid deletion (figure 1.12). The 
motheaten viable mutations affect the substrate binding pocket of the PTP domain, and 
reduce SHP-1 activity by 80% in comparison to that of wild-type SHP-1.
Motheaten individuals can be identified several days post partum by the appearance of skin 
abscesses. These abscesses manifest as patchy alopecia as the mice develop, giving them 
their characteristic motheaten appearance, from which they take their name (figure 1.13). 
This distinctive phenotype is attributed to the accumulation of activated neutrophils within 
the epidermis of the skin. Indeed, motheaten pathology is dominated by over-expansion of 
myelomonocytic lineage cells. Motheaten mice succumb to an inflammatory pathology that 
includes haemorrhagic pneumonitis accompanied by the accumulation of expanded myeloid 
cell populations within the alveoli of the lung (Shultz et al., 1997).
The ex-vivo study of myeloid cells form motheaten mice confirms their hyper-reactivity. 
Bone marrow granulocytes form motheaten viable mice exhibit enhanced proliferative 
responses to the growth factor G-CSF (Tapley et al., 1997). The enhanced proliferation is also 
evident for macrophages from motheaten mice, in response to GM-CSF (Jiao et al., 1997). In 
addition, macrophages from motheaten mice exhibit an increased adhesion and spreading, 
which is accompanied by dysregulated detachment (Roach et al., 1998). Similarly, bone 
marrow motheaten neutrophils are hyperadherent and demonstrate decreased chemotaxis, 
which may be attributed to a decrease in de-adhesion (Kruger etal., 2000).
In NK cells, SHP-1 plays a role in regulating cytotoxic function and the polarisation of lipid 
rafts. Inhibitory receptors expressed by NK cells, such as KIRs, contain ITIMs that are capable 
of recruiting and activating SHP-1 (Binstadt et al., 1996; Burshtyn et al., 1996; Nakamura et 
al., 1997). KIR engagement appears to disrupt an early adhesion step in the NK killing 
program, which is mediated primarily by integrins. This precludes the formation of stable 
conjugates between an NK cell and its target (Burshtyn et al., 2000). Substituting the 
intracellular domain of KIR with full length SHP-1 also blocks conjugate formation thereby 
demonstrating a critical role for SHP-1 in the inhibition of adhesion. Under activatory 
conditions a NK cell undergoes rapid polarisation, which is associated with the accumulation 
of lipid rafts (Lou et al., 2000), signalling proteins, talin and lysosomes at the immunological 
synapse that forms between a NK cell and a potential target cell (Vyas et al., 2002; Vyas et 
al., 2001). KIR engagement is associated with the inhibition of NK cell polarisation towards a 
target cell. Indeed, the engagement of KIR dramatically inhibits raft polarisation and is 
dependent on the activity of SHP-1 (Lou et al., 2000).
In B cells, SHP-1 has been implicated in the negative regulation of signals from antigen 
receptors. B cells from motheaten mice hyperproliferate in response to stimuli through the 
BCR (Pani et al., 1995). Additionally, SHP-1 deficient B cells possessing a transgenic BCR
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undergo antigen induced death when stimulated with cognate peptide, which is an effect 
not seen in normal B cells (Cyster and Goodnow, 1995). SHP-1 deficient B cells also exhibited 
an elevated level of intracellular Ca2+(Ono et al., 1997). Studies involving B cells that express 
a dominant negative form of SHP-1 have similarly indicated elevated levels of Ca2+, and also 
a marked increase in cell adhesiveness (Dustin et al., 1999). SHP-1 binds to a number of 
ITIM-containing receptors in B cells, including CD22, CD72 and PIR-B. When each of these 
inhibitory receptors is separately co-ligated with the BCR, activation induced mobilisation of 
Ca2+ is depressed (Aldachi et al., 1998; Blery et al., 1998; Smith et al., 1998). Furthermore, B 
cells deficient for either CD22 or CD72 are hyper-responsive to BCR triggering and exhibit 
enhanced Ca2+ and proliferative responses (Nitschke et al., 1997; O'Keefe etal., 1996; Pan et 
al., 1999).
Although T cells are not involved in the pathology observed in motheaten and motheaten 
viable mice, it does not preclude a role for SHP-1 in T cells (Yu et al., 1996). Indeed, SHP-1 
has been implicated in having a negative regulatory role in T cells, thereby raising TCR 
signalling thresholds.
SHP-1 has been demonstrated to associate with several receptors in T cells, including LAIR-1, 
CD22 and CEACAM-1. Cross-linking the human inhibitory receptor, LAIR-1, on peripheral T 
cells inhibits anti-CD3 induced killing of target cells. Other studies have demonstrated that 
SHP-1 constitutively associates with LAIR-1 at the cell membrane of the human Jurkat T cell 
line and human peripheral T cells. This association is independent of TCR triggering, 
indicating the LAIR-l/SHP-1 complex mediates a basal tonic inhibition of TCR signalling. The 
introduction of catalytically inactive form of SHP-1 to T cells leads to an increase in TCR 
triggering, but without the required coengagement of any inhibitory receptors with the TCR. 
CD22 has also been confirmed as a ligand of SHP-1 in mouse T cells (Sathish et al., 2004). 
Ligation of CD22 on naive T cells has been reported to inhibit anti-CD3 induced T cell
proliferation. In addition, T cells from CD227' mice hyperproliferate upon TCR triggering 
(Sathish et al., 2004). Engagement of CEACAM-1, which is expressed by T cells following 
activation, inhibits IL-2 production and proliferation in human T cells by association with 
SHP-1 (Chen et al., 2008). Engagement of the TCR and crosslinking of the inhibitory receptor, 
ILT2, inhibits early TCR triggered events via recruitment of SHP-1 and leads to suppression of 
actin cytoskeletal re-organisation (Saverino et al., 2000). Interestingly, the preferential 
expression of ILT2 on CD4+ leukaemic, Sezary cells, may assist with their malignancy, as it 
confers resistance to activation induced apoptosis following CD3/TCR engagement when 
compared to autologous CD4+ILT2* cells (Nikolova et al., 2002). Moreover, evidence suggests 
that SHP-1 may influence the activities of the cytoskeleton, and associated actin 
polymerisation in T cells (Dietrich et al., 2001). It has also been demonstrated that 
motheaten viable T cells have a greater in vitro chemotactic response to the chemokine, 
SDF-1 (Kim et al., 1999).
As discussed earlier, TCR signalling plays an important role during T cell maturation in the 
thymus. SHP-1 deficiency leads to increased positive selection of thymocytes in motheaten 
mice expressing MHC class I or II restricted transgenic TCR (Carter et al., 1999; Johnson et al., 
1999; Plas et al., 1999; Zhang et al., 1999b), which is consistent with lowered thresholds for 
TCR activation. Moreover, SHP-1 deficiency leads to an increased TCR signal strength 
whereby TCR signals too weak to induce survival, are sufficiently strong in the absence of 
SHP-1 to elicit positive selection. In addition, the introduction of a dominant negative form 
of SHP-1 in to mice by transgenesis recapitulates the findings obtained from motheaten and 
motheaten viable mice (Plas et al., 1999; Zhang et al., 1999b).
Ex-vivo functional analysis of thymocytes from motheaten and motheaten viable mice has 
demonstrated that they proliferate to a greater degree and also secrete increased amounts 
of IL-2 when stimulated with anti-TCR/CD3 antibodies (Lorenz et al., 1996; Pani et al., 1996;
Sathish et al., 2001; Zhang et al., 1999b). Similarly, SHP-1 deficient peripheral T cells 
expressing transgenic TCRs also exhibit an enhanced proliferative response when stimulated 
by cognate peptide/MHC complexes (Carter et al., 1999; Johnson et al., 1999; Zhang et al., 
1999b). These data demonstrate that SHP-1 raises the threshold of TCR signalling. The 
hyper-responsive phenotype has also been observed following the introduction of a 
dominant negative form of SHP-1 in to T cell hybridomas (Carter et al., 1999; Plas et al., 
1996) and the human Jurkat T cell line (Plas et al., 1996).
In addition, SHP-1 deficient peripheral T cells from mice expressing transgenic TCRs 
proliferate more at all intensities of TCR stimulation with cognate antigen (Carter et al., 
1999; Johnson et al., 1999; Zhang et al., 1999a). This indicates that even the strongest of TCR 
signals is unable to override the effect of SHP-1 activity, suggesting that SHP-1 does not 
necessarily act on pathways disseminating from the TCR. Costimulatory molecules such as 
CD28 (Viola and Lanzavecchia, 1996) are involved in lowering thresholds of TCR 
responsiveness. Indeed, data indicates that increased stimulus from CD28 eliminates the 
proliferative differences detected between SHP-1 deficient and sufficient thymocytes 
(Sathish etal., 2001).
By using the intracellular dye, CFSE, it has been demonstrated that a greater proportion of 
TCR transgenic motheaten T cells from a given population have the ability to enter into cell 
division following TCR triggering (Sathish et al., 2007). This data was supported by the 
observation that a greater proportion of SHP-1 deficient T cells downregulate their TCR upon 
stimulation with cognate peptide loaded APCs, which is a consequence of increased antigen 
encounter by the SHP-1 deficient T cells. At a cellular level, SHP-1 deficient T cells exhibit the 
ability to form more stable conjugates with APCs displaying cognate antigen (Sathish et al.,
2007), which may contribute to their hyper-proliferative phenotype.
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Figure 1.10: Overall structure of SHP-1
A schematic representation of the crystal structure of human SHP-1. The colour graduates from 
blue (N terminal) to red (C terminal) and the secondary domains are labelled accordingly.
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Figure 1.11: The binding of SHP-1 to tandem phosphorylated ITIMs releases it from auto-inhibition.
SHP-ls catalytic activity is regulated by the interaction of its N terminal SH2 domain with the protein tyrosine phosphatase domain. The phosphorylation of tyrosine 
residue of ITIM's belonging to inhibitory receptors allows SHP-l's SH2 domains to bind in tandem. This binding event leads to allosteric changes in the structure of 
SHP-1 thus relieving the PTP domain from auto-inhibition and also recruits SHP-1 to the plasma membrane. The physiological substrates of SHP-1 have yet to be 
elucidated, although it seems that SHP-1 may act upon cytoskeletal components or regulators.
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(A) Wild-type SHP-1 transcript
H N -SH 2 C-SH2 PTP -----
L i i i i i i i i i
10 300 329 639741 1542 1785
(B) Motheaten SHP-1 transcript
226
T
408
A 101 bp deletion, with the resulting frameshift encoding an 
aberrant transcript with a premature termination.
(C) Motheaten viable SHP-1 transcripts
N— N-SH 2 C-SH2 PTP
11
1074 1075 
A 69 bp insertion
N— N-SH 2 C-SH2 PTP
A 15 bp deletion
Figure 1.12: Schematic representation of wild-type, motheaten and motheaten viable SHP-1 
mRNA transcripts
The motheaten allele contains a single nucleotide deletion of the Shp-1 gene, which leads to a 
frameshift that creates a premature codon at position 408 of the mRNA transcript (B). The 
motheaten allele contains a Thymidine to Adenosine base pair (bp) substitution in the Shp-1 gene 
corresponding to an intron spliced between residues 1074 and 1075 of the mRNA. The substitution 
creates a cryptic splice donor producing two aberrant mRNA transcripts containing either an 
insertion of 69 bp or a deletion of 15 bp within a conserved region of the protein tyrosine 
phosphatase domain of SHP-1 (C).
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LittermateMotheaten
Figure 1.13: A motheaten mouse and a littermate at 10 days old.
Motheaten mice are distinguishable from littermate mice due to the characteristic patchy 
alopecia and tissue necrosis, which gives them a distinctive appearance, from which they 
take their name. The typical life expectancy of a motheaten mouse is 21 days, w ith Home 
Office stipulations requiring their sacrifice by approximately day 14 post partum. 
Motheaten viable mice have a similar appearance but have an extended life expectancy of 
63 days.
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1.12 Aims of the study
With in vitro studies of SHP-1 deficient CD8+ T cells demonstrating an enhanced response to 
antigenic stimulation, it was imperative to explore the in vivo role SHP-1 may have during 
CD8+ T cell responses to antigenic stimulation. Specifically, the aims of this study were:
1) To determine the role of SHP-1 during a primary CD8+ T cell response to antigenic 
challenge.
2) To determine the role of SHP-1 in the formation, and antigenic response of memory 
CD8+ T cells.
3) To utilise SHP-1 deficient CD8+ T cells in models of tumourigenesis in order to 
support its candidature for modulation during ACT therapies.
4) To establish whether SHP-1 expression could be modulated by using siRNA 
technology.
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Chapter 2 
Materials and Methods
2.1 Reagents and consumables
2.1.1 Antibiotics
Antibiotic solutions were sterile filtered through a 40pm syringe filter then stored at -20°C, 
or at 4°C for continuous use.
Ampicillin
Ampicillin was purchased from Sigma Aldrich [Gillingham, Dorset, U.K.] and reconstituted in 
dH20 to give a lOOmg/ml stock.
Neomycin (G418)
G418 disulphate salt powder was purchased from Sigma Aldrich and reconstituted in PBS to 
give a stock solution of 200mg/ml.
Puromycin
Puromycin was purchased from Autogen Bioclear [Wiltshire, U.K.] and diluted in serum free 
DMEM to give a O.lmg/ml stock.
2.1.2 Antibodies
Immunoblotting antibodies
Rabbit antiserum was raised to the tandem SH2 domains of mouse SHP-1 that had been 
cleaved and purified from a bacterially expressed GST-fusion protein. The SHP-1 antibody 
was generated by Dr. R. J. Matthews [Department of Medical Biochemistry and Immunology, 
Cardiff University, U.K.], in the laboratory of M. L. Thomas [WUMS, St. Louis, MO]. The
rabbit anti-actin polyclonal serum was purchased from Sigma Aldrich. The horseradish 
peroxidise (HRP) conjugated anti-rabbit secondary monoclonal antibody was purchased from 
Bio-Rad [Bio-Rad, Hercules, CA].
CD3 activating antibody
The biotin-conjugated anti CD3e monoclonal antibody, 145-2C11, was purchased from 
PharMingen [San Diego, CA].
Fluorescent conjugated anti-mouse antibodies for detecting cell surface protein expression
Anti-CD8a(Ly-2)PE antibody was purchased from Serotec [Oxford, U.K.]. Anti-CDllcFITC, anti- 
CD86pe, anti-TCRa(3PE, B220FITC and anti-CD 107aFITC antibodies were purchased from 
PharMingen.
2.1.3 Cell media and associated reagents
Dulbecco modified Eagle's minimal essential media (DMEM), Roswell Park Memorial 
Institute medium (RPMI), phosphate buffered saline (PBS), Hank's balanced salt solution 
(HBSS), L-glutamine, penicillin, streptomycin, sodium pyruvate and 0.5% trypsin in HBSS 
were purchased from Gibco, Invitrogen [Paisley, U.K.].
2.1.4 Chemicals
All chemicals were of analytical grade and obtained from Fisher Scientific [Leicester, U.K.], 
unless otherwise stated. Tris was obtained from Amersham Pharmacia Biotech 
[Buckinghamshire, U.K.]. Tween 20 and Nonidet P-40 (NP-40) were supplied by BDH [Poole, 
Dorset, U.K.].
2.1.5 Distilled water (dH20)
Distilled H20 was obtained from a Millipore reverse osmosis system followed by filtration 
through two ion exchange resin columns using a Millipore Milli-Q system.
2.1.6 Foetal calf serum
Foetal calf serum (FCS) was purchased from Sigma Aldrich and PAA Laboratories Limited 
[Pasching, Austria], and unless done so by the supplier, it was heat inactivated at 56°C for 30 
minutes.
2.1.7 lnterleukin-2 (IL-2)
Recombinant human IL-2 was purchased as 'Proleukin' from Chiron Limited [Harefield, U.K.] 
and reconstituted to lmg/ml under sterile conditions in ddH20, diluted to 20ng/ml in RPMI 
and stored in 1ml aliquots at -70°C. For continuous use, aliquots were thawed and stored at 
4°C.
2.1.8 Intracellular Dyes
CellTrace™ fa r red DDAO-SE
7-hydroxy-9H(l,3-dichloro-9,9,-dimethylacridin-2-one)-succinimydyl ester (DDAO-SE) was 
purchased from Invitrogen [Paisley, U.K.] and stored at -20°C in powder form. When 
required the powder was suspended in tissue culture tested sterile dimethyl sulphoxide 
(DMSO) to give a 40mM stock solution.
CSFE
Carboxyfluorescein diacetate Succinimydyl Ester (CFSE) powder was purchased from 
Invitrogen and suspended in ddH20 to give a lOmM stock solution, which was sterile filtered,
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dispensed in to 10|il aliquots and stored at -20°C. Aliquots were used once and not re­
frozen.
2.1.9 NP68 peptide
NP68 is derived from the nucleoprotein of the influenza virus A/NT/60/68 (NP366-374) of 
sequence ASNENMDAM that binds H-2Db/ and is recognised by the cytotoxic TCR clone, F5. 
The peptide was obtained from Severn Biotech Limited [Kidderminster, U.K.] as a dry 
powder and reconstituted in ddH20 to make a lOmM stock, which was aliquoted and stored 
at -20°C.
2.1.10 Plasmid DNA
pMX expression plasmids containing either the NP68 epitope as a fusion gene with green 
fluorescent protein (GFP) or firefly luciferase (Luc) with yellow fluorescent protein (YFP) 
genes (separated by an IRES) were kind gifts from Dr. Ton Schumacher [The Netherlands 
Cancer Institute, Amsterdam, The Netherlands].
Plasmid for DNA sequencing was purified using a Qiagen [Crawley, U.K.] plasmid mini-prep 
kit. Plasmid for transfection was prepared using either an Invitrogen PureLink HiPure Plasmid 
filter Maxiprep kit or a Qiagen plasmid maxi-kit, and then stored at -20°C.
2.1.11 Retinoic acid
All-trans retinoic acid in powder form was purchased from Sigma Aldrich and suspended in 
PBS to make a lOmM stock, which was sterile filtered and stored at -20°C in black eppendorf 
tubes.
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2.1.12 Tissue culture plastic
All tissue culture flasks (T25, T75 and T180), petri-dishes and tissue culture plates (6, 24 and 
96 wells) were supplied by Fisher Scientific.
2.1.13 Viruses
The Influenza A virus and recombinant Vaccinia virus encoding the NP68 epitope were kinds 
gifts from Dr. A. Gallimore [Department of Biochemistry and Immunology, Cardiff University, 
U.K.]. Stocks were stored at -70°C.
2.2 Cell based techniques
2.2.1 Counting cells by trypan blue exclusion
An aliquot of cells was mixed with an equal volume of 0.1% trypan blue in PBS (w/v) and 
loaded on to an improved Neubauer haemocytometer [Weber Scientific International 
Limited, Lancing, U.K.] and viable cells (clear appearance) counted at 100 times 
magnification under white light.
2.2.2 Flow Cytometry
A FACSCalibur flow cytometer [BD Biosciences, San Jose, CA] fitted with an argon-ion 
(488nm) and red diode laser (635nm) and capable of four channels of fluorescent detection 
was used throughout this study. Acquired data was analysed using CellQuestPro [BD 
Biosciences, Oxford, U.K.] or FlowJo software [Tree Star Inc, Ashland, OR]. In addition, a 
DakoCytomation high performance MoFlo cell sorter [Central Biotechnology Service, Henry 
Wellcome Research Institute, Cardiff University] was used to physically sort cells on a single 
cell basis.
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2.2.2a Labelling cells with fluorescent conjugated antibodies
Cells were counted by trypan blue exclusion and lx lO 6 transferred to either a 96 well plate 
or 5ml FACS tube, centrifuged and then the plate flicked or the tube inverted to remove 
media. Cells were washed with staining buffer (PBS with 2% FCS), by centrifugation at 
ISOOrpm for 5.minutes at 4°C. The cells were incubated for 20 minutes on ice and in the dark 
with lOOpI of staining buffer containing 2pg of the desired antibody. Cells were then washed 
twice in labelling buffer and finally resuspended in 100-200pl of cell wash [BD Biosciences]. 
Cells were analysed in FACS tubes containing sheath fluid on a FACSCalibur flow cytometer.
2.2.2b Labelling cells with intracellular dyes
The intracellular dyes CFSE (excitation/emission 492 and 517nm) and DDAO 
(excitation/emission 600-647 and 656nm) were used throughout this study. The dyes enter 
the cell by passive diffusion where the succinimydyl ester group reacts with intracellular 
amines, which occur within proteins and other biomolecules, thereby forming fluorescent 
conjugates via strong covalent bonds. DDAO was used at a concentration of lOpM, whereas 
CFSE was used at various concentrations (0.2, 0.5, 2, 3 and 4pM) depending upon the assay 
requirements. Following the preparation of a single cell suspension, the cells to be labelled 
were collected by centrifugation and suspended in lOmls of HBSS. A 2X CFSE stock was 
prepared in lOmls of HBSS then combined with the cells to give a final volume of 20mls. 
Once the dye had been added to the cells they were immediately mixed by vortexing for 5 
seconds. Labelling was carried out in the dark, in a 37°C water-bath for 5 minutes. To quench 
any excess dye, either 20mls of complete DMEM or 4mls of neat FCS was added to the cells 
and left at room temperature for 2 minutes. For labelling with DDAO, the cells were treated 
in the same manner as for CFSE labelling, but 1.5mls of HBSS was used to both resuspend 
the cells post centrifugation and also to make the 2X DDAO stock, to give a final volume of
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3mls. Furthermore, the cells were labelled for 10 minutes and excess dye quenched with 
either 3mls of complete DMEM or 1ml of neat FCS. Labelled cells were kept on ice and 
shielded from light until required.
2.2.3 Protein analyses
Immunoblotting techniques were used to detect both endogenous levels of SHP-1 
expression in Jurkat cells that had been transiently transfected with shRNA sequences 
directed against SHP-1 transcripts, and also in Hela cells that had been stably transfected 
with plasmid DNA encoding mouse or human SHP-1. Actin was used as a control for this 
analysis.
2.2.3a Detergent lysis of cells
Cells were removed from culture, washed and counted. The cells were then pelleted and the 
supernatant carefully removed and the cells resuspended in the desired volume of ice cold 
detergent lysis buffer (150mM NaCI, 50mM Tris-HCI pH 8.0, 25mM NaF, ImM sodium 
orthovanadate 0.5% Nonidet P-40) containing protease inhibitors (lOpg/ml Aprotinin, 
10pg/ml Leupeptin, 10pg/ml Pepstatin A, ImM EDTA, ImM Phenylmethylsulfonylfluoride), 
which were added immediately prior to lysis. Cells were allowed to lyse for 30 minutes on 
ice. Unlysed cells and nuclear material was removed by centrifugation (Beckham GS15R) at 
13000rpm for 10 minutes at 4°C. The post nuclear supernatant was collected and mixed with 
6X sample buffer (0.35M Tris pH6.8, 1.65M Dithiothreitol, 33% glycerol (v/v), 10% SDS (w/v), 
0.12mg/ml bromophenol blue [Sigma Aldrich]) and, if not immediately required for analysis, 
stored at -20°C.
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2.2.3b SDS-Polyacrylamide Gel Electrophoresis
Proteins were resolved by using NuPAGE Novex 4-12% Bis-Tris pre-cast gels [Invitrogen] 
mounted in a XCell SureLock Mini-Cell [Invitrogen] which were filled with NuPAGE MOPS SDS 
running buffer [Invitrogen], according to the manufacturer's instructions. SDS-PAGE samples 
were boiled for 5 minutes at 100°C and microfuged at 13000rpm for 30 seconds. Samples 
were loaded into the wells of the gel by careful pipetting using gel tips. For size 
discrimination of the resolved proteins, 10pl of SeeBlue Plus 2 prestained standard protein 
ladder [Invitrogen] was loaded in to one well. The gels were resolved at 200 Volts for 1 hour.
2.2.3c Immunoblotting
Following electrophoresis, the gels were removed from the gel cassette and trimmed to 
remove the wells and gel foot. The gel was then equilibrated in ice cold transfer buffer 
(48mM Tris, 39mM Glycine, 13mM SDS and 20% Methanol) for 20 minutes. 
Polyvinylidenedifluoride (PVDF) membranes [Immobilon-P, Millipore, Bedford, MA] were cut 
to the exact size of the gel, wet with methanol for 10 seconds, rinsed in dH20 and 
equilibrated in transfer buffer for 20 minutes. Two pieces of blotting pad were also cut to 
the size of the gel and placed in the transfer buffer to equilibrate for 20 minutes. The PVDF 
membrane was placed directly beneath the gel while still in the transfer buffer, followed by 
one piece of blotting pad. The second piece of blotting pad was then placed on top of the gel 
to form a stack, which was then positioned on the cathode of a semidry transblot system 
[Bio-Rad]. Trapped air bubbles were removed by gently rolling the stack with a tissue culture 
pipette. The anode lid was clamped into position and the gels blotted for 16 minutes at 15 
Volts.
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2.2.2d Immuno-detection by Enhanced Chemiluminesence (ECL)
In order to block non-specific binding sites, the PVDF membranes were placed in blocking 
buffer (PBS containing 3% non-fat milk) for 1 hour at room temperature. The membranes 
were then incubated overnight with the primary antibody at a dilution of 1 in 5000 in 
blocking buffer, by constant rocking at 4°C. The PVDF membrane was then washed for 5 
minutes in washing buffer (PBS containing 0.05% Tween 20) followed by two 5 minute 
washes in PBS, by constant rocking at room temperature. Secondary HRP-conjugated anti­
rabbit antibody was added at a dilution of lp l in lOOOpI in blocking buffer and incubated for 
1 hour at room temperature by gentle rocking. The membranes were rinsed then washed 
three times for 10 minutes in washing buffer, followed by one wash in PBS at room 
temperature by constant rocking. Membranes were covered with a 1:1 mixture of ECL 
reagents 1 and 2 of [Amersham] and allowed to react for 1 minute. Membranes were 
subsequently sealed in a polythene sleeve and exposed to photographic film for 10 seconds 
to 10 minutes. The photographic films were developed automatically with a Compact X2 
Processor [X-Ograph Ltd., Wiltshire, U.K.].
2.3 Escherichia Coli
2.3.1 Culture media
LB broth (1% Bactotryptone (w/v) [Oxoid, Basingstoke, U.K.], 0.5% Bacto-yeast extract (w/v)
[Oxoid] 175mM NaCI, buffered to pH7.0) was autoclaved and allowed to cool at room 
temperature before the addition of antibiotics (lOOpg/ml final concentration of ampicillin).
LB agar was prepared by the addition of 1.5% Bacto-agar (w/v) to LB broth, autoclaved as 
before and cooled to 50°C before the addition of the antibiotics (lOOpg/ml final 
concentration of ampicillin). The LB agar was dispensed in to petri-dishes and allowed to set 
at room temperature before being stored at 4°C until required.
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2.3.2 Clonal selection
Bacteria collected from 1ml cultures by microfuge centrifugation, following transfection by 
heat-shock, or directly from frozen stocks, were streaked onto LB-ampicillin (lOOpg/ml) 
plates and allowed to grow for 16 hours in an incubator set at 37°C.
2.3.3 Clonal expansion
To obtain a starter culture, single colonies picked from plates were inoculated in 5mls of LB- 
ampicillin (lOOpg/ml) broth and incubated overnight at 37°C on an orbital shaker. 
Subsequently, 1ml of the bacteria starter culture was inoculated in to 500ml litre of LB- 
ampicillin broth and incubated as before. Bacteria were collected by centrifugation at 
6000rpm for 10 minutes at 4°C on a Sorvall Evolution centrifuge.
2.3.4 Storage of bacterial clones
500|il of a 5ml starter culture was added to 500pl of glycerol freezing buffer (65% glycerol, 
0.1M MgS04 and 0.23M Tris, pH 8.0) and stored at -70°C.
2.4 Tissue culture and cell lines
2.4.1 Culture conditions
Cell were cultured in either RPMI or DMEM (4.5g/L glucose and L-Glutamine), with 10% 
heat-inactivated FCS, 2mM L-glutamine, 100 lU/ml penicillin and lOOpg/ml streptomycin, 1 
mM sodium pyruvate and 60pM 2Me. Cells were maintained at 37°C in a Heraeus incubator 
with 5% C02. Adherent cells were grown to 50-90% confluence before being divided. When 
splitting adherent cells, they were removed from tissue culture plastic by incubation with 
either 0.5% trypsin in HBSS or PBS. Firstly, the media was removed from the cells, and the 
cells rinsed once with PBS. The cells were then incubated with trypsin for 5 minutes or warm 
(37°C) PBS for up to 30 minutes. Cells were then removed from the plate, filtered, washed by
centrifugation and finally passed through a 29G needle to create a single cell suspension 
before being returned to tissue culture plastic. Cells that were grown in tissue culture plates 
or petri-dishes were placed in a plastic ventilated container with a small reservoir filled with 
dH20.
2.4.2 Human transformed cell lines
The human leukaemic Jurkat cell line was cultured in complete RPMI at a density of 0.5- 
2xl06 cells per ml and split at a ratio of 1:10 every 4-5 days. Hela cells, which are an 
adherent human cervical carcinoma cell line were cultured in complete DMEM.
2.4.2a Production of Hela cells expressing mouse SHP-1
Hela cells were plated in six well plates (1.5x10s per well) and left for 24 hours prior to 
transfection with a plasmid (pSSFV) encoding a full length cDNA for mouse SHP-1. Media 
(2mls) was replaced 15 minutes prior to transfection. For each well to be transfected, 4pg of 
DNA was added to 100|il of 150mM NaCI, followed by brief vortexing and centrifugation. 
Separately, 6pl of Polyplus jetPEI [Autogen Bioclear] was added to lOOpI of 150mM NaCI. 
The jetPEI was added to the DNA and left to stand at room temperature for 30 minutes. The 
DNA preparation was added drop-wise to the cells and mixed gently and returned to the 
incubator for 24 hours, after which the media was replaced. Selection for stable 
transfectants began 48 hours post transfection, with an initial G418 concentration of 
1.5mg/ml. Once selected, as assessed by comparison to untransfected cells, the cells were 
maintained at 0.75-lmg/ml of G418 and grown for 4 weeks and tested for SHP-1 expression 
by immunoblot analysis.
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2.4.2b Production of Hela cells expressing human SHP-1
Hela cell were plated in T75 flasks and left for 24 hours ready for transfection with pSSFV- 
human SHP-1. The media was replaced prior to transfection. A calcium phosphate and 
plasmid DNA precipitate was prepared using a calcium phosphate transfection kit [Sigma] 
according the manufacturer's instructions. Briefly, a 450pl volume of CaCI^DNA mixture was 
prepared containing 20pg of DNA, 45pl of 2.5M calcium chloride and the corresponding 
volume of sterile molecular biology grade water. This was added drop-wise to 450pl of 2X 
HEPES-buffered saline (HeBs) whilst bubbling with a pipette pump and 5ml strippette fitted 
with a Gilson pipette tip. The mixture was vortexed for 1-4 seconds and left undisturbed for 
20 minutes at room temperature and then added to the cells. Selection of stable 
transfectants began 48 hours post transfection, with an initial G418 concentration of 
1.5mg/ml. Once selected, cells were maintained at 0.75-lmg/ml of G418 and tested for SHP- 
1 expression by immunoblot analysis.
2.4.2c Mouse GM-CSF production
The cell line, J558L, expressing mouse GM-CSF was a kind a gift from Professor Kim Bottomly 
[Yale University]. Cells were defrosted and allowed to grow unselected for 2-3 weeks 
followed by selection in lmg/ml G418 for a further 1-2 weeks. Cells were then removed 
from selection and allowed to grow for 7-10 days, until the media had started to turn yellow. 
The supernatant was harvested and any producer cells removed by centrifugation followed 
by sterile filtration through a 40pm syringe filter. Supernatant was stored at -20°C until 
required.
2.4.3 Viral Packaging cell line
A retroviral packaging cell line was used to produce virus from plasmid DNA encoding NP68 
with GFP or Luc with YFP.
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2.4.3a Phoenix cells
The Phoenix-amphotrophic cell line is based on the 293T cell line, which is a human 
embryonic kidney (HEK) cell line transformed with adenovirus Ela and carrying a 
temperature sensitive T antigen co-selected with neomycin. These cells were a kind gift from 
Dr. Richard Darley [Department of Haematology, Cardiff University, Cardiff, U.K.] and had 
previously been produced by Dr. G. P. Nolan [Department of Molecular Pharmacology, 
Stanford University, CA]. The phoenix-ampho cells were generated by stably transfecting 
HEK293T with a Moloney GagPol-IRES-CD8a construct with an RSV promoter and a pPGK 
hygromycin selectable marker. In addition, these cells have also been stably transfected with 
Moloney Amphoteric envelope gene driven by a CMV promoter and co-selected with the 
Diptheria toxin resistant gene. These cells were grown in complete DMEM in tissue culture 
flasks that had been batch tested to assess the tissue culture coating, thereby ensuring 
satisfactory adherence of the cells to the plastic.
2.4.3b Retrovirus production
A total of 7xl06 Phoenix cells were cultured in a T75 flask with complete DMEM 24 hours 
prior to transfection with plasmid DNA. Five minutes prior to transfection the media was 
replaced with 15ml of fresh media containing 25pM of chloroquine [Sigma Aldrich], which 
inhibits the degradation of DNA. A calcium phosphate transfection kit [Sigma Aldrich] was 
used according to the manufacturer's instructions to produce a calcium phosphate 
precipitate containing the desired DNA (as described for 2.4.2b). The following day the 
media was aspirated and replaced with 7.5ml of complete DMEM. Cells were then incubated 
at 33°C for 24 hours, followed by viral harvest. Viral supernatant was snap frozen and stored 
as 1ml aliquots in cryovials at -70°C. Any transient expression of the fluorescent proteins,
GFP and YFP, during the production of virus was assessed by using a fluorescent microscope.
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2.4.4 Transformed mouse cell lines
The mouse melanoma cell line, B16, was cultured in complete DMEM. Those cells that were 
destined for in vivo transfer were removed from tissue culture plastic by incubation with 
PBS, rather than with trypsin.
2.4.5 Production of mouse B16 melanoma cells expressing the NP68 epitope and luciferase 
gene
To enable in vivo studies of F5 CD8+ T cell mediated tumour protection and regression, it was 
necessary to produce B16 melanoma cells that expressed the NP68 epitope. Expression of 
the luciferase gene by murine tumour cell lines potentially allows tumour development and 
regression to be monitored in vivo by using an IVIS* imaging system 2000 [Xenogen, 
Alameda, CA].
2.4.5a Infection of B16 cells with retrovirus
Retrovirus was produced by transfecting Phoenix cells with an expression plasmid encoding 
the NP68 epitope with GFP (as a fusion protein) or with an expression plasmid encoding the 
luciferase and YFP genes (separated by an IRES). A total of 2.5x10s wild-type B16 cells were 
plated in T25 flasks 24 hours prior to infection. The media was removed and the B16 cells 
incubated at 37°C for 1 hour, in 1ml of complete media containing lOpg/ml of protamine 
sulphate [Sigma Aldrich], which is a cationic peptide that enhances the transduction of cells. 
The desired viral supernatant was then added to the flask, making a total of 2mls. Cells were 
incubated for 16-18 hours after which the media was replaced with fresh media and the cells 
allowed to rest for 5-6 hours. The process of incubation with protamine sulphate and 
subsequent viral infection was then repeated for a second time.
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To generate B16 cells expressing both the NP68 epitope and luciferase, wild-type B16 cells 
were first infected with the retrovirus encoding for luciferase and YFP. The infected cells 
then went through a process of assessment and single cell sorting to produce monoclonal 
cell lines expressing luciferase. A monoclonal cell line expressing luciferase was then super­
infected with a retrovirus encoding the NP68 epitope as a fusion protein with GFP.
2.4.5b Luciferase assay
In order to establish whether B16 cells infected with virus encoding the luciferase gene were 
indeed expressing the enzyme, the cells were assessed for YFP fluorescence as the luciferase 
and YFP gene are separated by an IRES. This was done by viewing the cells on a fluorescent 
microscope and analysing them on a FACSCalibur flow cytometer. In addition, a luciferase 
assay was performed to check for the expression of functional luciferase. A luciferase 
reporter assay was used according to the manufacturer's instructions [Promega]. Briefly, 
lx lO 6, 5x10s, 2.5x10s and 1.25x10s B16 cells infected with the retrovirus encoding the 
luciferase gene and lx lO 6 parental wild-type B16 cells were lysed on ice for 10 minutes, in 
lOOpI of passive lysis buffer. Following cell lysis, 50pl of each lysate was transferred to a well 
of a white 96 well plate. The "stop and glo" reagent was then added to each well at 10 
second intervals, with one well left as a blank containing 50pl of water and 50pl of the 
substrate. Luciferase activity was measured using a luminometer, with the data collected by 
Fluorostar software.
2.4.5c Single-cell sorting and clonal expansion of B16 cells
To separate cells expressing the luciferase gene a single cell sort was performed using a 
DakoCytomation high performance MoFlo cell sorter. Cells were separated based upon cell 
viability, as determined by forward and side scatter, and YFP fluorescence. The cells were 
sorted directly into the wells of a flat-bottomed 96 well plate and cultured for 4 weeks and
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retested for luciferase activity as described above. A monoclonal B16 cell line expressing the 
luciferase gene was then selected to be infected with the retrovirus encoding the NP68 
epitope as a fusion protein with GFP. This involved a process of infection (as described 
above), single cell sorting and assessment for GFP (flow cytometry) and NP68 expression (in 
vitro CTL assay).
B16 cells infected with virus encoding the NP68 epitope as a fusion protein with GFP were 
assessed for GFP expression under a fluorescent microscope at every stage during infection 
and by a FACSCalibur cell cytometer once the second round of infections was completed. 
The infected B16 cells were then single cell sorted using a DakoCytomation high 
performance MoFlo cell sorter. Cells were selected based upon cell viability, as determined 
by forward and side scatter, and GFP fluorescence. The GFP gate was set above the 
autofluorescence seen for the parental B16 cells. In addition to the above parameters, wild- 
type B16 cells infected with the retrovirus encoding the NP68/GFP were also sorted based 
on pulse-width, to ensure that only single cells were positively sorted. This additional 
parameter was not applied when sorting the B16 Luc/YFP cells that had been infected with 
the retrovirus encoding NP68/GFP. Wild-type and the B16 Luc/YFP B16 cells infected with 
the retrovirus encoding the NP68/GFP were sorted into the wells of flat-bottomed 96 well 
plate. In addition, lx lO 3 cells of the wild-type NP68/GFP cells were sorted into the same well 
to give a polyclonal population. The monoclonal cell lines were transferred from 96 well to 
24 well plate when a visible cluster of cells could be seen under the light microscope. As 
each clone reached 70% to 80% confluency, they were progressively moved from the 24 well 
plates to 6 well plates, T25 flasks and finally T75 flasks, at which point further analysis was 
performed and stocks prepared for freezing. The polyclonal population was transferred 
directly to T75 flasks, and allowed to reach 70% to 80% confluency before further analysis 
and preparation of stocks for freezing.
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2.4.5d Assessing GFP expression of monoclonal B16 cell lines
The next step in the process of generating the transgenic B16 GFP/NP and B16 
Luc/YFP/GFP/NP cells was to assess for GFP fluorescence by flow cytometry. The GFP 
fluorescence was assessed by overlaying histogram plots using FloJo software. For the B16 
GFP/NP cells, the autofluorescence from wild-type B16 cells was used as a comparative 
control. For the B16 Luc/YFP/GFP/NP cells, the autofluorescence from both wild-type B16 
cells and fluorescence from B16 Luc/YFP cells were used as a control. As a population of B16 
GFP/NP cells was already available prior to the generation of B16 Luc/YFP/GFP/NP cells they 
were also used as controls. The Luc/YFP/GFP/NP and GFP/NP cells were utilised in an in vitro 
CTL assays to establish whether the NP68 epitope was being presented at the surface of the 
cells by MHC class I molecules (as described in 2.8.3). For the B16 Luc/YFP/GFP/NP cells the 
expression of the luciferase gene was verified for a final time by performing a luciferase 
reporter assay as described in 2.4.5b, with 6xl04 cells used for each reaction. The controls 
included the parental B16 luc/YFP cells, wild-type B16 cells and also B16 GFP/NP cells.
2.4.6 Primary mouse cell cultures
2.4.6a Generation of dendritic cells
Mouse dendritic cells were produced from bone marrow pre-cursor cells by culturing them 
with mouse GM-CSF supernatant produced from a cell line (see 2.4.2c) or commercially 
available GM-CSF [Sigma]. Bone marrow was harvested from adult female C57BL/6J mice 
and cultured in lOmls of media supplemented with 2% GM-CSF supernatant or 20ng/ml of 
commercially available GM-CSF. Cells were cultured in bacteria grade petri-dishes with 5- 
6xl06 cells seeded on each plate. On day 3 or 4 of culture, lOmls of media containing 1% 
GM-CSF supernatant or lOng/ml of commercial GM-CSF was added to the cells. On day 6 or 
7 of culture, half of the media was removed from the dish and cells collected by
109
centrifugation at 1500rpm for 4 minutes. Cells were then resuspended in lOmls of fresh 
media containing 1% GM-CSF supernatant or lOng/ml of commercial GM-CSF, which was 
then added back to the dishes. Cells were matured on days 10, 11 or 12 as desired, by the 
addition of lpg/ml of lipopolysaccharide (LPS) [Sigma] to the cultures for 24 hours prior to 
harvest. The process of producing dendritic cells was assessed by various methods; including 
their ability to present NP68 peptide in both an in vivo and in vitro setting. The proportion of 
cells expressing the dendritic cell marker, CDllc+, was determined at the start and end 
points of culture by flow cytometry. In addition, the proportion of cells that expressed the 
costimulatory molecule, CD86, prior to and after maturation with LPS was also assessed by 
flow cytometry.
2.4.6b Producing mouse CD8+ F5 T cell blasts and their subsequent culture
The lymph nodes from motheaten and control F5 mice were harvested and a single cell 
suspension prepared (see 2.6.1a). In order to activate the CD8+ F5 T cells, spleens were taken 
from adult C57BL/6J mice, irradiated at 1700 centigrays (cGy), homogenised and then pulsed 
with 5pM NP68 peptide for 1 hour at 37°C. A total of 3xl06 lymphocytes were co-cultured in 
5mls of complete DMEM with 30xl06 NP68 peptide-pulsed splenocytes for 48 hours in six- 
well plates. The cells were then collected, washed twice and returned to flasks containing 
20mls of complete DMEM for each well harvested and supplemented with 360 lU/ml of rlL- 
2. Cells were then grown for a further 3-4 days before harvesting. In order to remove cellular 
debris and dead cells, the cells were resuspended in 30mls of ice cold HBSS and 5mls of 
foetal calf serum layered beneath them. This was followed by centrifugation at 1300rpm for 
4 minutes at 4°C and two further washes in ice cold HBSS.
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2.4.7 Cryopreservation of cell lines
Cells were removed from tissue culture and washed with HBSS by centrifugation at 1400rpm 
for 4 minutes at 4°C. Cells were resuspended in freezing buffer (90% FCS and 10% DMSO 
[Sigma]) to give 0.5-2xl06 cells per ml, and 1ml aliquots dispensed in to cryo-vials. The cryo- 
vials were placed in a Nalgene 5100 cryo freezing container [Merc Laboratory Supplies, 
Dorset, U.K.] for 24 hours at -70°C before being transferred to liquid nitrogen. Cells were 
removed from cryopreservation by thawing rapidly at 37°C (water-bath) and then washing in 
HBSS by centrifugation at 1500rpm for 5 minutes at 4°C, before being placed in culture.
2.5 Animals
2.5.1 Husbandry
All mice were generated in house at the Biomedical Services Unit (BSU) located at the School 
of Medicine, Heath Park, Cardiff University, tinder project license numbers 30/2266 and 
30/2125. Stock mice were kept in groups of between 5-10 animals per cage and breeding 
animals maintained as harems, with typically 1 male to 3 females. Mice were provided a diet 
of standard mouse chow and sunflower seeds, with water ad libitum. Mice were maintained 
in rooms with a temperature range of 18-22°C with 12 hour light-dark cycles. Mice were 
kept under pathogen free conditions in cages contained within an isolator or Scantainer Plus 
unit [Scanbur, Copenhagen]. Alternatively, mice were housed in cages covered with a filter 
membrane.
2.5.2 Breeding ofMotheaten Mice expressing the MHC class I restricted TCR, F5
Motheaten (me/me) mice lack expression of the SHP-1 protein and due to their early 
mortality were generated from the breeding of mice heterozygous at the motheaten locus
I l l
(me/+). The motheaten mice were used between the ages of 7 and 14 days, depending upon 
their health status.
In order to perform experiments using CD8+ T cells from both me/me and control mice 
(me/+ and +/+) in an antigenic context, a H-2Db restricted ot|3TCR transgene, named F5, that 
recognises a nonamer peptide (NP68) from influenza virus A/NT/60/68 nucleoprotein was 
introduced into the motheaten genetic background. Briefly, C57BL/10 mice expressing the 
F5 transgene were obtained from Dr. D. Kioussis (NIMR, Mill Hill, London) and bred with 
C57BL/6J me/+ mice, which were supplied by Dr. L. Shultz [Jackson Laboratory, Bar Harbor, 
Maine]. Subsequently, mice from the inter alia matings of the resulting FI offspring, which 
were homozygous for the F5 transgene, were maintained as a breeding colony heterozygous 
at the motheaten locus. Male mice produced from this colony, with the genotype F5homme/+ 
were mated with female C57BL/6J me/+ mice, to produce me/me, me/+ and wild-type (+/+) 
mice that were hemizygous (hem) for the F5 a0TCR transgene.
2.5.3 Genotyping of motheaten mice
Mice heterozygous at the motheaten locus were genotyped by performing PCR using reverse 
primers complementary to DNA sequences in intron 3 of the SHP-1 gene. The primers 
[Invitrogen] were 5'-TCC CTG GGA GCT TCC TGG CTC-3' and 5'-TAG GCA GCA GGA ACC CTG 
CAG-3', which amplify a genomic fragment of 738bp. Samples of DNA were obtained by 
digesting small sections of tail tissue in PCR lysis buffer (0.1M Tris, pH8.3, 2.5mM 
Magnesium Chloride hexahydrate, 50mM Potassium chloride, 0.45% v/v Nonidet P40, 0.45% 
v/v Tween 20 and O.lng/ml Gelatin) containing proteinase K (lOOpg/ml) at 56°C for 16-24 
hours. The proteinase K was then inactivated by heating the samples at 96°C for 10 minutes 
on a Techne PHC-3 thermal cycler [Techne, Oxford, U.K.]. Samples were microfuged at 
13000rpm for 5 minutes to sediment tissue material. The PCR reaction buffer contained
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20U/ml DyNAzyme EXT [Finnzymes, Finland], 2.5mM of each dNTP [Invitrogen], 10X 
DyNAzyme EXT buffer with 1.5mM MgCI2 [Finnzymes] and the primers, with 45pl being used 
for every 5pl of DNA. The PCR reaction was performed on a Hybaid Omn-E [Hybaid Limited, 
Basingstoke, U.K.].
The samples were then digested with 20U/ml of Taq 1 restriction endonuclease [New 
England Biolab, Hitchin, U.K.], for one hour at 65°C on a Hybaid Omn-E [Hybaid]. This 
restricts the DNA at a restriction site that is absent at the me/me locus, thereby enabling 
me/+ and +/+ mice to be identified. After digestion, 20pl of each sample was loaded onto a 
1% agarose gel containing ethidium bromide (0.4pg/ml) with 4pl of loading buffer (3.6mM 
Bromophenol Blue and 1.2M Sucrose), and run at 120 Volts for 45 minutes. In addition, lp l 
of 1Kb Plus DNA ladder [Invitrogen] was also loaded onto the gel.
2.5.4 Other genetic backgrounds
Mice lacking expression of the recombinase associated gene -1 (Rag-1^) were used 
throughout the study as lymphopenic recipient mice. They were maintained under sterile 
conditions in cages housed within an isolator.
2.6 In vivo methods
All experiments were performed in strict accordance with the Animals Scientific Procedures 
Act of 1986. They were performed in the BSU, under project license numbers 30/2266 and 
30/2125 and personal license number 30/6944.
2.6.1 Harvesting and preparation of mouse tissue
Typically, mice were killed by asphyxiation in a rising concentration of C02, followed by 
cervical dislocation. Unless otherwise stated, the single cell suspensions prepared from
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tissue were filtered and washed twice in ice cold HBSS, by centrifugation at 1500rpm for 4 
minutes at 4°C. Viable cells were counted by trypan blue exclusion.
2.6.1a Lymph nodes
Lymph nodes (inguinal, mesenteric, axial, brachial, popliteal, and sub-mandibular) were used 
as a source of lymphocytes and CD8+ T cells. In addition, adoptively transferred cells were 
retrieved from the lymph nodes for analysis. After excision, a single cell suspension was 
created by applying 10 strokes of a Jencons unifrom grade B.24 tissue homogeniser followed 
by filtering and washing.
2.6.1b Mesenteric lymph nodes
The mesenteric lymph nodes were excised from the gut and placed in the well of a 24 well 
plate and covered with 2mls of HBSS. The flat end of a plunger from a 2ml syringe was used 
to gently homogenise the lymph nodes. The suspension was taken up in lOmls of HBSS and 
filtered into a 50ml falcon tube, with the syringe plunger being used gently to assist the 
passing of the single cell suspension through the filter. The cells were then washed with ice 
cold HBSS.
2.6.1c Peyer's patches
Peyer's patches are lymphoid clusters found along the length of the small intestine and were 
used as a target site for migrating T cells. The small intestine was removed from the mouse 
and flushed with cold PBS by using a 10ml syringe and a blunted 19G needle. A rigid piece of 
plastic was placed through the lumen of the small intestine, which was gathered at one end 
of the plastic to aid dissection. The intestine was then moved back along the plastic rod and 
the Peyer's patches excised using a pair of curved scissors. The tissue was then processed in 
the same manner as for lymph nodes.
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2.6.Id  Spleens
Spleens were used as source of cells to generate target, reference and feeder cells. In 
addition, adoptively transferred cells were often retrieved from the spleens of recipient 
mice. Once excised, spleens were homogenised in HBSS with 2-5 gentle strokes of a Jencons 
tissue homogeniser. The single cell suspensions were filtered and then washed, by 
centrifugation at 1300rpm for 4 minutes at 4°C. The splenocyte pellet from each spleen was 
covered in 1ml of red blood cell lysis buffer [Sigma] and left undisturbed for 5 minutes. The 
splenocyte pellet was then agitated by gentle pipetting to give a single cell suspension 
followed by a further 2 minutes of lysis. The single cell preparation was made up to lOmls 
with HBSS and filtered prior to centrifugation at 1300rpm for 4 minutes at 4°C. If the 
splenocytes were to be used as feeder cells the process of homogenisation was performed in 
complete media and no subsequent washing or red blood cell lysis was required.
2.6.le  Lungs
The lungs of mice receiving B16 melanoma cells were taken as they represented the site of 
B16 cell growth following their intravenous transfer. The lungs were removed carefully from 
the mouse and blotted on tissue to remove excess blood. In order to generate a single cell 
suspension, the lungs were placed in the well of a 24 well plate and covered with 2mls of 
HBSS. The flat end of a plunger from a 2ml syringe was used to gently homogenise the lung. 
The suspension was taken up in lOmls of HBSS and filtered into a 50ml falcon tube, with the 
syringe plunger being used gently to assist the passing of the single cell suspension through 
the filter. If red blood cells were evident after the first wash, 1ml of red blood cell lysis buffer 
was added for 5 minutes whilst pipetting gently, followed by washing.
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2.6. I f  Blood
Blood was taken to retrieve adoptively transferred cells T cells for analysis. Firstly, the mouse 
was restrained and the tip of the tail sprayed with ethyl chloride BP [Acorus Therapeutics 
Limited, Durham, U.K.] and allowed to numb. A small section of the tail was removed at its 
tip and 30-50pl of blood taken by aspirating with a Gilson P200 pipette fitted with a small 
pipette tip. The blood was mixed immediately with an approximately equal volume of 
heparin [CP Pharmaceuticals Ltd, Wrexham]. If blood was required at the end of an 
experiment, it was taken via a cardiac puncture. The mouse was placed in a chamber, which 
was subsequently filled with anaesthetic gas (isofluorane) using oxygen as a carrier gas. Once 
the mouse showed signs of anaesthesia it was transferred to a face mask with a lower 
concentration of anaesthetic gas. A 28G needle was inserted below the sternum and a 
cardiac withdrawal of blood performed with a syringe containing 200pl of heparin. The 
blood was then made up to 5mls with HBSS and washed. The cell pellet was resuspended in 
red blood cell lysis buffer for 5 minutes, followed by washing and centrifugation. If 
necessary, the red blood cell lysis was repeated a second time, for 1-2 minutes.
2.6.lg  Bone marrow
Bone marrow precursor cells were required for culture in GM-CSF to produce dendritic cells. 
Bone marrow was taken from the femur and tibia of adult C57BL/6 female mice. A scalpel 
was used to cut away the majority of skin, muscle and connective tissue from the hind legs 
of a mouse, followed by the gentle removal of the leg from the hip socket by dissection with 
a small pair of scissors. Once removed, the soft tissue was further removed by rubbing the 
leg bones between tissue-paper. The femur was removed from the tibia by gentle 
manipulation of the knee joint, ensuring the bones remain intact at all times. The bones 
were dipped in 70% ethanol for 1 minute and then placed in ice cold PBS. The bone marrow
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was extracted by cutting both ends of the bone and flushing with ice cold PBS from a syringe 
fitted with 21G needle. The bone marrow was dispersed by repeated pipetting and then 
filtered before washing.
2.6. lh  Ovaries
Following Vaccinia virus transfer to the peritoneal cavity of mice the ovaries become 
infected and are therefore a potential site for activated CD8+ T cell migration. To retrieve 
adoptively transferred T cells from Vaccinia virus infected mice, the ovaries were removed 
from the abdominal cavity and prepared as described above for lymph nodes.
2.6.l i  Gut tissue
The gastrointestinal tract was excised in one piece extending from the stomach (proximal) to 
the anus (distal) and placed in cold PBS. The gut was then placed on a dampened tissue and 
kept moist with PBS at all times. Cross sections (approximately 5mm in length) were taken 
from the caecum, small and large intestines and placed in either formalin ready for transfer 
in to paraffin wax.
2.6.2 Immunomagnetic separation of CDS* T cells
Mouse CD8+ T cells were separated from single cell suspensions of lymphocytes using CD8 
antibody conjugated magnetic beads and MACS MS+ immunomagentic separation columns 
[Miltenyi Biotec, Surrey, U.K]. Cells were washed and suspended at a density of lxlO 7 cells 
per 90pl of ice cold sorting buffer (PBS supplemented with 2mM EDTA and 0.5% BSA), 
followed by the addition lQpl of magnetic beads per 1 xlO7 cells, and incubation at 4°C for 
15 minutes. MACS MS+ separation columns were attached to MiniMACS magnets and placed 
on a MiniMACS stand and primed once with 1ml of sorting buffer. The magnetically labelled 
cells were resuspended in sorting buffer and centrifuged at llOOrpm for 10 minutes, and
then placed onto the column in 500pl of sorting buffer. The column was washed three times 
with 500pl of sorting buffer and the run-through collected as the negative fraction. The 
columns were then removed from the magnet and the positive fraction eluted by applying 
lm l of sorting buffer to the column and flushing the cells out by using a column plunger.
2.6.3 Adoptive cell transfers
A number of different cell types were adoptively transferred to recipient mice; including 
naive CD8+ F5 T cells directly from donor mice, in vitro activated and expanded CD8+ F5 T 
cells, B16 melanoma cells, splenocytes and in vitro generated dendritic cells. The route of 
administration depended upon the role and type of cell being transferred. All procedures 
involving the transfer of cells and priming of mice were performed under sterile conditions 
in a class 2 microflow advanced bio-safety cabinet.
2.6.3a Donor mice
Naive CD8+ F5 T cells were purified from me/me, me/+ and +/+ mice by immunomagnetic 
separation. Splenocytes were prepared from adult C57BL/6 female or male mice.
2.6.3b Recipient mice
Lymphopenic mice were used in order to transfer and preferentially prime CD8+ F5 T cells 
without priming endogenous CD8+ T cells. Typically, female Ragl7' mice or sub-lethally 
irradiated female C57BL/6J mice were used for this purpose. For lymphodepletion by 
irradiation, mice were exposed to 650cGy of irradiation in a gamma cell irradiator, whilst 
being held securely within a purpose built restrainer. Once irradiated, mice were moved to 
scantainer cages, with a double positive pressure operating setting, ensuring mice received a 
constant supply of filtered air. Mice were usually used within 1-2 days of being irradiated.
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2.6.3c Intravenous transfer o f cells
Naive CD8+ F5 T Cells and splenocytes were prepared directly from donor mice and 
adoptively transferred, via a tail vein, to recipient mice in 200pl of HBSS using a sterile 29G 
insulin ultra comfort syringe. CD8+ T cells and B16 melanoma cells that had been taken from 
tissue culture were transferred in the same manner, importantly ensuring that the cells had 
been washed, filtered and kept at 4°C at all times prior to transfer. In order to dilate the 
blood vessels ready for intravenous transfer, mice were placed in a heating chamber set at 
37°C for up to an hour prior to injection. Mice were restrained in a purpose built rodent 
holder to provide easy access to the tail, and the tail wiped with a steret at the injection site 
prior to transfer. Once injected, the needle was removed from the vein while applying gentle 
pressure at the injection site to avoid loss of sample from the vein due to back-pressure, and 
also to stem any bleeding.
2.6.3d Peritoneal transfer of cells
Dendritic cells were administered to mice via the peritoneal cavity in lOOpI of HBSS in a 28G 
insulin syringe. Mice were manually restrained and held at a 45 degree angle to position the 
head downwards and away from the handler, thereby reducing the possibility of the needle 
contacting organs during injection. The abdomen of the mouse was wiped with a steret prior 
to transfer of the cells and the needle penetrated at a sufficient depth to enter the 
peritoneal cavity.
2.6.3e Subcutaneous transfer of cells
B16 cells were also transferred subcutaneously in lOOpI of HBSS using a 29G insulin ultra 
comfort syringe. The fur in the inguinal region on the underside of the mice was wiped with 
a sterile steret. The tip of the needle was used to part the hair and reveal the skin. The
needle was inserted subcutaneously to cover the bevel and the cells transferred, ensuring a 
bleb appeared beneath the skin with no leakage of cells.
2.6.4 In vivo antigenic stimulation of naive and memory CD8+ F5 T cells
Concomitantly with adoptive transfer of naive CD8+ F5 T cells, mice were primed with the 
NP68 peptide, which was either presented by adoptively transferred in vitro generated, 
matured and peptide pulsed dendritic cells, or by endogenous antigen presenting cells, 
through the subcutaneous administration of NP68 peptide in IFA or intranasal infection with 
influenza A virus. This process was sometimes repeated in the same mouse to elicit a 
memory T cell response.
2.6.4a Preparation of in vitro generated dendritic cells
Matured dendritic cells were taken from culture and washed in HBSS. The cells were then 
pulsed with 5pM NP68 peptide for one hour at 37°C in 5% FCS DMEM. The cells were 
collected and washed once before being suspended to give the desired number of cells per 
mouse in lOOpI of HBSS. The cells were then transferred into the peritoneal cavity (see 
2.6.3d).
2.6.4b Preparation and administration of NP68 peptide in IFA
Mice were primed with lOOpg of NP68 peptide in lOOpI of incomplete Freund's adjuvant, 
with a final volume made to 200pl with PBS. The IFA and PBS were mixed and left on ice for 
an hour to ensure complete mixture. Subsequent to adding the peptide, the mixture was 
vortexed and 200pl drawn up in to a 1ml syringe via a 19G needle. Once aspirated, the 19G 
was replaced with a 26G needle and kept on ice until injection. Mice were manually 
restrained and the site of injection wiped with a sterile steret. The IFA/NP68 was transferred 
subcutaneously, adjacent to the hind leg on the underside of the mouse. The needle was
inserted to sufficiently cover the bevel, the mixture injected steadily and the needle 
removed carefully to avoid loss of IFA/NP68 from the bolus that had formed. In some 
experiments it was necessary to give two doses of IFA/NP68 at different times, therefore the 
second dose of IFA/peptide was injected on the contra-lateral side of the mouse.
2.6.4c Infection with Influenza A virus
The mice were manually restrained and positioned on their back. The virus was administered 
drop-wise on to the nasal openings of the mouse via a Gilson pipette boy fitted with a small 
pipette tip, ensuring each drop had been inhaled. The mice were maintained in scantainer 
cages with a negative flow of air in order to comply with health and safety regulations.
2.6.5 The provision of target cells
In order to assess the CD8+ T cell response, mice received cell populations that acted as 
targets for the cytotoxic T lymphocytes. These were either NP68 peptide-pulsed B16 cells or 
splenocytes cells, or B16 cells that expressed the NP68 epitope.
2.6.5a The generation of splenocyte target and reference cells for in vivo transfer
Spleens were harvested from adult C57BL/6J mice, with typically one spleen providing a 
sufficient number of cells for two recipient mice. Target cells were generated by pulsing 
splenocytes with 5pM NP68 peptide for 1 hour in complete DMEM containing 5% FCS, at 
37°C. Reference splenocytes were treated in the same manner but left unpulsed. The 
splenocytes were then washed once with HBSS and the target cells labelled with 0.2pM CFSE 
and the reference cells labelled with 2pM CFSE (see 2.2.2b). Following labelling, the cells 
were counted by trypan exclusion and the same number of each cell type combined to give 
an approximate 1:1 ratio of target to reference cells. Prior to the combination of the bulk of 
the cells, the 1:1 ratio of targets to reference cells was often confirmed by flow cytometry.
Aliquots containing the same cell number from each cell population were combined and 
analysed. A histogram displaying the CFSE peaks was gated on viable cells, as determined by 
forward and side scatter, to reveal the proportion of cells in each CFSE labelled population. If 
an unsatisfactory ratio was seen, adjusted aliquots were then combined and run through the 
flow cytometer to confirm the desired 1:1 ratio. If necessary, the adjustment was then 
applied to the bulk of the cells. Once combined the cells were kept on ice until required.
2.6.5b The generation of B16 cell targets
Target B16 cells that were pulsed with NP68 were generated in the same manner as for 
splenocytes (see 2.6.5a). The production of B16 cells expressing the NP68 epitope is 
described in 2.4.5.
2.7 In vivo assays
2.7.1 CD8+ F5 T cell expansion assay
Two protocols were utilised to gauge the in vivo expansion of CD8+ T cells, whereby both 
involved the transfer of 2-3xl06 CD8+ F5 T cells from motheaten and control mice to 
recipient mice. The mice were primed with NP68 in IFA followed by seven days of in vivo 
expansion, after which the spleens were harvested.
Protocol 1: The recipient mice were irradiated and of the strain C57BL/6J. Splenocytes 
prepared from the spleens of recipient mice were stained with an anti-CD8PE antibody alone 
or in combination with anti-Thyl.2FITC antibody. The latter is an allelic marker which is 
expressed in different forms by the donor (Thyl.2) and recipient mice (Thyl.l), and 
therefore offered a way of further distinguishing donor from recipient cells during cell 
cytometry. Dot plots were generated and a lymphocyte gate defined based upon a forward 
and side scatter profile. The proportion of CD8+ cells was revealed by applying the
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lymphocyte gate to a dot plot displaying PE fluorescence (CD8) versus side scatter. 
Alternatively, PE fluorescence (CD8) was displayed versus FITC (Thyl.2). The CD8 gates were 
defined using samples from mice that received no T cells and also unstained samples.
Protocol 2: Ragl_/' recipient mice were used. Once the spleens had been harvested, 5xl05 
CFSE labelled splenocytes were added to the intact spleens prior to processing and cell 
counting. The splenocytes were then labelled with anti-CD8PE antibody and analysed by flow 
cytometry. Dot plots were generated displaying CFSE (reference cells) and PE fluorescence 
(CD8) by gating on a lymphocyte population as determined by forward and side scatter. A 
defined number of CFSE labelled events was acquired, and the number of CD8+CFSE' events 
were then expressed as a percentage of the CFSE+ reference population.
2.7.2 CTL assays
2.7.2a Primary CD8+ T cell response
Once purified by immunomagnetic separation, 2.5-3.5xl06 naive motheaten and control 
CD8+ F5 T cells were transferred intravenously to sub-lethally irradiated C57BL/6J mice. 
Concomitant with T cell transfer, mice were primed by the peritoneal transfer of 3-4xl06 
matured and NP68 peptide-pulsed dendritic cells or by the subcutaneous injection of NP68 
peptide in IFA. Alternatively, mice were primed with influenza A virus four days prior to T cell 
transfer. Six days post T cell transfer, lOxlO6 splenocyte target cells (pulsed with 5pM NP68 
peptide) labelled with 0.2pM CFSE and lOxlO6 splenocyte reference cells labelled with 2pM 
CFSE (see 2.2.2b) were co-transferred to each mouse, including control mice that did not 
receive any T cells. Twenty-four hours post transfer, the spleens were harvested, 
homogenised and the red blood cells lysed ready for analysis by flow cytometry. Histograms 
were generated by electronically gating on both viable cells, as determined by forward and 
side scatter, and CFSE+ cells, with the necessary number of events acquired to give a
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minimum of 200 cell counts (as displayed on the y-axis of the histogram) of the reference 
cell peak (CFSE high). Gates were set for each peak to reveal the percentage of cells residing 
in each peak. The data from the control mice and the equation shown below were used to 
work out the percent-specific lysis, allowing for any deviation from the anticipated 1:1 ratio 
of target to reference cells,
Percent-specific lysis = 100 -  (((% of target cells with T cells /  % of reference cells with T cells) 
/  {% of target cells with no T cells /  % of reference cells with no T cells)) x 100).
2.7.2b Memory CD8+ T cell response
Between l-3x l06 purified naive control or motheaten CD8+ F5 T cells were transferred to 
recipient mice, which were primed with either NP68 peptide-pulsed dendritic cells (3-4 xlO6) 
or NP68 in IFA. Six weeks post transfer, mice were primed for a second time with either 
NP68 peptide pulse dendritic cells or NP68 in IFA, as described for the initial priming. Seven 
days post recall, mice received lOxlO6 of CFSE labelled target and reference splenocytes. 
Mice were then sacrificed and the spleens analysed as described for the primary CTL assay.
In total, four protocols were used to assess the memory CD8+ T cells response. These 
differed in three aspects of the assay; how the T cells were initially primed, the type of 
recipient to which the T cells were transferred to, and how the T cells were recalled to elicit 
a memory T cell response.
Protocol numbers 1, 2 and 3 utilised Rag I '1' mice as the recipient mice, but differed with 
respect to how the T cells were initially primed and then recalled six weeks later. Protocol 1 
utilised IFA/NP68 for both primings, protocol 2 used IFA/NP68 for the initial priming and 
DCs/NP68 for the recall priming, and protocol 3, which used DCs/NP68 for both.
Protocol 4 utilised irradiated C57BL/6J mice, which were primed with NP68 in IFA. Eight 
weeks post transfer and priming, mice were primed for a second time with NP68 peptide- 
pulsed dendritic cells. A two-tailed Mann-Whitney nonparametric test, with 95% confidence 
intervals was applied to generate p values.
2.7.2c Effector memory responses
To further dissect CD8+ T cell memory responses, refinements were made to the above 
protocols. Mice received T cells and were primed as for protocol 1 above, with some mice 
receiving a second dose of peptide to recall the memory response. Other mice were not 
primed for a second time but did go on to receive the target and reference cell populations 
in order to specifically look at the effector memory CD8 T cell response.
In other experiments, 3xl06 or 5xl06 in vitro activated and expanded control or motheaten 
CD8+ F5 T cells were transferred to irradiated C57BL/6J recipient mice. Six weeks post 
transfer the mice were primed with NP68 peptide in IFA and the assay continued as 
described above.
2.7.3 In vivo tumour assays
2.7.3a Detecting adoptively transferred B16 cells by flow cytometry
To study the tumour protective capabilities of control and motheaten CD8+ F5 T cells, 
experiments were performed that involved transferring B16 cells labelled with intracellular 
dyes. Two populations of cells that had been labelled with different dyes (DDAO and CFSE) or 
different concentrations of CFSE were transferred to the same recipient mouse. The cells 
were partnered as follows with the total number of cells transferred shown in brackets; 
0.2/2pM CFSE (1.2xl06), lOpM DDAO/2pM CFSE (2.5x10s), 0.2/3pM CFSE (8x10s) and 
0.5/4pM CFSE (8x10s). The mice were sacrificed twenty-four hours post transfer and the
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spleens and lungs taken for flow cytometry. Mice that received no B16 cells were used to 
define the gates for DDAO or CFSE fluorescence, by gating above the autofluorescence 
present in these mice. Dot plots were generated to show DDAO or CFSE fluorescence against 
side scatter or DDAO and CFSE on the same plot.
2.7.3b Tumour protection assay
This assay involved transferring control and motheaten CD8+ F5 T cells prior to the transfer 
of B16 cells expressing the NP68 epitope. Groups of 2 to7 sub-lethally irradiated C57BL/6J 
mice received either lxlO4, 2xl04, 3.2xl04, 5xl04, lxlO 5, lx lO 6 or 3xl06 purified naive CD8+ 
F5 T cells intravenously. At the same time mice were primed subcutaneously with NP68 
peptide in IFA. Two, four or seven days post T cell transfer, mice received an intravenous 
infusion of either lx lO 5 or 2.5x10s B16 cells expressing the NP68 epitope. Two weeks post 
B16 cell transfer mice were sacrificed and the tumour nodules within the lungs enumerated. 
In one experiment mice were weighed at various time points over the duration of the assay. 
In addition, blood was taken at defined time points during the assay, and the lungs 
processed following sacrifice, in order to study the adoptively transferred CD8+ T cells. In two 
experiments, the lungs of the mice were fixed in 2% paraformaldehyde (equal volumes of 4% 
paraformaldehyde and cell wash) prior to being photographed, courtesy of the Medical 
Illustration Department [School of Medicine, Cardiff University]. When enumerating the 
nodules of mice, a limit of detection was set at 425 nodules, as nodule numbers above this 
value could not be enumerated accurately. A two-tailed Mann-Whitney nonparametric test, 
with a 95% confidence interval was applied to generate p values.
2.7.3c Tumour regression assay
Recipient mice were injected subcutaneously with lx lO 5 B16 cells expressing the NP68 
epitope. The developing tumours were assessed regularly by wetting the tumour with water
and measuring the perpendicular diameters with callipers. Two weeks post tumour 
implantation, mice with similar sized tumours were irradiated and received an intravenous 
transfer of lx lO 6 naive control or motheaten CD8+ F5 T cells. Mice were primed 
subcutaneously at the same time with NP68 peptide in IFA, on the contra lateral side of the 
mouse to tumour growth. The tumour was measured for a further 10 days, at which point 
the mice were sacrificed. Data was expressed as an mean of the perpendicular tumour 
diameters for each mouse against the time points at which the data was collected.
2.7.3d Tumour protection versus enhancement
These assays utilised either irradiated C57BL/6 mice or C57BL/6 F5Hom mice and were 
prepared in the same manner as described above, but with some exceptions; the number of 
T cells transferred was 3xl06 or 1.8xl06 and the corresponding number of B16 cells 
transferred was 1x10s or 1.75x10s. No adoptive CD8+ T cell transfer was performed when 
C57BL/6 F5Hom mice were used as recipients. As before, a two-tailed Mann-Whitney 
nonparametric test, with a 95% confidence interval was applied to generate p values.
2.7.4 T cell migration studies
In order to study T cell migration, differentially labelled motheaten and control activated 
CD8+ F5 T cells were transferred to the same mouse. This was followed by their retrieval 
from target tissue 16-24 hours post transfer. Cells were labelled with either 0.5pM CFSE or 
lOpM DDAO, and between 20xl06 and 70xl06 total cells were transferred intravenously to 
irradiated recipient mice. It was important to ensure a single cell suspension was being 
transferred and that the cells were kept on ice at all times prior to transfer. The dyes used to 
label the cell population (motheaten or control) were alternated between each cell type to 
eliminate the possibility of any dye specific effects on the T cells being labelled.
2.7.4a Migration to the Peyer's patches
127
To induce tissue specific homing of T cells to the small intestine, T cells were activated and 
expanded in the presence of lOnM retinoic acid for 4-5 days prior to intravenous transfer.
2.7.4b Vaccinia infected ovaries
Mice were irradiated and infected with 2xl06 plaque forming units of recombinant vaccinia 
virus expressing the NP68 epitope by injection into the peritoneal cavity. Mice received the T 
cell infusions 4 days post Vaccinia infection.
2.7.5 T cell infiltration into the bowel
A total of lxlO 6 CD8+ T cells from control C57BL/6 F5hem mice were transferred to female 
Ragl'/_ mice. A group of mice that received T cells also received a subcutaneous injection of 
NP68 peptide in IFA. Control mice did not receive T cells or NP68. The mice were weighed at 
regular intervals over the duration of the assay on a bench-top balance under sterile 
conditions. The mice were sacrificed 8 weeks post T cells transfer and their spleens, 
mesenteric lymph nodes, small and large intestines taken for analysis.
2.7.5a Histological characterisation of gut tissue
Gut sections were fixed in NB formaldehyde solution (NBFS) for 16-24 hours at 4°C. The 
tissue was then placed in an automated Shandon Tissue Processor and taken through serial 
dehydration cycles of ethanol and xylene (70% Alcohol (1 hour and 30mins), 90% Alcohol 
(lhour and 30mins), 100% Alcohol (1 hour), 100% Alcohol (1 hour), 100% Alcohol (1 hour), 
100% Alcohol (1 hour), 100% Alcohol (1 hour), Xylene (lhour and 30mins at room 
temperature), Xylene (2 hours at 37° C), Xylene (2 hours at 45° C)), before being permeated 
with wax at 60°C (10% Wax (2 hours at 60° C), 50%Wax (lhour and 30mins at 60° C) 70% 
Wax (lhour and 30mins at 60° C), 100% Wax (lhour and 30mins at 60° C)). Tissue was then 
embedded in wax blocks using a Shandon Histocentre. Serial sections, of 7pm thickness,
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were cut with a microtome and situated on superfrost microscope slides [Menzel-Glaser, 
Braunschweig, Germany].
2.7.5b Haematoxylin and eosin staining of gut tissue sections
The staining of paraffin sections was carried out in a well ventilated area, with all reagents 
contained in glass-topped staining dishes. After each stage involving deparaffinisation, 
haematoxylin staining, eosin staining and dehydration, the sections were washed in running 
tap water for 5 minutes followed by rinsing in dH20.
The sections were deparaffinised by immersion in three changes of xylene, for 5 minutes 
each, followed by descending grades of alcohol (100% x 2, 90% and 70%), for 3 minutes in 
each. Sections were placed in Mayer's Haematoxylin [BD Laboratories] for 1.5 minutes and 
the stain intensified by placing the sections in Scott's tap water [Sigma] for 30 seconds. 
Sections were then stained in 1% eosin [Fisher] for 1 minute. Dehydration was achieved by 
placing the sections in ascending grades of alcohol (90% and 100% x 3) for 2-3 minutes, 
followed by 3 washes in xylene, for 5 minutes in each. Finally, sections were mounted in 
Ralmounts mounting media [BD laboratories] covered with a glass cover-slip and then 
incubated for 12-24 hours in a 45°C oven to set.
2.8 In vitro assays
2.8.1 CD107a assay
As the name suggest, lysosomal associated membrane protein-1 (LAMP-1, CD107a), is a 
molecule found on the membranes of lysosomes (Rohrer et al., 1996). CD107a appears at 
the cell surface when lysosomes of cytotoxic CD8+ T cells fuse with the cell surface 
membrane in order to deploy their cytotoxic granules. CD107a can therefore be used as a 
measure of cytotoxic function. A total of 5xl04 in vitro activated and expanded CD8+ F5 T
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cells were placed in a U-bottomed 96well plate with B16 cells that had either been pulsed 
with 5pM NP68 or left unpulsed. The ratio of T to B16 cells was titrated (5:8, 5:4 and 5:2 for 
the first experiment and 1:40, 1:20, 1:10, 1:5, 2:5 and 1:1 for the second experiment) and 
performed in triplicate. T cells were also cultured without B16 cells. Each well contained 
200pl of complete DMEM, 0.2pl of golgi-stop™ [BD Biosciences], which halts export of 
proteins from, the golgi, and also 0.5pg of FITC conjugated anti-CD107a monoclonal 
antibody. Cells were spun at 1300rpm for 2 minutes at room temperature then incubated at 
37°C for 4 hours. Cells were pelleted at 2000rpm for 3 minutes at 4°C followed by staining 
with anti-CD8PE antibody. Cells were analysed for CD107a expression by flow cytometry. 
Contour plots were generated by gating on viable CD8+ cells, and the CD107a gate set by 
using the data from the wells that contained T cells and no B16 cells.
2.8.2 In vitro regulatory T cell assay
An in vitro protocol was used to look at the proliferation of control and motheaten CD8+ F5 T 
cells in the presence or absence of regulatory T cells (Tregs). For optimisation of assay 
conditions anti-CD3Bl° antibody coated (5pg/ml in PBS overnight at 4°C then 1 hour at 37°C 
prior to culture) or un-coated U-bottomed 96 well plates and anti-CD3B'° antibody coated 
flat-bottomed plates were used to culture T cells. Control CD8+ F5 T cells were purified from 
lymph nodes and labelled with 2pM CFSE and cultured with or without irradiated 
splenocytes from Ragl^' mice, with the number of T cells and splenocytes used per well as 
follows; 5x 104/ 2x 105, 10x 104/4x 105, 15x 104/2x 105 and 15xl04/6xl05. For the actual assay, 
15xl04 CFSE labelled T cells were co-cultured with 2xl05 Ragl'^ splenocytes on anti-CD3Bl° 
antibody coated U-bottomed plates. The Tregs were purified from the spleens of adult 
C57BL/6 mice based on CD4 and CD25 expression using immunomagnetic beads [Miltenyi 
Biotech]. Briefly, CD4 expressing T cells were selected first by depletion of non-CD4+ cells 
using an anti-biotin antibody cocktail and anti-biotin microbeads. Subsequently, CD25
expressing CD4 cells were selected by labelling the cells with anti-CD25PE and anti-PE 
microbeads. The ratios of T cell to Tregs were as follows; 0:1, 1:10, 1:5, 1:2, 1:1, 2:1 and 4:1 
with each condition performed once apart from the ratio of 0:1, which was performed in 
triplicate. T cells were also cultured in the absence of antibody, splenocytes and Tregs. For 
both the optimisation and final assay the cells were cultured for 72h at 37°C and once 
harvested, stained with anti-CD8PE antibody. During the analysis of flow cytometry data, 
histograms displaying CFSE were gated on viable CD8+ cells. The T cells that had been 
cultured alone were used to define the undivided CFSE peak. For the optimisation data the 
undivided peak was used to give a proliferation gate, with the proportion of cells residing 
within this gate established for each condition. For the final assay, the undivided peak was 
used in conjunction with the proliferation tool of FloJo software to establish how many T 
cells from the original population had entered in to proliferation. This data was then used to 
work out the percentage inhibition using the equation below:
Percentage inhibition = 100 - ((proportion of T cells entering in to proliferation from the 
initial population in the presence of Tregs /  proportion of T cells entering in to proliferation 
from the initial population in the absence of Tregs) x 100)
2.8.3 In vitro cytotoxicity assay
Two protocols were utilised to look at the killing of B16 cells. The first protocol was used to 
assess the degree of target cell killing by activated motheaten and control CD8+ F5 T cells. 
The second protocol was used to establish whether B16 cells infected with a retrovirus 
encoding NP68/GFP were displaying NP68:MHC class I complexes.
Protocol 1: Wild-type B16 cells were removed from culture and either pulsed with 5pM 
NP68 peptide at 37°C, in complete media (5% FCS) for 1 hour, or left unpulsed. The cells 
were washed once with HBSS by centrifugation at 1400rpm for 4 minutes at 4°C.
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Subsequently, the target cells that had been pulsed with NP68 peptide were labelled with 
0.2pM CFSE and the reference B16 cells that had not been pulsed were labelled with 2pM 
CFSE. Following labelling, the cells were counted by trypan blue exclusion and 15xl03 of each 
placed in the wells of U-bottomed 96 well plates. Previously activated and expanded CD8+ F5 
T cells were added to each well to give the following T cell to B16 cell ratios: 1:2, 1:1, 3:2 and 
2:1. The number of T cells added was based upon the total number of B16 cells present in 
each well. B16 cells were also cultured without T cells and an aliquot of T cells kept to aid 
analysis. Each condition was repeated in triplicate. Once the cells had been combined, the 
plate was spun at 1500rpm for 2 minutes then incubated at 37°C. After 4 hours, the cells 
were harvested by centrifugation and stained with anti-CD8PE antibody ready for analysis by 
flow cytometry. Histograms displaying CFSE were generated by gating on a CFSE+, CD8' and 
viable cell population. Gates were set for each CFSE peak and the proportion of cells that 
resided in each gate established. The data from the wells where the B16 cells were cultured 
without T cells and the equation shown in 2.7.2a was used to calculate the percent-specific 
lysis for each condition.
Protocol 2: An equal number B16 GFP/NP cells and wild-type B16 cells were placed in the 
wells of either 96 well flat bottomed plates (total of 2xl04 B16 cells) or 24 well plates (total 
of 8xl04 B16 cells) and allowed to adhere to the plastic overnight. The media was removed 
and replaced with complete DMEM. Previously activated and expanded CD8+ F5 T cells were 
placed in each well to give a CD8+ T cell to B16 cell ratio of 2:1 (4xl04 T cells for 96 well 
plates and 1.6xl05 T cells for 24 well plates). The B16 cells were also cultured in the absence 
of T cells. After 16 hours, the media was aspirated to remove dead or dying B16 cells along 
with the CD8+ T cells, followed by 1 further wash. The remaining cells were incubated with 
trypsin for 5 minutes and washed ready for staining with anti-CD8PE antibody prior to 
analysis by flow cytometry. Histograms were generated to display GFP fluorescence by
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gating on a viable CD8'cell population. Gates were set for each peak and proportion of GFP+ 
cells (target cells) compared to the autofluorescence from the wild-type B16 cells (reference 
cells).
2.9 Silencing of SHP-1 expression using shRNA technology
2.9.1 Candidate siRNA sequences for 5HP-1
A number of different online algorithms were used by James Hindley [Department of 
Medical Biochemistry and Immunology, Cardiff University] to identify siRNA target sites 
within the human SHP-1 transcript. The algorithms were performed with an integrated 
BLAST search to eliminate the possibility of non-specific targeting. Annotation of a map of 
the SHP-1 transcript sequence with the ten highest ranked target sites from each algorithm, 
allowed for the selection of the six most frequently identified potential target sites for 
cloning and functional testing.
2.9.1a Synthesis and annealing of the oligonucleotides
Oligonucleotides were synthesised for subcloning of the SHP-1 shRNA inserts in to the pTER+ 
vector. Each shRNA insert consisted of a 19 nucleotide (figure 2.1) and were flanked by 
overhanging Hind III and Bgl II restriction sites.
Complementary oligonucleotides were annealed in annealing buffer (lOOmM KAc, 2mM 
MgAc and 30 mM HEPES-KOH pH 7.4) by boiling for 5 minutes in a water bath, followed by 
cooling to room temperature.
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1)825
5'-G AT CCCGGT G AATGCGGCT G ACATTTTCAAG AG AAAT GT CAGCCGCATT CACCTTTTTGG AAA-37
2)989
5'-GATCCCGCAAGAACCGCTACAAGAATTCAAGAGATTCTTGTAGCGGTTCTTGCTTTTTGGAAA-3'
3)1112
5'-G ATCCCGCCCT GAT G AG AACGCTAATT CAAG AG ATT AGCGTT CT CAT CAGGGCTTTTTGG AAA-3'
4 )1236
5'-G AT CCCGG AG AAAGGCCGG AACAAATT CAAG AG ATTT GTT CCGGCCTTT CT CCTTTTTGG AAA-3'
5)1341
5'-G AT CCCAT ACAAACT CCGT ACCTT ATT CAAG AG AT AAGGT ACG G AGTTT GTAI I I I I IGGAAA-3'
6 )1550
S'-GATCCCGCACAGGCACCATCATTGTTTCAAGAGAACAATGATGGTGCCTGTGCTTTTTGGAAA^'
Figure 2.1 Synthesised shRNA sequences
Each shRNA consists o f a siRNA sense sequence (blue, underlined), a loop sequence (red), a 19 
nucleotide siRNA antisense sequence (blue) and five thym idines, which acts as a stop signal 
fo r RNA polymerase III. The num ber assigned to  each sequence represents the firs t base o f 
the 19 nucleotide target sequence.
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2.9.1b Cloning annealed oligonucleotides into the pTER+ plasmid
Ligation reactions were used to transform competent Escherichia Coli strain, DH5a, using 
heat shock for 20 seconds at 37°C. Transformed bacteria were then grown without selection 
in 1 ml of LB medium for 1 hour to allow synthesis of plasmid-encoded antibiotic resistant 
proteins. An aliquot (lOOpI) of the culture was streaked on to LB agar plates containing 
lOOpg/ml ampicillin and allowed to grow for 16 hours at 37°C. Untransformed cells were 
also cultured on ampicillin plates to ensure ideal selection conditions for the colonies that 
had been chosen. Colonies were picked from the agar plate and grown for 16-18 hours in 
5mls of LB broth containing lOOpg/ml of ampicillin. The plasmid was purified for each clone 
and the DNA quantitated using a spectrophotometer followed by sequencing of the shRNA 
inserts.
2.9.1c Sequencing the oligonucleotide inserts
Between 700-1000ng of plasmid DNA was used for PCR amplification ready sequencing. Up 
to 11.5pl of the DNA was added to 9.5pl of PCR reaction mixture (4pl of 5X primer, 4pl 5X 
enzyme and dNTP mixture (containing labelled ddNTPs) and 1.5pl of bovine growth hormone 
oligonucleotide). The PCR was performed on a Hybaid Omne-E for the following cycles: 96°C 
for 30 seconds, 50°C for 30 seconds and 60°C for 4 minutes (x25). The DNA was precipitated 
by the addition of 30pl dH20, 5pl sodium acetate and 140pl of ethanol to the DNA and 
incubation for 20 minutes at -20°C. The DNA was washed with 70% ethanol, collected by 
centrifugation at 13000rpm for 20 minutes, and resuspended in 150pl of ethanol ready for 
sequencing by the DNA sequencing facility of Cardiff University [Central Biotechnology 
Services, Henry Wellcome Research Institute, Cardiff University]. Clones with the correct 
DNA insert were amplified, purified and quantified.
2.9.Id  Functional testing of candidate shRNA sequences in Jurkat cells
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As Jurkat cells are transformed T cells, they express SHP-1 and were therefore used to test 
shRNA sequences targeting SHP-1. The Jurkat cells were transferred to fresh media (RPMI 
with 10% FCS) 24 hours prior to transfection with the plasmid DNA encoding the shRNA 
sequences. Between l-2x l07 cells were used per transfection. The cells were taken from 
culture, washed twice in HBSS by centrifugation at 1500rpm for 5 minutes at 4°C and then 
suspended to. give the desired number of cells in 400pl of complete RPMI. For each 
transfection, 15pg of the shRNA expression plasmid and 3pg of a GFP expression plasmid 
(pAL-190) were combined and sodium acetate (l/10th of the volume) and ethanol (2.5 times 
the volume) added before precipitating at -20°C for 20 minutes. The DNA was then collected 
by centrifugation at 13000 rpm for 10 minutes at 4°C, and allowed to dry at room 
temperature before being suspended in lOOpI of transfection buffer (10X HeBs buffer (1.4M 
NaCI, 249mM HEPES acidic, 3mM NahP04), 625pg/ml Herring sperm DNA and plain RPMI) 
with no additives. The DNA was added to the cells in a 4mm mammalian transfection 
cuvette. Cells were electorporated at 140 volts and 1000 pFar (capacitance) on a GenePulse 
Xcell electroporator [Bio-Rad]. The cells were left on ice for 10 minutes and then returned to 
culture for 48 hours before being single cell sorted. The cells were taken from culture and 
suspended in 500pl of complete RPMI in a FACS tube. Cells that had been electroporated in 
the absence of DNA were used to define a GFP positive gate. Cells that had been 
electroporated in the presence of DNA were sorted based on viability and GFP fluorescence. 
Cells were then analysed for SHP-1 expression by western blot analyses.
2.9.2 MISSION™ siRNA
Four sequence-verified shRNA lentiviral plasmids designed to target human SHP-1 (Accession 
number NM_002831) expression were purchased from Sigma as bacterial stocks. The 
parental plasmid background (pLKO.l-puro) contains a puromycin resistant gene, a U6
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prom ote r to  drive expression o f the  shRNA and a 21 nucleotide siRNA sense sequence fo r 
human SHP-1 (figure 2.2).
1) 2091
5'-CCGGCCTCTCCCTGACCCTGTATATCTCGAGATATACAGGGTCAGGGAGAGGTTTTT-3'
2)1712
5'-CCGGCCCAGTT CATT G AAACCACT ACT CG AGTAGTGGTTT CAAT G AACT G GGTTTTT -3"
3 )1326
5'-CCGGGCATGACACAACCGAATACAACTCGAGTTGTATTCGGTTGTGTCATGCTTTTT-3'
4 )1572
5'-CCGGCG ACAT G CT CAT G G AG AACAT CT CG AG AT GTT CT CCAT GAG CAT GT CGTTTTT-3'
5 )444
5'-CCGGCGGCACCAT CAT CCACCT CAACT CG AGTT G AGGTGG AT G ATGGTGCCGTTTTT-3'
Figure 2.2 MISSION™ siRNA shRNA sequences
Each shRNA sequence consists o f a sense siRNA sequence (blue, underlined), a loop sequence 
(red) and an antisense sequence (blue).
2.9.2a Functional testing o f the MISSION™ shRNA sequences in Hela cells
Hela cells expressing human SHP-1 were cultured in a T75 flask and allowed to  reach 50% 
confluence. A calcium phosphate transfection k it [Sigma A ldrich] was used according to  the 
m anufacturer's instructions to  produce a calcium phosphate precip ita te  contain ing 20pg o f
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the desired DNA, which was added to the cell cultures. The following day the media was 
aspirated and replaced with 10ml of complete DMEM containing 0.4pg/ml of puromycin, 
and lmg/ml of G418. The media was changed every 4 days, and the cells cultured for 4 
weeks prior to western blot analysis to evaluate SHP-1 expression.
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Chapter 3 
Exploring the role of SHP-1 in T cells during in vivo antigenic stimulation
3.1 Introduction
In vitro data has demonstrated that motheaten CD8+ T cells hyper-proliferate in response to 
antigenic stimulation when compared to control CD8+ T cells. This data has revealed that a 
greater proportion of motheaten T cells from a naive population enter into cell division upon 
stimulation with APCs loaded with cognate peptide (Sathish et al., 2007). These findings 
correlate with data showing that a greater proportion of motheaten versus control CD8+ T 
cells down regulate their TCRs when incubated with APCs presenting cognate peptide, which 
is a measure of antigen encounter by CD8+ T cells. It was further demonstrated that 
motheaten CD8+ T cells have the enhanced capability of forming more stable conjugates 
with APCs loaded with cognate peptide, which underlies, at least in part, the hyper- 
proliferative phenotype of motheaten CD8+ T cells. In other in vitro studies it has been 
shown that CD8+ T cells with a reduced level of SHP-1 expression exhibit an enhanced 
chemotactic response to a chemokine gradient (Kim et a i, 1999). It is therefore conceivable 
that T cells lacking SHP-1 expression may exhibit an enhanced response in an in vivo setting.
The impact of these in vitro observations has not been explored in an in vivo setting. 
Therefore, it was important to make this transition in the study of the role of SHP-1 in CD8+ T 
cells, as the physical requirements of a CD8+ T cell in a mammalian system during 
immunosurveillance and response to antigen are very different to that of a T cell that is 
interacting with APCs in tissue culture. Briefly, naive CD8+ T cells are endowed with receptors 
that allow them to adhere to and cross cellular barriers, thus leaving the cardiovascular 
system and entering secondary lymphoid organs. It is here that they may encounter their 
cognate antigen, and with the necessary requirements met become activated and undergo
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clonal expansion. An activated T cell then enters the lymphatics and returns to the 
cardiovascular system, from which it homes to peripheral sites of infection or tumour 
development, which also involves the adherence to and crossing of cellular barriers. It is in 
the periphery that a CD8+ T cell can then exert its effector function by specifically killing 
target cells. In addition, extrinsic factors to the T cell, such as the action of regulatory T cells 
and availability of cytokines, may influence the dynamics and magnitude of an antigenic 
driven CD8+ T cell response in an in vivo setting.
In order to study the in vivo role of SHP-1 in CD8+ T cells during an antigenic response, CD8+ T 
cells from motheaten and control mice were purified and adoptively transferred to recipient 
mice. Alternatively, naive T cells were first activated in vitro and expanded in the presence of 
IL-2 prior to their transfer to recipient mice. The adoptive transfer of T cells overcomes the 
early mortality associated with motheaten mice, which precludes any in vivo T cell studies 
being performed within these mice. The adoptive transfer also removes the T cells from an 
abnormal cytokine environment within the motheaten mouse, which could impact upon T 
cell behaviour. The study of antigenic T cell responses was feasible as the T cells from the 
motheaten and control mice expressed a transgenic TCR, F5, which can be stimulated with 
APCs presenting the cognate peptide, NP68. The T cells were either studied directly by 
recovering them from the recipient mice and using antibodies compatible with flow 
cytometry or the T cells were labelled prior to their transfer, to allow for their detection at 
different sites within the recipient mouse. To study T cell responses indirectly, mice that had 
already received naive CD8+ T cells went on to receive a population of target cells and the 
magnitude of the response assessed by the extent of target cell killing. An additional in vitro 
assay was also performed to explore the impact regulatory T cells on CD8+ T cell responses 
to antigenic stimulation.
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3.2 Mouse bone marrow cells cultured with GM-CSF are enriched for CDllc* cells and up- 
regulate CD86 following maturation with LPS
In order to conduct in vivo experiments exploring the role of SHP-1 in CD8+ T cells during 
antigenic stimulation, it was necessary to prime recipient mice that had received naive CD8+ 
F5 T cells. To achieve this goal, a protocol for generating dendritic cells in vitro from mouse 
bone marrow precursor cells was initially used.
Firstly, the supernatant from a GM-CSF producer cell line obtained from Professor Kim 
Bottomly (Yale University) was assessed for its ability to produce DCs, as it offered an 
economically favourable alternative to commercially available GM-CSF.
Cells harvested from the bone marrow of mice were cultured with either commercially 
available GM-CSF (lOng/ml or 20ng/ml at different time points) or supernatant from a GM- 
CSF producer cell line (used at 1% or 2% final volume at different time points). Following 10 
days of culture with commercial GM-CSF, the proportion of cells expressing the dendritic cell 
marker, CDllc, went from 5.6% to 77% (figure 3.1). The proportion of immature cells co­
expressing CDllc and the costimulatory molecule, CD86, was 1.79% and 9.44% for those 
cultured with commercially available GM-CSF and GM-CSF supernatant respectively (figures 
3.2A and B). Following maturation for a period of 24 hours with LPS, the proportion of cells 
co-expressing CDllc and CD86 was 21.9% and 21% for the cells cultured with commercially 
available GM-CSF and GM-CSF supernatant respectively (figures 3.2A and B).
3.3 In vitro generated dendritic cells present NP68 peptide to naive CD8* F5 T cells
To ensure that the in vitro generated dendritic cells were capable of presenting NP68 
peptide to naive CD8+ F5 T cells they were utilised in an in vitro T cell proliferation assay.
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Once matured, the dendritic cells were pulsed with NP68 peptide and co-cultured with CFSE 
labelled naive CD8+ F5 T cells. Cells were analysed by flow cytometry and histograms 
generated and analysed using the proliferation tool of FlowJo software. Following four days 
of culture, 42.4% (figure 3.3A) and 59.7% (figure 3.3B) of the CD8+ T cells from the original 
population had entered into proliferation when cultured with DCs generated with either 
commercial GM-CSF or GM-CSF supernatant respectively. No spontaneous division of the T 
cells was seen in the absence of dendritic cells (data not shown).
3.4 Mice receiving naive CD8* F5 T cells and in vitro generated dendritic cells pulsed with 
NP68 peptide are capable of killing NP68 loaded target cells
To establish whether in vitro generated dendritic cells could both function and present NP68 
peptide in vivo, they were pulsed with NP68 peptide and co-transferred with CFSE labelled 
naive CD8+ F5 T cells to recipient mice. Upon transfer, DCs and T cells are required to migrate 
to secondary lymphoid organs prior to interacting with one another. Labelling the T cells 
with CFSE allowed T cell division to be tracked, which was used as a measure of how 
effective the DCs were at functioning in vivo.
DCs that had been generated by culturing bone marrow cells with commercially available 
GM-CSF were transferred intravenously (tail vein), subcutaneously (inguinal region) or into 
the peritoneal cavity of individual recipient mice. The intravenous cotransfer of dendritic and 
T cells proved to be detrimental to the mice as it lead to death soon after transfer, therefore 
the subcutaneous and peritoneal administration sites were explored further. Four days post 
dendritic cell and T cell transfer, the spleen, axial, brachial and inguinal lymph nodes were 
harvested and T cell proliferation assessed by flow cytometry. Figure 3.4 shows that the 
percentage of T cells entering into proliferation in mice receiving DCs either subcutaneously 
or peritoneally respectively was 23% and 32% in the spleen, 38% and 42% for the pooled
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axial and brachial lymph nodes, and 36% and 50% for the inguinal lymph nodes. In light of 
this data and the fact that the peritoneal transfer of DCs offered the most straightforward 
means of injecting a mouse all subsequent experiments involving dendritic cells used the 
peritoneal route of delivery.
To compare the efficiency of matured dendritic cells generated with either commercially 
available GM-CSF or GM-CSF supernatant to present NP68 peptide in vivo, DCs were 
transferred into the peritoneal cavity of individual sub-lethally irradiated mice that had also 
received naive CD8+ F5 T cells. Six days post T cell transfer the mice received CFSE labelled 
target (0.2pM) and reference cells (2pM), to assess the magnitude of the T cell response. 
The spleens were harvested after a further 24 hours for analysis by flow cytometry. A mouse 
receiving DCs generated with commercially available GM-CSF killed 47.5% of the target cells, 
compared to 48% of the target cells killed in the mouse receiving DCs generated with GM- 
CSF supernatant (figure 3.5).
Overall, it was established that mouse bone marrow cells cultured with supernatant 
containing GM-CSF produced DCs that could function and present NP68 peptide to 
adoptively transferred CD8+ F5 T cells as well as those raised with commercial GM-CSF. In 
addition, the transfer of dendritic cells to the peritoneal cavity of mice provided a 
convenient and effective way to administer the cells and prime CD8+ F5 T cells.
3.5 Mice receiving naive CD8* F5 T cells and the influenza A virus are able to kill NP68 
labelled target cells
As an alternative to using exogenous DCs to prime mice, the enlistment of endogenous DCs 
and other APCs to present NP68 peptide to CD8+ F5 T cells was assessed.
As the NP68 peptide is derived from the nucleoprotein of the influenza A virus, it was 
assessed whether infection with the virus could prime a transferred population of naive
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CD8+F5 T cells. Four mice were sublethally irradiated and three of them infected intranasally 
with the influenza A virus. Four days post infection, CFSE labelled lymphocytes from control 
F5 mice were transferred to one infected and one uninfected mouse. Four days later mice 
that had received T cells were sacrificed and their spleens and submandibular lymph nodes 
taken for analysis by flow cytometry. Histograms were generated and a gate set for those 
cells that had entered in to proliferation to reveal the percentage of cells residing within this 
gate. Figure 3.6 shows that a similar proportion of the transferred cells in the spleen (17%) 
and submandibular lymph nodes (19%) from the infected mouse and in the spleen (18%) 
from the uninfected mouse, were in the proliferating population. However, a greater 
proportion of cells were in the proliferating population (37%) in the submandibular lymph 
nodes of the mouse that had been infected (figure 3.6B).
Six days post T cell transfer the remaining two mice that received unlabelled T cells received 
CFSE labelled target and reference cells. Twenty-four hours later the mice were sacrificed 
and their spleens taken for analysis by flow cytometry. The infected mouse that received the 
lymphocytes killed 77.4% of the target cells (figure 3.6D).
The use of the influenza A virus to prime adoptively T cells had the potential to allow for the 
study of motheaten and control CD8+ F5 T cells in a system that is physiologically relevant 
with regards to the priming of the T cells. However, the necessity to prime mice with the 
virus prior to T cell transfer did not allow assays to be performed at short notice, which was 
often the case with motheaten mouse availability.
3.6 Mice receiving naive CD8+ F5 T cells and NP68 in IFA are able to kill NP68 labelled 
target cells
In order to explore other methods of priming mice receiving CD8+ F5 T cells which were 
more flexible, IFA was used to deliver NP68 to mice.
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Sub-lethally irradiated mice were injected subcutaneously (inguinal region) with NP68 
peptide in a mixture of incomplete Freund's adjuvant and PBS. Six days post T cell transfer 
and priming, mice received a population of CFSE labelled target (0.2pM) and reference cells 
(2pM). After a further 24 hours the spleens were taken for analysis by flow cytometry. Mice 
receiving T cells and primed with NP68 peptide in IFA killed 48% of the target cells (Figure 
3.7). This offered a more logistically convenient way of priming adoptively transferred CD8+ T 
cells as the motheaten mice were often available at short notice with the need for 
immediate use, which did not leave time for dendritic cells to be produced or mice to be 
primed with influenza virus.
3.7 Mice receiving naive motheaten CD8+ F5 T cells kill .more target cells during a primary T 
cell response than those mice receiving naive control CD8+ F5 T cells
In order to examine the magnitude of the in vivo response of both motheaten and control 
CD8+ F5 T cells to antigenic stimulation, the same number of naive CD8+ T cells from both 
control and motheaten mice were transferred to individual recipient mice. The T cell 
response was then measured indirectly by performing an assay that looked at the ultimate 
role of a CD8+ T cell, which is to directly kill target cells.
Sub-lethally irradiated mice received 3-3.8xl06 purified naive CD8+ F5 T cells intravenously. 
Mice were primed by the transfer of matured and NP68 peptide pulsed DCs into the 
peritoneal cavity. Control mice did not receive any T cells. Six days later, mice received CFSE 
labelled target (0.2pM) and reference (2pM) cells in order to assess the magnitude of the T 
cell response.
The data from three independent experiments demonstrated that mice receiving naive 
motheaten CD8+ F5 T cells killed more target cells than those mice receiving control naive 
CD8+ F5 T cells. The extent of target cells killed by mice receiving either control or
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motheaten T cells was 47% versus 69% (figure 3.8), 56% versus 84% (figure 3.9) and 54% 
versus 70% (data not shown) respectively.
3.8 Enhanced accumulation of motheaten CD8+ T cells in the spleens of recipient mice 
compared to the spleens of mice receiving control CD8+ T cells
In order to explore the possible reasons underlying the enhanced killing of peptide labelled 
target cells seen in mice receiving motheaten T cells, assays were performed that examined 
the in vivo expansion of control and motheaten CD8+ F5 T cells.
Purified naive motheaten and control CD8+ F5 T cell populations (2-3xl06) were transferred 
to sub-lethally irradiated mice. Mice were subcutaneously primed at the same time as T cell 
transfer with NP68 peptide in IFA. Control mice did not receive any T cells. Seven days later 
spleens were removed and the cells counted by trypan blue exclusion and stained with anti- 
CD8pe antibody (and for some assays also stained with anti-Thyl.2FITC antibody). The CD8+ T 
cells were expressed as a proportion of a lymphocyte gate, which was determined by the 
forward and side scatter profiles of the cells. This data was then used to calculate the 
absolute CD8+ T cell number (figure 3.10). From four independent experiments those mice 
receiving naive motheaten T cells had consistently more CD8+ T cells of a lymphocyte gate 
compared to mice receiving control T cells (summarised in figure 3.10). However, the data 
seemed to vary considerably between experiments, with the primary concern being the 
extent to which the total number of splenoctyes and also the percentage of cells residing 
within a lymphocyte gate varied between mice. To overcome the possibility that the process 
of red blood lysis was adversely affecting the total cell counts and that the irradiation of 
mice could have differing affects on the lymphocyte compartment of individual mice a 
second protocol was developed.
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In order to circumvent the need for irradiation, Rag-1 '^ mice were selected for use as 
lymphopaenic recipients. In addition, in order to control for the loss of cells during red blood 
cell lysis, a reference population of cells was introduced to the protocol to act as an internal 
control.
Rag-1 '^ mice received 3xl06 purified CD8+ F5 T cells and a subcutaneous injection of NP68 
peptide in IFA. Seven days post T cell transfer, spleens were removed and a defined number 
of CFSE labelled reference cells added to each sample prior to processing. Single cell 
suspensions were then prepared, stained with anti-CD8PE antibody and analysed by flow 
cytometry. A defined number of CFSE+ cell events were acquired and the CFSE/CD8* cells 
expressed as a comparative percentage of the CFSE+ reference cell population. In the mouse 
receiving naive motheaten CD8+ T cells the percentage was 31% compared to 16% for the 
mouse receiving naive control CD8+ T cells (Figure 3.11).
3.9 Mice receiving activated motheaten CD8+ F5 T cells kill more target cells than mice 
receiving activated control CD8+ F5 T cells
An in vitro study had previously shown that motheaten CD8+ F5 T cells they have an 
equivalent cytotoxic activity on a per cell basis to that of control CD8+ F5 T cells, when the 
target cells were NP68 peptide pulsed EL4 cells (Johnson et al., 1999). In order to explore the 
in vivo cytotoxic function of motheaten and control T cells on a per cell basis, equal numbers 
of in vitro generated activated T cells were transferred to recipient mice, which then 
received target cells to kill.
Naive CD8+ F5 T cells were activated in vitro for two days with NP68 pulsed splenocytes and 
then expanded for a further two days in IL-2. Initially, different numbers of activated control 
or motheaten CD8+ F5 T cells were transferred to establish an optimum T cell number in 
relation to the number of target and reference cells transferred (20xl06 in total). Therefore,
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lOxlO6, 20xl06 and 30xl06 of control CD8+ F5 T cells were transferred to individual mice. 
Twenty-four hours later the mice received CFSE labelled target (2pM) and reference (0.2pM) 
cells, which were subsequently retrieved from the spleen after a further twenty-four hours. 
Those mice receiving lOxlO6 control CD8+ F5 T cells killed 89.3% and 74.8% of the targets 
(figure 3.12B), compared to 95%, 94.9% and 96.4% of the target cells killed by the mice that 
received the same number of motheaten CD8+ F5 T cells (figure 3.12E). Mice that received 
20xl06 control CD8+ F5 T cells killed 95.3% and 95% of the targets (figure 3.12C). Finally, one 
mouse that received 30xl06 control T cells killed 92.9% of the target cells (figure 3.12D).
As the killing within these mice had reached a near maximum, the number of T cells 
transferred in a subsequent experiment was reduced. Mice received 2xl06 control or 
motheaten T cells. Those receiving the control T cells killed 1.07%, 3.7% and 3.9% of the 
target cells (figure 3.13B), compared to 16%, 21% and 24% of the target cells killed in mice 
receiving motheaten T cells (figure 3.13C). This was not statistically significant (p=0.100) 
according to a non parametric Mann-Whitney test.
In a third independent experiment mice received 5xl06 of either control or motheaten T 
cells. Those mice receiving control T cells killed 32%, 38.6% and 41.1% of the target cells 
(figure 3.14B), whereas those receiving motheaten T cells killed 42%, 52% and 52.9% of the 
target cells (figure 3.14C). Again, this was not statistically significant (p=0.100) according to a 
non parametric Mann-Whitney test.
3.10 Altered ratios of motheaten CD8+ F5 T cells in the blood and Payer's patches of 
recipient mice
As the efficiency at which naive and activated CD8+ T cells home to secondary lymphoid 
organs and peripheral sites may influence the outcome of an antigenic CD8+ T cell response,
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a protocol was developed to compare the homing capabilities of control and motheaten 
CD8+ F5 T cells.
The primary reason for these experiments was to further investigate the underlying basis for 
the enhanced killing of peptide labelled targets by mice receiving SHP-1 deficient CD8+ T cells 
when compared to those receiving control CD8+ T cells. In support of a SHP-1 effect on T cell 
migration, in vitro studies have demonstrated that a reduction in SHP-1 expression in T cells 
leads to an enhanced chemotactic response (Kim et al., 1999). In addition, SHP-1 has been 
shown to play an important role in myeloid cell adhesion and homing, as demonstrated in 
the motheaten mouse (Shultz et al., 1997) and by in vitro studies (Roach et al., 1998).
Ideally, the homing capacity of both naive and activated CD8+ T cells would be studied but 
the limited availability and young age of motheaten mice meant that not enough naive T 
cells would have been available to transfer to recipient mice at any one time. The vast 
number of secondary lymphoid organs in a recipient mouse would have resulted in a wide 
distribution of a limited number of transferred naive T cells and therefore precluded 
detection by flow cytometry. As a result naive T cells were first activated and expanded in 
vitro to generate enough T cells to transfer in vivo.
It has been previously reported that T cells primed in the presence of retinoic acid exhibit a 
preferential homing capacity to gut associated tissue (Stagg et al., 2002). This offered a 
means of focusing the migratory behaviour of transferred activated T cells to a site that 
could be harvested and analysed. In order to study the homing capabilities of motheaten 
and control T cells in parallel within the same mouse, two intracellular dyes were used to 
differentially label the T cells. When labelling motheaten and control T cells for transfer, 
both dyes were used for both cell types to eliminate the possibility of any dye induced 
effects on the T cells.
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The intracellular dye CFSE had already been used for labelling T cells destined for various 
assays; therefore a second intracellular dye was required to label T cells. The first 
requirement of a prospective partner dye for CFSE was that its emission spectra was 
different to that of CFSE. The dye also needed to be non-toxic to cells and resistant to 
excessive bleaching when exposed to light. The intracellular dye, DDAO, met these 
requirements and was therefore used to label T cells.
Firstly, the Peyer's patches, which are lymphoid clusters found along the length of the small 
intestine, were excised from C57BL/6 mice to confirm that T cells could be detected in this 
gut associated lymphoid tissue. Samples were stained in order to examine both T cells and B 
cells by flow cytometry. Figure 3.15A revealed populatkms of both lymphocytes residing in 
the Peyer's patches. This meant that adoptively transferred T cells should potentially migrate 
to this tissue.
Initial concentrations of retinoic acid (lpM) proved to be toxic to the T cells, so the final 
concentration used for T cell culture was lOnM. Lymphocytes from control and motheaten 
mice were co-cultured for 2 days with irradiated splenocytes loaded with NP68 peptide, then 
expanded for 3 days with IL-2. Initially, a CFSE labelled population of control CD8+ F5 T cells 
was transferred to non-irradiated recipient mice. Upon harvesting the Peyer's patches, the 
CFSE labelled cells could not be distinguished from the autofluorescence of this tissue. 
Therefore, T cells were transferred to either Rag-17' mice or sub-lethally irradiated mice, 
which possess no or limited numbers of lymphocytes at this site respectively. The Peyer's 
patches in the Rag-17’ were difficult to detect and therefore excise, but this was not the case 
for the Peyer's patches in the irradiated mice. Twenty four hours post transfer CFSE labelled 
cells were present in the blood, spleen and Peyer's patches (figure 3.15C, D and E). A lower 
proportion of CFSE labelled cells was seen in the mesenteric (figure 3.15G), axial, brachial 
(figure 3.15H) and inguinal lymph nodes (Figure 3.15F). In an independent experiment, T
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cells that had been activated in vitro in the absence of retinoic acid did not appear in the 
Peyer's patches twenty-four hours post transfer, but were present in the blood, spleen and 
lungs (figure 3.16).
Twenty-four hours following the transfer of 25xl06 of both motheaten and the control 
activated CD8+ F5 T cells that had been labelled with either CFSE or DDAO, the blood and 
Peyer's patches were taken for analysis by flow cytometry. In two independent experiments, 
recipient mice had a greater proportion of motheaten compared to control T cells in their 
blood. Conversely, mice had a greater proportion of control versus motheaten T cells in their 
Peyer's patches. The ratio of motheaten T cells to control T cells in the blood of mice was 
1.66:1 (CFSE:DDAO) and 1.63:1 (DDAO:CFSE) for the first experiment (Figure 3.17B and C), 
and 2.3:1 (CFSE:DDAO) and 1.56:1 (DDAO:CFSE) for the second experiment (Figure 3.18C and 
D). The ratio of motheaten T cells to control T cells in Peyer's patches in the first experiment 
was 0.68:1 (CFSE:DDAO) and 0.65:1 (DDAO:CfSE) (figure 3.17E and F), and for the second 
experiment it was 0.46:1 (CFSE:DDAO) and 0.78:1 (DDAO:CFSE) (figure 3.18F and G).
Due to the ability of T cells to both enter and exit the Peyer's patches, it was decided that 
this was not an ideal model for studying T cell migration. Ideally, the tissue to which the T 
cells migrate would be the final destination for the T cells, thereby leading to their 
accumulation in the tissue. Consequently, this would allow any differences in the numbers of 
motheaten or control CD8+ T cells found in the tissue to be attributed to their capacity to 
migrate.
3.11 In vitro activated T cells labelled with intracellular dyes are evident in the ovaries of 
Vaccinia virus infected and non-infected mice following adoptive transfer
In addition to using the Peyer's patches as a tissue to study T cell homing, virally infected 
tissue was also evaluated as a possible means to study the homing capabilities of motheaten
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and control CD8+ T F5 cells. The vaccinia virus has a tropism for the ovaries when transferred 
into the peritoneal cavity of mice.
T cells were activated for 2 days with irradiated splenocytes pulsed with NP68 peptide, then 
expanded for a further two days in IL-2. A total of 20xl06 control T cells was labelled with 
either the intracellular dye, DDAO, or CFSE and transferred intravenously to mice that had 
been infected four days previously with recombinant vaccinia virus expressing the NP68 
peptide. The same number of labelled T cells was also transferred to a mouse that had not 
been infected with the vaccinia virus. The ratio of CFSE to DDAO labelled cells was checked 
by flow cytometry prior to adoptive transfer (figure 3.19A), with a ratio of 1.52:1 in favour of 
CFSE labelled cells. Twenty-four hours following the transfer of the T cells, the blood, spleen 
and ovaries were taken from each mouse for analysis by flow cytometry. The T cells were 
present in all tissues taken from both the infected and un-infected mice. The CFSE to DDAO 
labelled cell ratios for the infected and uninfeeted mice respectively, were 1.05:1 and 0.88:1 
in the blood, 1.02:1 and 1.02:1 in the spleens and 1.43:1 and 1.21:1 in the ovaries (figure 
3.19).
In light of these observations it would be necessary to repeat such experiments and establish 
whether the total number of cells differed between infected and uninfected mice.
3.12 Motheaten CD8+ F5 T cells exhibit a greater resistance to regulatory T cell induced 
inhibition on T cell proliferation than control CD8+ F5 T cells
The regulatory influence of CD4+CD25+Foxp3+ T cells on CD8+ T cells can have profound 
effects upon the outcome of a T cell response to antigen. In vitro assays were performed to 
establish whether there were any differences in the resistance of control and motheaten 
CD8+ T cells to the action of regulatory T cells. This assay looked at the proliferation of CFSE
152
labelled naive control and motheaten CD8+ F5 T cells in the presence or absence of 
CD4+CD25+ regulatory T cells.
Firstly, pilot experiments were performed to establish the ideal tissue culture conditions to 
give optimum T cell proliferation in the absence of regulatory T cells. This was achieved by 
culturing T cells in U- or flat-bottomed 96 well plates, in the presence or absence of both 
anti-CD3B'° antibody (coated plates) and irradiated splenocytes (devoid of T cells).
Anti-CD3Bl° antibody or splenocytes were used in isolation to stimulate 5xl04 CD8+ T cells in 
U-bottomed 96 well plates. This induced means of 45% and 10% of the respective T cells to 
appear in a dividing gate (figure 3.20A). Anti-CD3Bl° antibody was also used in combination 
with either 2xl05 or 4xl05 splenocytes to stimulate 5xl04 or lOxlO4 T cells respectively. This 
resulted in means of 18% and 32% of the T cells residing in the proliferating gate respectively 
(figure 3.20A).
In a second control assay, anti-CD3Bl° antibody was used in combination with 2xl05 or 6xl05 
splenocytes to stimulate 15xl04 T cells in either U- or flat-bottomed 96 well plates. This 
resulted in means of 70% and 71% of T cells cultured in the U-bottomed plates in the 
dividing gate compared to means of 60% and 61% for those in flat-bottomed plates (figure 
3.20B).
For the final assay, a total of 15xl04 motheaten or control T cells labelled with CFSE was 
cultured in U-bottomed 96 well plates coated with anti-CD3Bl° and 2x10s splenocytes. 
Regulatory T cells were purified by immunomagnetic separation based upon CD4 and CD25 
expression and added to each well to give the following Treg to T cell ratios; 0:1, 1:10, 1:5, 
1:1, 1:2, 2:1, 4:1. Each condition was performed singly apart from the 0:1 ratio, which was 
performed in triplicate. The T cells were co-cultured for four days and then harvested and 
stained with anti-CD8PE antibody and analysed by flow cytometry. Histograms displaying
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CFSE fluorescence were gated on viable and CD8+ cells. The histograms were analysed using 
the proliferation tool of FlowJo software. The undivided peak was set using the data from 
wells of T cells that had been cultured without Tregs and anti-CD3Bl° antibody (figure 3.21). 
This setting was then applied to each of the histograms to give the percentage of cells that 
had entered into proliferation from the initial T cell population. From this data, the 
percentage of inhibition was calculated (figure 3.22) by comparing the proportion of T cells 
that had entered in to proliferation in the presence of Tregs (ratios 1:10 to 4:1 for figures 
3.21A and B) to the proportion of T cells that had entered into proliferation in the absence of 
Tregs (0:1 ratio for figures 3.21A and B). Figure 3.22 shows this data graphically, with a 
greater inhibition of control CD8+ F5 T cell proliferation detected than that detected for 
motheaten CD8+ F5 T cell proliferation at all Treg to T cell ratios. At the Treg to T cell ratios of 
1:10 and 1:5, motheaten CD8+ F5 T cells were not inhibited, whereas there was 16.5% and 
21.4% inhibition of control CD8+ F5 T cell proliferation. At the four higher Treg to T cell 
ratios, the percentage inhibition for control CD8+ F5 T cells was 28.5% (0.5:1), 46.8% (1:1), 
38.2% (2:1) and 58.8% (4:1), whereas for motheaten CD8+ F5 T cells this was 8.9% (0.5:1), 
25.8% (1:1), 21% (2:1) and 36.6% (4:1) (figure 3.22).
3.13 Summary of results
The employment of adoptive cell transfer techniques during this study allowed motheaten 
and control CD8+ F5 T cells to be studied in an in vivo setting. This represented an advance in 
the study of SHP-l's role in CD8+ T cells.
All methods trialled for the priming of mice (adoptive transfer of in vitro generated DCs 
pulsed with NP68, infection with the influenza A virus and subcutaneous injection of NP68 in 
IFA) that received CD8+ F5 T cells, proved to be successful. Logistically, the subcutaneous
injection of NP68 in IFA proved to be most convenient when considering the sporadic nature 
of motheaten mice availability and the age that they had to be used.
It was demonstrated that mice receiving motheaten (SHP-1 deficient) CD8+ F5 T cells and in 
vitro cultured DCs exhibited and enhanced primary T cell response, with regards to the 
expansion of the motheaten CD8+ T cells and as a result, the proportion of NP68 labelled 
target cells killed.
To further explore the possible reasons underlying the enhanced killing of peptide labelled 
targets seen in the absence of SHP-1, attempts were made to investigate other aspects of T 
cell function in vivo. Moreover, in addition to the assays used to study in vivo T cell 
expansion, assays were also developed to explore in vivo T cell migration and in vivo 
cytotoxicity on a per cell basis. These assays would require further optimisation in order for 
conclusive data to be obtained.
Finally, an in vitro assay was developed to explore the regulatory action of Tregs on the 
proliferation of motheaten and control CD8+ F5 T cells. Although the assay worked in 
principle, with T cell proliferation being inhibited in the presence of the Tregs, the assays 
would need repeating in order for data to be validated.
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Figure 3.1: Bone marrow cells cultured with GM-CSF are enriched for CDllc+ cells
Bone marrow was harvested form C57BL/6 mice and cultured with commercially 
available GM-CSF for ten days. The cells were then harvested and stained with anti- 
CD11cfitc antibody and analysed by flow cytometry. Freshly harvested bone marrow was 
also stained with anti-C D llcFITC antibody. The dot plots generated were gated on viable 
cells and the gate set according to the autofluorescence seen in an unstained sample 
(data not shown). The proportion of bone marrow cells expressing C D llc  was 5.6% and 
after ten days of culture this increased to 77%.
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Figure 3.2: Mouse bone marrow cells cultured with supernatant containing GM-CSF or commercially 
available GM-CSF for 10 days have a similar proportion of CD11+CD86+ cells after maturation with LPS
Bone marrow cells from mice were cultured with supernatant containing GM-CSF (1% and 2% at 
different time points) or commercially available GM-CSF (lOng/ml or 20ng/ml at different time points) 
for 10 days. Cells were matured for 24 hours in the presence of 20pg/ml of LPS. Cells were taken before 
and after maturation and stained with anti-CD llcPE and anti-CD8FITG antibodies ready for flow 
cytometry. Pseudocolour dot plots were gated on a viable cell population to show C D llc  and CD86 
expression. Unstained cells were used to set the quadrant and the percentages of cells residing in each 
quarter shown. The proportion of the cells co-expressing C D llc  and CD86 went from 9.44% when 
immature to 21% once matured (A) for the cells that were cultured with GM-CSF supernatant and from 
1.79% to 21.9% for the cells cultured with commercially available GM-CSF (B).
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Figure 3.3: Mouse bone marrow cells cultured with supernatant containing GM-CSF or 
commercially available GM-CSF present NP68 peptide to CD8+ F5 T cells
Bone marrow cells from mice were cultured with supernatant containing GM-CSF (1% and 2% at 
different time points) or commercially available GM-CSF (lOng/ml or 20ng/ml at different time 
points) for 10 days. Dendritic cells were then matured and pulsed with NP68 peptide. Dendritic 
cells from both sources were then co-cultured with CFSE labelled purified naive CD8+ F5 T cells 
for four days. The cells were then analysed by flow cytometry and the histograms displayed to 
show CFSE fluorescence. The data was analysed by FlowJo software to reveal the number of 
cells from the original T cell population that had entered into proliferation, with the 
percentages shown for each histogram. When naive CD8+ F5 T cells were cultured with dendritic 
cells that had been generated by culturing with commercially available GM-CSF, 42.4% of them 
entered into proliferation (A). For the T cells cultured with GM-CSF supernatant, 59.7% of them 
entered into proliferation (B).
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Figure 3.4: Adoptively transferred naive CD8* F5 T cells proliferate in mice receiving NP68 
loaded dendritic cells
Dendritic cells were generated by culturing mouse bone marrow cells with commercially 
available GM-CSF. They were matured with LPS and pulsed with NP68 peptide prior to being 
transferred to recipient mice. A total of lxlO6 dendritic cells were transferred either 
subcutaneously (A) or in to the peritoneal cavity (B) of individual mice. Mice also received 
4xl06 naive control CD8+ F5 T cells labelled with 4pM CFSE. Four days later the mice were 
sacrificed and the spleens and axial, inguinal and brachial lymph modes taken and prepared 
for flow cytometry. Histograms displaying CFSE were gated on viable and CFSE* cells. A gate 
was set over the T cells that had entered into proliferation and the percentage of cells within 
this gate displayed for each histogram. T cell proliferation was present in all lymphoid tissues 
taken from both mice.
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Figure 3.5: Mouse bone marrow cells cultured with supernatant containing GM-CSF or 
commercially available GM-CSF are able to present NP68 peptide to F5 T cells in an in vivo 
context
Bone marrow cells from mice were cultured with supernatant containing GM-CSF (1% and 2% at 
different time points) or commercially available GM-CSF (lOng/ml or 20ng/ml at different time 
points) for 10 days. Dendritic cells were then matured and pulsed with NP68 peptide. A total of 
3x l06 dendritic cells were transferred into the peritoneal cavity of irradiated mice at the same 
time as the intravenous transfer of 2x l06 purified naive control CD8+ F5 T cells. Six days later, 
mice received lOxlO6 target (0.2pM CFSE and pulsed with NP68) and lOxlO6 reference 
splenocytes (2pM CFSE) intravenously. Twenty-four hours post transfer, mice were sacrificed 
and their spleens taken for analysis by flow cytometry. The percentage of target cells killed is 
shown for each histogram. Any deviation from the anticipated 1:1 ratio of target to reference 
cells in the mice not receiving T cells (A) was used to adjust the percentage killing in the mice 
receiving T cells. The mouse that received naive T cells and dendritic cells that had been 
cultured with commercially available GM-CSF killed 47.5% of the target cells (B) and the mouse 
that received the dendritic cells that had been cultured with GM-CSF supernatant killed 48% of 
the target cells (C).
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Figure 3.6: Mice receiving naive CD8+ F5 T cells and the influenza A virus were able to mount a T cell 
response
Four mice were sub-lethally irradiated and three of them were infected intranasally with the influenza A 
virus (B, C and D). Four days later one mouse that had been infected (B) and one that was uninfected (A) 
received CFSE labelled lymphocytes from control F5 mice. The two remaining infected mice received 
unlabelled lymphocytes from control F5 mice (C and D). Four days post transfer the mice that received 
CFSE labelled lymphocytes were sacrificed and their spleens and submandibular lymph nodes taken for 
analysis by flow cytometry. Histograms were gated on viable and CFSE* cells with a gate showing cells that 
had entered into proliferation. A similar proportion of cells was found in the proliferating gate in the 
spleens from both mice (A and B) and in the submandibular lymph nodes of the uninfected mouse (A). A 
greater proportion of cells in the submandibular lymph nodes was seen in the proliferating gate from the 
infected mouse (B). Six days post T cell transfer the mice that received unlabelled lymphocytes received 
CFSE labelled target and reference cells. Twenty-four hours later the spleens were taken for analysis by 
flow cytometry. Any deviation from the anticipated 1:1 ratio of target to reference cells was adjusted for 
by using the data from the infected mouse that did not receive any T cells (C). The infected mouse that did 
receive naive CD8+ F5 T cells killed 77.4% of the target cells (D).
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Figure 3.7: A mouse receiving naive control CD8+ F5 T cells and NP68 subcutaneously in IFA was 
able to kill NP68 loaded target cells
A sub-lethally irradiated mouse received 3xl06 naive control CD8+ F5 T cells and also a 
subcutaneous injection of NP68 in IFA (B). A control mouse did not receive any T cells (A). Six days 
following T cell transfer, mice received CFSE labelled target (pulsed w ith NP68) and reference cells. 
Twenty-four hours later, mice were sacrificed and their spleens removed for analysis by flow 
cytometry. The percentage of target cells killed is shown for each histogram. Any deviation from 
the anticipated 1:1 ratio was corrected for by using the data from the control mouse (A). The 
mouse that received naive CD8+ F5 T cells killed 48% of the target cells (B).
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Figure 3.8: A mouse receiving naive motheaten CD8+ F5 T cells kills more target cells during a primary 
T cell response than a mouse receiving naive control CD8+ F5 T cells
Sub-lethally irradiated mice received 3.8xl06 naive control (B) or motheaten (C) CD8+ F5 T cells 
intravenously and a peritoneal transfer of 3x l06 in vitro matured and NP68 pulsed dendritic cells. A 
control mouse (A) did not receive any T cells. Six days post T cell transfer, mice received lOxlO6 target 
(0.2|iM CFSE and pulsed with NP68) and lOxlO6 reference splenocytes (2pM CFSE) intravenously. 
Twenty-four hours post transfer, mice were sacrificed and their spleens taken for analysis by flow 
cytometry. Histograms were gated on viable and CFSE+ cells. The percentage of target cells killed is 
shown for each histogram. Any deviation from the anticipated 1:1 ratio o f target to reference cells in 
the mice not receiving T cells (A and D) was used to adjust the percentage killing in the mice receiving T 
cells. Those mice receiving naive motheaten CD8+ F5 T cells (C) killed more target cells than those 
receiving control CD8+ F5 T cells (B).
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Figure 3.9: A mouse receiving naive motheaten CD8+ F5 T cells kills more target cells during a 
primary T cell response than a mouse receiving naive control CD8+ F5 T cells
Sub-lethally irradiated mice received 3x l06 naive control (B) or motheaten (C) CD8+ F5 T cells 
intravenously and a peritoneal transfer of 3x l06 in vitro matured and NP68 pulsed dendritic cells. A 
control mouse (A) did not receive any T cells. Six days post T cell transfer mice received lOxlO6target 
(0.2pM CFSE) and lOxlO6 reference splenocytes (2pM CFSE) intravenously. Twenty-four hours post 
transfer mice were sacrificed and their spleens taken for analysis by flow cytometry. Histograms 
were gated on viable and CFSE+ cells. The percentage of target cells killed is shown for each 
histogram. Any deviation from the anticipated 1:1 ratio of target to reference cells in the mice not 
receiving T cells (A and D) was used to adjust the percentage killing in the mice receiving T cells. The 
mouse that received naive motheaten CD8+ F5 T cells (C) killed more target cells than the mouse that 
received control CD8+ F5 T cells (B).
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Figure 3.10: Mice receiving naive motheaten CD8+ F5 T cells have more CD8+ cells in their 
spleens than mice receiving control CD8+ F5 T cells
Naive CD8+ F5 T cells were purified from control and motheaten mice. Either 3x l06 (A) or 
2x l06 (B, C and D) of each population were transferred intravenously to recipient mice. Each 
mouse was primed subcutaneously with NP68 peptide in IFA. Seven days post T cell transfer 
each mouse was sacrificed and the spleen removed for analysis, following red blood cell lysis 
the splenoctyes were counted by trypan blue exclusion. The cells were then stained with 
anti-CD8PE (A and B) and anti-Thyl.2FITC (C and D) antibodies and analysed by flow cytometry. 
A lymphocyte gate was defined as determined by forward and side scatter and the 
percentage of CD8+ or CD8+Thyl.2+ of this gate established for each mouse. In turn the 
absolute number of CD8+ T cells was determined by using the initial cell counts. For each 
independent experiment the mice that received naive motheaten CD8+ F5 T cells had 
consistently rr\ore CD8+ cells in their spleens than mice that received control CD8+ F5 T cells.
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Figure 3.11: A mouse receiving naive motheaten CD8+ F5 T have a greater proportion of CD8+ cells 
in their spleen after seven days, when compared to a mouse receiving naive control CD8+ F5 T 
cells
Rag-1'7' mice received 3x l06 naive control (B) or motheaten (C) CD8+ F5 T cells intravenously and a 
subcutaneous injection of NP68 peptide in IFA. A control mouse (A) did not receive any T cells. 
Seveh days post transfer the mice were sacrificed and their spleens taken. Prior to  homogenisation 
a defined number of CFSE labelled splenocytes was added to each sample before labelling with anti- 
CD8pe antibody. The cells were then analysed by flow cytometry, during which a defined number of 
CFSE+ cell events was acquired. Histograms were gated on a lymphocyte population to display the 
CD8+ cells. The percentages represent the proportion of CD8+ cells in comparison to the CFSE 
labelled reference cells. For the mouse that received naive control CD8+ F5 T cells this was 16% (B), 
in comparison to 31% for the mouse that received naive motheaten CD8+ F5 T cells (C).
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Figure 3.12: Mice receiving in v itro  activated control or motheaten CD8+ F5 T cells were able to kill target cells
Naive CD8+ F5 T cells from control and motheaten mice were activated in vitro w ith NP68 peptide-pulsed 
splenocytes for 2 days and expanded for a further 2 days with IL-2. Cells were washed and prepared for 
intravenous transfer to recipient mice. Mice received eitherlOxlO6 (B), 20xl06 (C) or 30xl06 (D) of control CD8+ 
F5 T cells or lOxlO6 motheaten CD8+ F5 T cells (E). A control mouse did not receive any T cells. Twenty-four 
hours later all mice received target and reference cell populations via an intravenous injection. Twenty-four 
hours later the mice were sacrificed and the spleens taken and prepared for analysis by flow cytometry. 
Histograms were generated by gating on viable and CFSE+ cells, with the percentage of target cells killed 
displayed for each histogram. Any deviation from the anticipated 1:1 ratio of target to reference cells was 
adjusted for by using data from the mouse that did not receive any T cells (A).
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Figure 3.13: Mice receiving activated motheaten CD8+ F5 T cells kill more target cells than mice 
receiving activated control CD8+ F5 T cells
Naive CD8+ F5 T cells from control and motheaten mice were activated in vitro with NP68 peptide- 
pulsed splenocytes for 2 days followed by further expansion for 2 days with IL-2. Cells were washed 
and prepared for intravenous transfer to recipient mice. A total of 2 x l06 of control or motheaten 
CD8+ F5 T cells were transferred to each mouse. A control mouse did not receive any T cells. Twenty- 
four hours later all mice received target and reference cell populations via an intravenous injection. 
Twenty-four hours later the mice were sacrificed and the spleens taken and prepared for analysis by 
flow cytometry. Histograms were generated by gating on viable and CFSE+ cells, with the percentage 
of target cells killed displayed for each histogram. Any deviation from the anticipated 1:1 ratio of 
target to reference cells was adjusted for by using data from the mouse that did not receive any T 
cells (A). All three mice that received activated motheaten CD8+ F5 T cells (B) killed more of the 
target cells than the mice that received activated control CD8+ F5 T cells (C).
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Figure 3.14: Mice receiving activated motheaten CD8+ F5 T cells kill more target cells than mice 
receiving activated control CD8+ F5 T cells
Naive CD8+ F5 T cells from control and motheaten mice were activated in vitro with NP68 peptide- 
pulsed splenocytes for 2 days and further expanded for 2 days with IL-2. Cells were washed and 
prepared for intravenous transfer to recipient mice. A total of 5x l06 of control or motheaten CD8+ F5 
T cells were transferred to each mouse. A control mouse did not receive any T cells. Twenty-four 
hours later all mice received target and reference cell populations via an intravenous injection. 
Twenty-four hours later the mice were sacrificed and the spleens taken and prepared for analysis by 
flow cytometry. Histograms were generated by gating on viable and CFSE+ cells, with the percentage 
of target cells killed displayed for each histogram. Any deviation from the anticipated 1:1 ratio of 
target to reference cells was adjusted for by using data from the mouse that did not receive any T 
cells (A). All three mice that received activated motheaten CD8+ F5 T cells (B) killed more of the 
target cells than the mice that received activated control CD8+ F5 T cells (C).
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Figure 3.15: CD8+ F5 T cells activated and expanded in vitro in the presence of retinoic acid are 
found in the Peyer's patches of a recipient mouse
The Peyer's patches from C57BL/6 mice contained both T cells and B cells (A), suggesting 
transferred T cells would migrate to this tissue. Naive control CD8+ F5 T cells were activated in vitro 
and expanded in IL-2 for 5 days in total. This was done in the presence of lOnM retinoic acid. A 
mouse was sub-lethally irradiated twenty-four hours prior to the intravenous transfer of 25xl06 T 
cells labelled with 2pM CFSE. The blood, spleen, Peyer's patches, inguinal lymph nodes, brachial 
lymph nodes and axial lymph nodes were taken twenty-four hours postT cell transfer and prepared 
for flow cytometry.' Dots plots were gated on a lymphocyte gate, as determined by forward and 
side scatter. The pre-transfer CFSE labelled cells (B) were used to define the CFSE+ gate with the 
percentage of cells residing within this gate shown for each plot. The labelled cells were present in 
the blood (C), spleen (D) and Peyer's patches (E), with less in the mesenteric lymph nodes (G). Small 
numbers were present in the inguinal (F), axial and brachial lymph nodes (H).
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Figure 3.16: CD8+ F5 T cells activated in vitro  in the absence of retinoic acid are found in the 
blood, spleen and lungs but not the Peyer's patches of recipient mice
CD8+ F5 T cells were activated in vitro and expanded in IL-2 for 5 days in total. This was done in the 
absence of retinoic acid. Mice were sub-lethally irradiated twenty-four hours prior to the 
intravenous transfer of 25xl06 T cells labelled with 2pM CFSE. The blood, spleen, Peyer's patches, 
and lungs were taken 24 hours post T cell transfer and prepared for analysis by flow cytometry. The 
dots plots were gated on a lymphocyte gate as determined by forward and side scatter. The pre­
transfer CFSE labelled cells (A) were used to define the CFSE+ gate with the percentage of cells 
residing within this gate shown for each plot. The labelled cells were present in the blood (B), 
spleen (C) and lungs (D) but not in the Peyer's patches (E).
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Figure 3.17: Altered ratios of motheaten CD8+ F5 T cells in the blood and Peyer's patches of recipient mice
CD8+ F5 T cells from motheaten and control mice were activated in vitro and expanded in IL-2 in the 
presence of retinoic acid. Mice were sub-lethally irradiated twenty-four hours prior to the intravenous 
transfer of 25xl06 motheaten and 25xl06 control T cells to the same mouse. The T cells were labelled with 
either 2pM CFSE or lOpM DDAO, and the dyes reversed for each T cell type to eliminate the possibility of 
any dye induced effects on the T cells. Two mice received T cells; the first had CFSE labelled motheaten T 
cells and DDAO labelled control T cells (B and E). The second mouse received DDAO labelled motheaten T 
cells and CFSE labelled control T cells (C and F). A third mouse did not receive any T cells (A and D). The pre­
transfer ratio of motheaten to control T cells was established by flow cytometry (data not shown) and any 
deviation from the anticipated 1:1 ratio was later used to adjust the ratios of the cells harvested from mice. 
The contour plots are gated on a lymphocyte gate as determined by forward and side scatter, with the two 
gates shown set above the background from the mouse that did not receive any T cells (A and D). The 
percentage of cells residing in each gate is shown, and the ratio of motheaten to control T cells is shown in 
the lower left of each plot. For both mice, a greater proportion of motheaten T cells was found in the blood 
compared to control T cells (B and C). In the Peyer's patches a greater proportion of control T cells was 
found in comparison to motheaten T cells (E and F).
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Figure 3.18: Altered ratios of motheaten CD8+ F5 T cells in the blood and Peyer's patches of recipient 
mice
Motheaten and control CD8+ F5 T cells were activated in vitro and expanded in IL-2 in the presence of 
retinoic acid. Sub-lethally irradiated mice received 25xl06 motheaten and 25xl06 control T cells. One 
mouse received motheaten T cells labelled with CFSE and control T cells labelled with DDAO (C and F). 
The second mouse received CFSE labelled motheaten T cells and DDAO labelled control T cells (D and G). 
A third mouse did not receive any T cells (B and E). The contour plots were gated on a lymphocyte gate 
with the two fluorescent gates set above the background from the mouse that did not receive any T 
cells (B and E). The percentage of cells is shown for each gate and the ratio of motheaten to control T 
cells is shown in the lower left o f each plot. The ratio was adjusted for any deviation from the 
anticipated 1:1 ratio o f DDAO labelled to CFSE labelled cell by using the pre-transfer plots. For both 
mice, a greater proportion of motheaten T cells was found in the blood compared to control T cells (C 
and D). In the Peyer's patches a greater proportion of control T cells was found in comparison to 
motheaten T cells (F and G).
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Figure 3.19: Activated CD8+ F5 T cells labelled with DDAO or CFSE are detected in the ovaries of 
recipient mice
Mice were sub-lethally irradiated twenty-four hours prior to peritoneal injection of lx lO 6 P.F.U. 
of recombinant Vaccinia virus encoding the NP68 epitope. Four days post Vaccinia infection mice 
received at total of 20xl06 CD8+ F5 T cells that were labelled with either CFSE or DDAO. The T 
cells had been activated in vitro and expanded for four days with IL-2. Immediately prior to 
intravenous transfer o f the T cells the ratio o f DDAO labelled to CFSE labelled cells was confirmed 
by flow cytometry (A). Twenty-four hours post adoptive transfer o f T cells the mice were 
sacrificed and the blood, spleen and ovaries taken and prepared for flow cytometry. Contour 
plots displaying fluorescence were gated on a viable cells and the autofluorescence seen in the 
mouse that did not receive T cells was gated out. The percentage of cells residing in each 
quadrant is shown for each plot. Labelled cells were detected in the blood, spleen and ovaries of 
both the infected and un-infected mice (C and D). The proportion of DDAO and CFSE labelled T 
cells in the tissues of the mice was similar to the proportion that was initially transferred (A).
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Figure 3.20: Optimal naive CD8+ F5 T cells proliferation seen in anti-CD3Bio coated U- 
bottomed plates when co-cultured with splenocytes
Flat-bottomed and U-bottomed plates were coated with 5pg/ml of anti-CD3B,° antibody 
overnight at 4°C and then incubated at 37°C for an hour. Either 5xl04 (a), lOxlO4 (a) or 
15xl04 (b) purified CD8+ CFSE (2pM) labelled T cells were plated out with antibody alone 
(a and b), splenocytes alone (a) or with antibody and different numbers (in brackets) of 
splenocytes from Ragl7' mice. Three days later cells were harvested and labelled with 
CD8pe. Cells were then analysed by flow cytometry and the percentage of cells in the 
proliferating gate plotted for comparison.
A) Motheaten CD8+ F5 T cells B) Control CD8+ F5 T cells
175
cuu
Figure 3.21: Regulatory T cells inhibited both naive control and motheaten CD8+ F5 T cells 
proliferation
Naive CD8+ F5 T cells were purified from control and motheaten mice and labelled with 2pM CFSE. 
Regulatory T cells were purified form the spleens o f adult C57BL/6 mice based upon CD4 and CD25 
expression. These were co-cultured fo r four days with splenocytes from Rag-17' mice in U-bottomed 
96 well plates coated with anti-CD3Bl° antibody. This was done at seven Treg to T cell ratios, as shown 
for each histogram. T cells were also cultured alone in un-coated plates. Each condition was 
performed once apart from the 0:1 ratio, which was performed in triplicate. Cells were harvested 
and stained with anti-CD8PE antibody and analysed by flow cytometry. Histograms displaying CFSE 
fluorescence were gated on CD8+ cells. Data was analysed using the proliferation tool of FlowJo 
software. The undivided population (in red) was defined using the data from wells were T cells were 
cultured w ithout Tregs and anti-CD3B'° antibody. This was set for each histogram plot to reveal the 
percentage of cells from the original population that had entered in to proliferation (shown for each 
histogram, with the mean displayed for the 0:1 ratio). From this data the percentage inhibition was 
calculated (Figure 3.22).
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Figure 3.22: Greater regulatory T cell induced inhibition on naive control CD8+ F5 T cell 
proliferation than on naive motheaten CD8+ F5 T cell proliferation
Naive CD8+ F5 T cells were purified from control and motheaten mice and labelled with 2pM CFSE. 
Regulatory T cells were purified form the spleens of adult C57BL/6 mice based upon CD4 and CD25 
expression. These were co-cultured fo r four days with splenocytes from Rag-17' mice in U-bottomed 
96 well plates coated w ith anti-CD3Bl° antibody. This was done for seven Treg to T cell ratios. Each 
condition was performed once apart from the ratio of 0:1, which was performed in triplicate. Cells 
were harvested and stained w ith anti-CD8PE antibody and analysed by flow cytometry. Histogram 
displaying CFSE fluorescence were gated on CD8+ cells and analysed using the proliferation tool of 
FlowJo software (figure 3.21). The percentage inhibition was then calculated by comparing the 
proportion of naive T cells that had entered into proliferation for each condition with the 
proliferation seen when the T cells had been cultured w ithout Tregs (this figure). At each ratio a 
greater degree of Treg induced inhibition of T cell proliferation was seen for control CD84 F5 T cells 
than motheaten CD8+ F5 T cells.
Chapter 4
Investigating the role of SHP-1 in in vivo CD8+ T cell memory responses
4.1 Introduction
An important feature of CD8+ T cells is their ability to persist as memory cells, which are 
capable of responding more efficiently upon re-encounter with cognate antigen. 
Consequently, a memory T cell pool has the potential to provide enhanced protection 
against viral infection or tumour development and therefore the factors influencing memory 
CD8+T cell generation and behaviour require investigation.
Memory CD8+ T cells differentiate during a primary response when naive CD8+ T cells are 
stimulated by cognate antigen. In humans, there are two main memory CD8+ T cell subtypes, 
known as central and effector. The subtypes are distinguished based upon their role and 
tissue location (Sallusto et ol., 1999), as determined by their expression of key genes. Central 
memory CD8+ T cells act as stem cells for the memory T cell pool, as they maintain the ability 
to divide. They are predominantly found in secondary lymphoid organs as they express cell 
surface molecules that allow them to home to these sites. Effector memory CD8+ T cells are 
mainly found in peripheral tissue and have the potential to exert immediate cytotoxic 
function as they produce molecules that are able to directly kill target cells.
Thus far, the potential role of SHP-1 in memory CD8+ T cell has not been explored, in either 
an in ex-vivo or in vivo context. However, the adaptation of protocols and assays developed 
during this study to look at primary in vivo CD8+ T cell responses to antigen has additionally 
allowed SHP-1 deficient CD8+ F5 T cells to be studied in in vivo memory responses.
Briefly, naive CD8+ F5 T cells were purified from both control and motheaten mice and 
transferred to individual recipient mice, which were primed with NP68 peptide. Mice were
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left for a defined period to allow a memory T cell pool to form, which was then recalled with 
a second dose of NP68 peptide. The memory CD8+ T cell response mounted by the recipient 
mice was assessed by providing CFSE labelled target (0.2pM) and reference (2pM) cells, as 
described above in chapter three. Control mice for each experiment did not receive any T 
cells but subsequently received the target and reference cells. Data from the control mice 
was used to adjust for any deviation from the anticipated 1:1 ratio of target to reference 
cells in recipient mice. During analysis, histograms were generated by gating on a viable and 
CFSE+ cell population.
During this study, experiments were performed that utilised different modes of priming the 
naive and memory CD8+ T cells within recipient mice, with the aim of defining a protocol to 
study memory CD8+ F5 T cells. In addition, a number of pilot experiments were performed, 
which had the potential to further dissect the role of SHP-1 in memory CD8+ T cell formation 
and function.
4.2 Mice receiving naive control CD8+ F5 T cells killed more target cells during a memory T 
cell response than mice receiving naive motheaten CD8+ F5 T cells, when the memory T 
cells are recalled by priming with NP68 peptide in IFA
Initially Rag-17' were used as recipient mice for the study of memory CD8+ F5 T cell 
responses. This ensured that it was exclusively the adoptively transferred T cells being 
studied over the duration of the assay.
In three independent experiments, Rag-17' recipient mice received an intravenous transfer 
of naive control or motheaten CD8+ F5 T cells and a subcutaneous injection of NP68 peptide 
in IFA. Control mice did not receive any T cells. In each of the successive experiments the 
number of CD8+ F5 T cells transferred was 3xl06, 2xl06 and 2.2xl06 respectively, as dictated 
by the availability of motheaten mice. Six weeks following T cell transfer, all mice received
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NP68 peptide in IFA as a subcutaneous injection. Seven days later, all mice received CFSE 
labelled target and reference cells intravenously. Twenty-four hours later, mice were 
sacrificed and their spleens taken for analysis by flow cytometry. Histograms were generated 
by gating on a viable and CFSE* cell population.
The data from three independent experiments showed that the mice that received naive 
control CD8+ F5 T cells killed 81% (figure 4.1B), 74% (figure 4.2B) and 72% (figure 4.3B) of the 
target cells during a memory response in comparison to 47% (figure 4.1C), 55% (figure 4.2C) 
and 37% (figure 4.3C) of the target cells killed in the corresponding mice that received naive 
motheaten CD8+ F5 T cells.
The spleens from the mice in the second experiment (74% and 55% of target cells killed by 
control and motheaten T cells respectively) were stained with anti-CD8PE antibody prior to 
flow cytometry. The proportion of CD8+/CFSE' cells of a lymphocyte gate in the spleen of the 
mouse that received naive control CD8+ F5 T cells was 26% (figure 4.2B) compared to 15.4% 
in the mouse that received naive motheaten CD8+ F5 T cells (figure 4.2C). For the mouse 
that did not receive any T cells the proportion of CD8+/CFSE' cells of a lymphocyte gate 
within the spleen was 8.97% (figure 4.2A). Therefore the enhanced killing seen in the mouse 
that received naive control CD8+ F5 T cells correlated with a greater proportion of adoptively 
transferred CD8+ cells at the site of killing.
4.3 The mode of priming memory control and motheaten CD8* F5 T ceils impacts upon the 
memory CD8+ F5 T cell response
During the early stages of the memory T cell studies it became an increasing concern that 
when NP68 peptide is administered in IFA it may bind to MHC class I molecules belonging to 
adoptively transferred T cells. This would potentially lead to fratricide within the adoptively 
transferred CD8+ memory T cell pool, which could in turn influence the memory T cell
180
response. Therefore, it seemed logical to explore a different mode of priming the memory T 
cells to see whether in made a difference to the memory response being detected.
Rag-1 '^ recipient mice received an intravenous transfer of 2.2xl06 naive control or 
motheaten CD8+ F5 T cells and a subcutaneous injection of NP68 peptide in IFA. Control mice 
did not receive any T cells. Six weeks following T cell transfer, mice were primed with either 
NP68 peptide in IFA as a subcutaneous injection, or by the peritoneal transfer of 3xl06 
matured and NP68 peptide-pulsed dendritic cells. Seven days later, all mice received CFSE 
labelled target and reference cells intravenously. Twenty-four hours later, mice were 
sacrificed and their spleens taken for analysis by flow cytometry. Histograms were gated on 
viable and CFSE+ cells to reveal the target and reference cells.
When mice were primed with NP68 peptide in IFA, for both the initial and recall priming, the 
mouse that received naive control CD8+ F5 T cells killed 72% of the target cells (figure 4.3B) 
compared to 37% of the target cells being killed in the mouse that received naive motheaten 
CD8+ F5 T cells (figure 4.3C). However, when mice were primed with NP68 peptide in IFA for 
the initial priming and matured NP68 peptide-pulsed DCs for the recall priming, the mouse 
that received naive control CD8+ F5 T cells killed 52% of the target cells (figure 4.3D) whereas 
the mouse that received naive motheaten CD8+ F5 T cells killed 80% of the targets (figure 
4.3E).
4.4 Mice receiving naive motheaten CD8+ T cells killed more target cells during a memory T 
cell response than mice receiving naive control CD8+ T cells, when memory T cells are 
recalled by priming with NP68 peptide-pulsed DCs
Previous data demonstrated that when memory T cells were primed with NP68 peptide in 
IFA, mice that received control CD8+ F5 T cells killed more targets than mice that received 
motheaten CD8+ F5 T cells (three experiments; figures 4.1, 4.2 and 4.3B and C), whereas
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when DCs pulsed with NP68 peptide were used to re-challenge mice for a second time the 
converse was seen (Figure 4.3C and 4.3D). In light of this, two further independent 
experiments were performed that used NP68 peptide-pulsed DCs to prime memory CD8+ F5 
T cells.
For each experiment Rag-1 '^ recipient mice received an intravenous transfer of naive control 
or motheaten CD8+ F5 T cells and a subcutaneous injection of NP68 peptide in IFA. Control 
mice did not receive any T cells. For the first experiment, mice received 2xl06 T cells (figure 
4.4), whereas 2.8xl06 were transferred in the second experiment (figure 4.5). Six weeks 
following T cell transfer, all mice including the control mouse, received 3xl06 matured and 
NP68 peptide-pulsed dendritic cells by peritoneal transfer. Seven days later, all mice 
received CFSE labelled target and reference cells intravenously. Twenty-four hours later mice 
were sacrificed and their spleens taken for analysis by flow cytometry. Flistograms displaying 
CFSE fluorescence were gated on viable and CFSE+ cells.
The data from two independent experiments demonstrated that the mice that received 
naive control CD8+ F5 T cells killed 68% (figure 4.4B) and 72% (figure 4.5B) of the target cells 
during a memory response in comparison to 78% (figure 4.4C) and 84% (figure 4.5C) of the 
target cells killed in the corresponding mice receiving naive motheaten CD8+ F5 T cells. This 
tallied with an earlier experiment where 52% of the target cells were killed by a mouse that 
received naive control CD8+ F5 T cells (figure 4.3D) compared to 80% of target cells killed by 
a mouse that received naive motheaten CD8+ F5 T cells (figure 4.3E).
4.5 Mice receiving naive motheaten CD8+ T cells killed more target cells during a memory T 
cell response than mice receiving naive control CD8+ T cells, when both naive and memory 
T cells are primed with NP68 peptide pulsed DCs
182
Previous data showed that the mode of priming memory T cells seemed to have an impact 
upon the memory response of control and motheaten CD8+ F5 T cells. To further explore this 
observation, an experiment was performed that utilised matured and NP68 peptide-pulsed 
dendritic cells to prime both naive and memory CD8+ F5 T cells.
Rag-1'  ^recipient mice received an intravenous transfer of lxlO6 naive control or motheaten 
CD8+ F5 T cells and a peritoneal transfer of 3.8xl06 matured and NP68 peptide-pulsed DCs. 
Control mice did not receive any T cells. Six weeks following T cell transfer, all mice received 
3xl06 matured and NP68 peptide-pulsed dendritic cells by peritoneal transfer. Seven days 
later all mice received CFSE labelled target and reference cells intravenously. Twenty-four 
hours later, mice were sacrificed and their spleens taken for analysis by flow cytometry.
The mice that received naive control CD8+ F5 T cells killed 61% and 62% of the target cells 
(figure 4.6B) during a memory response in comparison to 89% and 78% of the target cells 
killed in the mice that received naive motheaten CD8+ F5 T cells (figure 4.6C).
4.6 Mice receiving in vitro activated control CD8* T cells kill target cells during a memory 
response seven weeks post transfer
The data in chapter three demonstrated that after one week of antigen driven T cell 
expansion mice that received naive motheaten CD8+ F5 T cells had a greater proportion of 
CD8+ cells in their spleens compared to mice that received naive control CD8+ F5 T cells. It is 
a possibility that the enhanced expansion of motheaten CD8+ F5 T cells during a primary 
response may lead to the accumulation of more memory motheaten CD8+ F5 T cells, when 
compared to control CD8+ F5 T cells. This may explain the data shown earlier in this chapter 
demonstrating the enhanced killing of target cells by memory motheaten CD8+ F5 T cells 
following DC priming. To explore this hypothesis further an experiment was planned that 
involved transferring the same number of in vitro activated and expanded control and
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motheaten CD8+ F5 T cells to recipient mice. The mice would then be primed six weeks later 
followed by the administration of target and reference cells to assess the magnitude of the 
memory response. Although the lack of availability of motheaten mice did not allow this 
experiment to be conducted, a pilot experiment was nevertheless performed using control 
CD8+ F5 T cells to establish whether in vitro activated CD8+ F5 T cells could differentiate into 
memory cells and mount a response following their in vivo transfer.
Naive control CD8+ F5 T cells were activated in vitro for 2 days with NP68 loaded splenocytes 
followed by two days of expansion in IL-2. Cells were washed thoroughly and either 3xl06 or 
5xl06 transferred to Rag-17' recipient mice. A control mouse did not receive any T cells. Six 
weeks post T cell transfer the mice were primed with 3xl06 matured and NP68 peptide- 
pulsed DCs that were transferred into the peritoneal cavity. Six weeks later all mice received 
CFSE labelled target and reference cells intravenously. Twenty-four hours later the spleens 
were taken and prepared for flow cytometry.
The mouse that received 3xl06 activated T cells killed 64% of the targets (figure 4.7B) and 
the mouse that received 5xl06 T cells killed 85% of the targets (figure 4.7C) thus 
demonstrating the feasibility of the proposed assay.
4.7 A mouse kills target cells during a memory T cell response without being primed for a 
second time
Memory CD8+ T cells are found in two main subsets, those that can provide immediate 
effector action (effector memory) and those that expand upon antigenic stimulation (central 
memory). In order to potentially distinguish the contributions of central and effector 
memory T cells to a memory response in mice receiving control or motheaten CD8+ F5 T 
cells, a further pilot experiment was performed that looked at both the effector and central 
memory response.
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Two Rag-17' recipient mice received 2.5xl06 control CD8+ F5 T cells and a subcutaneous 
injection of NP68 peptide in IFA. Control mice did not receive any T cells. Six weeks following 
T cell transfer, one mouse received 3xl06 matured and NP68 peptide-pulsed DCs by 
peritoneal transfer in order to look at the total memory CD8+ T cell response. The second 
mouse did not receive a re-challenge with DCs in order to examine the effector memory 
CD8+ T cell response. Seven days later all mice received CFSE labelled target and reference 
cells intravenously. Twenty-four hours later, mice were sacrificed and their spleens taken for 
analysis by flow cytometry.
The mouse that received naive CD8+ F5 T cells and two challenges with NP68 peptide killed 
59.1% of the target cells (figure 4.8C). The mouse that received naive CD8+ F5 T cells and a 
single challenge with NP68 peptide killed 41.8% of the target cells (figure 4.8B), which can be 
attributed to the action of effector memory CD8+ F5 T cells. The difference in the number of 
targets killed between the two mice can be attributed to the action of the central memory 
CD8+ F5 T cells.
4.8 Mice receiving naive motheaten CD8+ F5 T cells kill more target cells during a memory T 
cell response than mice receiving naive control CD8+ F5 T cells
As the memory T cell studies progressed it became increasingly apparent that the transfer of 
naive CD8+ F5 T cells was having a negative effect on the health of the Rag-17' recipient 
mice. Towards the end of the assay (at 6-7 weeks) those mice that had received T cells 
started to lose condition; their fur became dull, they exhibited weight loss and had 
diarrhoea. Due to both ethical reasons and the concern that this may affect the memory T 
cell response an alternative protocol was sought.
As Rag-17' mice lack any regulatory T cells it was proposed that the decline in health maybe 
due to the unchecked activity of the transferred CD8+ F5 T cells in the tissue of the
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gastrointestinal tract. Therefore sub-lethally irradiated mice were used instead of Rag-l'/_ 
mice as their T cell compartments (including Tregs) would recover over the duration of the 
assay.
A group of three mice received either lxlO 6 naive control or motheaten CD8+ F5 T cells. A 
group of four mice did not receive any T cells. All mice were primed subcutaneously with 
NP68 peptide in IFA. The mice remained healthy throughout the assay, with the only evident 
side effect of the irradiation (650cGy) being the greying of the fur. Six weeks post-transfer, 
each mouse received 3xl06 matured and NP68 peptide-pulse DCs via the peritoneal cavity. 
Seven days later all mice received CFSE labelled target and reference cells intravenously. At 
this point a control mouse was irradiated and received the CFSE labelled target and 
reference cells. Twenty-four hours later all mice were sacrificed and their spleens prepared 
for analysis by flow cytometry.
No target cells were killed by the mice that did not receive any T cells but were primed in the 
same manner as those that did (figures 4.9B and 4.10), indicating that the recipient mice 
were unable to mount an endogenous CD8+ F5 T cell response under these conditions. The 
mice that received naive control CD8+ F5 T cells killed 3.6%, 10.7% and 22% of the target 
cells (figures 4.9C and 4.10), whereas the mice that received naive motheaten CD8+ F5 T cells 
killed 32%, 53% and 56% of the target cells (figures 4.9D and 4.10). The difference in the 
number of target cells killed between the two sets of mice was not statistically significant 
(P=0.1).
4.9 Rag-1^ * mice receiving naive CD8+ F5 T cells develop colitis
An experiment was performed to further investigate the progressive wasting exhibited by 
Rag-17' mice involved in the study of memory T cell responses. A group of three Rag-17' mice 
received naive CD8+ F5 T cells and NP68 in IFA (mice 4, 5 and 6). Two Rag-17' mice received
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naive CD8+ F5 T cells but no NP68 (mice 7 and 8). A control group of mice did not receive 
CD8+ F5 T cells or NP68 (mice 1, 2 and 3). Each group of mice was kept in separate cages in 
order to monitor for symptoms of colitis.
Mice that received CD8+ F5 T cells and NP68 produced loose stools from 2 weeks onwards, 
whereas those that received T cells alone produced loose stools from weeks 6-7 onwards. 
The control group remained healthy throughout the experiment. The body weight of the 
mice was monitored weekly for the duration of the assay. The controls, mice 1, 2 and 3 (no T 
cells and no NP68) gained 26.4% (mean) of their initial body weight over the duration of the 
assay (8 weeks) (figure 4.11). Mice that received T cells but no NP68 (numbers 7 and 8) 
initially gained 5.3% (mean) of their initial body weight but subsequently lost 7.44% (mean) 
of their maximum body weight (weeks 3 and 4 for individual mice) (figure 4.11). Finally, mice 
that received both T cells and NP68 (numbers 4, 5 and 6) lost 3.4% (mean) of their initial 
body weight, and 18.3% (mean) of their maximum body weight (weeks 3 and 5 for individual 
mice) over the duration of the assay (figure 4.11). As mice had lost a considerable 
percentage of their body weight by week 8 the assay was terminated and tissues harvested 
for further analysis.
4.10 Mice receiving naive CD8+ F5 T cells exhibit splenomegaly, lymphomegaly and a 
cellular infiltrate into their large intestine
Eight weeks post T cell transfer (as described for 4.9) mice were sacrificed and tissues taken 
for analyses. Upon dissection, it was immediately apparent that all mice that had received T 
cells and NP68 (numbers 4, 5 and 6) had splenomegaly, lymphomegaly (mesenteric lymph 
nodes) and an enlarged large intestine, when compared to control mice. One mouse that 
had received T cells but no NP68 peptide (number 8) also exhibited a similar gross pathology 
to that of the mice that also received NP68 peptide. The second mouse that received T cells
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but no NP68 (number 7) did not exhibit splenomegaly but did exhibit lymphomegaly 
(mesenteric lymph nodes) and a slight enlargement of the large intestine.
The spleen and mesenteric lymph nodes were harvested and homogenised and the total cell 
number counted by trypan blue exclusion (figure 4.12). Control mice that did not receive T 
cells or NP68 peptide (numbers 1, 2 and 3) had 2.02x10s, 4x10s and 4.8x10s (mean of 
3.6x10s) total cells in their spleen, whereas mice that had received T cells and NP68 (number 
4, 5 and 6) had on average, 17 times more T cells in their spleen (mean of 6.4xl07). For the 
two mice that had received T cells but no NP68 (numbers 7 and 8), one (number 7) had 
similar numbers of cells in its spleen (2.96x10s) to that of the control mice, whereas the 
second mouse (number 8) had 27 times more cells (9.7xl07) than the control mice (figure 
4.12). The cells from the mesenteric lymph nodes were also counted by trypan blue 
exclusion (figure 4.12). Control mice that did not receive T cells (numbers 1, 2 and 3) had 
3.2xl05, 4.75x10s and 3xl05 (mean of 3.65x10s) in their mesenteric lymph nodes. Compared 
to control mice those that had received T cells with NP68 (numbers 4,5 and 6), or T cells 
alone (numbers 7 and 8), had 3.6 and 3.8 times the number of cells in their mesenteric 
lymph nodes respectively.
In order for histological analysis to be performed on tissue from the gastrointestinal tract, 
proximal, medial and distal sections were taken from the small and large intestine, set in 
paraffin wax and stained with haematoxylin (H) and eosin (E).
The small intestines from mouse 3 (no T cells and no NP68), 4 (recipient of T cells and NP68) 
and 7 (recipient of T cells) were stained with H and E and viewed under a light microscope at 
lOx magnification. Mouse 3 and 4 had no cellular infiltrate in the small intestine, whereas 4 
had discreet clusters of cells at the base of the villi adjacent to the muscle surrounding the 
gut (figure 4.13). Sections from the large intestines were analysed (lOx magnification) for
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mouse 3 (no T cells and no NP68), mice 4 and 5 (recipients of T cells and NP68), and mice 7 
and 8 (recipients of T cells). No cellular infiltrate was present in the sections of the large 
intestine from mice 3 and 7. Mouse 4 had a significant influx of cells at the bass of the villi 
throughout the section viewed (figure 4.13). The infiltrate also extended into the villi itself, 
between the crypts and when compared to mice 3 and 7 an elongation of the villi was 
evident. Mouse 5 also exhibited a cellular infiltrate between the crypts of the villi and also 
within the muscle tissue surrounding the gut tissue. A section of the large intestine from 
mouse 8 was also analysed, but unfortunately the muscle tissue surrounding the gut and the 
base of the villi was not present. Despite this, a cellular infiltrate was evident between the 
crypts of the villi (figure 4.13.2).
Upon greater magnification (20x) there was evidence of cryptitis in mice 4, 5 (recipients of T 
cells and NP68) and 8 (recipient of T cells) (figure 4.14). Cryptitis involves the movement of 
cells of the immune system across the epithelia of the crypts, thus entering the crypts 
themselves.
4.11 Summary of results
Assays that were initially developed to look at the role of SHP-1 in primary in vivo T cell 
responses were adapted to enable the role of SHP-1 in memory T cells to be studied.
To begin, NP68 peptide in IFA was used to prime both naive and memory CD8+ F5 T cells in 
recipient mice. With this approach, mice receiving naive control CD8+ F5 T cells killed more 
target cells during a memory T cell response than mice receiving motheaten CD8+ F5 T cells. 
However, when DCs were used to prime the memory T cells the converse was seen, with the 
mice that received motheaten CD8+ F5 T cells killing more target cells than the mice 
receiving control CD8+ F5 T cells. Mice receiving motheaten CD8+ F5 T cells also killed more 
target cell when naive and memory CD8+ F5 T cells were stimulated with DCs.
As Rag-17' mice developed colitis when receiving CD8+ F5 T cells a new protocol to study 
memory T cell responses was developed, which involved using sublethally irradiated mice. 
The revised protocol also demonstrated that mice receiving motheaten CD8+ F5 T cells killed 
more target cells than mice receiving control CD8+ F5 T cells.
Rag-17' that developed colitis as a result of CD8+ F5 T cell transfer and exhibited a cellular 
infiltrate into their large intestine, as shown by histological analysis.
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Figure 4.1: A mouse receiving control CD8+ F5 T cells kills more target cells during a memory T 
cell response than a mouse receiving motheaten CD8+ F5 T cells, when memory T cells were 
primed with NP68 in IFA
Rag-17' mice received either 3x l06 control (B) or motheaten (C) CD8+ F5 T cells intravenously and 
also a subcutaneous injection of NP68 in IFA. A control mouse did not receive any T cells (A). Six 
weeks following T cell transfer, mice received NP68 peptide in IFA as a subcutaneous injection. 
Seven days later, mice received CFSE labelled target and reference cells. Twenty-four hours later, 
mice were sacrificed and their spleens taken for analysis by flow cytometry. The percentage of 
target cells killed is shown for each histogram. Any deviation from the anticipated 1:1 ratio of 
target to reference cells in the control mouse (A) was used to adjust the data from mice that 
received T cells. The mice that received control CD8+ T cells killed more targets (B) when compared 
to the mice that received motheaten T cells (C).
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Figure 4.2: A mouse receiving control CD8+ F5 T cells kills more target cells during a memory T cell 
response than a mouse receiving motheaten CD8+ F5 T cells, when memory T cells are primed with 
NP68 in IFA
Rag-17' mice received either 2 x l0 6 control (B) or motheaten (C) CD8+ F5 T cells intravenously and NP68 in 
IFA subcutaneously. A control mouse did not receive any T cells (A). Six weeks following T cell transfer, 
mice received NP68 peptide in IFA as a subcutaneous injection. Seven days later, mice received CFSE 
labelled target (pulsed w ith NP68) and reference cells. Twenty-four hours later, mice were sacrificed and 
their spleens taken and stained w ith anti-CD8PE antibody, ready for analysis by flow cytomerty. The 
percentage of target cells killed is shown for each histogram. Any deviation from the anticipated 1:1 ratio 
of target to reference cells was corrected for by using the data from the control mouse (A). The contour 
plots show the proportion of CFSE'/CD8+ cells residing in a lymphocyte gate, as determined by forward 
and side scatter. The mice that received control CD8+ T cells killed more targets (B) when compared to 
the mice that received motheaten T cells (C). In addition, the mouse that received control T cells had a 
greater proportion of CD8+ cells in its spleen (B) compared to the mouse that received motheaten T cells 
(C).
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Figure 4.3: The mode of priming memory control and motheaten CD8+ F5 T cells influences the 
magnitude of the memory T cell response
Rag-r/_ recipient mice received 2 .2xl06 naive control (B and D) or motheaten (C and E) CD8+ F5 T 
cells intravenously. Concomitantly to  T cell transfer, mice were primed subcutaneously with NP68 
peptide in IFA. A control mouse did not receive any T cells (A). Six weeks post T cell transfer mice 
received either a peritoneal transfer o f 3 x l0 6 matured and NP68 peptide pulsed DCs (D and E) or a 
subcutaneous injection o f NP68 in IFA (B and C). Six days later mice received an intravenous 
infusion of CFSE labelled target and reference cells. Twenty-four hours post transfer, mice were 
sacrificed and their spleens taken for analysis by flow cytometry. The percentage of target cells 
killed is shown for each histogram. Any deviation from the anticipated 1:1 ratio of target to 
reference cells in the mouse tha t received no T cells (A) was used to  adjust the percentage killing in 
the mice receiving T cells. The mouse that received control T cells (B) killed more target cells than 
the mouse that received motheaten T cells (C), when primed for a second time with NP68 in IFA. 
However, when DCs were used fo r priming memory T cells the mouse that received motheaten T 
cells (E) killed more target cells compared to the mouse tha t received control T cells (D).
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Figure 4.4: A mouse receiving naive motheaten CD8+ F5 T cells killed more target cells during a 
memory T cell response than a mouse receiving naive control CD8+ F5 T cells, when memory T 
cells were primed with NP68 loaded dendritic cells
Rag-17' mice received either 2x l06 naive control (B) or motheaten (C) CD8+ F5 T cells intravenously 
and also a subcutaneous injection of NP68 in IFA. A control mouse did not receive any T cells (A). 
Six weeks following T cell transfer, mice received a peritoneal transfer of 3x l06 matured and NP68 
peptide-pulsed dendritic cells. Seven days later mice received CFSE labelled target (pulsed with 
NP68) and reference cells. Twenty-four hours later mice were sacrificed and their spleens taken 
ready for analysis by flow cytometry. The percentage of target cells killed is shown for each 
histogram. Any deviation from the anticipated 1:1 ratio of target to reference cells was corrected 
for, by using the data from the control mouse (A). The mouse that received naive motheaten CD8+ 
F5 T cells killed more targets (C) when compared to the mouse that received naive control CD8+ F5 
T cells (B).
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Figure 4.5: A mouse receiving naive motheaten CD8+ F5 T cells kills more target cells during a 
memory T cell response than mice receiving naive control CD8+ F5 T cells, when memory T cells 
are primed with NP68 loaded dendritic cells
Rag-17 mice received either 2.8xl06 naive control (B) or motheaten (C) CD8+ F5 T cells 
intravenously and also a subcutaneous injection o f NP68 in IFA. A control mouse did not receive 
any T cells (A). Six weeks following T cell transfer mice received a peritoneal transfer of matured 
and NP68 peptide-pulsed DCs. Seven days later mice received CFSE labelled target and reference 
cells. Twenty-four hours later, mice were sacrificed and their spleens taken ready for analysis by 
flow cytometry. The percentage of target cells killed is shown for each histogram. The mouse that 
received naive motheaten CD8+ F5 T cells killed more targets (C) when compared to the mouse 
that received naive control CD8+ F5 T cells (B).
195
A) No T cell transfer B) Naive control C) Naive motheaten
CD8+ F5 T cell transfer CD8+ F5 T cell transfer
V)
C
=3o
u
IDu
Figure 4.6: Mice receiving naive motheaten CD8+ F5 T cells kill more target cells during a memory T 
cell response than mice receiving naive control CD8+ F5 T cells, when naive and memory T cells are 
primed with NP68 loaded dendritic cells
Rag-17' mice received either 1 .5x l0 6 naive control (B) or motheaten (C) CD8+ F5 T cells intravenously 
and also 2 .5x l0 6 in vitro matured and NP68 peptide-pulsed DCs. A control mouse did not receive 
any T cells (A). Six weeks following T cell transfer, mice received 3 x l0 6 matured and NP68 peptide- 
pulsed DCs. Seven days later, mice received CFSE labelled target (pulsed with NP68 peptide) and 
reference cells. Twenty-four hours later, mice were sacrificed and their spleens taken ready for 
analysis by flow cytometry. The percentage of target cells killed is shown for each histogram. Any 
deviation from the anticipated 1:1 ratio of target to reference cells in the control mouse (A) was 
used to adjust the data from mice that received T cells. The mice receiving naive motheaten CD8+ F5 
T cells killed more target cells (B) when compared to the mice that received naive control CD8+ F5 T 
cells (C).
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Figure 4.7: Mice receiving in vitro activated and expanded CD8+ F5 T cells mount a memory T 
cell response
Naive CD8+ F5 T cells were activated and expanded in vitro for four days. Rag-17' recipient mice 
received an intravenous transfer of either 3 x l0 6 (B) or 5 x l0 6 (C) activated T cells. A control 
mouse did not receive any T cells (A). Six weeks post T cell transfer, mice were primed 
subcutaneously with NP68 peptide in IFA. Six days later, all mice received CFSE labelled target 
(pulsed with NP68 peptide) and reference cells intravenously. Twenty-four hours post transfer 
mice were sacrificed and their spleens taken for analysis by flow cytometry. The percentage of 
target cells killed is shown for each histogram. Any deviation from the anticipated 1:1 ratio of 
target to reference cells in the mice not receiving T cells (A) was used to adjust the percentage 
killing in the mice receiving T cells. Those mice that received the activated T cells were able to 
mount a memory T cell response (B and C), with the mouse that received 5 x l0 6 T cells (C) killing 
more targets than the mouse that received 3 x l0 6T cells (B).
197
A) No T cell transfer
c3o
u
IDu
5 6  34 4 3  68
Targets 
cells 1
/
Reference cell:
B) Naive CD8+ F5 T cell transfer 
(Primed once)
42 86
41.8% killing
C) Naive CD8+ F5 T cell transfer 
(Primed twice)
29 .0 1 70.95
59.1% killing
CFSE
Figure 4.8: A mouse kills target cells during a memory response without being primed for a 
second time
Rag-17' mice received 2 .5 x l0 6 naive control CD8+ F5 T cells intravenously and also a subcutaneous 
injection of NP68 in IFA (B and C). A control mouse did not receive any T cells (A). Six weeks 
following T cell transfer one mouse that received T cells was primed subcutaneously with NP68 
peptide in IFA (C). The second mouse was not primed (B). Seven days later all mice received CFSE 
labelled target and reference cells. Twenty-four hours later mice were sacrificed and their spleens 
taken ready for analysis by flow cytomerty. The percentage of target cells killed is shown for each 
histogram. Any deviation from the anticipated 1:1 ratio was corrected for, by using the data from 
the control mouse (A). The mouse that received T cells and was primed for a second time killed 
59.1% of the target cells (B). The mouse that received T cells but was not primed for a second time 
killed 41.8% of the target cells (C).
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Figure 4.9: Mice receiving naive motheaten CD8+ F5 T cells kill more target cells when compared to mice 
receiving naive control CD8+ F5 T cells
Sublethally irradiated mice received either lx lO 6 naive control (C) or motheaten (D) CD8+ F5 T cells. 
Another group of mice did not receive any T cells (B). All mice were primed subcutaneously with NP68 in 
IFA. A control mouse did not receive any T cells or NP68 (A). Seven weeks following T cell transfer mice 
received 3.8xl06 matured and NP68 peptide-pulsed dendritic cells intraperitoneally. Eight days later mice 
received CFSE labelled target and reference cells intravenously. Twenty-four hours later, mice were 
sacrificed and their spleens taken and prepared for flow cytometry. The percentage killing is shown for 
each histogram and was also plotted to enable statistical analysis to be performed (Figure 4.10).Any 
deviation from the anticipated 1:1 ratio o f target to reference cells was corrected for by using the data 
from the control mouse (A). The mice receiving no T cells did not kill any target cells (B). All mice that 
originally received naive motheaten CD8+ F5 T cells (B) killed more target cells than mice that received 
naive control CD8+ F5 T cells (C).
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Figure 4.10: Mice receiving naive motheaten CD8* T cells kill more target cells when compared to mice 
receiving control T ceils
Sub-lethally irradiated mice received either lx lO 6 naive control or motheaten CD8+ F5 T cells. Another 
group of mice did not receive any T cells. All mice were primed subcutaneously with NP68 in IFA. A 
control mouse did not receive any T cells or NP68. Seven weeks following T cell transfer mice received 
3 x l06 matured and NP68 peptide-pulsed dendritic cells intraperitoneally. Eight days later, mice received 
CFSE labelled target (pulsed w ith  NP68) and reference cells intravenously. Twenty-four hours later mice 
were sacrificed and the ir spleens taken and prepared fo r flow  cytomerty. Histograms were generated 
showing the target and reference cell populations (Figure 4.9). The percentage o f target cells killed was 
calculated for each mouse (this figure). The mice that received no T cells did not kill any target cells (B). 
All mice that received naive motheaten CD8+ F5 T cells (B) killed more target cells than mice that 
received naive control CD8+ F5 T cells (C). The difference in the percentage of target cells killed between 
the mice that received either naive control or motheaten CD8+ F5 T cells was not statistically significant 
(P=0.1).
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Figure 4.11: Mice receiving CD8+ F5 T cells lose body weight
Mice received lx lO 6 CD8+ F5 T cells and NP68 in IFA (□) or CD8+ F5 T cells alone (A). Control
mice did not receive T cells or NP68 (o). The weight o f the mice was monitored weekly for the
duration of the assay.
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Figure 4.12: Mice receiving NP68 and naive CD8+ F5 T cells have a greater number of cells in their 
spleens and mesenteric lymph nodes than mice receiving no T cells
Five Rag-17' recipient mice received lx lO 6 naive CD8+ F5 T cells intravenously (A). Three other mice did 
not receive any T cells (A). Mice 4, 5 and 6 were primed subcutaneously w ith NP68 peptide in IFA, with 
all other mice not being primed (A). Seven weeks post T cell transfer, mice were sacrificed and the 
spleens, mesenteric lymph nodes and both the small and large intestines taken for analysis. A single 
cell preparation of the spleens and mesenteric lymph nodes was prepared and counted by trypan blue 
exclusion. All mice receiving T cells had similar total cell numbers in their mesenteric lymph nodes (A 
and B). All three mice that received T cells and were primed, and one mouse that received T cells but 
was not primed, had similar total cell counts in their spleens (A and B). The mice that did not receive 
any T cells had the lowest number o f cells in their spleens and mesenteric lymph nodes (A and B).
Figure 4.13: Cell infiltrate in the large intestine of mice receiving CD8+ F5 T cells. Mice received CD8+ F5 T cells and NP68 in IFA (mice 4, 5 and 6) or CD8+ F5 T cells alone (mice 7 
and 8). Control mice did not receive T cells or NP68 (Mice 1, 2 and 3). Sections from the small and large intestines were taken from all mice eight weeks post T cell transfer and 
mounted in paraffin wax. Haemotoxylin and eosin staining was performed on sections from mouse 3 (1A and IB), 2 (2A and 2B), 5 (3), 7 (4A, 4B and 4C) and 8 (figure 4.13). The 
image of each section (lOx magnification) is positioned with the muscle at the bottom, and lumen of the gut at the top (see 1A). No infiltrate was seen in the small intestine of 
mouse 3 (1A) and 4 (2A). The section of the small intestine from mouse 5 had not been stained. The section of the small intestine from mouse 7 had clusters of cells (arrow, 4A), 
which were not present throughout the section (4B). Mouse 4 exhibited a cell infiltrate (arrow) at the base of the villi (circle), which extended into the villi towards the lumen of 
the gut (arrow, 2B). This was not evident in mouse 3 (IB) and 7 (4B). Mouse 5 had a cell infiltrate in the muscle surrounding the section and also between the crypts (3).
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Figure 4.14: Cryptitis in mice receiving CD8+ F5 T cells
Mice received CD8+ F5 T cells and NP68 in IFA (mice 4, 5 and 6) or CD8+ F5 T cells alone (mice 7 
and 8). Control mice did not receive T cells or NP68 (mice 1 and 2). Sections from the small and 
large intestines were taken from all mice eight weeks post T cell transfer and mounted in paraffin 
wax. Haemotoxylin and eosin staining was performed on sections from mouse 3 (figure 4.12), 4 
(1), 5 (4 and 5), 7 (figure 4.12) and 8 (2). The image of each section is positioned with the muscle 
at the bottom, and lumen of the gut at the top. Each mouse exhibited a cell infiltrate into the 
muscle and villi of the large intestines. In addition, mice that received CD8+ F5 T cells also 
displayed signs o f cryptitis, where cells of the immune system cross the epithelia and enter the 
crypts (arrowhead). Images displayed at 20x magnification.
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Chapter 5
The role of SHP-1 in anti-tumour CD8+ T cell responses
5.1 Introduction
In chapter 3 it was demonstrated that the lack of SHP-1 expression in CD8+ F5 T cells resulted 
in an enhanced in vivo primary CD8+ T cell response to antigenic stimulation. Mice that 
received naive motheaten CD8+ F5 T cells had a greater proportion of CD8+ cells within their 
spleens and killed more target cells (NP68 peptide pulsed splenocytes) when compared to 
mice that had received naive control CD8+ F5 T cells.
To explore these findings further, assays were performed to establish whether the enhanced 
CD8+ T cell response seen in the absence of SHP-1 expression could be harnessed to improve 
an anti-tumour CD8+T cell response.
A mouse model of tumour development was combined with protocols and techniques that 
had previously been developed during this study. The mouse melanoma cell line known as 
B16 has been used extensively to study both tumour development and treatment. The B16 
cells can be transferred either intravenously or subcutaneously to recipient mice. When 
transferred intravenously, the B16 cells home to the lungs where they develop into 
pulmonary tumours. After a period of fourteen days the tumours appear as small pigmented 
nodules and can therefore be enumerated. This mode of transfer is used as a model of 
tumour metastases. When transferred subcutaneously, the B16 melanoma cells form a solid 
tumour mass, which is can be monitored by measuring with callipers.
In order to use the B16 melanoma cells in conjunction with purified CD8+ TCR transgenic F5 T 
cells from both motheaten and control mice, the tumour cells were either pulsed with the 
NP68 peptide or transfected to constitutively express the NP68 epitope. In this context the
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NP68 peptide was being used as a model for either a tumour-specific or tumour-associated 
antigen.
5.2 In vitro activated control CD8+ F5 T cells kill NP68 peptide pulsed B16 melanoma cells in 
an in vitro setting
An in vitro cytotoxic T lymphocyte (CTL) assay was performed to establish whether CD8+ F5 T 
cells were capable of killing NP68 peptide-pulsed B16 cells. Naive CD8+ F5 T cells from 
control mice were activated in vitro for two days with NP68 peptide-pulsed splenocytes 
followed by two days of expansion with IL-2. Three components were combined to establish 
whether the CD8+ F5 T cells could kill the NP68 peptide labelled B16s. These were activated 
CD8+ F5 T cells, NP68 peptide-pulsed B16 cells labelled with 0.2pM CFSE and un-pulsed B16 
cells labelled with 2pM CFSE. The NP68 peptide-pulsed B16 cells acted as a target cell 
population whereas the un-pulsed cells acted as a reference cell population to establish the 
proportion of target cells that were killed. The ratio of CD8+ T cells to the total number of 
B16 cells was titrated, with the number of T cell added being determined by the total 
number of B16 cells. The target and reference B16 cells were used at a 1:1 ratio.
After four hours of co-culture, the cells were harvested and labelled with anti-CD8PE 
antibody ready for analysis by flow cytometry. Histogram plots were gated on CD8 negative 
cells and a viable cell population (Representative plots are shown in figures 5.1A to 5.IE). 
B16 cells were also cultured without T cells and the data shows that the target to reference 
B16 cell ratio remained at 1:1 (figure 5.1A).
At a T to B16 cell ratio of 1:2 the proportion of target B16 cells killed was 4%, 5% and 8% 
(figures 5.IB and 5.IF). At a ratio of 1:1, 19%, 21% and 24% of the target B16 cells were 
killed (figures 5.1C and 5.IF). At a ratio of 3:2, 23%, 24% and 28% of the target B16 cells 
were killed (figures 5.ID and 5.IF) and at a ratio of 2:1, 29%, 34% and 37% of the target B16
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cells were killed (figures IE and IF). This demonstrated that activated CD8+ F5 T cells were 
capable at killing B16 cells.
5.3 Sub-lethally irradiated mice have fewer lung tumour nodules compared to non­
irradiated mice fourteen days post intravenous transfer of wild-type B16 cells
As a preliminary step to the in vivo studies which involved the intravenous transfer of B16 
cells to recipient mice, a control experiment was performed to establish how many B16 cells 
could be transferred to mice that had been sub-lethally irradiated. Irradiating mice was a 
necessary aspect of the in vivo studies that involved the adoptive transfer of CD8+ F5 T cells 
as it removed any endogenous T cells that may have responded to the NP68 peptide.
Mice were sub-lethally irradiated twenty-four hours prior to the intravenous transfer of 
either 1x10s, 5xl04 or 2.5xl04 wild-type B16 cells. Three non-irradiated mice received 1x10s 
wild-type B16 cells. Fourteen days post transfer the mice were sacrificed and the tumour 
nodules in their lungs enumerated.
The non-irradiated mice that received 1x10s B16 cells had 108, 112 and 150 tumour nodules 
in their lungs compared to 55, 65 and 77 in the lungs of the irradiated mice receiving the 
same number of B16 cells (figure 5.2). The difference in the number of nodules between the 
two sets of mice was not statistically significant (p=0.1). Irradiated mice that received 5xl04 
B16 cells had 40 and 50 tumour nodules in their lungs and a mouse that received 2.5xl04 
B16 cells had 18 tumour nodules in its lung (figure 5.2). This intriguing result was pursued 
later in this chapter.
Overall, this data suggested that an equivalent number of B16 cells that are normally 
transferred to non-irradiated recipient mice can be transferred to irradiated mice.
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5.4 B16 cells labelled with intracellular dyes are detected in the lungs of mice twenty-four 
hours following intravenous transfer
The next step in the tumour studies was to develop an in vivo assay that allowed the killing 
of B16 cells by control and motheaten CD8+ F5 T cells to be studied. An assay that involved 
the transfer of differentially labelled target (NP68 peptide-pulsed) and reference B16 cells to 
mice that had previously received naive CD8+ F5 T cells was initially trialled. This involved 
performing pilot assays to establish whether fluorescently labelled B16 cells could be 
detected in the lungs of sub-lethally irradiated recipient mice following their intravenous 
transfer.
To begin, a total of 1.2xl06 B16 cells labelled with either 0.2pM or 2pM CFSE were 
transferred intravenously to the same recipient mice. A control mouse did not receive any 
B16 cells. A total of three mice received CFSE labelled B16 cells, but the cells proved to be 
toxic to one mouse, which died soon after B16 cell transfer. After twenty-four hours the 
remaining mice were sacrificed and the spleens and lungs taken for analysis by flow 
cytometry. The gates were set above the autofluorescence found in the spleen and lungs of 
the mouse that did not receive any B16 cells (figures 5.3A and B). There were no CFSE 
labelled cells detected in the spleens of recipient mice (figures 5.3C and E). However, the 
two mice receiving B16 cells had CFSE labelled cells within their lungs but the differentially 
CFSE labelled B16 cell populations could not be distinguished (figures 5.3D and F).
In a subsequent pilot assay the number of B16 cells transferred was reduced to potentially 
avoid any toxic side-effects to recipient mice. Also, a different combination of fluorescent 
dyes was used to label the B16 cells to assist with their detection in the lungs of recipient 
mice. Therefore, a total of 5xl05 B16 cells labelled with either 2pM CFSE or lOpM DDAO 
were transferred to a recipient mouse. A control mouse did not receive any T cells. Twenty
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four hours later the mice were sacrificed and their lungs taken for analysis by flow 
cytometry. Dots plots were gated on viable cells and the fluorescence from CFSE and DDAO 
displayed as single plots, versus side scatter (figures 5.4A, B, C and D), or on the same dot 
plot (figures 5.4E and F). The gates defining fluorescent cells were set above the 
autofluorescence found in the lungs of the mouse did not receive any B16 cells (figures 5.4A, 
C and E). The differentially labelled B16 cells were apparent in the lungs of the recipient 
mouse but in low numbers (figures 5.4B, D and F).
In an attempt to address the problems associated with detecting fluorescently labelled B16 
cells in sufficient numbers and distinguishable from the background fluorescence in the 
lungs of recipient mice a third pilot assay was performed. A recipient mouse received a total 
of 8xl05 B16 cells that had been labelled with either 0.2pM or 3pM CFSE. A second mouse 
received 8xl05 B16 cells labelled with either 0.5pM or 4pM CFSE. A control mouse did not 
receive any B16 cells. Even though the number of B16 cells transferred was not immediately 
toxic to the recipient mice they appeared to go in to a state of mild shock (lethargic and not 
responsive to surrounding stimulus) following B16 cell transfer, but recovered after 30 
minutes. Mice were sacrificed twenty-four hours post B16 cell transfer and their lungs taken 
for analysis by flow cytometry. The gates defining fluorescent cells were set above the auto­
fluorescence found in the lungs of the mouse not receiving any B16 cells (figure 5.5A). The 
mouse that received B16 cells labelled with 0.2pM and 3pM CFSE had fluorescent cells 
within its lung but the differentially labelled populations were not distinguishable (figure 
5.5B). The mouse that received B16 cells labelled with 0.3pM and 4pM CFSE had two evident 
populations of fluorescently labelled cells within its lung (figure 5.5C).
The approach of labelling B16 cells with fluorescent dyes in order to study the killing of 
tumour cells was not pursued any further, as cells were not always detectable upon
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retrieval, and the number required for transfer to allow detection had adverse side-effects 
on the recipient mice.
5.5 A similar number of B16 nodules are present in mice receiving CD8+ F5 T cells and 
either B16 cells pulsed with NP68 peptide or unpulsed B16 cells
An alternative method was sought to that using fluorescently labelled B16 cells to look at the 
in vivo killing of NP68 peptide-pulsed B16 cells by CD8+ F5 T cells. The proposed alternative 
protocol involved transferring NP68 peptide labelled B16 cells to mice that had already been 
primed NP68 in IFA and were recipients of either naive control or motheaten CD8+ F5 T cells. 
The enumeration of the nodules in the lungs of the mice fourteen days post B16 cell transfer 
was predicted to be an indirect readout of the number of B16 cells initially killed upon their 
intravenous transfer.
To assess the feasibility of the alternative protocol, sub-lethally irradiated mice received 
3xl06 naive control CD8+ F5 T cells intravenously and a subcutaneous injection of NP68 
peptide in IFA. Seven days post T cell transfer mice received either 1x10s B16 cells that had 
been pulsed with NP68 peptide or 1x10s B16 cells that had not been pulsed. Fourteen days 
post B16 cell transfer the mice were sacrificed and the B16 nodules in the lungs enumerated. 
Mice that received un-pulsed B16 cells had 345, 233, 261 and 200 tumour nodules in their 
lungs compared to 215, 305, 267 and 199 tumour nodules in the lungs of mice that received 
B16 cells pulsed with NP68 peptide (figure 5.6). Any difference in the number of lung tumour 
nodules between the two groups of mice was not statistically significant (p=0.8857). 
Presumably, the NP68 peptide is lost from the surface of the B16 cells once transferred in 
vivo. As attempts to develop a protocol using B16 cells pulsed with NP68 peptide were 
unsuccessful it was necessary to produce B16 cells that constitutively expressed the NP68 
eptiope.
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5.6 Successful infection of B16 cells with a retrovirus encoding the NP68 epitope as a 
fusion protein with GFP
One approach to producing B16 cells expressing the NP68 was to use a cDNA construct that 
encodes the NP68 epitope as a fusion protein with GFP.
Retrovirus encoding the NP68 epitope as a fusion protein with GFP was produced by 
transfecting a packaging cell line, known as Phoenix, with the corresponding cDNA. At the 
point of viral harvest, between 80-90% of the Phoenix cells were fluorescent when viewed 
under a fluorescent microscope (data not shown).
Wild-type B16 cells were infected twice with the retrovirus on subsequent days. As a control 
for the infection protocol, a previously verified control retrovirus encoding GFP (named 
Pinco) was also used to infect B16 cells. Seven days post-infection, the cells were analysed 
for GFP expression by flow cytometry. Histograms displaying GFP fluorescence were gated 
on viable cells as determined by forward and side scatter. The B16 cells infected with the 
control retrovirus encoding GFP were 35% GFP positive (figure 5.7B). Those B16 cells 
infected with the retrovirus encoding GFP as a fusion protein with the NP68 epitope were 
19.1% GFP positive (figure 5.7C). Subsequently, B16 cells infected with the virus encoding 
the NP68 peptide as a fusion protein with GFP were single cell sorted based upon viability, 
pulse width and GFP fluorescence. A polyclonal B16 cell population (originally lxlO4 cells) 
was GFP positive two weeks post cell sorting (figure 5.8A). A total of twenty-four wells of a 
96-well plate received individual B16 cells and from these, two monoclonal cells lines were 
grown successfully. Both monoclonal cell lines were GFP positive five weeks following single 
cell sorting (figures 5.8B and C).
5.7 B16 cells infected with a retrovirus encoding the NP68 epitope are killed in vitro by 
CD8+ F5 T cells
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An in vitro CTL assay was performed to test for the constitutive expression and the 
presentation by MHC class I of the NP68 epitope by B16 cells that had been infected with a 
retrovirus encoding the NP68 epitope as a fusion protein with GFP.
Naive CD8+ F5 T cells were activated in vitro with NP68 peptide-pulsed splenocytes for two 
days followed by their expansion for a further two days with IL-2. Both monoclonal B16 cell 
lines expressing GFP were tested for the surface presentation of the NP68 epitope. Parental 
B16 cells and the GFP positive B16 cells were plated-out at a 1:1 ratio twenty-four hours 
prior to the addition of the activated T cells (figures 5.9A and C). The B16 cells were then 
incubated with the activated T cells for sixteen hours, followed by staining with anti-CD8PE 
antibody prior to analysis by flow cytometry. Histograms displaying CFSE fluorescence were 
generated on viable and CD8' cells. Over 99% of the GFP positive cells of both monoclonal 
cell lines were killed by the activated CD8+ F5 T cells (figures 5.9B and D).
5.8 Mice receiving 3xl06 naive control CD8+ F5 T ceils and 1.5x10s B16 cells expressing the 
NP68 epitope are clear of lung tumours
To establish whether the B16 cells that express the NP68 epitope could both grow and be 
killed in an in vivo setting, B16 cells were transferred to irradiated recipient mice, that had 
previously received naive control CD8+ F5 T cells, or to mice that had received no T cells.
Sub-lethally irradiated mice received 3xl06 naive control CD8+ F5 T cells intravenously. These 
were activated by the subcutaneous injection of NP68 peptide in IFA. Control mice did not 
receive any T cells. Seven days post T cell transfer, all mice received 1x10s B16 cells that 
expressed the NP68 epitope. Fourteen days later the mice were sacrificed and the 
pigmented tumour nodules in their lungs enumerated. Those mice that did not receive any T 
cells had 101, 89, 90 and 79 tumour nodules within their lungs (figure 5.10). The mice that
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were primed and the recipients of CD8+ F5 T cells had no tumour nodules within their lungs 
(figure 5.10).
5.9 Complete protection from tumour development in the lungs of mice receiving either 
naive control or motheaten CD8+ F5 T cells
The B16 cells expressing the NP68 epitope were utilised to establish whether there was any 
difference in protection from tumour development in the lungs of mice that received either 
naive control or naive motheaten CD8+ F5 T cells. Sub-lethally irradiated mice received 
purified naive CD8+ F5 T cells intravenously and NP68 peptide subcutaneously in IFA. After a 
defined number of days, the mice then received a population of B16 cells expressing the 
NP68 epitope. Fourteen days post B16 cell transfer, the mice were sacrificed and the 
pigmented nodules in their lungs enumerated. Control mice for each experiment did not 
receive any T cells but did receive the B16 cells. Four independent experiments were 
performed to help establish how many CD8+ T cells and B16 cells to transfer to recipient 
mice, and also the duration between T cell and B16 cell transfer to give an acceptable level 
of tumour development.
Initially, 3xl06 naive control or motheaten CD8+ F5 T cells were transferred to individual 
mice. Four days later, mice received 1x10s B16 cells expressing the NP68 epitope. Those 
mice that did not receive any T cells had 50, 80 and 110 tumour nodules in their lungs 
whereas the mice receiving naive control or naive motheaten CD8+ F5 T cells had no tumour 
nodules within their lungs (figure 5.11A).
In three subsequent experiments the number of B16 cells transferred was increased to 
2.5x10s and the duration between T cell and B16 cell transfer was reduced to two days. In 
addition, for each subsequent experiment the number of naive control or naive motheaten 
CD8+ F5 T cells transferred was lxlO 6, 1x10s and 5xl04. The number of tumour nodules in
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the lungs of the control mice that did not receive T cells, were as follows: 240, 262 and 320 
for the experiment where mice received lxlO 6 T cells (figure 5.11B); 200, 260 and 340 for 
the experiment where mice received 1x10s T cells (figure 5.11D) and 144, 258 and 288 for 
the experiment where mice received 5xl04 T cells. For each experiment the mice that 
received either naive control or motheaten CD8+ F5 T cells had no tumour development in 
their lungs after fourteen days (figure 5.11B, C and D).
5.10 Similar tumour nodule formation in mice receiving either lxlO4 control or motheaten 
CD8* F5 T cells or no T cells
As no tumour development was seen in the lungs of mice that received 5xl04 naive control 
or motheaten CD8+ F5 T cells, and 2.5x10s B16 cells expressing the NP68 epitope, the 
number of T cells transferred was reduced further.
Sub-lethally irradiated mice received lxlO4 control or motheaten naive CD8+ F5 T cells and 
NP68 peptide subcutaneously in IFA. One day post T cell transfer, all mice had an 
intravenous transfer of 2.5xl05 B16 cells expressing the NP68 peptide. Fourteen days later 
the mice were sacrificed and the pigmented nodules in their lungs enumerated. Those mice 
receiving no T cells had 302, 288 and 345 tumour nodules in their lungs (figure 5.12). Those 
mice receiving naive control CD8+ F5 T cells had 275, 345 and 280 tumour nodules in their 
lungs (Figure 5.12) compared to 325, 299 and 269 tumour nodules in the lungs of mice that 
received naive motheaten CD8+ F5 T cells (figure 5.12). There was no significant difference in 
the number of tumour nodules between the three groups of mice (No T cell transfer versus 
control CD8+ F5 T cell transfer: p = 0.7. No T cell transfer versus motheaten CD8+ F5 T cell 
transfer: p = 0.4. Control CD8+ F5 T cell transfer versus motheaten CD8+ F5 T cell transfer: p = 
0.7)(figure 5.12).
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5.11 Reduced tumour nodule formation in mice receiving 2xl04 naive motheaten CD8* F5 
T cells compared to mice that receiving no T cells
As a result of the equivalent lung tumour nodule formation seen in mice that received no T 
cells and mice that received either lxlO4 naive control or naive motheaten CD8+ F5 T cells 
the number of adoptively transferred T cells was increased for subsequent assays.
Sub-lethally irradiated mice received 2xl04 control or motheaten naive CD8+ F5 T cells and 
NP68 peptide subcutaneously in IFA. Twenty-four hours post T cell transfer all mice had an 
intravenous transfer of 2.5x10s B16 cells expressing the NP68 peptide. Fourteen days later 
the mice were sacrificed and the pigmented nodules in their lungs enumerated. Those mice 
receiving no T cells had 299, 345, 380 and 398 tumour nodules in their lungs (figure 5.13). 
Those mice receiving naive control CD8+ F5 T cells had 240, 255 and 301 tumour nodules in 
their lungs (figure 5.13). Finally, the mice that received motheaten naive CD8+ F5 T cells had 
169, 210 and 258 nodules in their lungs (figure 5.13), which was a statistically significant 
reduction (p = 0.05) when compared to mice that did not receive any T cells. Any difference 
in the number lung tumour nodules between mice that received naive control or naive 
motheaten CD8+ F5 T cells was not statistically significant (p=0.4).
5.12 Reduced tumour nodules formation in the lungs of mice receiving 3.2xl04 motheaten 
naive CD8+ F5 T cells, when compared to mice receiving 3.2xl04 control naive CD8+ F5 T 
cells
With lxlO4 T cells giving no protection to mice receiving B16 cells and with 2xl04 naive 
motheaten CD8+ F5 T cells giving some protection from lung tumour development the 
number of T cells transferred was increased further. Two pairs of sub-lethally irradiated mice 
received either 3.2xl04 naive control or motheaten CD8+ F5 T cells concomitantly with the 
subcutaneous injection of NP68 peptide in IFA. A third pair of sub-lethally irradiated mice did
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not receive any T cells. After one day all mice had an intravenous transfer of 2.5x10s B16 
cells expressing the NP68 peptide. Fourteen days later the mice were sacrificed and the 
lungs photographed (figure 5.14) from one set of mice and the pigmented lung nodules 
enumerated for all mice (figure 5.15). Figure 14 illustrates the degree of tumour load in the 
lungs of the mice, with highly pigmented lungs having a greater tumour load. The lungs from 
the mouse not receiving any T cells and the mouse that received control naive CD8+ F5 T 
cells had many pigmented tumour nodules. In contrast the lungs of the mouse that received 
motheaten CD8+ F5 T cells appeared normal. The enumeration data revealed that the mice 
receiving no T cells had 254 and 289 tumour nodules in their lungs (figure 5.15). Those mice 
receiving naive control CD8+ F5 T cells had 168 and 125 tumour nodules in their lungs 
compared to 0 and 2 tumour nodules in the lungs of mice that received naive motheaten 
CD8+ F5T cells (figure 5.15).
As only two mice for each group were used for this experiment no statistical analysis was 
performed, therefore the experiment was repeated with more mice in each group.
5.13 Significantly enhanced protection against lung tumour formation in mice receiving 
3.2xl04 naive motheaten versus control CD8+ F5 T cells
A group of six sub-lethally irradiated mice received either 3.2xl04 naive control or 
motheaten CD8+ F5 T cells. Another group of six mice did not receive any T cells. All mice 
that received T cells were primed subcutaneously with NP68 peptide in IFA. One day 
following T cell transfer, all mice received an intravenous infusion of 2.5x10s B16 cells 
expressing the NP68 peptide. Fourteen days post B16 cell transfer mice were sacrificed and 
the lungs photographed (figure 5.16) prior to the enumeration of the pigmented lung 
tumour nodules (figure 5.17). Those mice that did not receive any T cells and those that 
received naive control CD8+ T cells had highly pigmented lungs when compared to the mice
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that received motheaten CD8+ F5 T cells (figure 5.16). Mice that received motheaten naive 
CD8+ F5 T cells had significantly (p=0.0022) fewer tumour nodules (12, 14, 91, 98, 116 and 
170) in their lungs compared to mice receiving control naive CD8+ F5 T cells (225, 239, 251, 
281, 305 and 315) (figure 5.17). Two of the mice that did not receive T cells died before the 
end of the assay and the remaining four mice had over 425 nodules in their lungs (figure 
5.17).
In a further independent experiment, all conditions were kept the same as the previous 
tumour protection assay (as described above). Briefly, sub-lethally irradiated mice were 
primed subcutaneously and received either 3.2xl04 naive control or motheaten CD8+ F5 T 
cells followed by 2.5x10s B16 cells a day later. Only a sufficient number of motheaten CD8+ 
F5 T cells were available for three recipient mice during this experiment. Fourteen days post 
B16 cell transfer the three mice that were recipients of motheaten naive CD8+ F5 T cells had 
significantly (p=0.023) fewer tumour nodules in their lungs (0, 0 and 53) compared to six 
mice that received control CD8+ F5 T cells (98, 122, 200, 226, 283 and 296) (figure 5.18). Four 
of the mice that did not receive any T cells had over 425 nodules in their lungs with the 
remaining two mice having 159 and 315 lung tumour nodules (figure 5.18).
5.14 Activated motheaten CD8+ F5 T cells exhibit an enhanced effector function on a per 
cell basis when compared to activated control CD8+ F5 T cells
In order to explore the potential factors that may contribute to the enhanced protection 
from lung tumour development seen in mice that received naive motheaten CD8+ F5 T cells, 
in vitro assays were performed that looked at the effector function of activated control and 
motheaten CD8+ F5 T cells on a per cell basis.
Previous experimental work (Johnson et al., 1999) had demonstrated that there was no 
difference in the degree of direct target cell killing by control and motheaten CD8+ F5 T cells
217
on a per cell basis, when the target cells were NP68 peptide-pulsed mouse EL4 cells. The aim 
here was to explore the effector capabilities of activated control and motheaten CD8+ F5 T 
cells when the targets were B16 cells.
In vitro assays were performed to look at the surface expression of CD107a on activated 
control and motheaten CD8+ F5 T cells upon encounter with target B16 cells. In addition, the 
direct killing of target B16 cells by control and motheaten CD8+ F5 T cells was also studied.
5.14a A greater proportion of activated motheaten CD8+ F5 T cells upregulate CD107a 
upon encounter with B16 cells expressing the NP68 epitope in comparison to activated 
control CD8+ F5 T cells
When a CD8+ T cell encounters a target cell, it releases cytotoxic granules that are capable of 
directly killing the target cell. These granules are released from intracellular vesicles which 
fuse with the cell surface membrane. As a result of this fusion, CD107a molecules, which line 
the inside of the vesicle's membrane, are displayed on the surface of the cell. Therefore, the 
appearance of CD107a on the surface of the CD8+ T cells is an indicator of its direct 
encounter with an appropriate target cell.
In an initial experiment in vitro activated control and motheaten CD8+ F5 T cells were 
incubated with either B16 cells that had been pulsed with NP68 peptide or left un-pulsed. 
This was done in triplicate and at three B16 to T cell ratios (5:8, 5:4 and 5:2). The assay 
media contained both an anti-CD107aF,TG antibody and golgi-stop. After four hours of 
incubation, the cells were harvested and stained with an anti-CD8PE antibody and analysed 
by flow cytometry. Contour plots were gated on a viable CD8+ cell population and displayed 
as CD8 versus CD107a (representative plots shown in figure 5.19). The CD107a positive gate 
was set above the fluorescence seen in the absence of B16 cells (figures 5.19A and D). There 
was minimal up-regulation of surface CD107a in the presence of un-pulsed B16 cells for both
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control (figure 5.19B and figure 5.20) and motheaten (figure 5.19E and figure 5.20) CD8+ F5 T 
cells. In the presence of NP68 peptide pulsed B16 cells, a greater proportion of motheaten 
CD8+ F5 T cells up-regulated CD107a on their cell surface (figure 5.19F and figure 5.20) in 
comparison to control CD8+ F5 T cells (figure 5.19C and figure 5.20). This was not statistically 
significant according to a non-parametric Mann-Whitney test.
In a subsequent assay, all conditions were kept the same but with six B16 to T cell ratios 
(1:40, 1:20, 1:10, 1:5, 2:5 and 1:1) being used in an attempt to titrate the degree of CD107a 
upregulation detected on the surface of the T cells. The data was generated in the same 
manner as the previous assay (as described above). At each ratio, a greater proportion of 
activated motheaten CD8+ F5 T cells up-regulated CD107a expression on their cell surface 
(Figure 5.21D and figure 5.22) in comparison to activated control CD8+ F5 T cells (Figure 
5.21B and figure 5.22). This was not statistically significant according to a non-parametric 
Mann-Whitney test.
5.14b Activated motheaten versus control CD8+ F5 T cells kill a greater proportion of NP68 
peptide-pulsed B16 cells
In order to look at the direct killing of target B16 cells by activated control and motheaten 
CD8+ F5 T cells an in vitro CTL assay was performed.
Naive CD8+ F5 T cells from control and motheaten mice were activated and expanded in vitro 
for four days prior to use. Wild-type and B16/NP cells were plated out at a 1:1 ratio twenty- 
four hours prior to the start of the assay. The activated T cells were added to the B16 cells to 
give five different T cell to B16 cell ratios (1:10, 1:5, 1:1, 5;1 and 10:1), with the number of T 
cells added determined by the total number of B16 cells used in each well. Each condition 
was performed in triplicate and cells were harvested after 4 hours and stained with anti- 
CD8pe antibody followed by analysis by flow cytometry. Histograms displaying GFP
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fluorescence were generated by gating on a viable CD8' cell population (Figure 23 shows 
representative histogram plots). The percentage killing was calculated by comparing the 
GFP+ B16 cells to the GFP' cells and adjustments made for any deviation from the anticipated 
1:1 ratio of target to reference B16 cells by using data from wells where B16 cells were 
cultured in the absence of T cells (figure 5.23A). No B16 cells were killed by activated control 
CD8+ F5 T cells, at the ratios of 1:10, 1:5 and 1:1 (figure 5.23B and figure 5.24), whereas B16 
cells were killed by the motheaten CD8+ F5 T cells at the ratio of 1:1 (figure 5.23C and figure 
5.24). At the ratios of 5:1 and 10:1 more B16 cells were killed by the motheaten CD8+ F5 T 
cells than the control CD8+ F5 T cells (figure 5.24). This was not statistically significant. 
according to a non-parametric Mann-Whitney test.
5.15 Development of in vivo assays to examine other aspects associated with the 
enhanced tumour protection seen with motheaten CD8* F5 T cells
To further compare the antigen induced response of naive control and naive motheaten 
CD8+ F5 T cells in mice with developing tumours in their lungs, a control experiment was 
performed to assess the feasibility of measuring other parameters alongside the 
enumeration of the tumour lung nodules.
The ultimate aim of such experiments would be to further define the underlying reason(s) 
for the enhanced protection from lung tumour development seen in mice that received 
naive motheaten CD8+ F5 T cells. As motheaten mice were no longer available at this point 
of the study, the feasibility of the assays was assessed using CD8+ F5 T cells from control 
mice.
A group of seven sub-lethally irradiated mice received 3.2xl04 control naive CD8+ F5 T cells. 
A group of six mice did not receive any T cells. All mice were subcutaneously primed with 
NP68 peptide in IFA. One day following T cell transfer, all mice received an intravenous
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infusion of 2.5x10s B16 cells expressing the NP68 peptide. Fourteen days post B16 cell 
transfer, mice were sacrificed and the tumour lung nodules enumerated. Mice that received 
control naive CD8+ F5 T cells had significantly (p=0.0022) fewer tumour nodules (0, 0, 5, 10, 
22, 57 and 78) in their lungs compared to mice that received no T cells (116, 124, 198, 201, 
215 and 235) (figure 5.25). This result was consistent with earlier assays with regards to the 
reduced tumour formation in mice receiving T cells but, the overall number of tumour 
nodules forming in the lungs of mice was reduced.
The CD8+ T cells were monitored directly throughout the assay by taking blood from mice 
(figure 5.26) and also looking at the CD8+ T cells present in the lungs of the mice at the end 
of the assay (figure 5.27).
5.15a A greater proportion of CD8+ T cells are present in the blood of irradiated mice 
receiving naive control CD8+ F5 T cells when compared to irradiated mice receiving no T 
cells
Peripheral blood was taken from one mouse that received T cells (Figure 5.26D) and one that 
did not receive T cells (figure 5.26C) on days 1, 4, 7, 11 and 15 following T cell transfer. The 
blood was processed and stained with anti-CD8PE antibody ready for analysis by flow 
cytometry. Dot plots were gated on a lymphocyte gate as determined by forward and side 
scatter. Aliquots of blood from each mouse were pooled and left unstained in order to 
define the CD8+ gate above any autofluorescence (figure 5.26A). Blood was also taken from a 
non-irradiated mouse to assist with analysis by revealing the location of the CD8+ cells on the 
dot plots (figure 5.26B).
A greater proportion of CD8+ cells were seen in the mouse that had received an adoptive 
transfer of CD8+ F5 T cells, which was above the recovering endogenous CD8+ T pool 
following sub-lethal irradiation. On days 1, 4, 7,11 and 15 the respective proportions of cells
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in the CD8+ gate for the mouse that received T cells and the mouse that did not receive T 
cells were 3.36% versus 2.44%, 11% versus 5.07%, 7.07% versus 3.62% (data acquired on a 
different flow cytometer to that used on other days), 7.49% versus 3.01% and 6.12% versus 
1.92% (figure 5.26).
5.15b A greater proportion of CDS* cells were present in the lungs of mice receiving control 
naive CD8* F5 T cells when compared to mice receiving no T cells
Fourteen days following B16 cell transfer, mice were sacrificed and the tumour nodules in 
the lungs enumerated. The lungs were then homogenised from three mice that had received 
T cells and three mice that received no T cells. The cell preparations were stained with anti- 
CD8pe antibody to enable analyses by flow cytometry. Aliquots of blood from each mouse 
were pooled and left unstained in order to define the CD8 positive gate above the auto­
fluorescence (figure 5.27A). Dot plots were gated on a lymphocyte gate as determined by 
forward and side scatter.
As shown in figures 5.27B and 5.27C, the mice that received T cells had 19.4%, 14.2% and 
14.9% CD8 positive cells in the lymphocyte gate compared to 4.21%, 3.42% and 5.54% CD8 
positive cells in the lymphocyte gate of the mice that received no T cells. Therefore, the 
adoptively transferred CD8+ T cells could be detected above the endogenous CD8+ cells 
present in the lungs of sub-lethally irradiated mice.
5.15c Mice receiving B16 cells lost weight over the duration of the tumour protection 
assay, regardless of T cell transfer, whereas those that did not receive any B16 cells gained 
weight
In addition to monitoring the CD8+ T cells during the control assay, the impact of differing 
tumour loads on the physical health of the mice was also monitored. It had been observed in
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previous tumour protection assays that mice with lower tumour loads maintained a better 
state of general health; therefore the mice were weighed over the duration of the assay.
Mice were initially weighed prior to sub-lethal irradiation (-1) and then again on day(s) 1, 3, 
7, 9; 11, 13 and 15 following T cell transfer. All mice that were irradiated lost weight from 
the point of irradiation (Day -1) to the transfer of T cells (Day 0) (figure 5.28A). Mice that had 
not been irradiated gained weight over the same time period (figure 5.28A). From the point 
of B16 cell transfer (Day 1) those mice that had received T cells lost 4.44% of their initial 
body weight between days 2 and 15 (figures 5.28A and 5.28B). Over the same time period 
mice that received B16 cells but no T cells lost 6.74% of their initial body weight (figures 
5.28A and 5.28B). Mice that had been irradiated but were not the recipients of T cells or B16 
cells gained weight over the same time period, with an overall gain of 6.01% of their initial 
body weight (figures 5.28A and 5.28B). Those mice that were left untreated also gained 
weight, with a growth of 6.20% of their initial body weight (figures 5.28A and 5.28B).
5.16 Partial regression and delayed growth of a subcutaneous B16 melanoma in a mouse 
receiving motheaten naive CD8+ F5 T cells
In order to study the relative efficiency of motheaten and control CD8+ F5 T cells in a model 
of T cell induced tumour regression, ten mice received a subcutaneous injection of 1x10s B16 
cells expressing the NP68 epitope. The tumours were monitored by measuring their 
perpendicular diameters with a set of callipers (figure 5.29). Two mice did not develop 
tumours at the site of transfer. The remaining tumours grew at different rates and reached 
differing sizes by day fourteen (figure 5.29).
Three of the mice with similar sized tumours were chosen to study tumour regression. They 
were sub-lethally irradiated twenty-four hours prior to the transfer of either lx lO 6 
motheaten or lxlO6 control naive CD8+ F5 T cells. A third mouse did not receive any T cells.
The tumour in the mouse that received no T cells continued to grow over the duration of the 
assay. It grew from an average diameter of 2.2mm on day 1, to 8mm on day 17, which 
represented a 3.6 fold increase in size (figure 5.30). After an initial period of size reduction 
between day(s) 1 and 5 following T cell transfer, the tumour in the mouse that received 
naive control CD8+ F5 T cells grew from 3.1mm on day 5 to 7.9mm on day 15, representing a
2.5 fold increase in size (figure 5.30). The tumour in the mouse that received naive 
motheaten CD8+ F5 T cells grew from 2.5mm, on day 1 following T cells transfer, to a 
maximum size of 6.3mm on day 8. From this point the tumour reduced in size to 3.6mm on 
day 11, representing a 2.2 fojd reduction in size (figure 5.30). The tumour then continued to 
grow and reached a size of 4mm on day 18, which was 2 fold less than the size of the tumour 
in the mouse receiving no T cells and 1.98 fold less than the size of the tumour in the mouse 
receiving naive control CD8+ T cells.
5.17 Successful co-infection of B16 cells with a retrovirus encoding the Luciferase gene and 
a retrovirus encoding the NP68 epitope
To enable the tumour regression studies to progress, a more accurate method of monitoring 
the size of a developing tumour is necessary. One possibility is the use of a whole body 
imaging unit that can detect bioluminescence. However, to detect luminescence from 
genetically engineered tumour cells required the production of B16 cells expressing the 
luciferase gene. Once mice have been injected with luciferin, which is the substrate for the 
luciferase enzyme, the imaging unit allows the mice to be maintained under anaesthetic 
whilst it captures bioluminescent images of the tumour. This ultimately allows for the 
accurate imaging and quantification of both pulmonary and subcutaneous tumours during 
development and potential regression.
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A recombinant retrovirus encoding the luciferase gene and the YFP gene (separated by an 
IRES) was produced by transfecting the packaging cell line, Phoenix, with the corresponding 
cDNA. At the point of viral harvest no YFP fluorescence was detected when viewing the cells 
under a fluorescent microscope (data not shown).
Wild-type B16 cells were infected twice with the retrovirus on subsequent days. At each 
stage of infection the cells were viewed under the fluorescent microscope, but no YFP 
fluorescence could be detected (data not shown). The infected B16 cells were also assessed 
for luciferase activity by performing an in vitro luciferase assay. The cells exhibited luciferase 
activity, with the parental B16 cells being used as a negative control (figure 5.31A).
In view of this result, it was decided to perform a single cell sort based upon viability. 
However, when cells were analysed using a MoFlo cell sorter it revealed a weak YFP signal. 
Therefore, cells were sorted based upon cell viability and YFP fluorescence (figure 5.31B). 
Twelve monoclonal cells grew from a total of 84 sorted cells, one of which (number 8) had a 
poor growth profile and was therefore not used for further analysis. After an expansion of 
five weeks the cells were re-tested for luciferase activity. Four of the monoclonal cell lines 
exhibited low luciferase activity (numbers 1, 4, 10 and 12), with the remaining eight having 
higher levels of luciferase activity (figure 5.31C). The monoclonal cell line designated number 
11 was chosen for further manipulation due to its high luciferase activity and similar growth 
profile to the parental B16 cell line. This cell line also exhibited low YFP expression when 
analysed by a FACScalibur flow cytometer (Figure 5.32A).
The luciferase expressing monoclonal B16 cell line (number 11) was then infected twice on 
subsequent days, with a retrovirus encoding the NP68 epitope as a fusion protein with GFP. 
Seven days post infection the cells were single cell sorted based upon viability and GFP
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expression. At this point 56.4% of the cells were expressing GFP (figure 5.32B). The cells 
were single cell sorted based upon cell viability and GFP fluorescence (figure 5.32C).
From a total of one hundred and sixty-eight sorted single cells, eighteen of them grew to a 
stage that allowed for further analysis. Whilst in culture it became evident that clones 1, 8, 
14 and 18 had very slow growth and as a result were not used any further. After three weeks 
of expansion the remaining cell lines were assessed for GFP expression by flow cytometry. 
The level of GFP expression was compared to that of a previously generated B16 cell line 
that expressed GFP as a fusion protein with the NP68 epitope and the autofluorescence 
from wild-type B16 cells. The parental cell line that expressed YFP was also used as a control 
during analysis. Clones six and seven both expressed GF;P (figure 5.33A) but had an abnormal 
appearance (granular cytoplasm and multiple dendrites) under the light microscope when 
compared to the parental cell line. Clone three expressed no GFP but appeared to still 
express some YFP (figure 5.33B). Clones two and nine had a bi-fluorescent GFP profile, with 
both GFP+ and GFP' cells being present (figure 5.33B). In light of this data, clones 6, 7, 3, 2 
and 9 were not used for further analysis. The remaining nine clones (4, 5, 10, 11, 12, 13, 15, 
16 and 17) all expressed GFP (Figure 4A), with a distribution of expression comparable to the 
GFP fluorescence from a cell line previously generated during this study. In addition, all nine 
clones exhibited luciferase activity (figure 5.34B).
The nine B16 Luciferase/YFP/GFP/NP monoclonal cell lines were then tested for the surface 
presentation of NP68 peptide by MHC class I molecules. Each clone was plated out with an 
equal number of wild-type B16 cells and allowed to adhere to the plastic for 24 hours. 
Previously activated CD8+ F5 T cells were then added to the B16 cells at a 2:1 ratio of T cells 
to B16 cells. As a control, B16 cells were also cultured without T cells. In addition a 
previously generated B16 cell line that had already been tested for NP68 peptide
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presentation at their cell surface was used as a positive control for the killing assay (figure 
5.35J). Twenty-four hours later, the CD8+ T cells and dead B16 cells were washed from the 
wells and the remaining B16 cells removed by incubation with trypsin. Cell were then 
analysed by flow cytometry, with histograms being generated showing GFP fluorescence by 
gating on a viable B16 cell population as determined by forward and side scatter. The 
majority of each clone was killed by the CD8+ F5 T cells as seen by the disappearance of the 
GFP+ peak (figure 5.35).
5.18 Significantly enhanced tumour formation in the lungs of irradiated mice receiving 
control CD8* F5 T cells, when compared to irradiated mice receiving no T cells
To further explore the intriguing observation that sub-lethally irradiated mice had fewer lung 
tumour nodules when compared to non-irradiated mice (figure 5.2) an additional 
experiment was performed. Mice were irradiated six days prior to the intravenous transfer 
of lxlO5 wild-type B16 cells. A second group of mice were not irradiated but received the 
same number of B16 cells. Fourteen days post transfer, the mice were sacrificed and the 
tumour nodules in their lungs enumerated.
As shown in figure 5.36 the non-irradiated mice had 40, 41, 58 and 62 tumour nodules in 
their lungs compared to 8, 9, 15 and 18 tumour nodules in the lungs of the irradiated mice 
receiving the same number of B16 cells. The difference in the number of tumour nodules 
between the two sets of mice was statistically significant (p=0.01).
A second group of four irradiated mice received 3xl06 purified control naive CD8+ F5 T cells 
intravenously five days prior to the transfer of lx lO 5 B16 cells. The mice were also primed 
subcutaneously at the same time as T cell transfer with NP68 peptide in IFA. The mice had 
99, 111, 154 and 168 tumour nodules in their lungs, which was significantly more than 
irradiated mice that had not received any T cells (p = 0.01) (figure 5.36).
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5.19 A tumour specific CD8+ T cell response protects against lung tumour development, 
whereas a non-specific CD8+ T cell response promotes lung tumour formation
With the availability of both wild-type B16 cells and B16 cells expressing the NP68 epitope 
an experiment was performed to look at the impact of both a tumour-specific and non­
specific CD8+ T cells response on tumour development in the lungs of mice.
A group of twelve sub-lethally irradiated mice received 1.8xl06 purified control naive CD8+ 
F5 T cells intravenously. A second group of twelve sub-lethally irradiated mice did not 
receive any T cells. A third group of twelve mice were not irradiated and did not receive any 
T cells. All mice that were recipients of T cells were primed subcutaneously with NP68 
peptide in IFA at the same time as T cell transfer.
Three days post T cell transfer six of the irradiated mice that received T cells, six of the 
irradiated mice that did not receive T cells and six of the mice that were not irradiated or 
recipients of T cells then received an intravenous infusion of either 1.75x10s B16 cells 
expressing the NP68 epitope or 1.75x10s wild-type B16 cells. Fourteen days post B16 cell 
transfer, all mice were sacrificed and the lung tumour nodules enumerated.
The mice that were irradiated and not recipients of T cells had significantly fewer tumour 
nodules when compared to non-irradiated mice. This was regardless of the type of B16 cells 
transferred; the non irradiated mice that received the wild-type B16 cells had 199, 210, 244, 
299, 301 and 325 tumour nodules in their lungs (figure 5.37A) compared to 59, 73, 94, 148, 
202 and 247 tumour nodules in the lungs of irradiated mice that also received wild-type B16 
cells (figure 5.37B). The number of lung tumour nodules developing was statistically 
significant between the two groups (p = 0.026). The non irradiated mice that received the 
B16 cells expressing the NP68 epitope had 159, 225, 245, 261, 288 and 330 tumour nodules 
in their lungs (figure 5.37D) compared to 65, 81, 99,128,166 and 268 tumour nodules in the
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lungs of irradiated mice that also received B16 cells expressing the NP68 epitope (figure 
5.37E). This number of lung tumour nodules developing was again statistically significant 
between the two groups (p = 0.041).
The mice that were irradiated and recipients of both CD8+ F5 T cells and wild-type B16 cells 
had 284, 348, 365, 385, 420 and 450 tumour nodules in their lungs (figure 5.37C), which was 
significantly more (p = 0.0022) than mice that had not received T cells but had received wild- 
type B16 cells (figure 5.37B). There were no tumour nodules in five of the six mice that had 
been irradiated and recipients of both CD8+ F5 T cells and B16 cells expressing the NP68 
epitope, with the sixth mouse having two tumour nodules in its lungs (figure 5.37F). This was 
significantly less (p=0.022) than the mice that had not received T cells but had received the 
B16 cells expressing the NP68 epitope (figure 5.37E).
5.20 Tumour specific CD8* T cells protect from tumour developments, whereas non­
specific CD8+ T cells promote tumour growth
A group of eleven F5 TCR transgenic mice were primed subcutaneously with NP68 peptide in 
IFA. A second group of 12 F5 TCR transgenic mice were left un-primed. Three days post 
priming five primed and six un-primed mice received 2xl05 wild-type B16 cells. At the same 
time six primed and six un-primed mice received 2xl05 B16 cells expressing the NP68 
epitope. Fourteen days post B16 cell transfer the mice were sacrificed and the tumour 
nodules in their lungs enumerated.
As shown in figure 38 those mice that were primed with NP68 peptide and recipients of wild- 
type B16 cells had significantly more (p = 0.0043) tumour nodule in their lungs (290, 330, 
338, 425 and 450) (figure 5.38A) than mice that were not primed (130, 167, 186, 197, 210 
and 285) (figure 5.38B) and recipients of wild-type B16 cells. Those mice that were primed 
with NP68 peptide and recipients of B16 cells expressing the NP68 epitope had virtually no
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tumour formation in their lungs (figure 5.38C). This was also the case for the mice that had 
not been primed and were recipients of the B16 cells expressing the NP68 epitope (figure 
5.38D).
In order for SHP-1 to be targeted to improve human T cell function, means are required to 
modulate its expression. In aim of this, siRNA sequences that target human SHP-1 were 
tested in vitro for their efficacy at downregulating SHP-1.
5.21 Partial downregulation of SHP-1 expression in Jurkat cells using siRNA sequences 
identified by online algorithms
Online algorithms were utilised to identify candidate siRNA sequences to target SHP-1 
expression. The algorithms were performed with an integrated BLAST search in order to 
remove siRNA sequences with the potential to mediate downregulation of other proteins. 
The first nucleotide of each 19 nucleotide siRNA sequence was used to annotate a map of 
the SHP-1 transcript (figure 5.39). The six most frequently identified siRNA sequences (figure 
5.39) were synthesised as DNA that encoded for the corresponding shRNA. Each shRNA 
sequence was cloned into expression vector, ready for functional testing (see materials and 
methods: 2.9).
Jurkat cells were used for the functional testing of the siRNA sequences, as they express 
SHP-1. Due to the cost of sorting cells by flow cytometry is was important to establish the 
minimum number of cells that could be used to give an interpretable SHP-1 signal during 
western blot analysis. A titration was performed using 4xl07, 2xl07, lxlO7 and 5xl06 cells 
per ml of lysis buffer. SHP-1 protein could be detected at all cell densities, but with an ideal 
number of cells being lx lO 7 or above (figure 5.40).
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Electroporation was used as the method for introducing plasmid DNA to the Jurkat cells. As 
electroporation is not 100% efficient with regards to transfection, means were required to 
identify those cells that had taken up the DNA. In order to achieve this goal, shRNA plasmid 
was used in conjunction with a GFP expression plasmid at a 5:1 ratio respectively. At this 
ratio, the likelihood of a GFP expressing cell to also express the shRNA was high. Typically, 
lxlO7 cells were electroporated in the presence of the DNA, with up to 50% of the cells 
surviving the process. Approximately 2-4% of the surviving cells expressed GFP and were 
subsequently sorted by flow cytometry. Jurkat cells that had not been transfected with DNA 
were used to define a GFP positive gate. In addition, Jurkat cells that had been transfected 
with plasmid DNA containing no shRNA sequence, and the GFP plasmid were also sorted in 
the same manner. Each sample took approximately one hour to sort and gave 3xl05 cells for 
immunoblot analysis.
Following immunoblotting, densitometry was used to adjust for any differences between 
each sample, as determined by the actin band for each sample. The actin band with the 
highest density was identified, and the necessary adjustments required to normalise the 
other actin bands was then applied to the SHP-1 bands. The adjusted densities of the SHP-1 
bands were then compared to the density of the SHP-1 bands from the cells that had been 
transfected with plasmid containing no shRNA sequence. Sequences 1341 and 1550 
mediated no SHP-1 knockdown, whereas 1236, 825, 989 and 1112 mediated 25%, 10%, 23% 
and 22% SHP-1 knockdown respectively (figure 5.41).
In order to repeat the functional testing of candidate siRNA sequences it was necessary to 
develop a revised siRNA screening protocol, which allowed for more efficient transfection of 
cells and a more economically favourable method of isolating cells.
231
5.22 Successful production of Hela cells expressing mouse and human SHP-1
Due to their non-adherent nature, Jurkat cells proved challenging to transfect, as seen with 
the 2-4% success rate above. Adherent cell lines are recognised to be more readily 
transfected, and also by methods that are not as harsh as electroporation. In light of this,
Hela cells, which are a transformed adherent cell line, were chosen to genetically modify in 
order to express either mouse of human SHP-1. Mouse SHP-1 was introduced using a 
transfection reagent called jetPEI, whereas human SHP-1 was introduced using calcium 
phosphate. This was due to the availability of the reagents at the time of cell line generation.
In addition, calcium phosphate proves more cost effective than jetPEI, and therefore allows 
greater numbers of cells to be transfected at any one’time. The use of plasmids containing 
the neomycin resistance gene allowed cells to be selected without the need for flow 
cytometry. This proved advantageous when taking into consideration the cost of sorting 
cells. Furthermore, the periodic blocking of the flow cytometer during cell sorting often 
meant low numbers of cells were obtained, which precluded analysis by immunoblotting 
techniques. Transfected cells were selected by G418 treatment, and between 30% and 50% 
of the transfected Hela cells survived by the time all untransfected cells had died. Four 
weeks post antibiotic selection both cells lines were expressing the corresponding SHP-1 
(Figure 5.42A and B). Interestingly, the parental Hela cells used for the generation of human 
SHP-1 expressing cells were also expressing some SHP-1 (Figure 5.42B).
5.23 Successful reduction of human SHP-1 expression in Hela cells receiving MISSION™ 
shRNA sequences
Concomitant with the production of Hela cells expressing human SHP-1, commercially 
produced shRNA sequences for targeting SHP-1 were becoming available. Specific algorithms 
are used by companies to identify groups of siRNA sequences for each protein, which should
yield at least one shRNA capable of mediating downregulation of the protein being targeted. 
Sigma-Aldrich produced four such sequences for human SHP-1, which were subsequently 
tested for their efficacy at downregulating SHP-1 in Hela cells.
Plasmid DNA was prepared for transfection using calcium phosphate and the cells 
transfected. The cells were selected with puromycin and G418 for a total of six weeks. 
Immunoblotting and densitometry analysis revealed that sequence 444 did not mediate 
SHP-1 knockdown, but sequences 1712, 1572 and 1376 gave 56%, 61% and 53% SHP-1 
downregulation respectively (figure 5.43).
5.24 Summary of results
It was previously demonstrated during this study that SHP-1 deficient CD8+ F5 T cells exhibit 
an enhanced in vivo expansion and cytotoxic capacity. In order to explore the possibility of 
harnessing these findings to improve adoptive cell transfer immunotherapy strategies, a 
mouse model (B16 melanoma) of tumourigenesis was used. In pursuit of this aim, B16 
tumour cells were produced that constitutively express the NP68 epitope and could 
therefore be used in conjunction with F5 CD8+ T cells from transgenic motheaten and 
littermate mice.
It was conclusively demonstrated that SHP-1 deficient T cells provide superior protection 
against tumour development in a lung model of tumourigenesis. In addition, preliminary 
data indicates that SHP-1 deficient CD8+ T cells may also mediate enhanced regression of 
established solid tumours. In light of these observations, B16 cells were produced that 
express the luciferase gene, and would therefore allow future tumour studies to be 
performed in a non-invasive and quantitative manner, by using a whole body imaging unit 
that detects bioluminescence.
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In order for CD8+ T cells lacking SHP-1 expression to be used in a therapeutic setting, it would 
be necessary to induce SHP-1 downregualtion in human T cells. In light of this, candidate 
siRNA sequences were screened for their efficacy at mediating SHP-1 expression. At best, a 
commercially available shRNA sequence mediated 61% reduction in SHP-1 expression. This 
was achieved in Hela cells that had been generated to express the human SHP-1 gene.
Finally, it was demonstrated that tumour non-specific CD8+ T cells have a pro-tumoural role 
in a mouse model of lung tumour development, whereas a tumour specific CD8+ T cell 
response was completely protective.
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Figure 5.1: Activated CD8+ F5 T cells kill NP68 peptide pulsed B16 cells
CD8+ F5 T cells were activated in v itro for two days and expanded for a further 3 days in IL-2. B16 cells were 
either pulsed with NP68 peptide (target cells) or left unpulsed (reference cells). Those B16 cells pulsed with 
NP68 peptide were labelled w ith 0.2pM CFSE, whereas those that had not been pulsed were labelled with 
2pM CFSE (A). Equal numbers o f target and reference B16 cells were then co-cultured, in U-bottomed 96 
well plates, with the corresponding number o f activated CD8+ F5 T cells. The ratio of CD8+ F5 T cells to B16 
cells was based upon the total number o f B16 cells in each well, w ith each condition being performed in 
triplicate (F). After 4 hours the cells were removed from the wells and stained with anti-CD8PE antibody. 
Cells were analysed by flow  cytometry and the histograms (A to  E, representative histograms) 
electronically gated on CD8 and CFSE+ cells. The percentage killing (F) was assessed by comparing the 
target cell population to  the reference cells. B16 cells were killed at all ratios by the activated CD8 F5 T 
cells.
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Figure 5.2: Sub-lethally irradiated mice have fewer lung tumour nodules than non-irradiated 
mice
Mice were sub-lethally irradiated twenty-four hours prior to the intravenous transfer o f either 
1x10s, 5x l04 or 2 .5xl04 wild-type B16 cells. Three non irradiated mice received 1x10s wild-type 
B16 cells. Fourteen days post B16 cell transfer the mice were sacrificed and the lung tumour 
nodules enumerated. The irradiated mice had fewer lungs tum our nodules when compared to 
the non-irradiated mice that had received the same number o f B16 cells. This difference was 
not statistically significant (p = 0.1).
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Figure 5.3: CFSE labelled B16 melanoma cells are present in the lungs of mice twenty-four hours 
post intravenous transfer
Mice were sub-lethally irradiated twenty-four hours prior to cell transfer. B16 cells were labelled 
with either 0.2pM or 2pM CFSE, and 6 x l0 5 of each population was transferred intravenously to 
the same recipient mouse (C,D and E,F). One mouse did not receive any B16 cells (A and B). 
Twenty-four hours post transfer the mice were sacrificed and the spleens and lungs taken and 
prepared for flow cytometry. The CFSE positive gates were set by using the data from the mouse 
that did not receive any T cells (A and B). CFSE labelled cells were not detected in the spleens of 
recipient mice (C and E) but CFSE positive cells were evident in the lungs (D and F), although the 
two populations of CFSE labelled B16 cells could not be distinguished.
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Figure 5.4: Detection of B16 ceils labelled with either CFSE or DDAO are detected in the lungs of a 
mouse twenty-four hours post intravenous transfer
Recipient mice were sub-lethally irradiated twenty-four hours prior to  the transfer of B16 melanoma 
cells. B16 cells were labelled w ith either 2pM CFSE or 10pM DDAO and 2.5xlOsof each population was 
transferred intravenously to a recipient mouse (B, D and F). A second mouse did not receive any B16 
cells (A, C and E). Twenty-four hours post transfer, the mice were sacrificed and the lungs 
homogenised and analysed by flow  cytometry. The dot plots show the cells obtained from the lungs, 
with the gates set above the autofluorescence found in the control mouse (A, C and E). Dot plots are 
displayed to show the labelled cells individually, fo r CFSE (B) and DDAO (D) against side scatter, or on 
the same plot (F). Cells labelled with either DDAO or CFSE were detected in the lungs of the recipient 
mouse (B, D and F).
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Figure 5.5: Detection of B16 melanoma cells labelled with different concentrations of CFSE cells in 
the lungs of a recipient mouse
Recipient mice were sub-lethally irradiated twenty-four hours prior to transfer of B16 melanoma 
cells. B16 cells were labelled w ith either 0.2|iM, 0.5pM, 3pM and 4pM CFSE and paired as shown 
above (B and C). A total o f 8 x l0 5 B16 cells were transferred intravenously to each recipient mouse. A 
third mouse did not receive any B16 cells (A). Twenty-four hours post transfer the mice were 
sacrificed and the lungs homogenised and analysed by flow cytometry. The dot plots show the cells 
obtained from the lungs, w ith the gates set above the autofluorescence found in the mouse that did 
not receive any B16 cells (A). CFSE labelled cells were detected in the lungs of the mouse that 
received B16 cells labelled w ith 0.2pM or 3pM CFSE (B), although the two populations could not be 
detected. CFSE labelled cells were also detected in the lungs o f the mouse that received B16 cells 
labelled with 0.5pM or 4pM CFSE (C), with both populations being evident.
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Figure 5.6: A similar number of B16 lung tumour nodules are present in mice receiving 
CD8+F5 T cells and either B16 cells pulsed with NP68 peptide or unpuised B16 cells
Sub-lethally irradiated mice received 3 x l0 6 naive control CD8+ F5 T cells and a 
subcutaneous injection o f NP68 peptide in IFA. Seven days post T cell transfer, mice 
received either 2 x l0 5 w ild-type B16 cells that had been pulsed w ith 5pM NP68 peptide or 
2x l05 wild-type B16 cells tha t were left unpulsed. Fourteen days post transfer the mice 
were sacrificed and the lung tum our nodules enumerated. There was no significant 
difference between the number o f tum our nodules in the lungs of mice from each group (p 
= 0.8857).
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Figure 5.7: Successful infection of B16 cells with a retrovirus encoding the NP68 epitope as a 
fusion protein with GFP
B16 melanoma cells were plated out tw enty-four hours prior to infection. Cells were then 
incubated with protam ine sulphate for 1 hour prior to the addition of an equal volume of 
supernatant containing either a control retrovirus, encoding GFP (B), or a retrovirus encoding GFP 
as a fusion protein w ith the NP68 epitope (C). After a further 24 hours the process was repeated 
for a second round of infection. The degree of GFP expression was assessed by flow cytometry 7 
days post infection. Gates w ere defined based upon the autofluorescence from the parental B16 
cell line (A), w ith the percentage of cells residing in each gate displayed for each histogram. The 
B16 cells infected with the control retrovirus w ere 35% GFP positive (B) whereas the cells infected 
with the retrovirus encoding the NP68 epitope were 19.1% GFP positive (C).
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Figure 5.8: Successful cloning of B16 melanoma cell expressing the NP epitope as a fusion 
protein with GFP
A) Polyclonal B16 cell line
j Parental B16 cells 
□  GFP/NP B16 cells
B) Monoclonal C) Monoclonal B16 cell line number 2B16 cell line num ber 1
B16 cells that had been infected w ith a retrovirus encoding the NP68 epitope as a fusion protein 
with GFP were single cell sorted based upon cell viability, GFP expression and pulse width. The 
overlay histogram plots w ere gated on a viable cell population as determ ined by forward and side 
scatter. A polyclonal cell line (originally lx lO 4 cells) was GFP positive 2 weeks following single cell 
sorting (A). Two monoclonal B16 cell lines were GFP positive 5 weeks post single cell sorting (B 
and C).
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Figure 5.9: B16 cells infected with a retrovirus encoding the NP68 epitope are successfully killed 
by activated CD8+ F5 T cells
Wild-type B16 cells w ere plated out at an approximate 1:1 ratio with monoclonal B16 cells 
expressing the NP68 peptide as a fusion protein with GFP (A and C). After twenty-four hours 
activated control CD8+ F5 T cells w ere added to the B16 cells and incubated for a further 16 hours 
(B and D). B16 cells w ere also incubated w ithout activated CD8+ F5 T cells (A and C). Cell were 
harvested and stained w ith anti-CD8PE and analysed by flow  cytometry. Over 99% of the B16 cells 
were killed by the CD8+ F5 T cells (B and D).
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Figure 5.10: Mice receiving 3 x l0 6 CD8+ F5 T cells and 1.5x10s B16 cells expressing the 
NP68 epitope are clear of lung tum our nodules
A group of three sub-lethally irradiated mice received 3 x l0 6 naive control CD8+ F5 T cells 
and a subcutaneous injection o f NP68 peptide in IFA. A second group of three mice did not 
receive any T cells. Seven days post T cell transfer all mice received an intravenous infusion 
o f 1.5x10s B16 expressing the NP68 epitope. Fourteen days post transfer the mice were 
sacrificed and the lung tum our nodules enumerated. There were no lung tumour nodules 
in the mice tha t received an adoptive transfer o f naive CD8+ F5 T cells seven days prior to 
B16 cell transfer. Mice tha t did not receive CD8+ F5 T cells had 129, 90 and 79 tumour 
nodules in the ir lungs. The solid line represents the mean tum our nodule number.
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Figure 5.11: Complete protection from B16 tumour formation in the lungs of mice receiving 
naive control or motheaten CD8+ F5 T cells
In four independent experiments sub-lethally irradiated mice received either naive control or 
motheaten (Me) CD8+ F5 T cells and also a subcutaneous injection of NP68 in IFA. For each 
subsequent experiment mice received 3xl06 (A), lx lO 6 (B), 1x10s (C) or 5xl04 (D) naive CD8+ F5 T 
cells. The number of B16 cells expressing the NP68 epitope transferred to each mice was either 
1x10s (A) or 2.5x10s (B, C and D) and the time between T cell and B16 cell transfer was either 4 
(A) or 2 days (B, C and D). Mice were sacrificed fourteen days post tumour cell transfer and the 
tumour nodules in their lungs enumerated. Mice that did not receive any T cells all developed 
lung tumour nodules, with a greater number seen in mice that received 2.5x10s B16 cells (B, C 
and D) than those that received lx lO 5 B16 cells (A). Mice that received either control or 
motheaten CD8+ F5 T cells had no tumour formation within their lungs after fourteen days.
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Figure 5.12: Similar lung tum our formation in mice receiving no CD8+ F5 T cells and mice 
receiving either lx lO 4 naive control or motheaten CD8+F5 T cells
Recipient mice were sub-lethally irradiated twenty-four hours prior to  adoptive cell transfer. Two 
groups of mice received either lx lO 4 naive control or motheaten CD8+ F5 T cells intravenously. A 
third group of mice received no T cells. Concomitantly to  T cell transfer, each mouse was primed 
subcutaneously w ith NP68 peptide in IFA. The following day 2.5x10s B16 melanoma cells 
expressing the NP68 epitope were transferred intravenously. Fourteen days post tumour cell 
transfer mice were sacrificed and the tum our nodules in the ir lungs enumerated. The solid line 
shows the mean for each pair o f mice. All mice had similar tum our nodule formation in their 
lungs, regardless o f T cell transfer or the type of T cells transferred.
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Figure 5.13: Statistically significant reduced lung tumour formation in mice receiving 2xl04 naive 
motheaten CD8+F5 T cells in comparison to mice that did not receive any T ceils
Recipient mice were sub-lethally irradiated tw enty-four hours prior to  adoptive cell transfer. A group of 
three mice received either 2 x l0 4 naive control or motheaten CD8+ F5 T cells intravenously. A third 
group containing four mice did not receive any T cells. Concomitantly w ith  T cell transfer, each mouse 
was primed subcutaneously w ith  NP68 peptide in IFA. The following day, 2.5x10s B16 melanoma cells 
expressing the NP68 epitope were transferred intravenously. Fourteen days post tum our cell transfer, 
mice were sacrificed and the pigmented tum our nodules in the lungs enumerated. The mice that 
received naive motheaten CD8+ F5 T cells had significantly fewer (p = 0.05) lung tum our nodules than 
mice that did not receive any T cells. Any difference between the number o f lung tum our nodules in 
mice that received either control or motheaten CD8+ F5 T cells were not statistically significant (p = 0.4). 
The solid line represents the mean for each group.
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Figure 5.14: A reduced tumour load in the lungs of a mouse receiving naive motheaten CD8+ F5 T cells
Recipient mice were sub-lethally irradiated twenty-four hours prior to adoptive cell transfer. Pairs of 
mice received either 3 .2x l04 naive motheaten or control CD8+ F5 T cells intravenously. A third pair of 
mice received no T cells. Concomitantly w ith T cell transfer, each mouse was primed subcutaneously 
with NP68 peptide in IFA. The following day 2.5x10s B16 melanoma cells expressing the NP68 epitope 
were transferred intravenously. Fourteen days post tum our cell transfer mice were sacrificed and the 
lungs from one mouse from  each pair of mice was photographed (this figure) and the number of lung 
tumour nodules enumerated fo r all mice (Figure 5.15). The B16 melanoma nodules appear as 
pigmented nodules. The mouse that did not receive any T cells had highly pigmented lungs (A). The 
mouse that received naive control CD8+ F5 T cells had a greater tum our load (B) than the mouse that 
received naive motheaten CD8+ F5 T cells (C).
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Figure 5.15: A reduced number of tumour nodules in the lungs of mice receiving naive 
motheaten CD8+ F5 T cells, when compared to those mice receiving naive control CD8+ F5 T 
cells
Recipient mice were sub-lethally irradiated twenty-four hours prior to  adoptive cell transfer. Two 
pairs o f mice received 3 .2x l04 naive control or motheaten CD8+ F5 T cells intravenously. A third 
pair of mice received no T cells. Concomitantly to  T cell transfer, each mouse was primed 
subcutaneously w ith NP68 peptide in IFA. The following day, 2.5x10s B16 melanoma cells 
expressing the NP68 epitope were transferred intravenously. Fourteen days post tum our cell 
transfer, mice were sacrificed and their lungs photographed (figure 5.14) prior to the 
enumeration of the tum our nodules (this figure). The mice tha t recevied naive motheaten CD8+ 
F5 T cells had less lung tum our nodules than the mice tha t received naive control CD8+ F5 T cells. 
The solid line shows the mean fo r each pair o f mice.
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Figure 5.16: A reduced tumour load in the lungs of mice receiving naive motheaten CD8+ F5 T cells
Recipient mice were sub-lethally irradiated twenty-four hours prior to  adoptive CD8+ T cell transfer. 
Groups of six mice received either 3 .2xl04 naive control or motheaten CD8+ F5 T cells intravenously. A 
third group of six mice did not receive any T cells. Concomitantly w ith T cell transfer, each mouse was 
primed subcutaneously w ith NP68 peptide in IFA. The following day, 2.5x10s B16 melanoma cells 
expressing the NP68 epitope were transferred intravenously. Fourteen days post tumour cell transfer, 
mice were sacrificed and the ir lungs removed and photographed (this figure) prior to the enumeration 
of the tumour nodules (Figure 5.17). Two mice from the group that did not receive T cells died on days 
11 and 12 post tum our cell transfer. The mice that did not receive any T cells (A) and the mice that 
received naive control CD8+ F5 T cells (B) had highly pigmented lungs, indicating a high tumour load in 
comparison to mice tha t received naive motheaten CD8+ F5 T cells (C).
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Figure 5.17: Statistically significant reduced lung tumour nodule formation in the lungs of mice 
receiving naive motheaten CD8+ F5 T cells
Recipient mice were sub-lethally irradiated twenty-four hours prior to  adoptive cell transfer. Groups of 
six mice received either 3 .2x l04 naive motheaten or control CD8+ F5 T cells intravenously. A third group 
of six mice did not receive any T cells. Concomitantly w ith T cell transfer, each mouse was primed 
subcutaneously w ith NP68 peptide in IFA. The following day 2.5x10s B16 melanoma cells expressing the 
NP68 epitope were transferred intravenously. Fourteen days post tum our cell transfer, mice were 
sacrificed and the lungs photographed (Figure 5.16) prior to  the enumeration o f the pigmented tumour 
nodules (this figure). There were significantly less tum our nodules in the lungs of mice receiving naive 
motheaten CD8+ F5 T cells, compared to those mice receiving naive control CD8+ F5 T cells (p = 0.0022). 
Two mice from the group that did not receive T cells died on days 11 and 12 post tum our cell transfer 
and therefore were not included in the analysis. The dashed line represents the upper lim it at which the 
tumour nodules can be enumerated and the solid lines show the mean fo r each group.
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Figure 5.18: Statistically significant reduced lung tumour nodule formation in mice receiving naive 
motheaten CD8+ F5 T cells in comparison to mice receiving naive control CD8+ F5 T cells
Recipient mice were sub-lethally irradiated twenty-four hours prior to  adoptive cell transfer. A group of 
three mice received 3 .2xl04 naive motheaten CD8+ F5 T cells intravenously. A second group containing 
six mice received an equivalent number o f naive control CD8+ F5 T cells intravenously. A further six 
mice did not receive any T cells. Concomitantly w ith T cell transfer, each mouse was primed 
subcutaneously w ith NP68 peptide in IFA. The following day 2.5x10s B16 melanoma cells expressing the 
NP68 epitope were transferred intravenously. Fourteen days post tum our cell transfer mice were 
sacrificed and the pigmented tum our nodules in the lungs enumerated. There were significantly fewer 
tumour nodules in the lungs o f the mice receiving naive motheaten CD8+ F5 T cells, compared to mice 
receiving naive control CD8+ F5 T cells (p = 0.023). The dashed line represents the upper lim it at which 
the tumour nodules can be enumerated and the solid line represents the mean for each group.
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Figure 5.19: Activated control and motheaten CD8+ F5 T cells upregulate CD107a upon encounter w ith  NP68 
peptide-pulsed B16 cells
In vitro activated T cells were co-cultured w ith either un-pulsed (B and E) or NP68 peptide pulsed (C and F) 
B16 cells at three different ratios (shown in bottom left hand corner of each plot). Each condition was 
performed in triplicate (Figure 5.20), w ith representative data shown here. The media contained both FITC- 
conjugated CD107a antibody and golgi-stop™. Cells were harvested after four hours and stained with anti- 
CD8pe antibody prior to  analysis by flow  cytometry. Contour plots were electronically gated on a viable and 
CD8 positive cell population. The CD107a gate was set above the fluorescence seen in the absence of B16 cells 
(A and D), with the percentages o f cells residing in the gate shown for each plot. Both control and motheaten 
CD8+ F5 T cells upregulated CD107a in the presence o f B16 cells pulsed w ith NP68 peptide (C and F).
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Figure 5.20: A greater proportion of activated motheaten CD8* F5 T cells upregulate CD107a 
upon encounter w ith  cognate peptide pulsed B16 cells in comparison to  activated control CD8+ 
F5T cells
Naive T cells form  control and motheaten mice were activated and expanded in vitro fo r four days 
prior to  use. T cells were co-cultured w ith  either un-pulsed (B and E) or NP68 peptide pulsed (C and 
F) B16 cells in U-bottomed 96 well plates at three different ratios. The media contained both a 
FITC-conjugated CD107a antibody and golgi-stop™. A fter four hours the cells were labelled with 
anti-CD8PE antibody and analysed by flow  cytometry. Contour plots were generated and gated to 
show the proportion o f T cells tha t had up-regulated the ir surface expression o f CD107a (Figure 
5.19). The data from  figure 5.19 was plotted to  show the percentage up-regulation versus ratio of 
B16 to T cells (this figure). Both activated control and motheaten CD8+ F5 T cells showed minimal 
spontaneous up-regulation o f CD107a upon encounter w ith un-pulsed B16 cells (■ and •) . A 
greater proportion o f activated motheaten CD8+ F5 T cells (□) up-regulated the surface expression 
of CD107a in comparison to  activated control CD8+ F5 T cells (o). For each condition, the difference 
in CD107a expression between motheaten and control T cells was not statistically significant, 
according to  a Mann-W hitney test.
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Figure 5.21: A greater proportion of activated control and motheaten CD8+ F5 T cells upregulate 
CD107a upon encounter with NP68 peptide-pulsed B16 cells
Naive T cells form motheaten and control mice were activated and expanded in vitro for four days prior 
to use. T cells were co-cultured w ith NP68 peptide pulsed B16 cells in U-bottomed 96 well plates at five 
different B16 cell to  T cell ratios (shown in bottom left hand corner o f each plot). Each condition was 
performed in triplicate (Figure 5.22), w ith representative data shown here. The assay media contained 
both FITC-conjugated CD107a antibody and golgi-stop™. Cells were harvested after four hours and 
stained with anti-CD8PE antibody prior to analysis by flow  cytometry. Contour plots were electronically 
gated on a viable and CD8 positive cell population. The CD107a gate was set above the fluorescence seen 
in the absence of B16 cells (A and C), w ith the percentages of cells residing in the gate shown for each 
plot. At each ratio a greater proportion of activated motheaten CD8+ F5 T cells (D) upregulated CD107a in 
the presence of B16 cells pulsed with NP68 peptide (C and F) when compared to activated control CD8+ 
F5T cells (B).
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Figure 5.22: A greater proportion of activated motheaten CD8+ F5 T cells upregulate CD107a 
upon encounter with NP68 peptide-pulsed B16 cells than activated control CD8+ F5 T cells
Naive T cells from motheaten and control mice were activated and expanded in vitro for four 
days prior to  use. T cells were co-cultured w ith  NP68 peptide pulsed B16 cells in U-bottomed 96 
well plates at five d ifferent B16 cell to  T cell ratios. Each condition was performed in triplicate 
(this figure). The assay media contained both a FITC-conjugated CD107a antibody and golgi- 
stop™. Cells were harvested after 4h and stained w ith  anti-CD8PE antibody prior to analysis by 
flow cytometry. Contour plots were electronically gated on viable and CD8 positive cell 
populations (figure 5.21), and the CD107a gate set above the fluorescence seen in the absence 
o f B16 cells. At each ratio a greater proportion o f activated motheaten CD8+ F5 T cells (□) up- 
regulated CD107a in the presence o f B16 cells pulsed w ith NP68 peptide when compared to 
activated control CD8+ F5 T cells (o). For each condition, the difference in CD107a expression 
between motheaten and control T cells was not statistically significant according to  a Mann- 
Whitney test.
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Figure 5.23: Activated motheaten CD8+ F5 T cells kill more B16 cells expressing the NP68 epitope 
than activated control CD8+ F5 T cells
Naive CD8+ T cells from  control and motheaten mice were activated and expanded in vitro for four 
days prior to use. T cells were co-cultured with wild-type and NP68 expressing B16 cells (GFP positive) 
at 5 different ratios (shown for each histogram). Triplicates for each condition were performed (Figure 
5.24) with representative data shown here. After four hours o f co-culture the cells were stained with 
anti-CD8PE antibody and analysed by flow cytometry. Histograms were gated on viable and CD8 
negative cell populations. Activated motheaten CD8+ F5 T cells killed more target B16 cells (C - ratio of 
1:1, 5:1 and 10:1) than activated control CD8+ F5 T cells (B).
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Figure 5.24: Activated motheaten CD8* F5 T cells kill more B16 cells expressing the NP68 
epitope in comparison to activated control CD8+ F5 T cells
Naive CD8+ T cells from  motheaten and control mice were activated and expanded in vitro for 
four days prior to  use. T cells were co-cultured w ith  w ild-type and NP68 expressing B16 cells 
(GFP positive) at 5 d ifferent ratios, w ith  the ratio based upon the tota l number o f B16 cells 
(target and reference cells). Triplicates fo r each condition were performed (this figure). After 
four hours o f co-culture the cells were stained w ith  anti-CD8PE antibody and analysed by flow 
cytometry. Histograms were gated on a viable and CD8 negative cell population (Figure 5.23). 
The activated motheaten CD8+ F5 T cells did not kill any target B16 cells at the ratios o f 1:10 and 
1:5 (□). Control CD8+ F5 T cells did not kill B16 cells at the ratios o f 1:10, 1:5 and 1:1 (o). 
Activated motheaten CD8+ F5 T cells killed more target B16 cells (□) than activated control CD8+ 
F5 T cells (o) at the T cell to  B16 cell ratios o f 1:1, 5:1 and 10:1. For each condition, the 
difference in B16 cells killed by motheaten and control T cells was not statistically significant, 
according to  a Mann-W hitney test.
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Figure 5.25: Significantly reduced tum our nodule formation in the lungs of mice receiving naive 
control CD8* F5 T cells
Recipient mice were sub-lethally irradiated twenty-four hours prior to  adoptive cell transfer. A 
group of seven mice received 3 .2x l04 naive control CD8+ F5 T cells. A further six mice did not 
receive any T cells. Concomitantly w ith  T cell transfer, each mouse was primed subcutaneously w ith 
NP68 peptide in IFA. The follow ing day, 2.5x10s B16 cells expressing the NP68 epitope were 
transferred intravenously to  all mice. Fourteen days post B16 cells transfer, the mice were sacrificed 
and the tum our nodules in the ir lungs enumerated. Significantly fewer (p=0.0012) tumour nodules 
were present in mice that received control CD8+ F5 T cells, when compared to mice that did not 
receive any T cells. The solid line shows the mean fo r each group. The physical condition of the mice 
during the assay was monitored by weighing them at regular intervals (figure 5.28). In order to 
monitor transferred T cells, blood was taken at various time points from one mouse that did not 
receive any T cells and one mouse that received T cells (figure 5.26). Once the lungs had been 
harvested the proportion o f CD8+ cells w ithin the lungs of three mice from each group was also 
examined (figure 5.27).
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Figure 5.26: Adoptively transferred CD8+ F5 T cells are detected in the blood of mice
This assay was conducted as an adjunct to  the experiment described in figure 5.25. Peripheral blood was 
taken from a tail vein on day(s) 1, 4, 7, 10 and 15 following adoptive transfer o f naive CD8+ F5 T cell. One 
mouse that received no T cells (C) and one mouse that received naive control CD8+ F5 T cells (D) were used 
over the duration of the assay for blood analysis. In addition, blood was also taken from a non-irradiated 
mouse (B) and aliquots o f blood from  each mouse were pooled and left unstained (A) to enable the CD8 
positive gate to be set. The blood was depleted o f red blood cells and stained w ith anti-CD8PE antibody and 
analysed by flow cytometry. The blood taken on day 7 was analysed using a different FACSCalibur to that on 
the other days. Dot plots were gated on a lymphocyte gate as determined by forward and side scatter and 
the number shown in the gate is the percentage o f CD8+ cells residing within that gate. A greater proportion 
of CD8+ cells were seen in the mouse that received T cells compared to the mouse that did not receive T 
cells.
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Figure 5.27: Adoptively transferred CD8+ F5 T cells are detected in the lungs o f mice
The assay was a component of the tum our protection experiment described in figure 5.25. 
Fourteen days post tum our cell transfer, mice were sacrificed and the lung tumour nodules 
enumerated (figure 5.25). The lungs o f three mice from each group were homogenised and 
stained w ith anti-CD8PE antibody and analysed by flow  cytometry. Dot plots were gated on a 
lymphocyte gate and the CD8 positive gate set above the autofluorescence of an unstained lung 
cell preparation (A). The number in each gate shows the percentage o f CD8+ cells of the 
lymphocyte gate. There was an accumulation o f CD8+ T cells in the lungs o f mice that had 
received T cells (C), which was above that found in the mice that received no T cells (B).
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Figure 5.28: Mice receiving B16/NP cells lost weight over the duration of a tumour protection 
experiment
This experiment was a component o f the experiment described in figure 5.25. Mice were 
weighed prior to  sub-lethal irradiation (day -1) and again on day(s) 1, 3, 7, 9, 11, 13 and 15 
following T cell transfer (A). Mice received naive CD8+ F5 T cells on day 0 and B16/NP cells on day 
1. Mice that were not recipients o f either T cells or B16 cells gained weight over the duration of 
the assay, w ith irradiated mice gaining 2.88% o f the ir initial body weight and non-irradiated mice 
gaining 9.98% (B). From the point o f B16 cell transfer (day 1) those mice that received B16 but no 
T cells lost 6.74% o f the ir initial body weight in comparison to a loss o f 4.44% seen for the mice 
that received B16 and naive CD8+ F5 T cells (B).
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Figure 5.29: Subcutaneous B16 tumour growth over 14 days
Ten recipient mice received a subcutaneous injection o f 1x10s B16 cells expressing the NP68 
epitope. The perpendicular diameter o f each tum our was measured w ith callipers on day(s) 
1, A, 6, 8,10, 12 and 14 post tum our cell transfer. The average diameter o f each developing 
tumour was plotted against the day that it was measured. Two o f the mice did not develop 
a tumour at the site o f transfer. Tumours grew in all other mice at d ifferent rates and with a 
range of sizes seen at day fourteen. Three mice w ith similar sized tumours (*) were used to 
study tum our regression (Figure 5.30).
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Figure 5.30: Partial regression and delayed growth of a subcutaneous B16 melanoma in a mouse 
receiving naive motheaten CD8+ F5 T cells
Mice received lx lO 6 B16 melanoma cells expressing the NP68 epitope subcutaneously. Thirteen days 
post tumour challenge mice were sub-lethally irradiated. A fter a further twenty-four hours, mice 
received either lx lO 6 naive control or motheaten CD8+ F5 T cells. A third mouse received no T cells. 
Mice were subsequently primed subcutaneously w ith NP68 peptide in IFA. The perpendicular 
diameters o f each tum our were measured w ith callipers and the mean of the diameters plotted 
against the number o f days post T cell transfer. The tum our in the mouse that received naive control 
CD8+ F5 T cells reduced in size between days 1 and 5, then grew to the same size of the tum our in the 
mouse that did not receive any T cells. The tum our in the mouse receiving naive motheaten CD8+ F5 T 
cells exhibited regression between days 8 and 11, followed by delayed growth until the end of the 
assay.
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Figure 5.31: Production o f monoclonal B16 cell lines expressing the luciferase gene
Wild-type B16 cells were infected twice on subsequent days w ith a retrovirus encoding the 
luciferase and YFP. Eight days post infection the cells were assayed for luciferase activity, which 
revealed enhanced luciferase activity when compared to the background activity seen with wild- 
type B16 cells (A). The cells were then single cell sorted based on cell viability and YFP fluorescence 
by using wild-type B16 cells to  set the sorting gates (B). Twelve monoclonal cell lines were 
successfully grown but one (number 8) had a poor growth habit and was not included in further 
analysis. After five weeks of expansion the remaining cell lines were assayed for luciferase activity. 
All eleven monoclonal cell lines exhibited luciferase activity but to varying degrees (C). The cell line 
designated number 11, which had the highest luciferase activity, was chosen for further 
manipulation.
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Figure 5.32: Infection of B16 luciferase/YFP cells with a retrovirus encoding the NP68 epitope as 
a fusion protein with GFP
B16 cells that were infected w ith a retrovirus encoding luciferase and YFP were sorted based on 
cell viability and YFP fluorescence (figure 5.31). Five weeks post single cell sorting the monoclonal 
cell lines were assessed for luciferase activity (Figure 5.31). One of the luciferase positive B16 cell 
clones (number 11) was chosen for further manipulation. Firstly, the cells were analysed by flow 
cytometry for YFP expression (A). Histograms were gated on viable cells as determined by forward 
and side scatter, revealing YFP expression (A). This cell line was then infected twice on subsequent 
days with a retrovirus encoding the NP68 epitope as a fusion protein w ith GFP. Six days later, 
56.4% of the cells were positive for GFP fluorescence (B). The infected cells were then single cell 
sorted based on cell viability and GFP fluorescence (C).
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Figure 5.33: Differential GFP expression by B16 luciferase/YFP cells infected with a retrovirus 
encoding the NP68 epitope as a fusion protein with GFP
B16 cells expressing the luciferase gene (Clone 11, figure 5.31) were infected twice on subsequent 
days with a retrovirus encoding the NP68 epitope as a fusion protein w ith GFP. Three weeks post 
single cell sorting, fourteen monoclonal cell lines were assessed for GFP expression by flow cytometry. 
The overlay histograms were gated on a viable cell population as determined by forward and side 
scatter. Their fluorescence was compared to wild-type B16 cells (white dashed line), parental B16 cells 
that expresses the luciferase gene w ith YFP (white line) and also a previously generated B16 cell line 
that expresses GFP as a fusion protein w ith the NP68 epitope (grey dashed line). Nine of the fourteen 
monoclonal cell lines generated expressed GFP (Figure 5.34). Cell lines 6 and 7 also expressed GFP (A) 
but their growing profile was inferior to that o f the parental cell line. Cell lines 2 and 9 had a bi- 
fluorescent profile, w ith  GFP+ and GFP' cells evident on the histogram (B). Cell line 3 did not express 
GFP but appeared to express some YFP (B).
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Figure 5.34: GFP expression and luciferase activity of B16 luciferase/YFP cells infected with a 
retrovirus encoding GFP and NP68
B16 cells expressing the luciferase gene (clone 11, figure 5.31) were infected twice on subsequent 
days with a retrovirus encoding the NP68 epitope as a fusion protein w ith GFP. Three weeks post 
single cell sorting each monoclonal cell line was assessed for GFP expression by flow cytometry. 
The overlay histogram was gated on a viable cell population as determined by forward and side 
scatter. The fluorescence from  GFP was compared to both wild-type B16 cells (dashed white line) 
and the parental B16 cell line that expresses the luciferase gene w ith the YFP gene (white line). 
Nine (Numbers shown in key) o f the fourteen monoclonal cell lines had a similar growing habit to 
the parental cell line and all nine expressed GFP (A). The level o f GFP expression was greater than, 
similar to or less than that o f a previously generated B16 cell line that expresses GFP as a fusion 
protein with the NP68 epitope (Grey dashed line) (A). All nine cell lines were then tested for 
luciferase activity (B).
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Figure 5.35: B16 luciferase/YFP cells infected with a retrovirus encoding the NP68 epitope as a fusion 
protein with GFP are killed by activated CD8+ F5 T cells
B16 cells expressing the luciferase gene were infected on subsequent days w ith a retrovirus encoding the 
NP68 epitope as a fusion protein w ith GFP. Four weeks post single cell sorting, the cells were assessed for 
NP68 presentation at the ir surface. Each cell line was plated out at a 1:1 ratio w ith wild-type B16 cells 
twenty-four hours prior to the addition o f in vitro activated CD8+ F5 T cells. B16 cells were also cultured 
without T cells. Previously generated B16/NP cells were used as a positive control for the killing (J). 
Twenty-four hours later the wells were washed to remove the T cells and then the B16 cells removed with 
trypsin. Cells were analysed by flow cytometry and histograms gated on a viable B16 cell population as 
determined by forward and side scatter. The vast majority o f each cell line were killed over the duration of 
the assay, with all o f cell line number 5 being killed (B).
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Figure 5.36: CD8+ T cells enhance tum our nodule formation in the lungs of mice
Mice were sub-lethally irradiated or left untreated. Four irradiated mice received 1x10s wild-type 
B16 cells six days after irradiation. A second group o f mice were not irradiated but received the 
same number o f B16 cells. Fourteen days later the irradiated mice had significantly fewer lung 
tumour nodules compared to  the non-irradiated mice (p = 0.01). A second group of four irradiated 
mice received 3 x l0 6 naive control CD8+ F5 T cells five days prior to  the transfer of 1x10s wild-type 
B16 cells. The mice were also primed subcutaneously w ith NP68 peptide in IFA. These mice had 
significantly more lung tum our nodules than irradiated mice tha t did not receive any T cells 
(p=0.01). The solid lines show the mean for each group.
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Figure 5.37: A tumour-specific CD8+ T cell response protects mice from tumour formation, whereas 
a non-specific CD8+ T cell response promotes tum our formation
A group of twelve sub-lethally irradiated mice received 1 .8xl06 purified naive CD8+ F5 T cells and 
subcutaneous injection o f NP68 peptide in IFA (C and F). A second group of twelve irradiated mice 
and also a group o f twelve non-irradiated mice did not receive any T cells (A, B, D and E). Three days 
post T cell transfer, mice received intravenous infusions o f e ither 1.75x10s wild-type B16 cells (A, B 
and C) or 1.75x10s B16 cells expressing the NP68 epitope (D, E and F). Fourteen days post B16 cell 
transfer, mice were sacrificed and the nodules in the ir lungs enumerated. As previously 
demonstrated mice tha t were sub-lethally irradiated had significantly fewer nodules in their lungs 
compared to non-irradiated mice (figure 5.36). This applied to  mice that received either wild-type 
B16 cells (A versus B, p = 0.026) or B16 cells expressing the NP68 epitope (D versus E, p = 0.041). 
Furthermore, mice receiving CD8+ F5 T cells and wild-type B16 cells exhibited an enhanced number 
of nodules in the ir lungs in comparison to mice that did not receive T cells (B versus C, p = 0.0022). In 
contrast, those mice tha t received CD8+ F5 T cells and the NP68 expressing B16 cells were clear from 
tumour nodules in the lungs in comparison to  mice that received the NP68 expressing B16 cells and 
no T cells (E versus F, p = 0.0022). The solid line shows the mean for each group of mice.
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Figure 5.38: Mice primed w ith  NP68 peptide in IFA have significantly more lung tumour 
nodules than mice that are not primed
Groups o f F5 TCR transgenic mice were either primed subcutaneously w ith  NP68 peptide (A and 
C) or left un-primed (B and D). Three days post priming mice received either wild-type (WT) B16 
cells (A and B) or B16 cells expressing the NP68 (NP) epitope (C and D). Fourteen days post B16 
cell transfer, mice were sacrificed and the tum our nodules in the ir lungs enumerated. Mice that 
were either primed or le ft un-primed and the recipients o f B16 cells expressing the NP68 
epitope were virtua lly tum our free (C and D). The mice tha t were primed and recipients of wild- 
type B16 cells (A) had significantly more (p=0.0043) tum our nodules in the ir lungs in comparison 
to mice tha t were not primed (B).
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Figure 5.39: Algorithm-identified candidate sequences within the SHP-1 transcript for siRNA 
targeting
Online algorithms were utilised to identify suitable sequences within the SHP-1 transcript for 
targeting with siRNA. The algorithms utilised an integrated BLAST search to eliminate sequences that 
could have potential off-target effects. The SHP-1 transcript was annotated according to the first 
nucleotide of the sequences (19 nucleotides) deemed suitable fo r siRNA targeting (blue arrow). 
These were subsequently synthesised into shRNA sequences and cloned into plasmid vectors ready 
for functional testing in Jurkat cells (figure 5.41).
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Figure 5.40: SHP-1 protein detection in Jurkat cells by imm unoblot analysis
In preparation for shRNA screening, a titration was performed to establish the minimum 
number of cells that could be used to allow SHP-1 detection. Jurkat cells were taken from 
culture and lysed to give lx lO 6, 5x10s, 2.5x10s and 1.25x10s cells per 25pl of lysis buffer. Six 
times loading buffer was added to each lysate and 20pl of each sample loaded onto SDS- 
PAGE gels ready for im m unoblot analysis.
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Figure 5.41: Reduced SHP-1 expression in Jurkat cells receiving shRNA expression plasmids
Jurkat cells were electroporated in the presence of plasmid DNA encoding six individual shRNA 
sequences, and also a GFP expression plasmid, at a 5:1 ratio respectively. To act as a control, Jurkat 
cells were also electroporated in the presence of the plasmid DNA that did not contain a shRNA 
encoding sequence (vector alone). The cells were cultured for 48 hours post electroporation before 
being sorted on a single cell basis by flow cytometry. Cells were sorted based on GFP expression, 
with untransfected cells being used as a control to define a GFP positive gate. Cells were then 
prepared for im m unoblot analysis to detect SHP-1 levels. ImageJ software was used for 
densitometry analysis, with the level of SHP-1 protein being normalised according to the level of 
actin detected. The percentage downregulation was then calculated by comparison to 
untransfected parental Jurkat cells expressing SHP-1 (control). Two of the shRNA sequences (2 and 
3) did not mediate any reduction of SHP-1, whereas four sequences were successful at knocking 
down SHP-1 expression to some degree (1, 4, 5 and 6).
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Figure 5.42: Successful introduction of mouse and human SHP-1 genes to Hela cells
Cells were transfected with plasmid DNA encoding a neomycin resistance gene and either 
mouse (A) or human SHP-1 (B) genes. DNA was prepared by using either JetPEI reagent (A) or 
calcium phosphate (B) and subsequently delivered to the Hela cells. Forty-eight hours post 
transfection the cells were cultured with 1.5mg/ml of G418. Four weeks post antibiotic 
treatment cells were assessed for SHP-1 expression by western blot analysis, with SHP-1 
being detected in both cell lines.
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Figure 5.43: Reduced SHP-1 expression in Hela cells receiving MISSION,M shRNA plasmids
Hela cells expressing the  human SHP-1 gene were transfected with a plasmid expressing the 
puromycin resistance gene, and one of four different shRNA sequences targeting SHP-1 
expression. The cells w ere selected in 0.4pg/m l of puromycin for six weeks prior to 
immunoblot analysis for SHP-1 protein. ImageJ software was used for densitometry analysis, 
with the level of SHP-1 protein being normalised according to the level of actin detected. The 
percentage downregulation was then calculated by comparison to untransfected parental 
Hela cells expressing SHP-1 (control). Three of the shRNA sequences were successful at 
mediating partial knockdown of SHP-1 expression.
Chapter 6 
Discussion
6.1 Aims and challenges of the study
The ultimate aim of this study was to elucidate the role of SHP-1 in CD8+ T cells in an in vivo 
setting. This was facilitated by the availability of motheaten mice and their littermates, 
which provided SHP-1 deficient and sufficient CD8+ T cells respectively. As the early mortality 
of motheaten mice precluded direct in vivo T cell studies from being performed, adoptive 
cell transfer techniques were used throughout this study. The availability of 
immunomagnetic separation techniques allowed CD8+ T cells to be purified from donor 
motheaten and littermate mice and subsequently transferred to recipient mice, where they 
could be studied. In addition, the expression of the transgenic TCR, F5, by the donor mice 
allowed CD8+ T cells to be studied in an antigenic context by using the peptide, NP68.
A practical consideration that was echoed throughout this study was the number of 
motheaten mice available at any given time. Although the motheaten allele is inherited in a 
Mendelian manner, the number of motheaten mice actually produced is below that 
expected, when considering the total number of mice born. Homozygosity at the motheaten 
allele may hinder the development of motheaten embryos, thereby precluding successful 
gestation. The motheaten pups may also not compete as well as littermates during weaning. 
In addition, the financial constraints of supporting very large mouse colonies to produce 
more motheaten mice also influenced the number of motheaten mice produced. Overall, 
these factors had a direct impact upon the availability of naive motheaten CD8+ F5 T cells for 
experimentation. On average, lx lO 6 CD8+ T cells were purified from a single motheaten 
mouse, and approximately 2-5 motheaten mice were available at the same time. Therefore, 
assays were designed in such a way as to be compatible with numbers of motheaten CD8+ T
278
cells available. Wherever possible, experimental conditions were performed in multiples and 
experiments repeated on separate occasions. T cell numbers sometimes precluded multiple 
repeats of a condition within an experiment, and in these circumstances, assays were 
repeated in order to validate the data being acquired.
6.2 Priming CD8+ F5 T cells in vivo
Several methods of priming adoptively transferred CD8+ F5 T cells were initially trialled, and 
all proved to be successful at eliciting an in vivo CD8+ F5 T cell response. The first method 
involved the in vitro generation of DCs by culturing bone marrow precursor cells with the 
cytokine, GM-CSF. Commercially available GM-CSF and supernatant from a GM-CSF producer 
cell line were tested for their ability to yield DCs for in vivo use. Both sources of GM-CSF 
were able to enrich bone marrow cultures for DCs, as assessed by CDllc expression, and 
also DCs that upregulated costimulatory molecule ligands upon LPS treatment. As a result, 
the DCs were functionally viable and able to present NP68 peptide to CD8+ F5 T cells, in both 
an in vitro and in vivo setting. As the GM-CSF supernatant was readily available, more 
economically favourable, and capable of producing DCs of the same quality as those 
produced with commercially available GM-CSF, it was the preferred choice for routine use 
during this study. DCs were administered into the peritoneal cavity of recipient mice, as it
not only provided the most straightforward mode of transfer, but also gave equivalent CD8+
F5 T cell responses as the subcutaneous route. An ongoing logistical challenge of this study 
was the coordination of DC cultures with the availability of motheaten mice. Both the early 
mortality of the motheaten mice and Home Office regulations meant the appearance of a 
motheaten mouse within a litter gave a window of approximately 5-7 days, in which the 
mice had to be used. This often did not give sufficient time to produce DCs, which required 
10-14 days of culture. One approach would have been to routinely set-up DC cultures so that 
DCs were available at all times. Although feasible, this would have meant the routine
sacrifice of mice for their bone marrow, with no guarantee that the resulting DCs would have 
been used. Therefore, in accordance with the 'three Rs' (reduction, refinement and 
replacement) outlined by the Home Office, other modes of priming CD8+ F5 T cells were 
explored. The second mode of priming T cells utilised the Influenza A virus. As the NP68 
peptide is derived from the nucleoprotein of Influenza A, mice infected with the virus 
generate the peptide and present it to adoptively transferred T cells. Although this 
represents a more physiological relevant mode of priming T cells, it still required forward 
planning as mice needed to be infected several days prior to T cell transfer. Finally, the 
subcutaneous administration of NP68 in IFA utilised endogenous DCs to present the peptide 
to transferred CD8+ F5 T cells. This proved to be convenient, straightforward and efficacious 
at eliciting a T cell response in recipient mice and was therefore used routinely to prime 
mice, unless deemed unsuitable for a particular assay (discussed later for memory cell 
assays). The amount of NP68 peptide required for priming mice with IFA was far greater than 
that required for pulsing DCs ready for in vivo transfer. Despite this, the ethical costs and 
cost of consumables and media required for producing DCs on a regular basis offset some of 
the financial cost of using more NP68 peptide.
6.3 The role SHP-1 in primary CD8+T cell responses
The ultimate role of a CD8+ T cell is to clear cognate antigen, and in doing so eliminate 
malignant cells or cells that harbour pathogens. In vitro studies of SHP-1 deficient T cells 
have demonstrated that they possess an enhanced capability at forming cellular conjugates 
with APCs (Sathish et al., 2007). Consequently, a greater proportion of SHP-1 deficient naive 
CD8+ T cells from a given population enter into cellular division (Sathish et al., 2007). The in 
vivo relevance of these observations was undetermined until this study, which successfully 
demonstrated that mice that received a naive population of motheaten CD8+ F5 T cells were 
capable of killing more target cells (NP68 pulsed splenocytes) than mice that received
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control CD8+ F5 T cells. These data represent a significant advance in SHP-1 related research. 
The transition from studying T cells in vitro to an in vivo setting is an important one to take, 
as the physical requirements of CD8+ T cells during the detection and response to cognate 
antigen in vivo are very different to those found in an in vitro setting. CD8+ T cells are 
required to traffic to secondary lymphoid organs in search of antigen, and following 
activation and clonal expansion, migrate to peripheral sites of inflammation or infection.
As the above protocol looked at the killing of target cells in the spleen of recipient mice it 
cannot be said whether effector cells generated in the spleen were solely responsible for the 
killing, or T cells primed in other lymphoid organs also contributed to target cell clearance. 
The latter would involve two migratory steps for the T cells, firstly to the lymphoid organ in 
which they would be primed and then to the spleen via the lymph and blood. As SHP-1 has 
been implicated in having a role in immune cell migration (Kim et oi., 1999) it would be 
reasonable to assume that SHP-1 deficient T cells may exhibit an enhanced ability to migrate 
to both lymphoid organs and peripheral sites harbouring target cells. In light of this, assays 
were performed to explore this hypothesis (discussed later). In addition, the above protocol 
could be developed further to ensure both migratory events are involved in the killing of 
target cells in the spleen. By infecting mice with Influenza A virus the adoptively transferred 
CD8+ F5 T cells would be primed in lung-associated lymph nodes. Therefore, the priming 
would take place at sites that are distant from the site of target cell killing (spleen), thereby 
ensuring the T cells are required to migrate from the lymph nodes to the spleen. This 
approach may reveal further differences in the number of target cells killed between mice 
receiving either motheaten or control CD8+ F5 T cells.
The observation that more targets cells were killed by motheaten CD8+ F5 T cells raised the 
question, why does SHP-1 deficiency in CD8+ T cells lead to enhanced in vivo CTL activity? 
One possibility is that the enhanced killing of target cells could be attributed to the presence
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of more CTLs. This would be a plausible explanation given the hyperproliferative phenotype 
of naive motheaten CD8+ T cells seen in vitro. A protocol that was initially used during this 
study to measure in vivo CD8+ T cell expansion suggested that SHP-1 deficient CD8+ T cells do 
undergo an enhanced in vivo expansion. Despite this general trend, components of the 
protocol did not allow for the production of concise and reproducible data. The protocol 
gauged CD8+ T cell expansion by either looking at the absolute number of cells seen in the 
spleens of recipient mice, or by comparison of CD8+ T cells to a lymphocyte population of 
cells during analysis of flow cytometry data. The necessary step of lysing red blood cells prior 
to enumeration of splenocytes was associated with the formation of cell clumps, which 
meant cells were lost from the samples. Although efforts were made to minimise the 
occurrence of clumping their continued presence meant cells were lost from samples in a 
non-uniform manner, thereby giving data that was unreliable with regards to the absolute 
number of cells present in each spleen. It also became apparent that sub-lethally irradiating 
recipient mice altered their lymphocytes in a manner unique to each mouse. This resulted in 
a different proportion of cells residing in the lymphocyte population for each individual 
mouse. Therefore, expressing CD8+ T cells as a proportion of a lymphocyte gate also 
precluded the generation of accurate data. In light of this, a second protocol was developed 
to study in vivo CD8+ T cell expansion. In order to overcome the issue of cells clumping prior 
to analysis, a fluorescently labelled (CFSE) reference population of cells was added to each 
sample prior to its preparation for flow cytometry. As the clumping does not discriminate 
between the splenocytes and the CFSE labelled population the latter acted as an internal 
control. This allowed the CD8+ T cells to be compared to the reference cell population rather 
than cells within a lymphocyte gate. This approach proved successful and it was 
demonstrated that motheaten CD8+ T cells exhibit an enhanced in vivo expansion. Although 
Rag-17' mice were used at this stage of study, the use of a CFSE labelled reference
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population of cells would also have been compatible with using irradiated mice as recipients. 
To further explore the expansion data the intracellular dye, CFSE, could potentially be used 
to track T cell proliferation in vivo. This would be informative with regards to establishing the 
proportion of adoptively transferred CD8+ F5 T cells that actually enter into proliferation, and 
also the number of subsequent cell divisions. Control experiments (data not shown) 
indicated that approximately 6xl06 naive CD8+ T cells would be required to perform this type 
of assay, as this number would allow for loss of cells during the labelling process, and also 
for their detection in vivo.
Prior to this study, in vitro CTL data have demonstrated that there are no differences 
between the cytotoxic function of motheaten and control CD8+ F5 T cells on a per cell basis 
(Johnson et al., 1999). In contrast to this observation, in vivo data from this study seem to 
suggest that SHP-1 deficient CD8+ T cells kill more target cells on a per cell basis. The 
optimisation of these experiments proved to be challenging with regards to the number of in 
vitro activated and expanded CD8+ F5 T cells to transfer in relation to the number of target 
cells that were subsequently administered. As the extent of target cell killing varied greatly 
between assays it would be necessary to repeat this assay to ensure reliable data were being 
acquired. In addition, a number of control experiments would also need to be performed to 
ensure the enhanced CTL activity seen when transferring equal numbers of activated CD8+ 
F5 T cells was only attributable to enhanced CTL function on a per cell basis. Firstly, the cells 
could be labelled with different intracellular dyes and transferred in equal numbers to the 
same mouse. This would reveal whether or not motheaten and control CD8+ F5 T cells have 
the same homing capabilities to the spleen, as any difference in migration could influence 
the number of target cells killed. Naive motheaten and control CD8+ F5 T cells exhibit the 
same in vitro division index, which is the number of cell divisions cells undergo once cells 
have entered into proliferation. It would be necessary to confirm the same was true for in
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vitro activated CD8+ F5 T cells once they have been transferred in vivo. This could be 
achieved by using CFSE to label the T cells prior to in vivo transfer, followed by analysing cells 
from the spleen by flow cytometry. Any differences in the division index between activated 
motheaten and control CD8+ F5 T cells would indicate that different numbers of CTL had 
been generated and therefore this could influence the extent of target cell killing.
As indicated above, it has previously been demonstrated that CD8+ T cells expressing 
reduced levels of SHP-1 exhibit an enhanced in vitro chemotactic response. The implication 
of this finding is that an enhanced in vivo trafficking ability of SHP-1 deficient CD8+ T cells 
could contribute to the enhanced CTL response discussed earlier. Enhanced migration could 
potentially affect the efficiency at which antigen is detected in secondary lymphoid tissues 
and also the speed at which antigen is cleared in the periphery. Ideally, this study would 
have looked at the trafficking behaviour of naive motheaten and control CD8+ F5 T cells mice 
to lymph node. However, due to the limited number of motheaten T cells available at any 
one time and the large number of lymph nodes present within a mouse, it seemed 
unfeasible that naive T cells could be detected in lymph nodes following their in vivo 
transfer. As naive CD8+ F5 T cells could be activated and expanded in vitro, thus generating 
decent numbers of T cells for experimentation, assays were developed that examined the in 
vivo migration of adoptively transferred activated T cells. The fluorescent dye, DDAO, proved 
to be a good partner dye for CFSE when labelling different populations of T cells ready for 
transfer to the same recipient mouse. DDAO was non-toxic at the concentration used during 
this study and did not bleach excessively, therefore allowing cells to be distinguished from 
the autofluorescence of endogenous cells during flow cytometry analysis. In order to 
retrieve cells from a mouse post adoptive transfer, a method of directing the T cells to a 
specific tissue or organ was required. The culture of CD8+ F5 T cells with NP68 peptide 
loaded APCs in the presence of retinoic acid confers a preferential homing ability to the T
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cells. Once transferred in vivo, the conditioned CD8+ T cells migrate to the Peyer's patches. 
This system was used to study the homing capabilities of motheaten and control CD8+ F5 T 
cells within the same recipient mouse. These assays revealed a difference with regards the 
distribution of the adoptively transferred cells, with more motheaten T cells present in the 
blood than the Peyer's patches, when compared to control T cells. Although the retinoic acid 
system worked with regards to conferring specific tissue homing capabilities to the T cells it 
was not an ideal tissue to use for T cell migration studies. The reasoning for this is that T cells 
not only enter Peyer's patches but also exit freely to return to the blood. For data acquired 
from this type of approach to be interpreted correctly, the tissue or organ used needs to be 
the end point for T cell migration, thereby leading to,an accumulation of T cells at that site. 
These experiments could be repeated, but with the Lamina propria also been taken for 
analysis, as this represents the tissue to which the T cells would ultimately migrate to. 
Alternatively, SIP receptor inhibitors (Chiba eto/., 1998) could be used to block the egress of 
the adoptively transferred T cells from the Peyer's patches, which would lead to their 
accumulation at this tissue site. With the Peyer's patches deemed unsuitable as a tissue to 
study T cell migration, a second protocol was explored for its feasibility to study T cell 
migration. The peritoneal transfer of recombinant Vaccinia virus to mice leads to infection of 
the ovaries, thereby providing a site for T cell migration. Indeed, fluorescently labelled T cells 
did appear in the ovaries post adoptive transfer, although this seemed to be independent of 
infection, and would therefore require further investigation to optimise this approach for 
future studies of T cell migration.
Ultimately, any T cell migration studies would need to be performed in conjunction with 
other experiments in order to interpret the data correctly. The expression level of 
chemokine receptors and adhesion molecules that are involved in the migration would need 
to be established for both naive and activated motheaten and control CD8+ T cells, as any
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differences could influence the migratory capabilities of the T cells. In previous studies it was 
shown that equivalent levels of LFA-1 (Sathish et al., 1999) are expressed by motheaten and 
control CD8+ F5 T cells. In addition, cells could be screened for expression of L-selectin and 
other molecules involved in T cell homing. Furthermore, if studies did reveal a difference 
between the migratory behaviours of motheaten and control T cells, their locality within the 
tissue being studied would need to be confirmed. This could be achieved by fixing and taking 
sections of the tissue and viewing them under a fluorescent microscope. This would 
establish whether T cells have extravasated and entered the tissue or remain associated with 
the lumen wall of the blood vessel. Ideally, real-time imaging would be used to observe the 
behaviour of motheaten and control CD8+ F5 T cells in the blood vessels that supply 
lymphoid or peripheral tissue.
Regulatory T cells play an important role in shaping the magnitude and quality of in vivo T 
cell responses. An in vitro assay was performed to establish the extent of Treg suppression 
on the proliferation of naive motheaten and control CD8+ F5 T cells. Although the majority of 
the in vivo assays performed during this study were carried out in lymphopaenic mice, which 
do not possess any Tregs, it was still considered an important assay to perform given the in 
vivo role of Tregs during T cell responses to antigen (Zou, 2006). Tregs were successfully 
purified from the spleens of mice based upon CD4 and CD25 expression, which was 
confirmed by flow cytomertry (data not shown, analysis perfomed by Dr. Gareth Betts, 
Department of Medical Biochemistry and Immunology, Cardiff University). Although the data 
from the Treg assay suggested that motheaten CD8+ T cells were more resilient to the 
inhibitory effects of Tregs, the data needs to be viewed with caution. Firstly, conditions were 
not performed in triplicate due to the limited availability of motheaten CD8 T cells. 
Furthermore, the enhanced proliferation of control versus motheaten T cells in response to 
anti-CD3 antibody stimulation is contradictory to previously published data (Lorenz et al.,
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1996; Pani et al., 1996; Sathish et al., 2001), which have demonstrated a hyperproliferative 
phenotype of motheaten CD8+ T cells upon anti-CD3 antibody stimulation. As the extent of 
suppression was calculated by using this data, it could be misleading and would therefore 
need to be repeated, and with T cell numbers permitting the different conditions performed 
in triplicate. Overall, the assay was successful with regards to the T cell proliferation being 
susceptible to Treg suppression and could be repeated and also developed further to look at 
other aspects of Treg activity. In addition to Tregs mediating T cell suppression via release of 
soluble factors (Turk et al., 2004) Tregs are also capable of conditioning APCs so the APCs are 
rendered less efficient at priming CD8+ T cells (Zou, 2006). In light of this, in vitro generated 
DCs loaded with NP68 could be used to prime naive CD8+ F5 T cells instead of using anti-CD3 
antibody. This approach to a Treg assay may be particularly relevant when considering the 
ability of SHP-1 deficient CD8+ T cells to form more stable conjugates with APCs.
6.4 The role of SHP-1 in memory CD8+ T cell responses
The ability of T and B cells to persist as long lived memory cells is a hallmark of the adaptive 
immune response. Immunological memory provides superior protection against re­
encounter with cognate antigen and is the basis of many successful vaccination regimens. It 
is also evident that the long term persistence of memory cells during ACT immunotherapy 
strategies correlates with an improved anti-tumour activity. Therefore, the factors that may 
influence the generation and function of memory T cells require ongoing investigation. This 
study provided the opportunity to explore the in vivo role of SHP-1 in memory CD8+ T cells.
Previous to the study, the early mortality of motheaten mice precluded direct in vivo studies 
from being performed within these mice, but with the development of adoptive T cell 
transfer techniques during this study, motheaten T cells could be studied for extended 
periods in recipient mice. Protocols that were developed to look at primary CD8 F5 T cells
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responses were adapted to study memory T cells. Mice were primed twice, firstly to elicit a 
primary response of adoptively transferred CD8+ T cells, and secondly to activate memory 
CD8+ T cells. Initially, irradiated mice were not used as recipients to study T cell memory, as 
their recovering T cell pool post irradiation meant endogenous T cells capable of responding 
to NP68 would have been present by the time of the second priming. As an alternative, Rag- 
l ' 1' mice were used as recipients as they are genetically lymphopaenic and therefore 
allowing the adoptively transferred cells to be preferentially studied. In the early stages of 
the study of memory CD8+ T cell responses, IFA was used to deliver NP68 peptide to mice for 
both the initial and recall priming, as it was convenient to use and also efficient at priming T 
cells in vivo. Using this form of priming, mice that received naive control CD8+ F5 T cells had 
an enhanced memory response compared to mice that received motheaten CD8+ F5 T cells. 
Based on this data, it appeared that the enhanced in vivo primary response seen with 
motheaten CD8+ F5 T cells did not necessarily translate to an enhanced memory response. 
Although an intriguing result, it was considered that the administration of NP68 in IFA may 
lead to the peptide binding to MHC class I molecules expressed by cell types other than 
APCs. This may include the memory CD8+ F5 T cells, thereby making them targets for direct 
cytolysis by other CD8+ F5 T cells. The extent of T cell fratricide may have been greater in 
mice that received motheaten T cells as more T cells would have been present due to 
enhanced in vivo expansion. This would increase the likelihood of T cells encountering one 
another, leading to more T cells being killed, thus leaving a reduced number to clear target 
cells. Although no data was generated to support this hypothesis it seemed a plausible 
explanation.
To establish whether the mode of priming did indeed influence the extent of target cells 
killed, subsequent experiments used in vitro generated DCs loaded with NP68 to prime 
memory CD8+ F5 T cells. Interestingly, with this approach, mice that received naive
motheaten CD8+ F5 T cells killed more target cells during a memory response than mice that 
received control CD8+ F5 T cells. This was also the observation for mice primed with DCs for 
both the initial and recall priming.
As the study of memory T cell responses progressed it became increasingly evident that the 
health of mice was declining towards the end of the experiment, and only in mice that 
received CD8+ F5 T cells. Symptoms included diarrhoea and weight loss, which are 
characteristic of colitis. In order to establish the underlying reason for the decline in the 
health of the Rag-1^ recipient mice an independent experiment was performed. Mice 
receiving NP68 in IFA and naive CD8+ F5 T cells were the first to develop diarrhoea and lost 
the greatest amount of their original body weight. Mice that received T cells alone went on 
to develop diarrhoea and also lost a considerable amount of body weight. Upon dissection, 
mice that received CD8+ F5 T cells had an enlarged colon, spleen and mesenteric lymph 
nodes. Histopathological analysis revealed a striking infiltrate of cells into the muscle and 
mucosa of the colon. The cells were later shown to be predominantly CD8+ T cells by 
fluorescent antibody staining (Performed by Dr. Jason Twohig from the Department of 
Biochemistry and Immunology, Cardiff University). The inflammation would have been 
anticipated to have had a significant impact on the absorptive function of the affected Gl 
tract and therefore explains the wasting seen with the mice. Although an interesting 
observation (discussed later), it was imperative to develop an assay that examined memory 
T cell responses in vivo without the above complications, as these could have an impact 
upon the memory T cell pool being studied. During the development of a new assay it was 
found that the initial reservations about using irradiated mice to study memory T cell 
responses were not justified. Mice that were concomitantly irradiated and primed with NP68 
in IFA did not exhibit a T cell response when primed for a second time. The lack of an 
endogenous T cell response could be due to the presence of the NP68 peptide and tolerance
289
mechanisms, which may influence the developing T cell pool as it recovers from irradiation. 
This indicated that the responses in mice that received adoptively transferred cells could be 
solely attributed to the exogenous cells. Using the new protocol it was demonstrated that 
mice that received naive motheaten CD8+ F5 T cells exhibited an enhanced memory 
response, although repeats would be necessary to validate this finding, and sufficient 
numbers of mice included to ensure statistical data could be generated.
Overall, by using three different protocols it was demonstrated that the transfer of a naive 
population of motheaten CD8+ F5 T cells allowed recipient mice to mount an enhanced 
memory response in comparison to the transfer of control T cells. The underlying reasons for 
this observation would need further investigation. During a primary T cell response it was 
shown that there was an enhanced expansion of T cells in the absence of SHP-1. Therefore, it 
would seem reasonable to hypothesise that the generation of more T cells during a primary 
response would translate to the formation of more memory T cells, resulting in the killing of 
more target cells. This interpretation would be independent of which linear model of 
memory T cell formation is accepted. The entry of more naive motheaten CD8+ T cells into 
cell division during a primary response could give rise to more memory T cell intermediates 
during differentiation to effector cells (naive - TCM -  TEM - effector). Alternatively, the 
generation of more effector cells from naive T cells in the absence of SHP-1 could then 
differentiate into more memory T cells (naive -  effector -  TEM -  TCM). The number of 
memory T cells could be assessed to establish whether greater numbers of memory 
motheaten T cells exist, both before and after antigenic stimulation. The protocol developed 
to look at T cell expansion during a primary response could also be used to study memory T 
cell expansion. In addition, assays involving the transfer of the same number of effector 
cells, rather than naive cells, would reveal whether the enhanced expansion of SHP-1 
deficient naive T cells is responsible for the generation of an enhanced memory response.
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Pilot experiments performed during this study demonstrated that this approach is feasible, 
as in vitro generated effector cells mounted a memory response after an extended period 
post in vivo transfer. Ideally, cells would be generated in mice, purified by immunomagnetic 
separation, and then transferred to recipient mice. It would also be necessary to ensure that 
T cells of exactly the same differentiation state were being transferred, as more naive T cells 
may remain in mice receiving control CD8+ F5 T cells than in mice receiving motheaten CD8+ 
F5 T cells. This could be achieved by using the fluorescent dye CFSE, which is diluted during 
cell division. This would allow motheaten and control CD8+ F5 T cells to be purified by flow 
cytometry based upon the division peak in which they reside. In addition to studying the 
numbers of memory T cells it would also be informative to investigate other potential 
reasons for the enhanced memory response seen in the absence of SHP-1. It is also possible 
that the enhanced ability of naive motheaten CD8+ F5 T cells to form conjugates may also 
apply to motheaten memory T cells and this may contribute to the hyperproliferative 
phenotype. Memory cells could be generated in vivo, purified using immunomagnetic 
techniques and used in ex-vivo or in vivo studies. By transferring the same number of 
memory motheaten and control CD8+ F5 T cells to individual recipient mice and stimulating 
them, it would provide valuable information concerning the latter stages of a T memory 
response. Similarly, in vivo generated memory cells could be utilised in in vitro assays, such 
as those which are routinely used to study T cell proliferation and CTL function. It would also 
be informative to explore whether SHP-1 influences the relative proportion of TCM and TEM 
CD8+ T cell subsets. Given the in vitro observation that SHP-1 deficient CD8+ T cells have the 
enhanced capability of forming conjugates with APCs, this may influence the type of memory 
T cell pool formed. This hypothesis is supported by in vivo models, which suggest that the 
dynamic interaction of T cells with APCs influences the differentiation of memory T cells. A 
pilot assay confirmed that it was possible to delineate an effector memory response from a
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total memory response. This assay is based on the contentious observation that TEM cells 
have the ability to provide immediate protection when compared to TCM cells. Despite this 
contention, the assay may nevertheless provide further information about the role of SHP-1 
in CD8+ T cell memory. Furthermore, in vivo generated memory T cells could be further 
characterised ex-vivo by looking at various surface markers. During the initial stages of T cell 
differentiation the IL-7 receptor has been shown to demarcate memory T cell precursors 
during clonal expansion (Huster et al., 2004) and could therefore be used to establish what 
proportion of activated motheaten and control T cells express this marker. Additionally, the 
expression of CD62L and CD28 could be assessed as their expression is associated with 
distinct memory T cell subsets.
6.5 The role of CD8+ T cells in inflammatory bowel disease (IBD)
As discussed earlier, Rag-17' mice that received CD8+ F5 T cells developed colitis due to an 
influx of CD8+ F5 T cells. Curiously, this only occurs when the transferred CD8+ F5 T cells are 
taken from donor mice that are transgenic for the F5 TCR and on a Rag-1+/+ background. 
Experiments performed by Dr. Jean G. Sathish, from our group, have demonstrated that 
disease does not develop when monoclonal CD8+ F5 T cells are transferred from mice of a 
Rag-17' background.
The F5 TCR uses the Va4 and vpil gene segments of the a and p chain variable-region gene 
families respectively (Palmer et al., 1989), and recognises the NP68 peptide in the context of 
the mouse MHC class I molecules H-2Db. On a Rag-1+/+ background the F5 transgenic TCR0 
chain is able to pair with endogenous TCRa chains, thereby creating novel TCRs at the 
surface of the CD8+ T cells (Simpson et al., 1995a). Therefore, the T cells have the ability to 
recognise peptide antigens other than NP68. Interestingly, the colitis inducing CD8 F5 T cells 
do not cause disease in the donor mice from which they were purified, which may be 
attributed to the suppressive actions of Tregs within these mice. The histological analysis of
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the bowels from the mice during this study highlights similarities to the bowels of patients 
with IBD.
In humans, IBD constitutes a group of chronic inflammatory conditions of the 
gastrointestinal (Gl) tract that affects a significant fraction of the population (Russel and 
Stockbrugger 1996; Shivananda et al., 1996). The two main forms of IBD are Crohn's disease 
(CD) and Ulcerative Colitis (UC), with differences between them attributed to the location 
and nature of the inflammation. Whereas UC is restricted to the colon and rectum, CD can 
affect any part of the Gl tract from the mouth to the anus. Microscopically, UC is restricted 
to the musocsal layer of the gut whereas CD can affect the entire bowel wall. Both CD and 
UC can also have extra-intestinal manifestations (Hendrickson et al., 2002). Although 
considerable progress has been made in the understanding of IBD, research has yet to fully 
define its aetiology. Studies have indicated that the inflammation associated with IBD may 
be caused by the complex interaction of various factors: including genotype (Bouma at al., 
2003; Taylor et al., 2003), the immune system (Podolsky 2002), and environmental 
components (Podolsky 2002). More specifically, animal models have demonstrated that 
CD4+ T cells are the main mediators of the inflammation seen in IBD (Strober et al., 2002; 
Powrie et al., 1993). The most favoured hypothesis involves the activation of CD4+ T cells by 
antigens derived from enteric bacteria. Alongside the role of CD4+ T cells in the 
pathogenesis, other immune cells, namely APCs, have been implicated in the induction of 
IBD (Malmstrom et al., 2001). Despite CD8+ T cells exhibiting an activated phenotype in IBD 
patients (Senju et al., 1991a; Senju et al., 1991b; Senju et al., 1991c; Muller et al., 1998), 
their role in the pathophysiology of IBD has not been fully investigated. Conflicting data have 
been acquired from a limited number of studies that have looked at the role of CD8+ T cells 
in models of intestinal inflammation. In a study of colitis performed in IL-2 deficient mice, 
CD8+ T cells did not appear to have a role in disease progression (Simpson et al., 1995b). In
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contrast, a Crohn's-like model (Kontoyiannis et al., 2002) and a study involving the adoptive 
transfer of auto-antigen specific CD8+ T cells (Steinhoff et al., 1999) both supported a role for 
CD8+ T cells in intestinal inflammation. In light of this, further investigations could potentially 
lead to the development of a mouse model that allows for an increased understanding of 
the role of CD8+T cells in the pathogenesis of IBD.
Adoptive transfer experiments could be repeated with different numbers of naive CD8+ F5 T 
cell, in order to establish a minimum number of CD8+ F5 T cells required to mediate disease. 
In addition, a scoring system could be used to determine the extent of disease and may 
include parameters such as the severity of inflammation, hyperplasia of mucosal epithelium 
and mucosal ulceration.
It would be imperative to ensure the pathophysiology seen in the Rag-17' mice was indeed 
attributable to the adoptively transferred CD8+ F5 T cells and not CD4+ T cells, which may 
contaminate the immunomagnetic cell preparations (95% pure for CD8+ T cells). This could 
be addressed by using anti-CD4 antibodies to deplete transferred CD4+ T cells, or by 
performing experiments in Rag-17' mice that lack expression of MHC class II molecules. 
Alternatively, experiments performed in Rag-17' mice that lack expression of B2M would also 
provide means of demonstrating that CD8+ are the primary force behind the 
pathophysiology seen in these mice. This approach would also confirm that the CD8+ T cells 
were expanding as a result of antigenic peptide presentation rather than due to the action of 
homeostatic cytokines, although this seems unlikely given the observation that CD8+ F5 T 
cells from a Ragl7' background do not induce disease.
It was also be informative to delineate whether the CD8+ F5 T cells are reacting to foreign 
antigens from bacteria in the gut or to autoantigens expressed by the Gl tract. The 
administration of antibiotics and the housing of mice under sterile conditions would ensure
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mice were free of gut bacteria. If disease developed under these conditions it would be likely 
that the transferred T cells were responding to auto-antigens expressed in the Gl tract.
6.6 In vivo tumour studies
In light of the data demonstrating that primary CD8+ T cell response are enhanced in the 
absence of SHP-1, studies were carried out to explore whether this could be exploited in a 
therapeutic setting. With the availability of the C57BL/6 mouse melanoma cell line, B16, 
assays were developed to study the properties of SHP-1 deficient CD8+ T cells at combating 
tumourigenesis. The premise of such experiments was to explore the possibility of 
eventually downregulating SHP-1 expression in tumour-specific human T cells in order to 
improve T cell adoptive immunotherapy strategies. Although encouraging clinical outcomes 
have been achieved from the adoptive transfer of CD8+ T cells during clinical trials, there is 
still a need for further optimisation in order for such approaches to be used in the clinic on a 
routine basis.
As the B16 melanoma cells metastasise to the lungs upon intravenous transfer, assays were 
initially trialled that involved the detection of fluorescently labelled B16 cells in the lungs of 
mice by flow cytometry. This approach proved to be unsuccessful due to side-effects 
exhibited by the mice when transferring the number of B16 cells that were required to allow 
detection of the cells in the lungs. A second approach involved transferring B16 cells that 
had been labelled with NP68 peptide to mice that had previously received naive CD8+ F5 T 
cells. The measurable parameter of this assay would have been the number of tumour 
nodules in the lungs of the mice fourteen days post B16 cell transfer, allowing comparisons 
to be made between mice receiving either naive motheaten or control CD8+ F5 T cells. 
However, this approach was not feasible, as an equivalent number of nodules formed in the 
lungs of mice that received naive control CD8+ F5 T cells followed one week later by either
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NP68 labelled or unlabelled B16 cells. This implied that the NP68 peptide is either lost from 
the surface of the cells or diluted between cells during cell division, thereby allowing the B16 
cells to escape cytolysis by the T cells.
In order for the tumour studies to proceed, B16 cells were engineered to constitutively 
express the NP68 peptide. This process involved producing virus using the retroviral 
packaging cell line, Phoenix, and the cloning of B16 cells expressing the NP68 peptide. This 
was facilitated by the expression of GFP as a fusion protein with the NP68 epitope. The NP68 
expressing B16 cells were successfully killed by activated CD8+ F5 T cells, in both an in vitro 
and in vivo setting, and were therefore used extensively during this study. The CD8+ F5 T 
cells were very efficient at preventing tumour development within the lungs of recipient 
mice. As a consequence, a number of optimisation experiments were necessarily performed 
in order to optimise tumour development and clearance. These assays established the 
number of T cells and B16 cells to transfer, the duration between transfer, and the order of 
cells transferred with the T cells being transferred first. As a result of defining the conditions 
for a tumour protection assay, it was demonstrated that the transfer of naive motheaten 
CD8+ F5 T cells conferred mice with enhanced protection against tumour growth. Mice that 
received naive motheaten CD8+ F5 T cells had significantly fewer tumour nodules in their 
lungs than mice that received control CD8+ F5 T cells.
It would be informative to establish the underlying reason for the enhanced anti-tumour 
response seen in the absence of SHP-1, and pilot experiments demonstrated that tracking 
the adoptively transferred T cells in the blood and lungs was a feasible approach. In vitro 
experiments were also performed to explore the underlying reasons for the enhanced anti­
tumour response seen in the absence of SHP-1. From one in vitro experiment it was 
established that motheaten CD8+ F5 T cells killed more B16 target cells on a per cell basis 
than control CD8+ F5 T cells. This apparent enhanced cytolysis is contradictory to previously
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published data showing equal killing by motheaten and control CD8+ F5 T cells on a per cell 
basis, when the target cells were EL4s. In light of this, experiments would ideally be 
performed again with both B16 and EL4 cells being used as targets. It may also be of interest 
to establish the expression of costimulatory molecule ligands by the target cells as it has 
been demonstrated that costimulation can enhance the effector function of T cells (Bai et 
al., 2001). A study of naive CD8+ T cells has shown that costimulation can override the 
proliferative differences detected between motheaten and control CD8+ F5 T cells, when 
using anti-CD3 antibody to stimulate the cells (Sathish et al., 2001). Therefore, it may be 
plausible that this differential requirement for costimulation may also be true for activated 
control and motheaten CD8+ F5 T cells. It was also established during in vitro investigations 
that a greater proportion of activated CD8+ F5 T cells express CD107a upon encounter with 
B16 target cells, which correlates with the enhanced killing seen on a per cell basis. This 
assay needed further optimisation as the T cells were extremely sensitive to antigen 
recognition, which resulted in maximal CD107a expression. This could be addressed by 
further increasing T cell to target cell ratios, or by titrating the concentration of NP68 
peptide that was used to label the B16 target cells. Again, it would be informative to repeat 
such an assay with EL4 cells, to establish if differences in cytolysis between the two T cell 
populations are dependent upon the cells being targeted. With repeated experiments and 
further improvements to the assays being used it would be possible to validate the results 
that examined the cytolytic function of motheaten and control CD8+ F5 T cells on a per cell 
basis. It would also be informative to look at other facets associated with effector function, 
such as the expression levels of molecules associated with cytotoxicity, including perforin 
and the granzymes.
Although an important milestone of this study, the demonstration that SHP-1 deficient CD8+ 
T cells provide an enhanced anti-tumour response in a prophylactic context does not
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translate to what happens in a clinical situation, where patients present with established 
tumours. In order to address this and acquire proof-of-principle data it would be imperative 
to progress to using mouse models of tumour regression rather than tumour protection. Due 
to time constraints of this study, this aim was not met, although some important ground­
work was carried out to enable such experiments to be performed in the future.
The B16 cells expressing the NP68 epitope were used to establish subcutaneous tumours, 
which grew in a non-uniform manner within a group of mice. This pattern of growth may be 
attributed to the injection technique, as ensuring the cells are administered sub-cutaneously 
rather than intra-dermally may impact on the growth kinetics of the tumour. Despite this 
disparity, mice with similar sized tumours were used for adoptive CD8+ T cell transfer 
experiments. Although this assay was limited by the number of recipient mice, it did reveal 
an encouraging result. The mouse that received naive motheaten CD8+ F5 T cells exhibited 
enhanced regression of the tumour and at the end point of the assay had a tumour that was 
smaller in size than the mouse that received either no T cells or naive control CD8+ F5 T cells. 
During this assay, it also became apparent that measuring the developing tumour with 
callipers may not be the most precise way to monitor tumour growth and regression. This 
was not a shortfall in the accuracy of the callipers to measure distances, but the nature of 
the subcutaneous tumours. Firstly, the tumours were not always uniform in shape, which 
could potentially lead to an over estimation of the size of the tumour mass. Additionally, the 
small size of tumour masses at certain times during the assays meant it was practically 
challenging to measure them accurately. Finally, the tumour masses being measured were 
not totally solid and therefore had the potential to be compressed during measurement, 
which could alter the readout from the callipers. Therefore, B16 cells were engineered to 
constitutively express the NP68 epitope and the enzyme, luciferase. The generation of these 
cells will enable an in vivo imaging unit that is capable of detecting bio-luminescence to be
used to monitor tumour growth in an non-invasive and quantitative manner. This would 
allow tumour regression studies to be performed in an accurate manner. Potentially, either 
the subcutaneous or pulmonary B16 model could be used, with B16 tumours established 
prior to T cell transfer. For the lung model, the tumours could be monitored at regular 
intervals throughout the assay without the need to sacrifice the mice. Despite the presence 
of an IRES between the genes for luciferase and YFP it was hard to detect any fluorescence 
from transfected cells until they had been cloned. Both a fluorescent microscope and a 
FACScalibur flow cytometer were unable to detect YFP fluorescence from polyclonal cells, 
even though the cells were positive for luciferase activity. A weak fluorescent signal was 
detected from polyclonal cells when using a Moflo flow cytometer, which aided the cloning 
of the B16 cells. Monoclonal cell lines were found to be weakly fluorescent when analysed 
by a FACScalibur flow cytometer. The low level of fluorescence may be attributed to the 
inefficiency of the IRES at initiating transcript translation.
The tumour models established also have the potential to be adapted to continue the 
studies of T cell migration, as developing tumours would be a target tissue for T cell 
migration.
6.7 siRNA studies
In order to exploit the findings of this study in a therapeutic setting it would be necessary to 
modulate SHP-1 expression in human CD8+T cells. The introduction of siRNA into CD8+T cells 
may offer a vital tool in regulating SHP-1 expression. During this study, several methods 
were used to screen candidate siRNA sequences for effective targeting of SHP-1 expression. 
Jurkat T cells constitute a suitable cell to test the candidate shRNA sequences as they 
express SHP-1. Electroporating the Jurkat cells in order to introduce DNA results in a 
dramatic loss of cells and therefore had an impact on the number of cells available for
immunoblotting. This limitation is further compounded by low transfection efficiencies, 
which means the time it takes to sort a sufficient number of cells by flow cytometry has 
financial implications. Overall this mode of testing candidate shRNA sequences is not very 
efficient. Hence, in attempting to overcome this issue, Hela cells were engineered to express 
mouse and human SHP-1, as they are more readily transfected by methods other than 
electroporation, such as DNA-containing calcium phosphate precipitates. Hela cells are also 
more selectable by antibiotic treatment when compared to Jurkat cells, which meant flow 
cytometry was not required for selecting transfected cells.
Overall, it was demonstrated that SHP-1 protein levels can be downregulated in either Jurkat 
cells or Hela cells expressing human SHP-1 by using shRNA, with a maximum reduction of 
53% seen during this study. Although it would be imperative to identify a siRNA sequence to 
give a more robust knockdown of human SHP-1 in CD8+ T cells it would also be advantageous 
to pursue a viable sequence that gave knockdown of SHP-1 in mouse CD8+ T cells. This would 
allow SHP-1 manipulated primary mouse T cells to be utilised in the types of assays 
developed during this study. Additionally, it was also allow comparisons to be made 
between manipulated T cells and motheaten T cells, and would give an indication of the 
degree of downregulation required to achieve the functional properties of T cells that are 
totally deficient of SHP-1 activity.
The recent optimisation of lentiviral production and infection techniques within our 
laboratory may further assist with the progress of the siRNA studies. Lentivirus can be 
produced that encode specific shRNA sequences and subsequently be used to infect desired 
cells. Indeed, data from our research group has shown that lentivirus can be used to transfer 
genes at high efficiency to Jurkat cells, and more importantly human PBMCs. Therefore, this 
area of research is poised ready for the testing of candidate shRNA sequences in human 
cells, in order to downregulate SHP-1 expression. The use of lentivirus offers the means of
transferring genetic material to cells that are not actively dividing, which is normally a pre­
requisite of other retroviruses for successful transduction. This could assist with the 
improvement of adoptive T cell tumour immunotherapy strategies, as SHP-1 expression 
could be ablated in naive human CD8+ T cells without the need for excessive ex-vivo 
activation. This would be favourable as it has been repeatable demonstrated that less 
differentiated T cell populations have the greatest in vivo impact on tumourigenesis 
(Klebanoff etal., 2005).
Ultimately, it would be desirable to use manipulated human CD8+ T cells in various assays to 
explore their functional properties. Human tumour specific T cell lines could be manipulated 
using identified SHP-1 specific shRNA sequences for targeting SHP-1 and then used in in vitro 
proliferation assays. Hopefully, this type of experiment would be able to recapture what has 
been previously observed with motheaten mouse CD8+ T cells, in terms of enhanced 
proliferation and cytolysis. Furthermore, the NOD SCID mouse model could also be utilised 
to study manipulated human T cells. As this mouse does not reject transferred human cells it 
would be possible to examine the CTL function of manipulated human CD8+ T cells in an in 
vivo model. Human PBMCs could be harvested and the CD8+ T cells purified and infected 
with lentiviruses that encode for both a tumour specific TCR, such as for Wilm's tumour 
antigen, and also a shRNA sequence to target SHP-1 expression. The T cells could be 
transferred in vivo, along with human leukaemia cells that express the Wilm's tumour 
antigen, and the extent of tumour cell engraftment assessed.
6.8 Pro-tumoural role of CD8+ T cells in a lung tumour model
During the optimisation of the tumour protection assay it was found that mice rendered 
lymphopaenic by irradiation developed significantly fewer pulmonary tumours when 
compared to mice that were not irradiated. Concomitant with this observation, Dr. Simone
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Cuff (Department of Medical Biochemistry and Immunology, Cardiff University) also 
observed reduced pulmonary tumour nodule formation when B16 cells were transferred 
intravenously to Rag-17' mice and also in mice that had been depleted of CD8+ T cells using 
an anti-CD8 antibody. Thus, the pro-tumoural phenomenon was demonstrated in three 
separate systems by using the pulmonary B16 model. The use of Rag-17' mice confirmed that 
the pro-tumoural observation in anti-CD8 antibody depleted mice was due to CD8+ T cell 
depletion rather than other CD8+ cell subsets, such as DCs (lyoda et al., 2002., McLellan et 
al., 2002). Interestingly, the pro-tumoural observation was not mirrored for subcutaneous 
B16 tumours, in both Rag-17' and CD8+ T cell depleted mice. The pro-tumoural pulmonary 
observation seems counter-intuitive when considering the premise of tumour vaccine 
strategies, which enlist CD8+ T cells to combat tumourigenesis, and also the positive 
correlation seen between CD8+ T cell tumour filtration and tumour patient prognosis (Chiba 
et al., 2004; Galon et al., 2006; Pages et al., 2005). In addition, the transfer of naive CD8+ F5 
T cells to recipient mice during this study provided complete protection from pulmonary 
tumour development when B16 cells expressing NP68. Whereas tumour-specific adaptive 
immune responses have the capacity for anti-tumoural activity the actions of non-specific 
adaptive immune responses on tumourigenesis have not been fully explored. Indeed, innate 
immune responses rather than adaptive immune responses have been associated with 
augmentation of tumour growth. Some studies have implicated CD8+ T cells with a 
regulatory role in a number of human tumours (Filaci et al., 2007). In addition, pro-tumoural 
CD8+ T cells have been described in a chemically induced tumour mouse model (Roberts et 
al., 2007), although the antigen specificity of the T cells was not defined.
In light of these findings, collaborative work was undertaken during this study to explore the 
pro-tumoural role of antigen specific CD8+ F5 T cells in the B16 pulmonary tumour model. 
This aim was facilitated by the availability of B16 cells generated during this study that
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expressed the NP68 epitope and also wild-type B16 cells that do not express the cognate 
antigen. The experimental findings demonstrated that an antigen specific CD8+ T cell 
response was potently anti-tumoural, whereas an antigen non-specific CD8+ T cell response 
was pro-tumoural in nature. The CD8+ F5 T cells could either have a pro-tumoural or anti- 
tumoural role depending upon the presence of absence of expression of the cognate antigen 
by the tumour cells being targetted. It can therefore be concluded that the T cells do not 
belong to a regulatory subset of T cells. Dr. Simone Cuff has further demonstrated that the 
absence of CD8+ T cells correlated with an increased number of NK cells in the lungs of mice 
with developing tumours. NK cells play an important anti-tumoural role in the B16 
pulmonary model as demonstrated by the extreme susceptibility of NK1.1 depleted mice to 
sub-tumoural doses of B16 tumour cells, and also by the increased anti-tumour response 
seen when NK cell activity is enhanced. These findings may have implications for tumour 
development when non-specific inflammatory conditions are present, such as during 
infection of the lungs or during therapeutic vaccination, which may elicit a CD8+ T cell 
response that is not specific for the tumour.
6.9 Overall summary and conclusions
During this study it has been conclusively demonstrated that the absence of SHP-1 in CD8+ T 
cells results in an enhanced in vivo response to antigenic stimulation. This is characterised by 
an enhanced in vivo expansion and an increase in cytotoxicity. Importantly, the enhanced in 
vivo activity of SHP-1 deficient CD8+ T cells provided superior protection against tumour 
formation in a lung model of tumour development.
In addition to an enhanced primary response in the absence of SHP-1, preliminary data from 
this study has indicated that SHP-1 deficient T cells exhibit an enhanced memory response.
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These data support the notion that SHP-1 expression could be targeted for downregulation 
in CD8+ T cells in order to improve the efficacy of adoptive T cell transfer immunotherapy 
strategies. Current strategies involve the ex-vivo generation of large number of T cells for in 
vivo transfer. Often, the in vivo function of the T cells is impaired due to their repeated ex- 
vivo stimulation, which leads to a terminally differentiated T cell phenotype. The 
downregulation of SHP-1 in T cells used for ACT immunotherapy may potentially overcome 
this problem. In the absence of SHP-1 expression, T cells could be transferred in a less 
differentiated state, without precluding the generation of sufficient T cell numbers to 
mediate tumour regression.
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Loss of Src Homology Region 2 Domain-Containing Protein 
Tyrosine Phosphatase-1 Increases CD8+ T Cell-APC 
Conjugate Formation and Is Associated with Enhanced 
In Vivo CTL Function1
Jean G. Sathish,2 Garry Dolton, Frances G. LeRoy, and R. Janies Matthews3
Extensive evidence has been accumulated to implicate the intracellular protein tyrosine phosphatase, Src homology region 2 
domain-containing protein tyrosine phosphatase-1 (SHP-1), as a negative regulator of TCR-signaling thresholds. Specifically, T 
cells from the SHP-1-deficient mouse, motheaten, exhibit a hyperproliferative phenotype when activated by cognate peptide-pulsed 
APCs. However, the cellular basis for this phenotype has not been fully explained. Using the intracellular fluorescent dye, CFSE, 
we show that a greater proportion of motheaten vs control naive CD8+ T cells undergo cell division when activated by peptide- 
pulsed APCs. Furthermore, there is a greater likelihood of TCRs on SHP-1-deficient vs control T cells binding to peptide/MHC 
ligands on APCs when using TCR down-regulation as an indirect measure of TCR engagement. In addition, T cell-APC conjugate 
assays provide direct evidence that a greater proportion of SHP-1-deficient T cells are capable of forming stable conjugates with 
APCs and this may explain, at least in part, their hyperproliferative response to TCR-triggered stimulation. The physiological 
relevance of the combined in vitro observations is demonstrated by the significantly enhanced in vivo expansion and CTL capacity 
generated in mice receiving adoptively transferred SHP-1-deficient naive CD8+ T cells when compared with control T cells. The 
Journal of Immunology, 2007, 178: 330-337.
A  necessary prelude to T  cell activation is the physical encounter and sustained contact with an APC. A pro­longed contact of the T  cell with the APC is essential to 
sustain TCR signaling and up to 20 h of such conjugation may be 
necessary for a naive T cell to commit to a program of full acti­
vation (1). Furthermore, the duration of stimulus received by the T  
cell when in contact with the APC determines its capacity to sub­
sequently respond to homeostatic and proliferative cytokines (2). 
In vivo-imaging studies (3-7) also point to lengthy interactions of 
T cells and dendritic cells (DCs)4 occurring within lymph nodes 
(LNs) and these interactions are thought to be a prerequisite for T  
cell activation.
The major physical mechanism by which T cells adhere to APCs 
is by the binding of lymphocyte integrins on the T  cell to their 
counterligands on the APC. Foremost among the adhesion mole­
cules required for supporting T  cell-APC conjugates is the /S2 in- 
tegrin, LFA-1, on T cells that binds to ICAM-1 on the APCs. T  
cells deficient in LFA-1 are impaired in their ability to form con­
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jugates with APCs (8) and likewise, Abs directed against LFA-1 
can block conjugate formation (9). T  cell integrins normally dis­
play a state of low-binding activity toward their ligands. However, 
engagement of TCRs by peptide-MHC complexes on the APCs 
initiates signals that lead to shape changes and reorganization of 
the T  cell actin cytoskeleton (10-13), ultimately resulting in the 
activation of integrins, primarily LFA-1 (14). The binding of T  cell 
integrins to their ligands on the APC supports a stable and physical 
cell-cell conjugate that provides the platform for sustained signal­
ing thus resulting in gene transcription, cytokine production, blast­
ing, and T cell proliferation (15).
It is clear that the cellular and molecular factors influencing T 
cell-APC conjugate formation need to be fully understood as they 
are predicted to have a significant impact on T  cell responsiveness 
and the eventual immune response. In addition to adhesion recep­
tors, several signaling molecules including adhesion and degran­
ulation-promoting adaptor protein (16, 17), Vavl (18), inducible T 
cell kinase (19) and Src kinase-associated phosphoprotein of 55 
kDa (20), and an intact actin cytoskeleton (21, 22) have been 
shown to be required or to assist in conjugate formation. However, 
negative regulators of conjugate formation have hitherto not been 
reported. The Src homology 2 domain containing protein tyrosine 
phosphatase-1 (SHP-l)-deficient motheaten mouse has been in­
strumental in demonstrating that SHP-1 functions to raise the sig­
naling thresholds required for triggering through the TCR in both 
T cell development and in peripheral T  cell activation (23, 24). To 
dissect the role of SHP-1 in T cells in an Ag-specific context, we 
have introduced the M HC class I-restricted transgenic TCR, F5 
(25), into the motheaten genetic background (26). The F5 TCR 
recognizes a peptide derived from the influenza A virus nucleo- 
protein, in the context of the MHC molecule H2-Db (27). When 
motheaten LN T  cells bearing the F5 TCR are stimulated with 
cognate peptide-pulsed APCs, they exhibit a greater degree of pro­
liferation as measured by tritiated thymidine incorporation (26)
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when compared with LN T cells derived from littermate controls. 
This finding is consistent with similar studies using different trans­
genic TCRs on the motheaten genetic background (23, 24). How­
ever, the cellular basis and in vivo significance of this hyperpro­
liferative phenotype has not been fully established.
In this study, population analyses of motheaten and control T  
cells were performed to examine whether SHP-1 influences the 
frequency with which individual T cells are able to enter into cell 
division. We found that SHP-1 activity has a striking impact on the 
ability of TCR-stimulated naive CD8+ T  cells to enter into cell 
division. In the absence of SHP-1, the likelihood of a T cell di­
viding following incubation with Ag-pulsed APCs was signifi­
cantly increased as demonstrated by a 2-fold increase in the pro­
portion of motheaten vs control T  cells that participate in clonal 
expansion. Further investigations demonstrated that the percentage 
of SHP-1-deficient vs control T  cells that had engaged TCRs was 
increased substantially and this correlated with an enhanced ca­
pacity of SHP-1-deficient T cells to form T  cell-APC conjugates. 
Importantly, the increased in vitro responses of SHP-1-deficient T 
cells could be replicated in an in vivo context whereby the adop­
tive transfer and in vivo activation of naive motheaten vs control 
CD8+ T cells resulted in an increased expansion of effectors and 
an elevated cytolysis of target cells.
Materials and Methods
Mice
C57BL/6J mice heterozygous at the motheaten locus (C57BL/6J m e/+) 
were originally obtained from Dr. L. Shultz at The Jackson Laboratory. 
The F5-transgenic TCR was introduced into the motheaten genetic back­
ground as described in Ref. 26 and motheaten and littermate control mice 
for experimentation were obtained from litters arising from pairings be­
tween C57BL/6J me/+  and F5hornozygous m e/+  mice. The F5 TCR uses the 
Va4 and V/311 gene segments of the TCR a- and /3-chain genes, respec­
tively. Motheaten and control mice were sacrificed between 9 and 13 days 
postpartum and LNs (inguinal, axial, brachial, and submandibular) har­
vested. C57BL/6J mice purchased from The Jackson Laboratory and 
C57BL/6J. Rag-1 mice provided by Dr. F. Powrie (Sir William Dunn 
School of Pathology, Oxford University, Oxford, U .K .) were maintained as 
breeding colonies in our animal facility. All animal experimentation was 
conducted in accordance with the U.K. Animal (Scientific Procedures) Act 
1986 under Project Licenses PPL 30/1715 and 30/2266.
Cells and cell cultures
The mouse B cell line, AB, was generated from H-2kxb bone marrow- 
derived B cells transformed with Abelson leukemia virus and was a gift 
from Prof. E. Simpson (Imperial College, London, U.K.; Ref. 28). This cell 
line was maintained in complete D M E M  supplemented with 50 /xM 2-ME. 
Bone marrow-derived DCs were grown as described in Ref. 29. Briefly, 
bone marrow was flushed from the tibia of C57BL/6J mice and cultured on 
bacteriological plates in complete RPM I 1640 supplemented with 200 
U/ml recombinant mouse GM-CSF (Sigma-Aldrich). At days 5 and 8, half 
the medium was replaced and 100 U/ml recombinant mouse GM-CSF was 
added. At day 10, 1 /xg/ml LPS was added and 24 h later, mature DCs were 
pulsed with 5 /xM NP68 and used experimentally. Purified C D8+ T cells 
were obtained by negative depletion of C D 4+ T  cells, B cells, and myeloid 
cells with CD4, CD1 lb, and B220 microbeads (Miltenyi Biotec) or where 
indicated by positive purification with CD8 microbeads (Miltenyi Biotec) 
and used in the experiments.
T cell proliferation assay
For cell division measured by CFSE dilution, purified C D 8+ T  cells were 
labeled with 2 /xM CFSE (Molecular Probes) for 10 min in HBSS at 37°C. 
Labeling was stopped by addition of FCS and cells were washed and re­
suspended in complete DM EM . A total of 1 X 106 CFSE-labeled T  cells 
were incubated with 1 X 106 irradiated, peptide-pulsed AB cells for 48 h. 
At the end of the stimulation, T cells were stained with anti-CD8aTC and 
acquired by flow cytometry. T  cell proliferation was measured by CFSE 
fluorescence dilution of the electronically gated C D 8+ T cell population. 
CFSE profiles were analyzed using the proliferation platform of the FlowJo 
software program (Tree Star). The division index indicates the average 
number of divisions that a T  cell in the starting population underwent and
the proliferation index is defined as the average number of divisions un­
dergone by those T  cells in the starting population that did divide.
Flow cytometry
Cells were washed and incubated with the indicated conjugated Abs in 
stain buffer (Cell Wash, 2% BSA, and 2 mM EDTA) for 30 min on ice. 
Conjugated Abs were obtained as follows; anti-CD8aTC was from Caltag 
Laboratories, anti-TCRa/3PE, anti-CD8aPE, anti-CD 11RTC, anti- 
CD49dFITC and antiCD49enTC were purchased from BD Pharmingen 
while anti-V/311FITC was a gift of Dr. D. Kioussis, National Institute for 
Medical Research (M ill Hill, London, U.K.). Following incubation, cells 
were washed and acquired on a flow cytometer (FACSCalibur; BD Bio­
sciences) and analyzed by CellQuest Software.
TCR down-regulation assay
Purified CD8+ T  cells were incubated with AB cells pulsed with a satu­
rating (10 /xM) concentration of NP68 peptide in FACS tubes for 4 h. At 
the end of the incubation, the cells were washed with Cell Wash (BD  
Biosciences) and stained with anti-V/31 l FrTC (K T-11) and anti-CD8aTC in 
stain buffer for 30 min on ice followed by washing. The cells were acquired 
on the flow cytometer and TCR down-regulation assessed on the electron­
ically gated C D 8+ T cell population. For anti-CD3-induced down-regula­
tion, T  cells were incubated with a titration of anti-CD3Bl° ranging from
1.25 to 20 /xg/ml on ice for 30 min followed by cross-linking with strepta- 
vidin (Pierce Biotechnology) for an additional 30 min on ice. The cells 
were then incubated at 37 °C for 45 min and TCR down-regulation stopped 
by addition of ice-cold Cell Wash (containing NaN3). Cells were then 
stained with anti-CDSa7^  and anti-TCRa/3PE, acquired on the flow cytom­
eter and TCR down-regulation was measured as indicated above.
Conjugate assay
A total of 1 X 106 AB cells that express H-2Db were labeled with 0.1 /xM 
CFSE, pulsed with peptide and incubated with 1 X 106 purified CD8+ T  
cells in FACS tubes. The tubes were vortexed and conjugates allowed to 
form by incubation at 37°C for 90 min. Nonspecific conjugates were dis­
persed by vortexing and cells fixed with 4%  paraformaldehyde. Cells were 
washed, stained with anti-CD8aTC, acquired by flow cytometry and ana­
lyzed on the electronically gated CD8+ T cell population for conjugate 
formation. Blocking experiments were conducted by incubating T cells 
with anti-CD18 integrin Ab (GAME-46; BD Pharmingen) before perform­
ing the conjugate assay.
Adhesion assay
Flat-bottom 96-well plates were coated overnight with 10 /xg/ml rICAM-1 
Fc chimera (Chemicon International) or 30 /xg/ml fibronectin (Sigma- 
Aldrich) in PBS with or without 10 /xg/ml anti-CD3. The plates were washed 
and blocked with 2.5% BSA for 2 h. Purified CD8+ T cells were labeled 
with 1 /xM of the fluorescent dye, 2',7'-bis(2-carboxyethyl)-5-(and-6)-car- 
boxyfluorescein, acetoxymethyl ester (Calbiochem), resuspended in 2.5% 
BSA in PBS and seeded at a density of 5 X 105/well. Cell adhesion was 
allowed to proceed for 30 min at 37°C followed by gently washing of the 
wells with warmed PBS, 2.5% BSA. Adhesion was quantified by recording 
fluorescence emission using a Fluostar Optima fluorescence microplate 
reader (BMG Labtech).
In vivo T cell expansion and cytotoxicity assays
To gauge T  cell expansion in vivo, 3.5 X 106 positively purified CD8+ T  
cells were injected i.v. into C57BL/6J. Rag-l_/~ recipient female mice. 
The recipient mice were subsequently challenged with 100 /xg of NP68 
peptide in IFA. Six days later, the mice were killed and spleens were 
harvested and homogenized. Before RBC lysis, the homogenized spleno- 
cytes were mixed with an additional reference splenocyte population to 
facilitate accurate quantitation of the expanded CD8+ T cells in the recip­
ient mice. The reference population consisted of 0.5 X 106 reference 
splenocytes that had been labeled with 0.2 /xM CFSE following their iso­
lation from a C57BL/6J mouse. The mixed splenocyte populations were 
stained with anti-CD8PE and analyzed by flow cytometry. The percentage 
of adoptively transferred and expanded CD8+ T  cells was assessed by 
comparison with a defined number of the CFSE-labeled reference spleno­
cytes. To measure in vivo cytotoxicity, 2-3 X 106 positively purified CD8 
T cells were injected i.v. into sublethally (650 cGy) irradiated C57BL/6J 
recipient female mice. Reference recipient mice received no T cells. In 
parallel, 4 X 106 mature DCs, pulsed with 5 /xM NP68 peptide, were 
injected i.p. into recipient mice. Six days later, splenocyte targets from 
naive mice were labeled with either 2 or 0.2 /xM CFSE. Splenocyte targets 
labeled with 0.2 /xM CFSE were pulsed for 1 h with 5 /xM NP68 while
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Control
10 pM NP68
Motheaten
10 pM NP68
Table I. Quantitative analysis o f motheaten and control CD8+ T cell 
proliferation in vitro
C  10° 101 102 103 104 10° 101 102  1Q3 104
B 100 pM NP88 100 pM NPfifl
10°  101 102 103 104 10°  101 102 103 104 
CFSE -------------------------- ►
FIG U R E 1. An increased proportion of motheaten F5 TCR T  cells are 
capable of proliferating following TCR stimulation. LN T cells from moth- 
eaten and littermate control mice expressing the F5 TCR were labeled with 
2 p.m of CFSE and incubated for 48 h with irradiated AB cells pulsed with 
10 or 100 pM NP68 peptide. The cells were stained with anti-CD8aTC, 
acquired by flow cytometry, and the electronically gated C D 8+ T  cell 
population analyzed for CFSE fluorescence. The percentage of naive T  
cells from the initial starting population that have entered into division is 
indicated in each histogram. Results are representative of three independent 
experiments.
the targets labeled with 2 /xM CFSE were left unpulsed. Equal numbers 
(10 x  106) of the two target populations were mixed and injected i.v. into the 
recipient mice. After an additional 24 h, recipient mice were killed, spleens 
harvested, single-cell suspensions prepared and the proportions of differ­
entially CFSE-labeled target cells were assessed by flow cytometry. The 
percent-specific lysis was calculated using the equation: percent-specific 
lysis = 100 — (((% survival in peptide-pulsed +  T  cells/% survival in 
unpulsed + T  cells)/(% survival in peptide pulsed +  no T  cells/% survival 
in unpulsed and no T cells)) x  100) (30).
Results
A higher frequency of motheaten T cells undergo cell division 
upon stimulation
Previous studies have demonstrated that SHP-1-deficient moth- 
eaten T cells hyperproliferate when stimulated by peptide-bearing 
APCs (23, 24, 26). In each of these studies, a consistent finding 
was that motheaten T  cells exhibited a higher proliferative capacity 
at all the doses of peptide tested. Although [3H]thymidine incor­
poration is a sensitive measure of proliferative activity, it does not 
distinguish between the possibility that a limited number of moth- 
eaten T cells underwent multiple rounds of cell division or that a 
larger proportion of the initial SHP-1-deficient T  cell population 
entered into cell division. Both these processes could account for 
the increased [3H]thymidine incorporation by motheaten T  cells 
when compared with control T  cells. Labeling T  cells with the 
intracellular fluorescent dye, CFSE, allows one to address this par­
ticular question. Therefore, we used CFSE labeling to track cell 
division in motheaten and control T  cells. As shown in Fig. 1, 
when control T cells were stimulated by APCs pulsed with 10 pM 
NP68, 32% of the initial C D8+ T  cell population underwent cell 
division. However, the same stimulus elicited an ~  2-fold increase 
(62%) in the proportion of motheaten T  cells that entered into cell 
division. An increase in the concentration of cognate peptide used 
to stimulate the T cells did not significantly alter the relative pro­
portions of motheaten and control T  cells induced to divide. A 
comparison of the proliferation indices for motheaten and control 
T cells suggested that once entered into cell cycle, the differences
Culture NP68 (pM) Division Index" Proliferation Index*
Control 10 0.4 1.2
100 0.5 1.3
Motheaten 10 0.9 1.4
100 1.4 1.4
° Measure of the average number of divisions that a T cell in the starting popu­
lation underwent.
* Measure of the average number of divisions undergone by a T cell that did 
divide.
between motheaten and control T cells in terms of number of sub­
sequent divisions are less pronounced (Table I). Finally, neither 
motheaten nor control T  cells underwent spontaneous cell division 
when incubated with unpulsed APCs (result not shown).
Higher proportion of motheaten T cells down-regulate TCRs in 
response to APCs
The increased entry into cell division (Fig. 1) was consistent with 
a lowered TCR-signaling threshold in the absence of SHP-1 but 
assumed equivalent engagement of TCR on motheaten and control 
T cells. It was therefore necessary to explore whether there was an 
altered likelihood of motheaten vs control T  cells encountering Ag 
presented by MHC class I on the APCs. It has been observed 
previously that in vitro TCR engagement by MHC/peptide com­
plexes or cross-linking with Abs triggers down-regulation of the 
TCR from the T cell surface (31). Accordingly, TCR down-regu­
lation can be used as a valid indicator of Ag encounter by a T  cell 
(21, 32). Therefore, we measured TCR down-regulation to ascer­
tain whether motheaten T  cells experienced an altered frequency of 
Ag encounter. It is important to note that equal proportions of 
motheaten and control CD8+ T cells purified from the LNs ex­
pressed the F5 TCR as assessed by staining with KT11, a mAb
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F IG U R E  2. A higher proportion of motheaten vs control F5 TCR T cells 
down-regulate TCRs following incubation with peptide-pulsed APCs. Pu­
rified motheaten and control CD8+ T  cells expressing the F5 TCR were 
incubated for 4 h with AB cells left unpulsed or pulsed with 10 p.M NP68 
peptide. Following incubation cells were stained with anti-v/311-FITC and 
anti-CD8aTC and TCR down-regulation assessed by flow cytometry on the 
electronically gated C D 8+ T cell population. The percentage of naive T 
cells that have down-regulated TCR is indicated in each dot plot. Results 
are representative of three independent experiments.
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FIG U R E  3. Equivalent down-regulation of F5 TCR on motheaten and 
control T cells following triggering with cross-linked soluble anti-CD3 Ab. 
Purified motheaten and control CD8+ T cells expressing the F5 TCR were 
left unstimulated or incubated with a titration of anti-CD3Bl° ranging from
1.25 to 20 /xg/ml for 30 min on ice followed by cross-linking with strepta- 
vidin for an additional 30 min. T cells were incubated for an additional 45 
min at 37°C before staining with anti-CD8TC and anti-TCRa/3PE and as­
sessed by flow cytometry for TCR down-regulation. The graph shows the 
mean percentage of triplicate samples of naive T  cells that have down- 
regulated TCR. Error bars represent SDs. Results are representative of 
three independent experiments.
specific for TCRs using the V/3/7 gene segment. As shown in Fig. 
2, when motheaten and control T  cells were incubated with un­
pulsed APCs, a small proportion (1-2% ) of each T cell population 
demonstrated a basal, low-level down-modulation of TCR. How­
ever, when control T cells were exposed to APCs pulsed with 
saturating concentration of cognate peptide, —20% of the total T  
cell population exhibited a down-regulation of cell surface TCRs. 
Furthermore, the same stimulus given to motheaten T  cells resulted 
in a >2-fold increase in the proportion (53%) of T cells with 
down-regulated TCRs. The important inference from this result is 
that motheaten T cells are endowed with an increased capacity to 
engage Ag-bearing APCs. It is possible, however, that the in­
creased TCR down-regulation of motheaten T  cells was due to an 
enhanced intrinsic capacity of these T  cells to down-regulate TCR  
rather than an increased frequency in engaging Ag-bearing APCs. 
To distinguish between these two possibilities, we measured TCR  
down-regulation following cross-linking with soluble anti-CD3 
Ab. This approach eliminates any contribution made to TCR
down-regulation by the interaction of the APC with the T cell. The 
anti-CD3 Ab is expected to cross-link TCRs on motheaten and 
control T cells to an equal degree. As demonstrated in Fig. 3, both 
motheaten and control T  cells revealed equivalent TCR down-reg­
ulation after 45 min of cross-linking the TCR/CD3 complex with 
a range of concentrations of anti-CD3 Ab. This indicates that, fol­
lowing direct CD3 cross-linking at least, the intrinsic process of 
TCR internalization proceeds to a similar degree in motheaten and 
control T cells.
Increased APC-T cell conjugate formation by motheaten T cells 
that is LFA-1 dependent
The enhanced down-regulation of TCR detected on motheaten vs 
control T  cells when presented with APC-bearing peptide but not 
with soluble anti-CD3 Ab was suggestive of an increased ability of 
motheaten F5 T  cells to engage APCs. Therefore, we predicted that 
motheaten T cells may have an altered capacity to form conjugates 
with peptide-pulsed APCs and performed conjugate assays to test 
this hypothesis. The AB cells were labeled with CFSE to facilitate 
identification of the T-B cell conjugates. Fig. 4 shows that when 
control CD8+ T  cells were incubated with AB cells pulsed with 
NP68 peptide at a concentration of 10 pM, the percentage of T 
cells that formed stable conjugates increased from a baseline of 
—6% to that of 28%. However, motheaten T  cells showed a sig­
nificantly higher frequency (57%) of conjugate formation when 
presented with the same concentration of peptide. The result of this 
experiment demonstrated that the lack of SHP-1 in the motheaten 
T cells confers an enhanced capacity to engage and form stable 
conjugates with the APC and this is manifested as an increased 
frequency of T  cell-APC conjugates.
Conjugate formation is supported by the binding of T cell inte­
grins to counterligands on the APC. LFA-1 is the critical integrin 
that mediates T-B cell conjugation (8) and it was therefore impor­
tant to investigate whether the motheaten T cells retained a similar 
dependence on LFA-1 engagement for conjugate formation. Con­
jugate formation was therefore examined following blocking of 
LFA-1-ICAM-1 interaction using an anti-LFA-1 Ab. Fig. 4 shows 
that when motheaten and control T cells were incubated with un­
pulsed APCs and anti-LFA-1 Ab, the basal level of conjugate for­
mation was reduced from 6 to 2% for both populations of T cells.
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FIG U R E 4. Increased number of L F A -1 -dependent APC-T cell conjugates formed by motheaten F5 T cells. Purified motheaten and control CD8+ T cells 
expressing the F5 TCR were incubated with or without anti-CD 18 Ab before incubation for 90 min at 37°C with AB cells labeled with 0.1 /xM CFSE and 
left unpulsed or pulsed with 100 pM NP68 peptide. Nonspecific conjugates were dispersed by vortexing and conjugates stained with anti-CD8TC. APC-T 
cell conjugates were identified by flow cytometry on the electronically gated CD8+ T  cell population based upon increased FSC and CFSE fluorescence 
o f conjugated cells. The percentage of naive C D 8+ T  cells that have formed conjugates with the APCs is indicated in each dot plot. Results are 
representative of three independent experiments.
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F IG U R E  5. Equivalent integrin expression and adhesion of motheaten 
and control T cells to plate-bound ICAM-1 and fibronectin. A, LN cells 
from motheaten and control were stained with anti-CD8TC and one of three 
FITC conjugates, anti-CDl la, anti-CD49d, and anti-CD49e. Integrin 
a-chain expression was assessed by flow cytometry on electronically gated 
populations CD8 ’ T cell populations. Histograms depicting integrin ex­
pression for motheaten and control T cells are shown and are representative 
of three independent experiments. Filled and bold-line histograms repre­
sent control and motheaten T cell, respectively. Staining with isotype- 
matched controls is indicated by the open histograms. B, Purified moth- 
eaten and control CD8+ T cells expressing the F5 TCR were labeled with 
1 p,M BCECF/AM and seeded at a density of 5 X  lCP/well precoated with 
10 /ig/ml rICAM-1 Fc chimera or 30 /u,g/ml fibronectin with or without 10 
/ig/ml anti-CD3. Cells were incubated for 30 min at 37°C followed by 
gentle washing and adhesion assessed as recorded fluorescence. Bar graphs 
show the mean percentages of bound T cells in each of the four experi­
mental conditions. Error bars represent SDs. Results are representative of 
five independent experiments.
Furthermore, blocking LFA-1 binding resulted in a similar com­
plete inhibition of conjugate formation for both the motheaten and 
control T  cells following activation with B cells pulsed with 10 pM  
NP68 peptide. It is therefore apparent from this result that moth- 
eaten T  cells retain an equivalent dependence on LFA-1 for con­
jugate formation when compared with control T  cells.
Equivalent adhesion o f motheaten and control T cells 
to ICAM-1 and fibronectin
Given the dependence upon LFA -1 for motheaten and control T  
cells to form conjugates, it is possible that the increased numbers 
of motheaten T  cells forming conjugates could be due to a higher 
expression of LFA-1 on the surface o f motheaten T  cells. To test 
this possibility, the expression o f the a-chain of LFA-1 and related 
T  cell integrins, V L A -4  and V L A -5 , was examined by flow cy­
tometry. As shown in Fig. 5A, both the motheaten and control T
cells displayed an equivalent expression of LFA -1, V L A -4 , and 
V L A -5 . W e conclude from these results that the differences in 
conjugate formation between motheaten and control T  cells cannot 
be attributed to differential integrin expression. Under resting con­
ditions, T  cell integrins do not exhibit a significant level of binding 
activity to their ligands. However, upon activating the T  cell 
through TC R  engagement, integrin binding to ligand is up-regu- 
lated by a modulation of integrin affinity and avidity (14). A l­
though the expression levels o f surface integrins are similar in the 
motheaten and control T  cells, it is possible that TCR-induced 
activation might result in enhanced integrin activation in the moth- 
eaten T  cells. This may then lead to increased conjugate formation. 
To examine this possibility, we fluorescently labeled motheaten 
and control T  cells and performed adhesion assays. T  cells were 
allowed to adhere onto wells coated with the LFA-1 ligand, 
IC A M -1 , either alone or in conjunction with anti-CD3 (Fig. 5B). 
Alternatively, T  cell adhesion to wells coated with the V L A -4  and 
5 ligand, fibronectin, either singly or in conjunction with anti-CD3, 
was analyzed (Fig. 5B). The combined results o f these experiments 
indicated that motheaten and control T  cells adhere to plate-bound 
integrin ligands to an equal degree, both basally and following 
anti-CD3 stimulation.
Enhanced in vivo expansion and cytolysis by motheaten T cells
The increased conjugation o f motheaten C D 8 + T  cells to APCs is 
likely to provide the basis for the enhanced proliferative capacity 
of these T  cells that is observed in vitro. However, the physiolog­
ical requirements placed upon a naive C D 8 + T  cell for expansion 
in vivo are more complex and include entry into peripheral LNs 
leading to encounter with Ag-presenting DCs. Hence, it was im­
portant to explore whether loss o f SHP-1 in C D 8 + T  cells also 
translates into enhanced expansion in vivo. The severe autoreactivity 
and early morbidity associated with the motheaten phenotype (33) 
precludes any direct in vivo experimentation. Therefore, to ad­
dress the issue o f in vivo relevance, equivalent numbers of naive 
F5 C D 8 + T  cells purified from either motheaten or littermate con­
trol mice were adoptively transferred into irradiated recipient mice 
that were then subjected to Ag challenge. Significantly increased 
percentages of motheaten vs control C D 8 + T  cells were detected 
in the spleens o f recipient mice 6-day posttransfer and following in 
vivo TC R  stimulation (Fig. 6A).
W e also examined whether the increased in vivo generation of 
SHP-1-deficient T  cell effectors following adoptive transfer and 
antigenic challenge correlated with an enhanced killing capacity. 
To address this question, equivalent numbers of naive F5 C D 8 + T  
cells from either motheaten or littermate control mice were adop­
tively transferred into irradiated recipient mice subsequently ad­
ministered with mature DCs pulsed with NP68 peptide. Six days 
later, after the generation o f mature effector C D 8 + T  cells, the 
mice were injected with equal numbers of splenocyte targets that 
had been pulsed or not with NP68 peptide and differentially la­
beled with CFSE. An additional 24 h later, the proportions of d if­
ferentially CFSE-labeled cells were assessed as a measure of in 
vivo C T L  activity. Fig. 6B  reveals that in vivo C TL  activity was 
readily detected in recipient mice receiving wild-type T  cells but 
the level o f killing was significantly increased (84 vs 56% ) in mice 
receiving motheaten T  cells. In reference recipient mice that re­
ceived no adoptively transferred T  cells, equivalent numbers of 
each population o f target splenocytes were detected. Importantly, 
these results demonstrate that the increased in vivo expansion of 
motheaten C D 8 + T  cells also extends to an elevated cytolysis of 
target cells.
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FIG U R E 6. Increased in vivo expansion and enhanced cytolytic activity 
of motheaten vs control F5 C D 8+ T  cells. A, A  total of 3.5 X 106 purified 
motheaten or control CD8+ T  cells expressing the F5 TCR were injected 
i.v. into C57BL/6J. Rag-1 recipient mice that were subsequently chal­
lenged with 100 fig of NP68 peptide in IFA. Six days later, the spleens 
were harvested and before RBC lysis, the homogenized splenocytes were 
mixed with an additional population of 0.5 X 106 reference splenocytes 
that had been labeled with 0.2 /u.M CFSE following their isolation from a 
C57BL/6J mouse. The mixed splenocyte populations were stained with 
anti-CD8PE and analyzed by flow cytometry. The relative percentage of 
adoptively transferred and expanded C D8+ T  cells was assessed by com­
parison with a defined number of the CFSE-labeled reference splenocytes 
and this is indicated in each histogram. Results are representative of three 
independent experiments. B, A  total of 2 -3  X 106 purified motheaten or 
control CD8+ T cells expressing the F5 TCR were injected i.v. into irra­
diated C57BL/6J recipient mice. A reference recipient mouse group re­
ceived no T cells. In parallel, 4 X 106 mature DCs pulsed with 5 /xM NP68 
peptide were injected i.p. into the recipients. Six days later, splenocyte 
targets were differentially labeled with either 2 or 0.2 jxM CFSE. The 
population of T cells labeled with the lower concentration of CFSE was 
pulsed for 1 h with 5 /xM NP68 before equal numbers of both populations 
were injected i.v. into the recipient mice. Spleens were harvested after an 
additional 24 h and the proportions of differentially CFSE-labeled cells 
assessed by flow cytometry. The marker regions, M l and M2, on the his­
tograms represent the NP68-pulsed and unpulsed splenocyte target popu­
lations respectively. The percentage of NP68-pulsed splenocyte targets 
killed is indicated in each histogram. Results are representative of three 
independent experiments.
Discussion
In this study, we have addressed the cellular mechanism that un­
derlies the hyperproliferative phenotype of SHP-1-deficient moth- 
eaten T cells and examined its in vivo relevance. The increased 
proliferation, as measured by thymidine incorporation, of SHP-1- 
deficient T cells upon Ag receptor stimulation could have resulted 
from an increase in the proportion of T  cells entered into cell 
division, an increase in the number of divisions, or a combination 
of these possibilities. To distinguish between the different possi­
bilities, the labeling of motheaten and control T  cells with the 
intracellular fluorescent dye, CFSE (34), has allowed us to analyze 
the proportion of each population entered into cell division fol­
lowing in vitro antigenic stimulation. The major conclusion from 
these experiments is that loss of SHP-1 results in an ~ 2-fold in­
crease in the percentage of naive C D8+ T cells entering into cell
division when exposed to APCs bearing the appropriate MHC/ 
peptide complex. Once committed to the first cell division, the 
subsequent number of cell divisions undertaken by motheaten and 
control T  cells appears similar.
The question therefore shifts as to why the probability of entry 
into cell cycle is significantly enhanced for individual SHP-1-de­
ficient T  cells following exposure to Ag-bearing APCs. Previous 
studies have suggested that TCR-signaling thresholds are lowered 
in the absence of SHP-1 (26). However, these conclusions have 
assumed an equivalent engagement of TCR on motheaten and con­
trol T  cells by appropriate M HC complexes on the surface of the 
APC. Using TCR down-regulation to interrogate the history of F5 
TCR engagement by H-2Db/NP68 ligand complexes on B cells, we 
noted a significantly increased likelihood of TCR engagement on 
motheaten vs control T  cells. Hence, the heightened proliferative 
responses of motheaten T cells in response to stimulation with 
cognate peptide-pulsed APCs most likely derive in part from the 
increased probability of TCR engagement. As a control, cross- 
linking with soluble anti-CD3 Ab demonstrated that there was no 
intrinsic difference between motheaten and control T cells for TCR 
internalization. However, previous data from others (35, 36) and 
our own group (37) has demonstrated that SHP-1-deficient T cells 
hyperproliferate in response to anti-CD3 cross-linking. The impli­
cation from these combined results is that while SHP-1 can influ­
ence the degree of engagement of TCR with its counterligand on 
the surface of the APC, the effects of SHP-1 on T cell responsive­
ness cannot be limited solely to the enhanced engagement of TCR 
but must also influence TCR-signaling thresholds.
When a T cell physically encounters an Ag-bearing APC, a con­
comitant shape change is induced in the T cell that causes the T 
cell to spread on the APC surface thus increasing the surface area 
of contact (38). In addition, relaxation of T  cell rigidity, a process 
regulated by ezrin-radixin-moesin proteins, facilitates efficient T  
cell-APC conjugate formation (39). Both the initial degree of ri­
gidity and capacity for spreading of the T cell membrane over the 
surface of the APC are dependent upon the cortical actin cytoskel­
eton and intriguingly a connection between SHP-1 and the regu­
lation of cytoskeletal processes has begun to emerge (40, 41). It is 
therefore plausible that an effect of SHP-1 activity on actin poly­
merization and cytoskeleton remodeling may underlie its ability to 
affect T  cell adhesion to APCs. One possibility is that loss of 
SHP-1 induces changes in the lymphocyte actin cytoskeleton that 
enhances the capacity of motheaten T  cells to scan the surface of 
neighboring APCs. This would increase the likelihood of TCRs on 
the surface of motheaten T cells engaging with MHC/peptide li­
gands on the APCs.
The enhanced probability of TCR engagement observed for 
SHP-1-deficient T cells is subsequently manifested in the in­
creased capacity of these T  cells to form stable cellular conjugates 
with the APC. Stable T  cell-APC conjugate formation results from 
TCR triggered increases in the binding activity of LFA-1. We 
therefore examined whether increases in LFA-1-binding activity, 
as measured by T  cell adhesion to the plate-bound LFA-1 ligand, 
ICAM-1, could be detected on motheaten T cells following anti- 
CD3 stimulation. Interestingly, while conjugate formation by 
SHP-1-deficient and control T cells could be shown to be critically 
dependent upon LFA-1, no significant differences in the level of 
expression or binding capacity of LFA-1 to ICAM-1 were detect­
able when comparing motheaten and control T cells following anti- 
CD3 stimulation. Therefore, it is possible that the SHP-1 effect on 
T cell-APC conjugation does not influence the signals that link 
TCR triggering to LFA-1 activity.
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An effect of SHP-1 on cell-cell adhesion has also been demon­
strated for NK cells whereby SHP-1 activity can induce a remark­
able suppression of NK cell cytolysis of targets. When SHP-1 is 
recruited and activated by an inhibitory killer Ig-like receptor, on 
the NK cell line, YTS, conjugates formed between the NK cell and 
target cells are dramatically reduced (42). Similar to our T  cell- 
APC conjugate system, NK cell-target cell conjugate formation is 
inhibited by the blocking of LFA-1 binding (42). The inhibition of 
NK cell killing also appears to be mediated via disruption of actin 
cytoskeleton remodeling whereby the guanine nucleotide ex­
change factor, Vavl, has been implicated as a direct substrate of 
SHP-1 (43, 44). Vavl is also a candidate substrate for SHP-1 in T  
cells although the results presented in this study imply that there 
may be at least one other substrate of SHP-1 that influences the 
ability of individual TCRs on the T  cell surface to engage MHC/ 
peptide complexes on the APC.
The overall significance of T  cell-APC conjugate formation is 
underscored by a number of in vivo imaging studies (3 -6 ) that 
have revealed a correlation between T  cell activation leading to 
proliferation and the ability of T cells to establish long-lasting 
stable contact with DCs. Further evidence for the critical relevance 
of T cell-APC conjugate formation also derives from recent ob­
servations (45, 46) indicating that T reg cells may affect the im­
mune response by reducing the capacity for contact formation be­
tween DCs and effector T cells. Clearly, a more comprehensive 
understanding of the cellular and molecular requirements for T  
cell-APC conjugate formation is needed. The increased percentage 
of conjugates formed with motheaten C D8+ T  cells would be pre­
dicted to result in increases in the number of T  cells capable of 
IL-2 synthesis and secretion as stable interactions between T  cells 
and APCs appear to be a prerequisite for IL-2 synthesis to proceed 
In an elegant in vitro imaging study, whereby transgenic CD4+ T  
cells expressing an IL-2 promoter GFP reporter construct were 
allowed to engage Ag-pulsed DCs, it was demonstrated that only 
a subset of those T cells that had prolonged and stable interactions 
with the DCs expressed IL-2 (47). Transient interactions between 
T cells and DCs were only sufficient for the expression of T  cell 
activation markers such as the a-chain of the IL-2R. We envisage 
that the greater number of stable conjugates formed with moth- 
eaten CD8+ T cells results in a higher proportion of T cells be­
coming IL-2 producers thereby increasing the recruitment of T  
cells into the proliferating population. Indeed, we have shown pre­
viously that a population of motheaten vs control T cells secreted 
more IL-2 when stimulated with peptide-pulsed APCs (26). The 
results reported here have established that motheaten T  cells can 
more readily form conjugates with the APC. However, once con­
jugates have been allowed to form, it remains to be established 
whether motheaten T  cells retain a further increased capacity for 
synthesizing IL-2 when compared with control T  cells.
The enhanced capacity for conjugate formation leading to in­
creased in vitro proliferative expansion displayed by SHP-1-defi­
cient CD8+ T cells is noteworthy. However, demonstrating effects 
in vitro does not necessarily equate to how T cells might respond 
in vivo whereby additional constraints are imposed. Indeed, a na­
ive CD8+ T cell must have the capacity to expand in peripheral 
LNs, differentiate into a mature CTL, and traffic from the Ag- 
draining LN to peripheral tissues before eventually lysing the ap­
propriate target cell. Hence, our observations demonstrating en­
hanced in vivo killing by a population of SHP-1-deficient naive 
CD8+ T cells following their adoptive transfer and in vivo expan­
sion are especially significant because they establish for the first 
time that loss of SHP-1 increases the proliferative capacity of T 
cells in an in vivo context extending to an elevation of CTL killing, 
the ultimate physiological challenge for a CD8+ T cell.
In conclusion, we provide evidence that SHP-1 negatively reg­
ulates the formation of conjugates between CD8+ T cells and 
APCs. This effect of SHP-1 activity must account, at least in part, 
for the hyperresponsive phenotype of motheaten T cells observed 
in the different parameters of T  cell function that have been mea­
sured (26). Importantly, the enhanced in vivo cytotoxicity of naive 
SHP-1-deficient T  cells highlights the validity of targeting SHP-1 
expression by small interfering RNA and pharmacological ap­
proaches to potentially boost human CD8+T cell function.
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